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Abstract 
Nogalamycin is a member of the anthracycline family of antitumour 
antibiotics.  These are potent cytotoxic agents and are routinely used in cancer 
chemotherapy.  Though nogalamycin is clinically insignificant, it does exhibit 
three distinct types of non-covalent binding to DNA.  Since most other 
anthracyclines bind to DNA by only one or two of these mechanisms, 
nogalamycin is an excellent model with which to probe the interaction of this 
class of anti-tumour agents with DNA. 
 
Here, we investigate the binding orientation and stoichiometry of nogalamycin 
in adjacent TpG(CpA) (and CpG(CpG)) intercalation sites using a 
combination of NMR techniques and NOE-restrained molecular dynamics 
simulations.  These methods are also employed to investigate the structure of 
GNA hairpin loops, which are considered to have important biological 
functions, and assess how their structure and stability are influenced by the 
introduction of nogalamycin at an adjacent site.  The effect of nogalamycin on 
extrahelical thymine bases incorporated onto either face of the intercalation 
sites is also investigated in this context. 
 
Binding of quadruplex-specific antibodies to telomeric DNA in Stylonychia 
lemnae macronuclei has recently been detected using immunofluorescence, 
providing direct evidence for the formation of quadruplex DNA structures in 
vivo.  Guanine-rich quadruplex structures have been extensively studied by 
NMR and x-ray crystallographic methods.  Previous structural studies have 
failed to unambiguously resolve the conformation preferred by less-stable A-
tetrads incorporated into DNA quadruplexes.  Additionally, little effort has 
been made to address the exact number of ions bound to these adenine-
containing structures.  This forms the basis of our study into quadruplex DNA. 
 
Finally, we endeavour to investigate the extent of hydration of both duplex 
and quadruplex structures using rMD methods, and to comapre hydration 
patterns in the liquid- and solid-state. 
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 1.  NMR Spectroscopy in Drug Discovery 
 
1.1 The Global Pharmaceutical Industry 
In 2003, the combined worldwide pharmaceutical market was US$491.8 
billion (1).  According to the PhRMA annual report 2000-2001 (169), 
pharmaceutical companies have almost doubled their Research & 
Development spending every five years since 1980.  For every $5 of sales 
revenue, $1 is reinvested in R&D.  Pharmaceutical companies need to ensure 
that there is a supply of new and better drugs in the pipeline to return on the 
substantial investments made in R&D.  It has been estimated that, in order to 
maintain their positions within the marketplace, the top ten pharmaceutical 
companies need 4-5 new drugs approved each year (1).  Most fall far short of 
this target, with only 1-2 new drugs receiving a marketing authorisation each 
year. 
 
1.2 Approaches to Drug Discovery 
The premise for the rational approach is that drug discovery based on 
knowledge of the three-dimensional structure of the chosen receptor molecule 
would reveal potential binding sites for drug molecules.  Structural 
information and modelling data are used to design or refine a drug that will fit 
precisely within the binding site, like a key in a lock.  Such information about 
the receptor structure can significantly improve the probability of obtaining a 
successful drug, while eliminating unlikely candidate structures at an early 
stage of the drug discovery process.  In the 1980s, modern drug discovery was 
dominated by the idea of rational drug design (228). 
 
With the emergence of combinatorial chemistry in the early 1990s came the 
promise of billions of molecules.  This pledge swung the pendulum away from 
the notion of designing one perfect molecule towards one of making many, 
many molecules and screening them all to find a small number of viable leads.  
Initial combinatorial libraries consisted exclusively of peptides (68;195).
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However, once a small number of organic libraries were prepared 
(25;26;51;191) this technology was enthusiastically embraced by the 
pharmaceutical industry at large. 
 
By the end of the 1990s, the impracticality of synthesising and cataloguing 
such a vast number of molecules began to become very apparent, causing the 
pendulum to swing back in the direction of rational drug design.  The idea of 
producing smaller subsets of directed combinatorial libraries was postulated in 
1995 (142).  The aim of this was to design smaller libraries, with a size range 
of 100-1000 molecules, which possess biological activities against specific 
targets.  During this period, some groups began experimenting with novel 
approaches to discovering leads in silico, a process that is now known as 3D 
database searching.  3D database searching involves the use of a virtual 
library of computational descriptions of drug molecules that any given 
combinatorial reaction scheme can produce.  The 3D structure of the drug-
binding site can be used to select those molecules that best satisfy the 
restraints of the pharmacophore, and these molecules can be synthesised in 
vitro and submitted for biological assay.  This is the currently a favoured 
method of drug design, which it is hoped will yield the greatest number of 
viable new drugs.  
 
The standard techniques used for 3D structure determinations are x-ray 
crystallography and NMR spectroscopy.  Modelling of potential drug 
receptors and drug-receptor complexes is studied using in silico molecular 
dynamics methods.  
 
1.3 X-ray Crystallography 
In order to determine the structure of drug compounds or drug-receptor 
complexes using x-ray crystallography, it is first necessary to have these 
molecules or composites available in crystal form.  This can be a major 
drawback, as the process of obtaining crystals of DNA and proteins can be 
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difficult, involving techniques such as dialysis, vapour diffusion and interface 
diffusion (55).  Techniques are being improved, however, and more than 
13000 protein structures have been solved by crystallographic methods at the 
time of this writing.  Once the macromolecule has been crystallised, and the 
crystal assessed for quality, a diffraction pattern is collected, from which a 3D 
electron density map can be calculated.  This can be refined to give rise to a 
final structural model of the biopolymer being studied.  The very nature of 
crystallisation, however, means that the observed molecules are frozen in 
space, like a camera snapshot, rather than in the natural liquid state as found in 
biological tissues. 
 
When a ligand can be co-crystallised with its receptor molecule, the binding 
site can be easily determined within the complex.  In instances where it is not 
possible to insert the ligand, the active site can often be inferred by 
comparison with other known structures.  Once the structure of the active site 
is known, potential drug molecules can be generated using computation 
chemistry methods.  This technique of inferring the location of the active site 
does not allow for conformational changes that may be induced in the target 
molecule by ligand binding.  Examples of some clinically significant drugs 
discovered using x-ray crystallography include amprenavir (AgeneraseP®P, 
GSK) and nelfinavir (Viracept P®P, Roche Products Ltd.), which were discovered 
by studying the interactions of potential drug compounds using crystal 
structure of both HIV protease (236;245) and lead compounds complexed with 
the protein (130;208;209;222;259).  The anti-influenza drugs zanamavir 
(RelenzaP®P, GSK) and oseltamavir (TamifluP®P, Roche Products Ltd.) were 
developed with extensive modelling of the crystal structure of influenza virus 
neuraminidase (44;132;184;231).  Though surface neuraminidses are known 
to undergo mutations, which account for different strains of flu viruses, gene 
sequencing studies have revealed a conserved portion that does not mutate 
(43;235).  X-ray crystallography revealed the structure of the conserved 
portion, and drug molecules were designed to fit into the cleft and prevent 
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neuraminidase form binding to sialic acid, which forms an important part of 
the life-cycle of the virus (130). 
 
1.4 NMR Spectroscopy 
Compared with x-ray crystallography, NMR has the advantage of being 
carried out in solution rather than requiring crystal samples.  Since solution 
states are more representative of the native environment of DNA and protein 
drug targets, NMR is more amenable to the study of drug-receptor 
interactions.  Macromoleclar structure determination using NMR spectroscopy 
typically involves four steps:  Following initial recording of NMR spectra, 
correlations between atoms and resonance peaks are established by means of 
spectral assignment.  The assigned spectra are then used to generate distance 
and angular restraints between atoms, which allow the three-dimensional 
structure to be calculated.  
 
NMR is limited to molecules with molecular weights of <35 kDa due to the 
phenomenon of spectral overlap, which is effectively a function of spectral 
resolution.  Since a Watson-Crick DNA base pair has approximately 24 
protons, a DNA sequence containing 20 base pairs can result in a 1D proton 
NMR spectrum with more than 480 peaks.  In such a case, assignment of the 
one-dimensional spectrum would prove impossible.  Solutions to this problem 
include using higher magnetic field strengths, and spreading the spectrum into 
two or more dimensions.  This size limitation has meant that NMR has been 
less useful than crystallography in rational drug design, as drugs have 
traditionally been targeted towards cellular proteins.  However, with the 
emergence of gene therapy, more and more therapeutic agents act at the level 
of nucleic acids.  The 3D structure of nucleic acids are primarily determined 
by the sequence of the bases on a local level, and so these biopolymers are 
more amenable to being broken down into smaller structural models than 
proteins, which often rely on long-range interactions between different 
domains to determine their tertiary structure.  NMR methods have recently 
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been employed to describe the interaction and stabilisation of quadruplex 
DNA by a fluorinated polycyclic methylacridinium salt (71;72), which had 
previously been shown to inhibit the enzyme telomerase in human tumour 
cells through a mechanism thought to involve stabilization of four-stranded G-
quadruplex structures formed by single-stranded telomeric DNA (82;93). 
 
The techniques of x-ray crystallography and NMR spectroscopy, when 
combined, can provide invaluable information for drug designers.  The precise 
binding topologies that can be generated using both techniques, together with 
dynamic properties derived from NMR, can be used to tailor-make drug 
molecules to fit is specific binding sites. 
 
1.5 Scientific Collaboration 
As the scope of what science as a whole can understand increases, so the 
extent of what individual scientists, limited by finite human memory and 
intelligence, can consider to be their field of expertise must decrease.  A little 
more than a century ago, an individual worker could expect to have an in-
depth knowledge of the extent of knowledge in chemistry, physics and 
biology.  As the depth of current knowledge increases, so fields of expertise 
must become more specialised.  What was once chemistry is now split into 
organic, inorganic, physical, biological and computational sub-categories, to 
name but a few.  As we gain more and more knowledge about each of these 
facets of chemistry, so each subcategory can itself be divided further into new 
subject areas, such as computational surface chemistry.  This increasing 
diversification and specialisation is not only evident in chemistry.  Indeed, 
similar trends can be observed across all disciplines of science.  In order that 
scientific endeavour does not become compartmentalised, it is essential that 
there is communication and collaboration between scientists working in each 
of these ever sub-dividing fields. 
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Within the field of cancer research, for example, an individual worker cannot 
be expected to possess the expertise to design, optimise and synthesise a 
potential chemotherapeutic drug, to conduct pharmacokinetic, 
pharmacodynamic and toxicological studies, and pre-clinical and clinical 
trials, to design a delivery system for the finished drug, to implement 
procedures, processes and equipment for large-scale commercial production, 
and to oversee the administration of the finished product.  However, what is 
expected of each the hundreds of individual scientists involved in each step of 
this process is that they can communicate what they have learned and achieved 
to the other scientists involved in the project, each of whom may have very 
diverse scientific backgrounds.  Most importantly, they must be able to 
effectively communicate their findings with those scientists involved in the 
steps directly before, and after, their own, as it is typically to these workers 
that their data may prove to be most useful.  For those scientists, 
predominantly x-ray crystallographers and NMR spectroscopists, involved in 
structure determination of biological targets, it is vital to be able to relay 
structural data, in a usable form, to synthetic chemists and others who wish to 
rationally design, optimise and synthesise drugs specific to these targets.  This 
is facilitated by the existence of a simple, standardised format, which can be 
used to describe all the relevant 3D topological data from macromolecular 
structure determinations. 
 
1.6 The Protein Data Bank 
The Protein Data Bank (PDB) is an archive of experimentally-determined 
three-dimensional structures of biological macromolecules, serving a global 
community of researchers, educators, and students.  The PDB began during 
the late 1960s and early 1970s with community discussions about the need for 
such a resource (17).  Protein crystallography was still in its infancy, but it was 
apparent to the producers of these structures as well as the potential users that 
every structure contained valuable information that needed to be archived and 
maintained.  In October 1971, an article appeared in Nature New Biology (5) 
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announcing the formation of the PDB.  The PDB file format was established 
early on (18) to contain the coordinates and related information, and still 
endures.  The archives contain atomic coordinates, bibliographic citations, 
primary and secondary structure information, as well as crystallographic 
structure factors and NMR experimental data, all presented in the standardised 
PDB format, which is accessible to all members of the scientific community.  
The PDB is the single worldwide repository for the processing and distribution 
of 3D structure data of large molecules of proteins and nucleic acids and, as 
such, is in invaluable tool in rational drug design. 
 
There are standardised procedures for depositing and exchanging three-
dimensional structural data derived by NMR spectroscopy.  Once deposited by 
a contributor, data are subjected to a series of computerised validation 
procedures: all the nomenclatures of the atoms and residues are standardised; 
the sequence records are checked for consistency and are checked against the 
sequence databases; the geometry of the macromolecule is checked against 
known standards for distances, angles, and chirality; stereochemical clashes 
and the chemistry of the small molecule ligands are checked; and the 
coordinate data are checked against the experimental data.  It is the goal of 
every worker involved in macromolecular 3D structure determination to 
produce structures that meet the stringent criteria for inclusion in the archives 
of the PDB. 
 
2.  Binding Studies of Nogalamycin with DNA 
 
2.1 Introduction 
2.1.1 Anthracycline Antibiotics 
In order for replication to occur, the nuclear DNA must first become 
dissociated from histones.  After replication has occurred, it must then be 
returned to its tightly packed state.  This constant winding and unwinding can 
lead to supercoiling; analogous to the flex on a cheap and often-used 
telephone.  A family of enzymes called topoisomerases, of which there are two 
members, removes supercoiling.  Type I topisomerases transiently cleave a 
single strand of DNA to allow passage of a second strand through the break, 
relieving supercoiling (9).  Type II topisomerases perform a different reaction, 
cleaving and opening one DNA duplex, passing a second duplex through the 
opening, and resealing the break (15;113). 
 
The mechanism by which anthracycline antibiotics kill the cancer cells is not 
fully understood, but the main mechanism is thought to be topoisomerase 
mediated strand breakage (67;85). The binding of the anthracycline antibiotics 
to the DNA is thought to stabilise the cleaved state of the DNA so that it is not 
resealed, resulting in a permanent double strand break, leading to cell death.  
Topoisomerases are most active during cell cycle periods of high DNA 
synthesis.  Generally speaking, the topisomerase concentration of proliferating 
tumor cells is elevated substantially over that found in normal somatic cells.  
This makes topoisomerases a semi-selective target for cancer chemotherapy. 
 
The presence of a glycoside ring at the C7 position of an anthracycline 
antibiotic, has been shown to play an important role in affecting topoisomerase 
specific poisoning (202).  Those agents possessing a sugar ring, such as 
nogalamycin, daunomycin and doxorubicin generally poison topisomerase I, 
but not topisomerase II.  In contrast, anthracyclines such as menogaril, a 
derivitave of nogalamycin without the nogalose sugar, are selective type I 
topisomerase poisons. 
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Fig.2.1: Chemical structures if the anthracycline anti-tumour antibiotics. 
 
2.1.2 Nogalamycin 
Nogalamycin (Fig.2.2) has been reported to show activity against 
experimental tumours in vivo, but is useless as a clinical chemotherapeutic 
agent due to the extent of the associated cardiotoxicity (197).  Isolated from 
the species Streoptomyces nogalator, nogalamycin is unique in that it 
possesses bulky sugars (nogalose and aminoglucose) on rings A and D 
respectively of its tetracyclic chromophore (7), and yet still binds strongly to 
double helical DNA by intercalation.  The nogalose sugar is attached to the C7 
position of ring A, whilst the aminoglucose sugar is attached to the C1 and C2 
positions of ring D of the aglycone chromophore.  Nogalamycin forms a stable 
intercalation complex with slow association and dissociation rates (64;65). 
 
Though the drug itself is clinically insignificant, the binding mechanism 
(212;240;241), stoichiometry and selectivity (64;65) of nogalamycin has been 
extensively studied.   
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Fig.2.2:  Chemical structure of nogalamycin, showing the numbering system 
employed on the planar chromophore, and the aminoglucose and nogalaose sugars. 
 
Nogalamycin exhibits three distinct types of non-covalent binding to B-form 
duplex DNA.  In common with all anthracyclines, the planar aglycone ring 
intercalates between stacked bases, causing localised unwinding of the helix 
and distortion of the bases (243).   The nogalose sugar resides within the 
minor grove and the amino sugar in the major groove.  Since most other 
anthracyclines bind to DNA by intercalation and either major or minor groove 
binding, nogalamycin is an excellent model with which to probe the 
interaction of this class of anti-tumour agents with duplex DNA. 
 
A number of studies have been carried out to show the relationship between 
the structure of nogalamycin and its analogues and their biological activity 
(70).  Nogalamycin is known to be a topoisomerase I poison (202).  Its 
analogue, menogaril, which lacks the nogalose sugar, is a topoisomerase II 
poison.  Both drugs exhibit antitumour activity.  However, they have been 
shown to have different cellular activities and target different stages of the cell 
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cycle.  It is known that nogalamycin can induce a 22q bend in DNA (183), and 
can trap topoisomerase I-cleavable complexes at specific sites on DNA (202).  
The stimulation of site-specific topoisomerase I-mediated DNA cleavage has 
been linked to the groove binding properties of anthracyclines and bis-
benzimidazoles.  It has been shown that these compounds preferentially bind 
and stabilise bent DNA domains suggesting a possible correlation between 
drug-induced bending and topoisomerase I poisoning (172).  The replacement 
of the DNA binding sequence for these drugs, with a sequence that introduces 
a bend in the helix, was shown to result in the stimulation of topoisomerase I-
mediated DNA cleavage under appropriate conditions (248).  This led to the 
hypothesis that nogalamycin-induced topoisomerase I-mediated DNA 
cleavage is a direct result of DNA bending. 
 
Other anthracyclines lack the bulky substituent on ring D that poses a 
mechanical problem for nogalamycin.   This molecule, which is essentially the 
shape of a dumbbell, with a minimum bell-width of 5.5 Å, can intercalate 
between base pairs that are only 3.4 Å apart in B-DNA.  Two theories that 
explain this phenomenon have been suggested:  The first (42) postulates that 
transient melting of the DNA helix is required in order for the drug to insert 
between the bases.  The helix then reforms around the drug.  The second 
binding hypothesis (243) involves elongation of the DNA along its helical 
axis, with associated unstacking and buckling of the base pairs, but without 
any disruption of base pair hydrogen bonds.  This requires the bulky sugar 
substituents on nogalamycin to flip from axial to equatorial positions to 
facilitate intercalation.  Major conformational changes for both the drug and 
the DNA are required in the latter theory. 
 
DNase I footprinting studies (65) have shown that the unusual structure of 
nogalamycin endows it with the ability to discriminate between different 
nucleotide sequences.  The selectivity is determined primarily by the local 
dynamic properties of the helix.  Nogalamycin has been shown to intercalate 
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only in the pyrimidine-purine steps, TpG (and symmetry related CpA) and 
CpG (CpG), and binds very poorly to purine-pyrimidine steps.  ApT (ApT) 
and TpA (TpA) pairs are very stable and difficult to unstack, and are poor 
binding sites for the drug. 
 
For nogalamycin, there is no steric preference for sugar conformation in either 
groove (42).  However, in all reported structures of nogalamycin-DNA 
complexes, including duplexes and hairpin loops (Section 3.7.1), the 
aminoglucose resides in the major groove and the nogalaose lies in the minor 
groove.  A combination of nonbonded forces, including VDW interactions, 
and solvent mediated H-bonds has been shown to stabilise the drug-DNA 
complex (212). 
 
2.1.3 Clinical Uses of Anthracyclines 
TDoxorubicinT is one of the most successful and widely-used anti-tumour drugs, 
and it is used to treat the acute leukaemias, lymphomas, and a variety of solid 
tumours, such as adenocarcinoma and malignant mesothelioma (breast and 
lung cancers).  It is given by fast running infusion, commonly at 21-day 
intervals.  Pharmacokinetic studies, determined in patients with various types 
of tumors undergoing either single or multi-agent therapy have shown that 
doxorubicin follows a multiphasic disposition after intravenous injection. The 
initial distributive half-life of approximately 5 minutes suggests rapid tissue 
uptake of doxorubicin, while its slow elimination from tissues is reflected by a 
terminal half-life of 20 to 48 hours. Steady-state distribution volumes exceed 
20 to 30 L/kg and are indicative of extensive drug uptake into tissues. Plasma 
clearance is in the range of 8 to 20 mL/min/kg and is predominately by 
metabolism and biliary excretion. Approximately 40% of the dose appears in 
the bile in 5 days, while only 5 to 12% of the drug and its metabolites appear 
in the urine during the same time period.  Binding of doxorubicin and its 
major metabolite, doxorubicinol (Fig.2.3(c)) to plasma proteins is about 74 to 
76% and is independent of plasma concentration of doxorubicin up to 2 mM.   
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Fig.2.3: Pathway of doxycycline metabolism in human cardiac cytosol:  Doxycycline 
(a) is converted to doxorubicinol (c) via the hydroxyaglycone (b). 
 
In human cardiac cytosol, enzymatic reduction at the 7-position and cleavage 
of the daunosamine sugar yields aglycones (Fig.2.3(b);(c)) (134).  High 
concentrations of cytosolic proteins cause doxorubicin hydrolysis as the first 
step and carbonyl reduction of the hydroxyaglycone as the second step.  The 
formation of these metabolites is accompanied by free radical formation, the 
local production of which may additionally contribute to the cardiotoxic 
activity of doxorubicin.  
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Cardiotoxicity has been a major factor in limiting use of the anthracyclines, 
doxorubicin and daunorubicin.  Toxicity is essentially of two kinds: acute, 
supraventricular tachycardia (197), which is a relatively uncommon 
complication, and a delayed, dose-related, cardiomyopathy (53), resulting in 
congestive heart failure.  Higher cumulative doses are associated with 
cardiomyopathy.  Special attention must be given to the cardiotoxicity induced 
by doxorubicin.  Irreversible myocardial toxicity, manifested in its most severe 
form by life-threatening congestive heart failure, may occur either during 
therapy or months to years after termination of therapy.  The probability of 
developing impaired myocardial function, based on a combined index of signs, 
symptoms and decline in left ventricular ejection fraction (LVEF) is estimated 
to be 1 to 2% at a total cumulative dose of 300 mg/m² of doxorubicin, 3 to 5% 
at a dose of 400 mg/m², 5 to 8% at a dose of 450 mg/m² and 6 to 20% at a dose 
of 500 mg/m² given in a schedule of a bolus injection once every 3 weeks. It is 
this specific cardiotoxicity that renders nogalamycin therapeutically useless.  
Because of the risk of symptomatic and potentially fatal heart failure, it is 
usual to limit total cumulative doses of doxorubicin to 450 mg/mP2 P body-
surface area.  
 
Cardiomyopathy and/or congestive heart failure may be encountered several 
months or years after discontinuation of doxorubicin therapy (80).  The risk of 
congestive heart failure and other acute manifestations of doxorubicin 
cardiotoxicity in children may be as much or lower than in adults.  Children 
appear to be at particular risk for developing delayed cardiac toxicity in that 
doxorubicin-induced cardiomyopathy impairs myocardial growth as children 
mature, subsequently leading to possible development of congestive heart 
failure during early adulthood.  Patients with pre-existing cardiac disease, the 
elderly, and those who have received myocardial irradiation should be treated 
cautiously.  Cardiac monitoring, for example by sequential radionuclide 
ejection fraction measurement, may assist in safely limiting total dosage.   
 
2.  Binding Studies of Nogalamycin with DNA 15
Treatment of doxorubicin-induced congestive heart failure includes the use of 
digitalis, diuretics, after load reducers such as angiotensin I converting enzyme 
(ACE) inhibitors, low salt diet, and bed rest. 
 
AdriamycinP®P, (Doxorubicin Hydrochloride for Injection, BP) is available as a 
sterile red-orange lyophilised powder for intravenous use only, in 10, 20 and 
50 mg single dose vials and a 150 mg multidose vial from Pfizer Ltd., 
(formerly Pharmacia Ltd.). 
 
CaelyxP®P, the liposomal form of doxorubacin, is licensed by the MCA (141) for 
the treatment of Kaposis sarcoma (KS), a cancer that develops in connective 
tissues such as cartilage, bone, fat, muscle, blood vessels or fibrous tissues, 
and also as a third-line treatment of metastatic ovarian cancer.  For decades 
KS was considered a rare disease that mostly affected elderly men of 
Mediterranean or Jewish heritage, organ transplant patients, or young adult 
African men (227). In the last 20 years, however, the vast majority of KS 
cases have developed in association with human immunodeficiency virus 
(HIV) infection and the acquired immunodeficiency syndrome (AIDS), 
especially among homosexual men (161).The mechanism of action of CaelyxP®P 
is identical to that of doxorubicin, but the active drug is encapsulated in a lipid 
bilayer microsphere formulated with surface-bound methoxypolyethylene 
glycol (MPEG).  The pegylated drug is protected from detection by the 
mononuclear phagocyte system (MPS) and, since it does not bind to plasma 
proteins and thus resides in the intravascular space, has a much smaller 
volume of distribution and much longer terminal half-life. 
 
PharmorubicinP®P, (Epirubicin Hydrochloride for Injection, BP), a sterile red-
orange solution for intravenous use only, is available in 10 mg single dose 
vials from Pfizer Ltd., (formerly Pharmacia Ltd.).  Epirubicin possesses 
essentially the same spectrum of activity as doxorubicin, as well as a 
quantitatively similar pattern of metabolism.  This agent has lower cardiac 
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toxicity relative to doxorubicin (197).  The cumulative maximum tolerable 
dose of epirubicin is 900 mg/mP2 P.  
 
Daunorubicin is used in the treatment of acute lymphocytic and acute 
granulocytic leukemias.  It is the drug of choice in the treatment of non-
lymphocytic leukemia. Daunorubicin is administered I.V. with a biphasic 
elimination curve with a terminal half-life of 1.5-10 hours.  The drug is 
primarily metabolised in the liver.  Unlike doxorubicin, renal excretion of drug 
and its metabolites occurs within six hours and the urine may turn bright red in 
colour.  The drug causes much the same type of cardiomyopathy as 
doxorubicin. The incidence has been reported to be 1.5% at a total dose of 
600mg/mP2 P and 12% at 1000 mg/mP2 P(197). 
 
Daunomycin is formulated as CerubidinP®P, a sterile red lyophilised powder of 
Daunorubicin Hydrochloride BP for intravenous use only, in 20 mg single 
dose vials, by Beacon Pharmaceuticals Ltd.  Daunorubicin is also available as 
a pegylated liposomal formulation for the treatment of KS (DaunoXomeP®P, 
Gilead Sciences.). 
 
2.1.4 Cooperativity in Drug-DNA Complexes 
In terms of nucleic acids with multiple binding sites, cooperativity can be 
defined as a thermodynamic effect, which describes the effect that one bound 
ligand has on the binding affinity of a second ligand.  Cooperativity arises 
when the changes in free energy of multiple species are mutually dependent.  
Cooperative interactions can be defined as either positive or negative, 
depending on whether the binding affinity of the second drug is enhanced or 
diminished by the presence of the first.   
 
Negative cooperativity, or anticooperativity, is often related to steric effects, 
resulting from an overlap of the binding sites (241;256).  Positive 
cooperativity is thought to be related to conformation changes in the DNA 
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(92;230).  Binding of the first ligand may promote a structural change in the 
DNA, making the second site more favourable for the second ligand.  This 
change may be permanent, as a result of drug binding, or transient, occurring 
only during part of the binding event. 
 
Cooperative binding has been identified between drug molecules that bind to 
DNA with varying modes of interaction, including intercalation (193) and 
groove binding (74;75).  The factors responsible for cooperativitity are 
presumably different, but ill-defined for each mode of binding.  The 
intercalation event involves distortion of the DNA helix, during which the 
binding of the first molecule may cause a conformational change at the second 
site, increasing its affinity to bind a second ligand.  Thus, the drug induced 
conformational change may be propagated from one site to the other. 
 
2.2 Experimental Design 
2.2.1 Project Overview 
End effects encompass the range of unfavourable interactions, either with the 
surrounding solvent or within the crystal lattice, that occur when the bulky 
sugars that bookend the nogalamycin chromophore overhang the ends of the 
oligonucleotide in which it is intercalated.  Here, we aim to assess the 
contribution of end effects on the orientation of nogalamycin bound to a 
terminally-located interacalation site by determining how far away the site 
must be from the terminus of an oligomer in order to negate their contribution.  
This will be assessed in terms of drug orientation within a symmetrical CpG 
intercalation site.  To address the question of the orientational preference of 
nogalamycin, we attempt to assess whether nogalamycin, complexed in a 2:1 
ratio with three oligonucleotides, each containing the core sequence 
d(CGATCG) B2 B, is oriented such that its sugars point towards the centre of each 
duplex or outwards towards its ends. 
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We are interested in investigating whether cooperativity exists in DNA 
sequences demonstrating the potential for communication between binding 
sites, but without the possibility of direct ligand-ligand interactions and, if so, 
in probing the cause of this phenomenon.  We aim to distinguish whether 
nogalamycin binds to two equivalent intercalation sites, each separated from 
the other by an ApT spacer, in a cooperative or anticooperative manner, or 
whether each binding event is independent of the other.  To achieve this, we 
have designed a simple qualitative model that can quickly assess whether there 
is communication between the sites or whether they are entirely independent 
of one another.  If the sites are shown to interact, the complexity of the P1 PH 
NMR spectra of the drug-DNA complex relative to the free DNA can be used 
to determine the nature of this interaction; either cooperative or 
anticooperative.  It is important to state at this point that this is not a 
thermodynamic study and, as such, does not attempt to quantify the degree of 
cooperativity.  Rather, we attempt here to qualitatively assess the relationship, 
vis-à-vis cooperativity, between the binding sites. 
 
2.2.2 Sequence Design 
Smith et. al. (212) have previously published the crystal structure of the 2:1 
complex of nogalamycin with d(TGATCA)B2 B, in which two nogalamycin 
binding steps are separated by an AT spacer.  In order to facilitate comparison 
between x-ray and NMR-refined structures (Section 5.4.2), this sequence was 
chosen as a starting point for this study.  To assess how the orientation of the 
drug is affected by end effects, the sequence d(CGATCG)B2 B, in which the TpG 
(CpA) intercalation steps are replaced with analogous CpG (CpG) steps, was 
also synthesised.   Following the study of these two complexes, the sequences 
d(TCGATCGA) B2 B and d(CTCGATCGAG) B2 B, in which each CpG site is flanked 
on its terminal face by one and two base pairs respectively, were synthesised 
to see what effect, if any, internalising the binding site would have on drug 
orientation.  To act as a control, and to aid in the assigning the NOESY spectra 
of these sequences, the sequences d(CTGATCAG) B2 B and d(CCTGATCAGG) B2 
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were also synthesised.  For the TpG-containing oligomers, CG base pairs were 
used to extend the sequence lengths, as these offered the greatest stability.  In 
the case of the CpG-containing sequences, one TA and one CG pair were used 
at each end.  Although this would be potentially less stable than using two CG 
pairs as before, it should improve the chemical shift dispersion on key areas of 
the NMR spectra. 
 
2.3 Materials & Methods 
2.3.1 DNA Synthesis & Purification 
All DNA sequences used were synthesized using an Applied Biosystems P®P 
394 phosphoramidite solid phase oligonucleotide synthesiser, by Mr John 
Keyte, School of Biomedical Sciences, University of Nottingham.  In each 
case, the sample volume was approximately 1.5 ml of 10 PM ssDNA, 
equivalent to roughly 20 mg of duplex DNA in total.  In preparation for HPLC 
separation, the DNA was centrifuged for 10 minutes at 13000 rpm.  The 
supernatant was further cleaned by syringe filtration through a 450 nm 
aperture width filter, to remove all insoluble impurities from the sample. 
 
The DNA was purified trityl on by reverse phase HPLC on a HyperSilP£P 10Pm 
ODS, 10x250 mm packed C18 semi-preparative column, using an acetonitrile 
gradient (0-70 % over a 30 minute timescale) and a TEAA buffer (pH 7.0).  
Approximately 80 % of the total purified DNA was retrieved, by separation of 
six to eight 250 Pl aliquots.  All the recovered fractions were then combined 
and any remaining acetonitrile removed by rotary evaporation.  The aqueous 
vestiges were freeze dried and reconstituted with ~10 ml distilled water, 
before being heated with an equal volume of 50 % aqueous acetic acid for 30 
minutes, to remove the DMT protecting group.  The acetic acid was 
sequentially extracted into three 200 ml portions of diethyl ether.  The aqueous 
fraction was dialysed, first against distilled water (2 L), then against a similar 
volume of NaHB2 BPOB4 B (100 mM), NaCl (1 M), to introduce sodium as the 
counter-ion.  After further dialysis with HB2 BO, the sample was lyophilised and 
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redissolved in 600Pl of HB2 BO.  To this was added NaCl (1 M, 70 Pl) and 
NaDB2 BPOB4 B (100 mM, 70 Pl), to aid duplex formation, 10Pl of the metal chelator 
EDTA (6mM), NaNB3 B(6 mM, 10Pl), to protect against microbial 
contamination, and the internal standard TSP (1.5 PM, 5 Pl).  After adjusting 
to pD 7.4 with NaOD (100 PM) and DCl (100 PM), the sample was again 
lyophilised and, finally, made up to 700 Pl with DB2 BO. 
 
2.3.2 Nogalamycin Preparation 
The nogalamycin was generously provided by Pfizer Inc. (formerly Pharmacia 
& Upjohn).  2.5 mg of solid nogalamycin was added to 300 µl of buffered (pD 
7.2) DB2 BO solution (0.1 M NaCl, 10 mM NaDB2 BPOB4 B, 0.1 mM EDTA).  The 
mixture was shaken is a cold room (4°C) for 24 hours.  The pH was adjusted 
to 7.5 using 0.1 M solutions of DCl and NaOD.  The sample was subsequently 
centrifuged to remove any undissolved solids. 
 
2.3.3 NMR Analysis 
NMR experiments were performed on either a Bruker Avance400 or Bruker 
DRX500 spectrometer.  All one-dimensional NMR experiments were 
recorded over 32768 data points in the f2 dimension, with spectral width of 
16.022 ppm and a relaxation delay time of 1.5 s.  Phase-sensitive Double 
Quantum Filtered COrrelated SpectroscopY (DQF-COSY) (171;177), TOtal 
Correlated SpectroscopY (TOCSY) (13), and NOE SpectroscopY (NOESY) 
(12) experiments were performed, collecting either 1024 or 2048 points in f2, 
and between 400 and 512 points in f1.  NOESY data at mixing times ranging 
from 75 ms to 300 ms were collected with a spectral width of 16.022 ppm in 
each dimension, with a delay time of 1.5 s.  Quadrature detection in f1 was 
achieved using states time-proportional phase incrementation (states TPPI).  
All TOCSY experiments employed a spin-locking field of 5 kHz.  All data 
were processed on an SGI P®P Indy R5000 or O2 workstation, using Bruker 
XWIN-NMR processing software.  Two-dimensional data were zero-filled 
to 2048 x 1024 points prior to Fourier transformation, optimised with a shifted 
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sine squared function in both dimensions, and treated with automatic baseline 
correction. 
 
2.3.4 Distance Restraints 
The NOESY experiment identifies protons in close spatial proximity.  For an 
isolated spin pair, the intensity of an observed NOE is inversely proportional 
to the sixth power of the distance between the protons causing it (10).  In 
macromolecular systems, the intensity of the NOE can be altered by cross-
relaxation to another nucleus during the mixing period (Ĳ) of the experiment.  
This phenomenon is known as spin-diffusion.  The NOE build-up curves for 
DNA systems such as these have been shown to have a strong linear 
characteristic for mixing times of less than 150 ms (249).  Since the mixing 
time is under experimental control, the distances can be linearly extrapolated 
to zero mixing time by collecting three low mixing time (<120ms) NOESY 
spectra, thus alleviating the effects of spin diffusion.   
 
In DNA, some fixed distances defined by the covalent structure of rigid areas 
in the macromolecule that correspond to well-resolved NOESY crosspeaks 
can be used to normailise other peak intensities using Equation 2.1.  To 
increase the accuracy of this procedure, different internal distances (DBref B) are 
used to reference NOE intensities (IBijB) corresponding to proton interactions in 
different environments.  NOEs involving sugar protons are referenced with 
deoxyribose H2'-H2" distances (I Bref B), which are known to be separated by 1.85 
Å.  Similarly, base proton separations are referenced relative to the cytosine 
H5-H6 distance (2.45 Å), while the thymine CHB3 B-H6 reference distance (3.00 
Å) is applied to NOEs involving methyl protons. 
 
6
6
refij
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ij II
D
D   
Equation 2.1:  Determination of the distance (D Bij B) between two protons i and j, with 
an NOE crosspeak intensity (I Bij B), calibrated for a known interproton separation (D Bref B) 
with a measured intensity (I Bref B). 
2.  Binding Studies of Nogalamycin with DNA 22
By combining this distance information with the fully assigned NOESY 
spectrum, a set of distance restraints for the complex can be generated.  These 
restraints can subsequently be incorporated into the AMBER force field 
(Section 3.3.4), restricting the number of conformations available to the 
structure. 
 
Assignment of all NOESY spectra was carried out using ANSIG (124), a 
program for the assignment of protein and nucleic acid P1 PH 2D NMR spectra 
using interactive graphics.  The spectra were integrated using the Bruker 
XWIN-NMR software suite.  The frequency-domain spectrum matrices, 
together with the sequence of the DNA complexes, were used as input data for 
ANSIG.  Typically, low-resolution (1024 x 1024) contour maps of the 
NOESY (Ĳ = 300 ms), TOCSY and DQF-COSY spectra of the sample were 
read into the program.  The centre of each discrete crosspeak on the NOESY 
contour plot was then marked with a cross, which was labelled with one 
proton assignment for each of the two frequency domains, FB1 B and FB2 B, using the 
procedure described in Section 2.4.2.  The crosspeaks were then connected in 
FB1 B and FB2 Buntil a complete spectral assignment was constructed.  The resulting 
ANSIG output files consisted of a list of frequency domain coordinates, 
corresponding to the centre of each crosspeak, together with an assignment in 
FB1 B and FB2 Bfor each. 
 
As for ANSIG, frequency-domain spectrum matrices were used as the input 
data for XWIN-NMR.  The integration regions around each crosspeak on 
the NOESY spectra were defined by enclosing them in boxes.  Once all peaks 
were enclosed, the integrals were computed.  For the crosspeak integration to 
work properly within XWIN-NMR, it was vital that when two or more 
crosspeaks overlapped (Fig.2.4), they should be separated, as areas of overlap 
would cause discrete peak volumes to be added to the total volume multiple 
times (Fig.2.4(a)), and so affect the accuracy of the integration.  In order to 
integrate overlapping peaks, a portion of each peak on the face opposite the 
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area of overlap was boxed (Fig.2.4(b)).  Once the volume within this box had 
been integrated, it was multiplied by an appropriate factor to create an isolated 
peak with intensity approximately equal to that of the original peak, had it not 
been overlapped (Fig.2.4(c)).  Obviously, this procedure gives rise to less 
accurate intensities than those obtained by direct measurement, and so the 
error bounds on the resulting distance restraints were increased accordingly. 
 
 
Fig.2.4:  Procedure for resolving overlapped peaks in XWIN-NMR. 
 
The integration procedure was carried out for three NOESY spectra with 
mixing times of 120, 100 and 75 ms respectively.  Since 2D NOESY contour 
maps possess 2-fold reflectional symmetry with a mirror line along their 
diagonals, the crosspeaks above, and below, the diagonal were treated as 
separate spectra, which can be mutually crosschecked.  Both above- and 
below-diagonal integrals were then used to generate inter-proton distances at 
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each mixing time using Equation 2.1.  There were not always three points on 
the NOE build up curve from which to extrapolate the zero-mixing time 
distance.  Often, some weaker NOEs did not appear on the lowest mixing time 
spectra, as they were given insufficient time to develop.  In such cases, there 
were only two points describing the build-up curve, and so its linearity could 
not be verified.  Though there is no reason to suspect that these curves did not 
have a significant linear component, this did warrant increasing the error 
bounds on the resulting distance restraints.  The XWIN-NMR output files 
comprised a list of two sets of coordinates, which correspond to the top-left 
and bottom-right corners of each integration region, together with the distance 
calculated from the integral within that region. 
 
The output files from ANSIG and XWIN-NMR were subsequently 
combined to give rise to six files, corresponding to three low mixing time 
NOESY spectra for above, and three corresponding spectra for below, the 
diagonal.  These files contained a list of labelled proton-proton distances.  The 
protocol for combining the interproton distances, from XWIN-NMR, with 
their assignments, from ANSIG, assumes that there will be only one 
assignment within each integration region, and that there is no overlap 
between adjacent regions.  Multiple hits were therefore discarded, 
emphasising the importance of clean spectra with clearly defined crosspeaks 
when generating distance restraints for rMD simulation.  
 
The labelled interproton distances from each of the 120, 100 and 75 ms spectra 
were extrapolated to zero mixing time.  The resulting distances from the 
above- and below-diagonal spectra were parsed against each other.  In 
instances where there was good correlation between two symmetry-translated 
crosspeaks, their associated distances were averaged.  If a crosspeak was 
absent in either spectrum, only one value was used.  Using this simple parsing 
method, erroneous and inaccurate peaks could be easily detected and removed. 
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For all of the rMD studies described in this thesis, the inherent error associated 
with distance calculations from the NOE data led to a 10% upper bound error 
being applied to all distances involving the non-exchangeable protons.  All 
distances involving the exchangeable protons were given a 25% upper bound 
error due to the degree of exchange with the solvent.  Distances obtained from 
indirectly integrated crosspeaks, and those extrapolated from incomplete 
build-up curves were also subject to a 20% error bound.  Distance restraints 
were compared visually with the distances of a structure derived from 
unrestrained molecular dynamics simulation, by using MolMol (123) software 
for molecular graphics and display. 
 
2.3.5 Drug Titration 
Previous NMR studies of nogalamycin-DNA complexes (181;256) have been 
concerned primarily with the structural characterisation by 2D methods.  In 
these studies, an excess (typically 3 equivalents) of solid nogalamycin was 
added to an aqueous solution of the duplex.  The resulting solution was then 
lyophilised and redissolved before adjusting the pH to 7.0 to precipitate the 
nogalamycin, which was subsequently removed by centrifugation.  In this 
study, the nogalamycin was titrated into the DNA solution in aliquots, and a 
1D P1 PH NMR spectrum of the forming complex was collected after each 
addition. 
 
2.3.6 Starting Structures 
A Cartesian coordinate model for the right handed Arnott B-form DNA 
structures, d(TGATCA) B2 B and d(CCTGATCAGG) B2 B, were generated using the 
NUCGEN module of AMBER 6.0 (29).  Using the LEaP module of the 
AMBER suite, a gap of approximately 10 Å was created at each intercalation 
step in order to accommodate the drug.  A model of the drug molecule, which 
had been previously parameterised, was manually docked into each widened 
step.  The orientation of the drug in each binding site was based on NOE data 
from the 2D spectra of the complexes (Section 2.4.3), and by reference to 
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previously published structures (210;212).  Sodium counter-ions were used to 
negate the negative charge on the DNA backbones, and the models were 
solvated to within a distance of 5 Å using boxes of 216 TIP3P H B2 BO molecules 
(105).  The period box size for nogalamycin-d(TGATCA)B2 B was approximately 
37x40x43 Å, and 37x40x55 Å for nogalamycin-d(CCTGATCAGG) B2 B.  In each 
case, the entire system was energy minimised to optimise bond lengths. 
 
2.3.7 Structure Calculations 
Minimisation was followed by ten rounds of unrestrained molecular dynamics 
simulation, using the protocol described in Section 4.3.5. 
 
2.3.8 Restrained Molecular Dynamics 
Following minimisation and unrestrained MD simulations, NMR restraints 
were introduced to the equilibrated structure and the system allowed to 
undergo restrained MD to satisfy the NMR restraints and search adequate 
conformational space under the influence of water molecules and cations.  A 
total of 248 NOE-derived distance restraints (124 per strand), each subject to a 
10% inherent error, were applied to nogalamcyin-d(TGATCA)B2 B, while 338 
restraints, 200 of which were subject to a 10% upper bound error and 138 with 
a 20% associated error bound, were applied toB Bnogalamcyin-
d(CCTGATCAGG) B2 B. Each system was subjected to rMD with all restraints 
active.  The former system underwent 2 ns of rMD and the latter was 
subjected to 1 ns simulation.  162 DNA-DNA distance restraints, 50 drug-drug 
and 36 drug-DNA restraints were applied to the hexamer complex.  The 
decamer was subject to 240 DNA-DNA distance restraints, 146 of which were 
subject to a 10% upper bound error.  Of the 52 drug-drug and 46 drug-DNA 
restraints applied to the longer model, 10% upper error bounds were 
associated with 24 and 30 respectively.  Autocorrelation plots, like that shown 
in Fig.2.5, showed that, in each case, independence from the starting structure 
was achieved after 350 ps. rMD was followed by energy minimisation.  
Snapshots were extracted throughout the rMD runs at picosecond intervals.  
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For the final averaged energy minimised structure of nogalamcyin-
d(TGATCA) B2 B, none of the applied distance restraints were violated by more 
than 0.5 Å, while only three deviated by more than 0.3 Å.  The mean pairwise 
RMSD, calculated for all heavy atoms, over the final 100 acquired snapshots 
was 0.60 (±0.1) Å.  The NMR restraints for nogalamcyin-d(TGATCA)B2 B were 
satisfied well within the two nanoseconds of simulation.  Similarly, in the final 
structure of nogalamcyin-d(CCTGATCAGG) B2 B, only five of the applied high-
quality (10% error) distance restraints were violated by more than 0.5 Å, while 
seven deviated by more than 0.3 Å.  All but one of the deviated restraints were 
associated with the fraying end residues of the complex.  The mean pairwise 
RMSD in this case, calculated over the final 100 acquired snapshots was 0.87 
(±0.1) Å.  This figure is reduced to 0.73 (±0.1) Å if only the core d(TGATCA) 
DNA atoms are considered. 
 
Fig.2.5:  Autocorrelation plot for the first 1 ps of the 2 ns rMD simulation of 
nogalamycin-d(TGATCA) B2B. 
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  nogalamycin- nogalamycin- 
  d(TGATCA) d(CCTGATCAGG) 
NOE-derived restraints    
drug-DNA 36 46 
DNA-DNA 162 240 
drug-drug 50 52 
Restraint Violations   
>0.3Å 3 7 
>0.5Å 0 5 
RMSD   
heavy atoms 0.60 (±0.1) Å 0.87 (±0.1) Å 
 
Table 2.1: Summary of modelling statistics for the final 100 ps of rMD trajectories of 
nogalamycin-d(TGATCA) (2 ps) and nogalamycin-d(CCTGATCAGG) (1 ps). 
 
2.4 Results & Discussion 
2.4.1 Titrations 
The 1D P1 PH NMR spectra for the free uncomplexed DNA duplexes 
d(TGATCA) B2 B, d(CTGATCAG) B2 B, d(CCTGATCAGG) B2 B,B Bd(CGATCG) B2 B, 
d(TCGATCGA) B2 B and d(CTCGATCGAG) B2 B are simplified, due to the self 
complementary nature of these sequences.  In each case, upon titration with 
nogalamycin, a 1:1 complex began to form, giving rise to a more complex 
spectrum, since there were now many more species of protons in magnetically 
different environments (Fig.2.6;2.7).  As the titration continued, the 2:1 
species was formed, and each spectrum simplified as symmetry was returned.  
Thus the complexity of the NMR spectrum alone was used as an indicator of 
the relative amounts of each complex at a given step in the titration.  The 
formation of a clean spectrum, with only one peak corresponding to each drug 
proton, indicates that a 2:1 complex, with dyad symmetry, was the final 
product.  In all previous structural studies of nogalamycin complexed in a 2:1 
ratio with symmetrical DNA oligomers (133;181;183;210;212;256), the 
intercalated nogalamycins have oriented themselves in opposite directions, so 
that the dyad symmetry of the free DNA is maintained in the complex.  The 
preservation of this 2-fold symmetry shows that both drugs intercalate in a 
symmetrical manner, either both oriented towards the centre, or both towards 
the ends, of the duplex.  In the case of the TpG-containing sequences, it can be 
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assumed that the drug is oriented towards the centre of the duplex.  However, 
for CpG-containing sequences, no assumptions are made about the binding 
orientation, except that they are the same for both drug molecules. 
 
 
 
Fig.2.6: 1D P1PH NMR spectra of the titration of d(TGATCA)B2B with nogalamycin (298 K, 
D B2BO), highlighting the aromatic region (6.8-8.0 ppm), at drug:DNA concentrations of 
(a) 0:1, (b) 1:2, (c) 1:1, (d) 4:3 and (e) 2:1.  The downward facing arrows highlight 
clearly defined signals that decrease upon addition of the nogalamycin.  Upward 
facing arrows indicate new signals that increase owing to complex formation. 
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Fig.2.7: 1D P1PH NMR spectra of the titration of d(CGATCG)B2B with nogalamycin (298 K, 
D B2BO), highlighting the aromatic region (6.7-7.9 ppm), at drug:DNA concentrations of 
(a) 0:1, (b) 1:2, (c) 1:1, (d) 4:3 and (e) 2:1.  Arrows are used as in Fig.2.6. 
 
2.4.2 Proton Assignments 
The NMR investigations of these drug-DNA complexes were undertaken by 
first characterising the free oligonucleotides.  This was followed by 
examination of the complexes formed upon reaction with nogalamycin.  The 
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duplexes and drug-DNA complexes were fully assigned using a combination 
of through space and through bond interactions from NOESY (Fig.2.8), 
TOCSY and DQF-COSY spectra, using a method loosely based on that 
described by Chazin & coworkers (34).   
 
 
 
Fig.2.8:  NOESY spectrum of d(CGATCG) B2B in D B2BO solution, recorded at 298 K with a 
mixing time of 300 ms. 
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It has previously been shown that H1' protons of B-form DNA typically come 
into resonance between 6.5 and 5.0 ppm, while H6/H8 protons resonate in the 
range 8.5-7.0 ppm (63).  Consequently, the starting point for the assignment of 
each of the uncomplexed DNA oligomers was the NOE interactions in this 
region of the NOESY spectrum i.e. the H6/H8-H1' assignment pathway 
(Fig.2.9).  The H6/H8 of the 5'-terminal residue will interact through space 
with the H1' of its own deoxyribose only, whereas subsequent H6/H8 protons 
will interact with both their own H1' protons and with the sugar protons of the 
preceding residue.   
 
 
 
Fig.2.9:  Schematic representation of the H6/H8-H1' assignment pathway starting at 
the 5'-terminal end of a DNA oligomer. 
 
Assuming that all NOEs in the H6/H8-H1' region have been detected, a 
crosspeak without a partner in the FB1 B dimension is likely to be the terminal 
intra-residue NOE.  The H6/H8-H1' assignment pathway can then be traced 
out to its terminus at the 3'-terminal H6/H8-H1' crosspeak (Fig.2.10).  Since 
their H5 protons resonate in the same frequency range as H1' protons, cytosine 
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residues will also show J-coupled peaks in this region of the DQF-COSY and 
TOCSY spectra.  These are useful indicators that the initial assignment is 
correct, as are thymine Me-H1' dipolar connectivities on the NOESY spectra. 
 
 
 
Fig.2.10:  Portion of the NOESY spectra of (a) d(CGATCG)B2B and (b) d(TCGATCGA)B2B, 
showing the H6/H8-H1' assignment pathway. 
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Once the initial connectivites have been verified, the P1 PH spin systems of the 
individual nucleotides can be traced out (Fig.2.11).  Often, all sugar protons 
can be identified on the DQF-COSY spectrum, but occasionally some H2" and 
H5" crosspeaks may be absent, dependant largely on the degree of sugar 
pucker (34).  However, if one of the H2'/2" or H5'/5" protons can be identified, 
the other can be easily assigned, as both protons will appear as pairs in the FB2 B 
dimension, separated by 0.0-0.9 ppm on the NOESY spectrum. 
 
H3
H5
H4
H5
H2
H2
H1
 
 
Fig.2.11:  Superimposed NOESY (black) and DQF-COSY (red/blue) spectra of P1PH 
spin system of the G2 (guanosine) nucleotide of d(CGATCG) B2B. 
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Fig.2.12:  NOESY spectrum of nogalamycin-d(TGATCA) B2B in D B2BO solution, recorded 
at 298 K with a mixing time of 300 ms. 
 
In the drug-DNA complex, H6/H8-H1' assignment pathway will be broken in 
two places, as a result of the increased separation between the nucleotides at 
the binding site required to facilitate nogalamycin intercalation.  This is caused 
by increased separation between the bases to facilitate the insertion of the 
drug.  The intensity of NOESY crosspeaks has been shown to be inversely 
proportional to rP6 P (11), and can typically only be observed for distances of 4.5 
Å or less.  However, the planar chromophore does have two non-exchangable 
protons, H3 and H11, which are detectable using the standard NOESY pulse 
sequence.  The nogalamycin H11 proton bridges the gap in the assignment 
pathway created by the increased base separation (Fig.2.13):  previous studies 
(210;241) have shown that the H11 proton is in close proximity to the H1' and 
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H6/H8 nuclei of the nucleotides at the intercalation site.  The sugar H1' 
protons form strong inter-molecular NOEs with the drug proton, giving rise to 
a new, extended assignment pathway in the H6/H8-H1' region of the NOESY 
spectrum, which can be traced out and related to the other DNA protons as 
before (Fig.2.14).  Additionally, it offers a good starting point for the 
assignment of nogalamycins 42 other non-exchangable protons.  Unlike 
d(CGATCG) B2 B and d(TCGATCGA) B2 B, the titration of nogalamycin into 
d(CTCGATCGAG) B2 Bdid not give rise to a clean P
1
PH spectrum indicative of a 
single species in solution.  Rather the spectrum (data not shown) was complex 
and broad, indicating that several species were present.  Given that the 1D P1 PH 
spectra of the shorter complexes (Fig.2.15), and of uncomplexed 
d(CTCGATCGAG) B2 Bwere so clean and sharp, this was considered to be as a 
result multiple orientations of the bound drug (Section 2.4.3). 
 
 
 
Fig.2.13:  Schematic representation of the H6/H8-H1' assignment pathway of a DNA 
oligomer intercalated with nogalamycin. 
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Fig.2.14: H6/H8-H1' region of the NOESY/DQF-COSY spectra of d(TGATCA)-
nogalamycin (2:1) complex. 
 
 
 
Fig.2.15:  Aromatic region (ppm) of the 1D P1PH spectra of (a) nogalamycin-
d(CGATCG) B2 B and (b) nogalamycin-d(TCGATCGA) B2. B 
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Nogalamycin always adopts the same orientation in a TpG intercalation site.  
The result of this is that the drug protons typically come into resonance in the 
same narrow band on the G scale, their chemical shifts largely unaffected by 
the nature of the adjacent bases.  Previous NMR studies of nogalamycin 
intercalated into DNA (181;241) prove extremely useful in assigning the 
complex studied here.  Additionally, many nogalamycin nuclei show unusual 
properties that can be used to distinguish them from other protons with similar 
chemical shifts.  For example, the tertiary amine of the aminoglucose sugar 
has a pKBaB of approximately 9.0, and is consequently protonated at the neutral 
pH at which these experiments are carried out.  At low temperatures, the N-
methyl substituents of the drug intercalated in a TpG site show two sharp 
peaks at G 2.8 and 3.0, because the rate of exchange of these two groups is 
slow.  However, at room temperature, the rate constant of exchange increases 
and the peaks begin to broaden and coalesce.  This phenomenon can be used 
to quickly identify these protons though they appear in a densely populated 
region of the spectrum. 
 
2.4.3 Drug Orientation 
Previous studies (210;212) have shown that when two nogalamycin molecules 
are intercalated into two symmetry-related TpG binding sites on a DNA 
hexamer, which are separated by a single ApT spacer, the drug molecules 
orient themselves such that their bulky sugars face towards the centre of the 
duplex.  However, since nogalamycin always adopts the same orientation in a 
TpG intercalation site (Section 2.1.2), there is no other possible orientation 
that the bound drugs can assume. 
 
Since the CpG intercalation site has two-fold symmetry, nogalamycin can 
theoretically adopt two orientations within the site, both of which fulfil the 
necessary criterion of allowing each sugar to reside in the correct DNA 
groove.  Though nogalamycin can theoretically bind in a terminally positioned 
CpG site such that its nogalose and aminoglucose sugars are oriented towards 
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the end of the oligomer, this is unlikely to happen due to so-called end effects.  
The NMR solution structures of the 2:1 complexes of nogalamycin-
d(CGTACG) B2 B have been determined by a quantitative treatment of two-
dimensional NOE crosspeak intensities (183).  The refined NMR structures 
retain major features of the crystal structure (133) in which the elongated 
aglycone chromophore is intercalated between the CpG steps with its nogalose 
and aminoglucose lying in the minor and major grooves, respectively, with 
each oriented towards the centre of the duplex.  In this case, if the two sugars 
of each intercalated nogalamycins pointed away from each other towards the 
end of the complex, they would overhang the ends of the DNA.  In the solid 
state, this would almost definitely affect crystal packing.  In the solution state, 
the interaction between the aqueous solvent and the numerous hydrophobic 
groups on the drug sugars would be unfavourable and potentially preclude the 
formation of this conformation.   
 
In the NMR-derived structures of the 2:1 complexes of nogalamycinB Bwith 
d(GCATGC) B2 B (181) and d(AGCATGCT) B2 B(256), the sugars of each 
intercalated drug point in opposite directions out towards the end of the DNA.  
Again, this is due to the unidirectional nature of the TpG intercalation sites, 
but it has been postulated (212) that even if these sites were replaced with their 
CpG cousins, to form d(GCGCGC) B2 B and d(AGCGCGCT) B2 B, this observation 
would be the same due to steric effects that would arise because the 
intercalation sites are adjacent and not separated by an ApT spacer as before.  
This phenomenon has been demonstrated by Williams & Searle (241), who 
demonstrated that the hexamer d(ATGCAT)B2 B is bound by nogalamycin in a 
1:1 ratio despite the fact it possesses two adjacent intercalation sites.  In this 
instance, steric effects caused by the insertion of the first drug molecule 
preclude binding of a second.  Furthermore, the suggestion has been made that 
these CpG-containing complexes would be unaffected by end effects, as the 
intercalation sites are not at terminal locations. 
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When nogalamycin is bound at a TpG or CpG site, the methyl and methoxyl 
groups of the nogalose sugar have been shown to interact with the minor 
groove side of the DNA bases stretching up to three base-steps from the 3' 
face of the chromophore.  This observation is used to determine the orientation 
of the drug within the intercalation site.  As we have stated, when a CpG 
binding site is located at the terminal of a DNA oligomer, it has been shown 
that nogalamycin prefers to bind in an orientation with its sugars pointing 
towards the middle of the helix, because in the opposite orientation the sugars 
will protrude beyond the terminal CG base pair.  However, in many of the 
hairpin structures studied recently (41;69), nogalamycin intercalates into a 
TpG site adjacent to the terminal base pair, with its sugars oriented towards 
the end of the oligomer.  This raises the question of how far away a binding 
site must be from the terminus of an oligomer in order to negate the 
contribution of end effects to drug orientation, and whether there are other 
cooperative factors at work that influence the binding site orientation. 
 
The orientation of the nogalamycin in the intercalation site can be verified by 
reference to drug-DNA NOEs in the NOESY spectra.  An essentially complete 
assignment of drug and DNA resonances for all six of the complexes studied 
here provides the starting point for identifying intermolecular NOEs that 
define the position and orientation of the bound antibiotic. 
 
Since nogalamycin can adopt only one orientation within a TpG site, the 
pattern of NOEs on the fully assigned NOESY spectra of d(TGATCA)B2 B, 
d(CTGATCAG) B2 B and d(CCTGATCAGG) B2 B proved to be a useful tool for 
determining the orientation of the drug in each of the CpG-containing 
sequences.  Similar patterns on the NOESY spectra of d(CGATCG) B2 B, 
d(TCGATCGA) B2 B and d(CTCGATCGAG) B2 B  would indicate that the drug 
molecules were oriented towards the centre of these oligomers, while differing 
patterns would suggest a different orientation.  For each pair of TpG- and 
CpG-containing oligonucleotides, d(TGATCA) B2 B & d(CGATCG)B2 B,B 
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Bd(CTGATCAG) B2 B& d(TCGATCGA) B2 B, and d(CCTGATCAGG) B2 B& 
d(CTCGATCGAG) B2 B, the pattern of NOEs in key regions of their NOESY 
spectra were broadly similar, indicating similar drug orientations in each.  The 
pattern of these interactions will be described in the context of the CpG-
containing sequences. 
 
The H6/H8-H1' assignment pathway of the d(CGATCG)B2 B complex 
(Fig.2.16(a)) provides a strong indication of the orientation of the drug.  If the 
intermolecular H1'ļnogalamycin-HBB11 and nogalamycin-H11ļH6 NOEs 
occur, as they do, across the C1pG2 step of the intercalation site, then the 
nogalose must point towards the centre of the helix.  If the nogalose and 
aminoglucose did overhang the ends of the DNA, these intermolecular 
interactions would be observed across the complementary C5pG6 step, and 
such is not the case.  This is also the case for the d(TCGATCGA)B2 B and 
d(CTCGATCGAG) B2 B complexes (Fig.2.16(b)), giving us an early indication 
that the mode of complexation is the same in these longer sequences. 
 
Since deoxyribose H1' and H3' protons form part of the floor of the minor 
groove in B-form DNA, the presence of NOE crosspeaks between these 
protons on specific residues, and substituents on the nogalose sugar can be 
used to verify that the nogalose resides in the minor groove and determine 
whether it is oriented towards the centre or towards the ends on the duplex.  
The pattern of intermolecular NOEs between the methoxy protons at the 2', 3' 
and 4' positions of nogalose, and the H1' and H3' protons on the central A3, T4 
and G5 nucleotides of d(CGATCG) B2 B (Fig.2.17(a)) can only be satisfied if the 
nogalose resides in the minor grove and points towards the centre of the 
duplex.  This observation holds for the complex of nogalamycin with 
d(TCGATCGA) B2 B (Fig.2.17(b)).  Additionally, in the longer sequence, there are 
no crosspeaks evident between the drug methoxy protons and those in the 
minor groove at the termini of the oligonucleotides.  In the NOESY spectrum 
(298 K, 300 ms) of d(TCGATCGA) B2 B, for example, there are no interactions 
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between the H1' protons on the terminal bases, T1 and A8, and the nogalose 
methoxy protons.  This shows conclusively that, in this case, the nogalamycin 
is oriented towards the centre of the duplex.   
 
 
Fig.2.16:  Portion of the NOESY spectrum (298 K, 300 ms) of (a) nogalamycin-
d(CGATCG) B2B and (b) nogalamycin-d(TCGATCGA) B2B, showing the H6/H8-H1' 
assignment pathway, and highlighting the drug H11 proton. 
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Fig.2.17:  Portion of the NOESY spectra (298 K, 300 ms) of (a) d(CGATCG)B2B and (b) 
d(TCGATCGA) B2B, highlighting interactions between nogalose methoxy protons and H1' 
protons on the floor of the minor groove in the conserved central portion of each 
oligomer. 
 
2.  Binding Studies of Nogalamycin with DNA 44
The NOESY spectrum of nogalamycin-d(CTCGATCGAG) B2 B proved 
impossible to fully assign, due to the presence of multiple species in solution.  
However, enough of the H1'-H6/H8 assignment pathway could be traced out 
to allow the interactions of nogalose with the floor of the minor groove to be 
examined.  Although the NOESY spectrum (288 K, 300 ms, pH 6.8) is broad, 
tentative assignments can be made between the drug methoxy protons and 
DNA H1' protons, demonstrating that the drug intercalates in both 
orientations, apparently without discrimination (Fig.2.18).  NOEs can be 
identified between the methoxy protons and both the central G4, A5 and T6 
residues and the T2, C7 and A9 nucleotides at the ends of the oligomer, 
strongly indicating that at least two species, with nogalamycin oriented both 
towards the centre and towards the ends of the duplex are present. 
 
In contrast to the extensive drug-DNA interactions in the minor groove, the 
number of contacts in the major groove is rather limited, though NOEs 
between the N-methyl protons and the central adenine and thymine H2" 
protons on the NOESY spectra of d(CGATCG) B2 B and d(TCGATCGA) B2 B (data 
not shown) are consistent with the orientation of the antibiotic suggested by 
the NOE patterns in the minor groove.   
 
Since the orientation of nogalamycin remains unchanged by the addition of a 
single base pair at the ends of the d(CGATCG)B2 B core, it would seem that this 
appendage is insufficient to encapsulate nogalamycin completely within the 
length of the oligomer when the drug is oriented towards its ends, and so 
counteract the end effects caused by the drug sugars overhanging the ends of 
the duplex and out into solution.  However, when two base pairs are added at 
each end, the nogalamycin can be completely incorporated within the length of 
the oligonucleotide with no overhang, and so end effects no longer affect 
binding orientation.  The presence of multiple species, with multiple binding 
orientations, indicates that each drug molecule is largely unaffected by the 
presence of the other in the adjacent site, and that end effects are the driving 
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force that determine the orientation of nogalamycin in terminally-located CpG 
intercalation sites.  Since the sites are separated by two base pairs, it stands to 
reason that the drug molecules are far enough apart to prevent direct 
interaction between their sugars, as the same level of separation between drug 
and solvent is sufficient to overcome the end effects.  The change to the 
topology of the DNA, which is necessary to facilitate intercalation, would 
appear to be localised, and not propagated to the adjacent site in a manner that 
affects binding orientation. 
 
 
 
Fig.2.18:  Portion of the NOESY spectrum (288 K, 300 ms) of d(CTCGATCGAG)B2B, 
highlighting interactions between nogalose methoxy protons and H1' protons on the 
floor of the minor groove. 
 
2.4.4 Evidence for Cooperative Interactions 
If we consider a system in which two equivalents of a drug are titrated into a 
DNA oligonucleotide containing two binding sites specific to that drug, then 
the rates of formation of each species can be defined in terms of two 
equilibrium binding coefficients, KB1 B and KB2 B, as described in Scheme 2.1.  By 
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defining a cooperativity coefficient, ĳ, equal to KB2 B/KB1 B, we can formulate a 
simple definition of what constitutes cooperativity:  for independent sites 
KB2 B=KB1 B, and consequently ĳ=1.  Similarly for cooperatively associated sites, 
KB2 B>KB1 B and ĳ>1, while for anticooperative interactions ĳ<1. 
 
 
 
Scheme 2.1:  Binding of a drug to a DNA oligomer with two drug specific binding 
sites. 
 
In an attempt to assess qualitatively the degree, if any, of cooperativity 
between two nogalamycin binding sites separated by an ApT spacer, we have 
constructed three binding models, which relate binding site occupancy at 
different drug:DNA ratios to cooperativity.  In the first model the drug 
partitions between two equally probable binding sites (ĳ=1).  In the second 
model, binding of the first drug increases the probability of a second binding 
event to unity (ĳ>>1), and in the third system, this probability is decreased to 
zero by the first binding event (ĳ<<1). 
 
As described in Section 2.3.5, 1D P1 PH NMR spectra of the forming drug-DNA 
complexes were collected following the titration of aliquots of nogalamycin.  
Well-separated resonances of protons from each of the free DNA, 1:1 and 2:1 
drug:DNA complexes were identified (Section 2.4.1) and integrated for each 
step of the titration. To plot a graph of the binding profile of nogalamycin with 
d(TGATCA) B2 B, for example, three peaks, representing one proton from each of 
the free DNA, 1:1 complex and 2:1 complex, were chosen and monitored 
throughout the titration (Fig.2.6).  The area under each peak was measured at 
each stage of the titration and used to quantify the percentage of each species 
present.  This allowed each step of the titration to be treated as a separate 
system, independent of any other step, and thus unaffected by any possible 
errors in experimental procedure or data handling.  The relative concentrations 
of nogalamycin and the oligonucleotides were plotted as a function of the 
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mole fraction of binding sites occupied.  For comparison with the three 
binding models.  If we consider a system with two equally probable binding 
sites that are not cooperatively linked (Fig.2.19(a)), and define x as the mole 
fraction of drug per binding site, we can derive binding curves that describe 
each. 
 
 
Fig.2.19:  Theoretical partitioning of nogalamycin between two equally probable 
binding sites. The graph shows free duplex replaced by 1:1 and 2:1 complex.  
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Assuming that the two binding sites are entirely independent of each other, it 
would be expected that, as the titration continues, the amount of free DNA 
would fall continuously.  Conversely, the amount of the 2:1 complex, would 
be expected to increase as the titration progresses.  The 1:1 complex, being an 
intermediate species and the first step in the production of the final product, 
should initially rise, as there is an excess of the free DNA from which it is 
formed early in the reaction.  However, as the titration continues, the free 
DNA becomes depleted and, consequently, the rate of production of the 1:1 
complex drops.  At the same time, following an initial lag-phase, the 
production of 2:1 complex will increase as the concentration of 1:1 complex 
decreases.  The combination of these two factors will lead to a maximum 
concentration of the intermediate 1:1 species half-way through the reaction, 
followed by its inevitable depletion (Fig.2.19).   
 
Cooperative drug binding in adjacent binding sites, as we have defined it for 
this qualitative study, can be identified by a reduction in intensity or absence 
of any recordable resonance of the 1:1 complex, and by the presence of the 2:1 
complex from low drug:duplex ratios during the titration.  Since neither site on 
an individual duplex can be occupied independently of the other, pairs of 
drugs and pairs of binding sites can be treated as single entities (Fig.2.20).  
Upon drug titration, resonances corresponding to the free DNA should 
decrease while new resonances corresponding to the 2:1 complex appear.  At 
the point of one equivalent of drug per duplex, we should be able to detect 
resonances corresponding to both the free and bound DNA.  Observing easily 
distinguished regions of the spectrum, such as the methyl region and the 
aromatic region, enables new resonances to be followed.  Typically, 
resonances of the complex formed can also be observed in previously 
unoccupied spectral regions (241).  Addition of further quantities of the drug 
would be expected to result in a decrease in the intensity of the signals of the 
free DNA until, at a ratio of two nogalamycin molecules per duplex, a single 
species corresponding to the 2:1 complex is retained (Fig.2.20).   
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Fig.2.20:  Cooperative binding of nogalamycin into two adjacent binding sites. The 
graph shows free duplex replaced by 2:1 complex.  
 
The shape of the anticooperative and cooperative binding curves are very 
similar.  However, given that two binding sites on the same duplex cannot be 
occupied simultaneously in the anticooperative model, only 50% of the total 
available sites will be occupied at the end on the titration (Fig.2.21).  As such, 
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the slopes of the graphs describing anticooperative binding will have twice the 
magnitude of those in the cooperative model, in which all sites are occupied 
following titration with nogalamycin.  This is based on ad hoc assumptions 
about the nature of the final products and, as such, cannot be used to 
distinguish between the two modes of binding.  For the anticooperative model, 
the addition of 2 equivalents of nogalamycin to the duplex does result in loss 
of the 2-fold element of symmetry upon complex formation.  Each signal on 
the 1D P1 PH NMR spectrum should therefore be replaced by two corresponding 
resonances for the complex in an anticooperative system.  This observation 
can be used to distinguish between the various modes of binding. 
 
If no communication exists between the sites, then our first model (Fig.2.19) 
should hold.  Since this model is empirically different to the other two, no 
additional means of identification is required.  However, the curves 
representing cooperativity and anticooperativity are very similar and must be 
distinguished by a combination of graph-fitting and examination of the P1 PH  
spectrum.  If there is cooperativity between the sites, only two species will be 
detectable in the P1 PH NMR, one corresponding to the free DNA and one to the 
emerging 2:1 complex, as a second drug introduced to the system after the first 
binding event will preferentially bind to the second site in the same DNA 
ligand, rather than bind to a different piece of free DNA.  The P1 PH spectrum of 
the complex should have one signal for each DNA proton, as the dyad 
symmetry is preserved.  If there is an anticooperative relationship between the 
binding sites, again only two species will be detectable as the titration 
progresses.  In this instance, formation of the 2:1 complex is precluded by the 
formation of the 1:1 complex.  Therefore, each DNA proton signal in the 
uncomplexed species should have two corresponding resonances in the P1 PH 
NMR of the complex, as the 2-fold symmetry do not exist in the 1:1 complex. 
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Fig.2.21:  Anticooperative binding of nogalamycin into two adjacent binding sites. The 
graph shows free duplex replaced by 1:1 complex.  
 
These models describe the extremes of cooperativity and anticooperativity 
(ĳ>>1 or ĳ<<1).  However, even these simple models can be applied to more 
complicated systems, where the degree of the cooperative interaction lies 
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somewhere between the two extremes of total preclusion or necessary 
inclusion of the second binding event.  As the degree of cooperativity 
increases, the apex of the curve representing the 1:1 complex (Fig.2.19) would 
lower, while the curves representing the free DNA and 2:1 complex would 
begin to lose their parabolic property, flattening out to become linear when the 
peak level of the 1:1 species is zero (Fig.2.20). 
The oligonucleotides, d(TGATCA)B2 B, d(CTGATCAG) B2 B, d(CCTGATCAGG) B2 B,B 
Bd(CGATCG) B2 B, d(TCGATCGA) B2 B and d(CTCGATCGAG) B2 B,  were each titrated 
with nogalamycin as described.  In each case, as the titration continued, the 
amount of free DNA fell continuously, while the amount of 2:1 complex 
increased.  The 1:1 complex was detectable throughout each titration.  The 1:1 
complex initially rose, and was then depleted, consistent with an intermediate 
species in the production of the 2:1 complex.  The level of production of the 
2:1 species was not constant throughout the duration of the complex, nor was 
the rate of depletion of free DNA.  Rather, production of the 2:1 species 
increased markedly during the second part of the titration, when the 1:1 
species began to deplete.  Conversely, depletion of the uncomplexed species is 
greatest during the early part of the titration, when 1:1 complex production is 
greatest.  The combination of these two factors will lead to a maximum 
concentration of the intermediate species half-way through the reaction.  In 
each case, the peak concentration of 1:1 complex occurs at between 48% and 
55% of total site occupancy, and is in the range 43-50%.  The total 
concentration of the 1:1 species never exceeds 50%, which is in good 
agreement with our models for independent binding sites.  This simple, 
empirical analysis of the titration curves clearly displays a system with two 
independent binding sites.  The data were fitted by least squares regression 
analysis to a polynomial function (Equation 2.2).  In each case the RP2 P value 
was in excess of 0.98, indicating a good fit of the data to the curves.  None of 
the curves described display any characteristics that would suggest any degree 
of cooperativity or anticooperativity. 
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Equation 2.2:  Second order polynomial fitted to titration curves.  a B1B, a B2B and a B3B are 
integers. 
 
 
contd. 
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Fig.2.22:  Actual partitioning of nogalamycin between two adjacent binding sites on 
(a) d(TGATCA) B2B, (b) d(CTGATCAG) B2B, (c) d(CCTGATCAGG) B2B,B B(d) d(CGATCG) B2B, (e) 
d(TCGATCGA) B2B and (f) d(CTCGATCGAG) B2B. 
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2.5 Conclusions 
We have demonstrated here that end effects are the primary driving force for 
determining the orientation of nogalamycin in neighbouring, terminally 
located, CpG intercalation sites.  Two base pairs provide sufficient separation 
to completely disconnect nogalamycin from the solvent when it is oriented 
such that its sugars point toward the end of a DNA oligomer.  This allows each 
drug to intercalate in two orientations in its symmetrical CpG(CpG) 
intercalation site, each of which satisfy the requirement for nogalose to reside 
in the minor groove.  It is unclear whether a conformer exists where both 
drugs are oriented towards the same end of the oligomer.  No previous studies 
have been reported in which this has been observed.  We can, however, state 
that two base pairs provide adequate separation between binding sites such 
that the intercalation event at one site does not affect the other. 
 
Non-adjacent intercalation sites bind nogalamycin in a non-cooperative 
manner.  The inclusion of an ApT spacer between two binding sites, either 
TpG or CpG, effectively allows them to achieve independence in terms of 
drug binding, which cannot be achieved in sequences with adjacent sites 
(256).  This property of site independence is unrelated to the orientation of the 
bound drugs, as demonstrated by the binding curves of d(CTCGATCGAG), in 
which the drug can adopt multiple orientations.   A minimised structure of the 
1:1 complex of nogalamycin with d(TGATCA)B2 B shows that the unoccupied 
TpG site is qualitatively similar to those found in the uncomplexed B-like 
DNA (data not shown).  The absence of any cooperativity between the sites 
would suggest that the second TpG site is largely unaffected by the 
intercalation event at the first, or at least not in any way that affects its binding 
affinity for the drug.   
 
In this study we have determined a family of high-resolution structures of each 
of the complexes of nogalamycin with d(TGATCA)B2 Band d(CCTGATCAGG) B2 B.  
The structures of nogalamycin-d(TGATCA)B2 Band nogalamycin-
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d(CCTGATCAGG) B2 Bare broadly similar, and the conserved central residues 
and intercalated drugs can be superimposed with an RMSD fit of 0.67 (±0.1) 
Å. 
 
Fig.2.23:  20 randonly chosen DNA structures from the last 500 ps of a 2 ns rMD 
simulation of nogalamycin-d(TGATCA)2 superimposed on the averaged structure of 
nogalamcyn from that portion of the rMD simulation. 
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Fig.2.24:  The average minimised structure from the last 100ps of a 1ns rMD 
simulation of nogalamycin-d(CCTGATCAGG) B2B.
3.  DNA Hairpin Loops and Bulges; Implications 
for Frameshift Mutagenesis 
 
3.1 Introduction 
3.1.1  Hairpin Loops in Nucleic Acids 
Hairpin loops are a basic unit of nucleic acid structure and have been shown to 
play important roles in a great number of important biological functions (251).  
Hairpins comprise a single-stranded loop region closed by a base-paired stem 
(Fig.3.1).  The stability of hairpin structures have been shown to increase with 
the number of base pairs in the stem region (27).  Thus, long complementary 
regions flanking either side of the loop region are good predictors of loop 
formation.  However, recent studies have shown that certain DNA and RNA 
hairpins, which contain specific loop sequences, are unusually stable (229).   
 
Hairpin structures in DNA and RNA, consisting of stem and loop regions, 
occur naturally in single-stranded DNA and RNA.  These structures are 
considered to have important biological functions (98).  The structures of 
unusually stable hairpins have been extensively studied, including the tetra-
nucleotide loops d(GAAA) (100), d(GTTA) (96), r(UNCG) (37;185;226) and 
r(GNRA) (94) (where N is any nucleotide and R is a purine nucleotide).  The 
latter two structures have been identified in ribosomal RNA (37;94), RNA 
coliophages (3), hammerhead ribozymes (95), group I catalytic introns (148), 
and in bacteriophage T4 mRNA (226). 
 
DNA sequences, such as d(CGGAAGC) and d(CGGAAGC) form 
extraordinarily stable DNA mini-hairpins (99;101;251).  Hirao et al. (101) 
compared a variety of sequence variants of the d(GCGAAGC) and 
r(GCGAAGC) hairpins.  Rapid mobility of these structures in denaturing 
electrophoretic conditions was observed.  The GAAA and GAA loops were 
found to be more stable than hairpins of other sequences and the different 
stabilities noted for DNA and RNA mini-hairpins were proposed to arise from 
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the different conformations of the stem structure in each.  The structure of the 
d(GCGAAGC) oligonucleotide was determined by NMR spectroscopy (98). 
The determined hairpin structure was folded back between the A4 and ABB5 
adenosines, and stabilised by two Watson-Crick base pairs in the stem region, 
and an additional non-Watson-Crick wobble G-A base pair in the GAA loop 
(Fig.3.2). Extensive base stacking interactions in the stem region were 
observed to further stabilise the hairpin structure. 
 
 
 
Fig.3.1: Schematic of the DNA mini-hairpin.  Cytosines are shown in red, guanines in 
blue, and adenines in yellow. 
 
The d(CGGAAGC) and d(CGGAAGC) hairpin sequences have been shown to 
occur frequently in biologically important regions, such as replication origins 
and promoter regions.  The GAAA hairpin loop exists in the replication 
origins of G4 phage ssDNA (97).  The GAA loop has been identified in the 
replication origins of herpes simplex virus (57) and bacteriophage ĳX174 
DNA (6), and in the promoter region of E-coli heat-shock gene (48). 
 
In a study by Yoshizawa et al. (251), all 64 variants of the sequence 
d(GCNNNGC), where N is one of the four DNA bases, were synthesised and 
characterised in terms of their ability to form stable hairpin structures.  
Mobility studies on polyacrylamide gels were again conducted to determine 
which DNA fragments formed a more compact structure. They also examined 
the resistance of each fragment to exonuclease activity using DNA 
polymerase.  NMR studies allowed the elucidation of much structural 
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information and highlighted the importance of the base-stacking interactions. 
Overall, these workers found that only hairpins with GNA loops formed 
extraordinarily stable trinucleotide-loop hairpins.  The hairpin structures 
described in this paper have increased thermostability and, again, show high 
resistance against nucleases.  The four fragments containing GAA, GGA, 
GCA and GTA loop sequences, d(CGGNAGC), were shown to have T BmB 
values of 76, 73, 71 and 70 °C respectively.  Some fragments, other than GNA 
hairpins, also formed loops, but these were markedly less stable, with TBmB 
values in the range 47-59 °C.  The enhanced stability of GNA loops is 
proposed to arise as a result of the formation of a sheared G-A pair (Fig.3.2).   
 
 
 
Fig.3.2:  Sheared G-A base pair. 
 
Moody & Bevilacqua (150) investigated whether the network of interactions 
involved in GNA loop folding and stabilisation communicated with each other 
to facilitate loop formation.  On the basis of base substitutions, they proposed 
that all interactions were interdependent and that these interactions formed in a 
highly co-operative manner.  They demonstrated that substituting either the 
guanine or the adenine in the sheared G-A pair for inosine, and thus deleting a 
single NH···N hydrogen bond, not only weakens the H-bonding array, but 
also weakens other interactions.  Based on these observations, we can propose 
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that the energetic contribution of a hydrogen bond in the context of a G-A base 
pair is artificially elevated by the co-operativity of loop formation.   
 
Other G-A functional group substitutions, which do not affect H-bonding, but 
do affect the electrostatic surface potential (ESP) of the bases, indicate that the 
vertical interaction of the G-C closing base pair with the guanine at the first 
position of the loop accounts for most of the hairpin stability (151) .  These 
investigations further suggest that these stacking interactions are mediated in 
part by the carbonyl and imino functional groups of the loop G.  By combining 
the data from these two sets of mutations, it is possible to deduce that 
favourable stacking interactions between the closing G-C pair and the loop 
guanine form the major stabilising factor in GNA loops; but that these 
interactions are facilitated by H-bonding within the loop, which hold the 
guanine in a complimentary orientation, by means of a sheared base pair. 
 
3.1.2  Summary of Structural Properties 
The examination of the structures of numerous nucleic acid hairpins have 
shown that the exceptional stability observed for such structures is a 
consequence of several stabilising interactions, the most obvious of which are 
the Watson-Crick base pair interactions in the stem region of the hairpin.  
Non-Watson-Crick base pairs, base-phosphate and base-sugar contacts further 
stabilise the loop section.  The loop of the GNA mini-hairpin is composed of a 
single nucleotide, i.e., the central N.  The first (G) and third (A) nucleotides 
take part in a non-Watson-Crick base pair and the entire structure is stabilised 
by base stacking interactions.  
 
3.1.3  Therapeutic Applications of DNA hairpins 
The property of nuclease resistance makes these hairpin structures amenable to 
the stabilisation of oligonucleotides.  Poddevin et al. (174), synthesized a 
series of 20-mer antisense phosphodiester oligonucleotides constituting of a 5'-
dodecameric sequence, complementary to the acceptor splice junction of 
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herpes simplex virus type 1 (HSV-1) pre-mRNAs, flanked on the 3' end by 
octameric sequences adopting hairpin-like structures of different stabilities.  
The presence of the minihairpins on the 3' end of the 20-mer phosphodiester 
oligonucleotides protected them against serum nuclease degradation, this 
protection being well correlated to the reported melting temperatures of the 
minihairpins, and to the gel mobilities of the 20-mer oligonucleotides.  The 
addition onto the 3' terminal of the most stable minihairpin increased more 
than eightfold the nuclease resistance of the linear antisense dodecamer.  This 
method has been further applied to the protection of antisense DNA 
oligonucleotides (4;118;119) and primers.  DNA oligonucleotides harbouring 
a hairpin sequence at the 3' terminus have been shown to prime the 
amplification of a wide range of templates ranging from plasmid DNA to plant 
and animal genomes (28). 
 
3.1.4  Bulged Bases in Duplex DNA 
Bulged structures in DNA are of general biological significance and are 
potential targets for therapeutic drugs.  They are common, non-helical features 
of RNA and DNA, and they may vary from single nucleotide bulges to 
multiple base bulges.  Bulges are known to be important in RNA for protein 
binding and tertiary folding (31;32).  In DNA, bulged bases play a role in 
frameshift mutagenesis in sequences with repeating base pairs (158).  DNA 
duplex regions often contain bulge loops in which there are one or more 
consecutive bases on one strand with no complementary bases, with which to 
form base pairs, on the other strand.  The smallest bulge loop has one unpaired 
base and is termed a single nucleotide bulge.  Structural studies have shown 
that single base bulges can assume two different conformations: They may 
form stacked-in structures, in which the unpaired base is stacked between 
adjacent bases, or looped-out structures, in which the unpaired base faces 
away from the helical axis.  There have been relatively few reports involving 
the characterisation of the interactions of bulged oligonucleotides with ligands.  
3.  DNA Hairpin Loops and Bulges 64
3.1.5  Adenine Bulges 
Patel et al. (163) collected proton and phosphorus NMR parameters of the 12-
mer duplex d(CGCGAATTCGCG) B2 B and the 13-mer duplex 
d(CGCPAPGAATTCGCG) B2 B to determine whether the extra non-complementary 
dA between base pairs 3 and 4 in the 13-mer duplex would disrupt the 
formation of a stable helix, loop out into solution or stack into the helix 
without causing a disruption. They observed that the inclusion of an additional 
dA residue into the helix did not rupture the adjacent Watson-Crick base 
pairing interactions, and that the adenosine stacked into the 13-mer duplex 
rather than form a bulge loop.  The H8 and H2 protons of the extra adenosine 
underwent large upfield shifts on formation of the 13-mer duplex from the 
melted single strand.  This unambiguously demonstrates the base stacked into 
the duplex, with the ring currents from the adjacent dG and dC base pairs 
shifting the adenosine base protons upfield.  A 15 ºC decrease in thermal 
stability for the duplex state was induced by the presence of the stacked, extra 
adenosine residue.  A similar study (90) was carried out on the sequence 
d(CGCPAPGAGCTCGCG) B2 B, in which the central AATT segment of Patels 
oligomer is replace with an AGCT segment.  Again the extrahelical dA 
stacked in without causing disruption to the flanking base pairs, but the 
duplex-strand transition midpoint was elevated, consistent with the 
introduction of two stronger C-G base pairs 
 
Furthermore, it has been demonstrated that an extrahelical adenosine stacks 
into the helix at all temperatures below the onset of the melting transition in 
solution, regardless of whether the non-pairing base is flanked by cytidines or 
guanosines (108).  For the self-complementary sequence 
d(CCGPAPGAATTCCGG) B2 B, NOEs were observed between the H2 proton of the 
extra dA and the imino protons of the flanking guanosines.  The oligomer 
d(CCGGAATTCPAPCGG) B2 B, in which the extrahelical base is sandwiched 
between two cytidine resiues, revealed through-space interactions between the 
H2 proton of dA and the imino protons of the guanosines that were base paired 
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with the flanking cytidines in the NOESY spectrum.  In each case the extra 
adenosine bulge site adopts a wedge conformation (Fig.3.3), confirmed by 
observed NOEs between adjacent base protons in the cytosine-cytosine in the 
former (GAG) 13-mer, and between protons in the guanosine-guanosine step 
in its sister (CAC) oligomer.  Interestingly, these NMR data are contradicted 
by X-ray crystal structures published at about the same time (106;149), in 
which the extrahelical adenosine adopts a looped-out formation.  This reflects 
a fundamental difference between solution and solid-state environments. 
 
 
 
Fig.3.3: Extrahelical adenosine flanked by cytosines (a), and guanosines (b). 
 
3.1.6  Guanine Bulges 
Like extrahelical adenosines, unpaired guanosines in B-form DNA duplexes 
have been shown to stack into the helix in a wedge conformation (247).  In 
each case the helix axis was bent by 18-23 ºC, in good agreement with gel 
mobility data obtained for the sequences (122).   
 
3.1.7  Cytosine Bulges 
Morden et al. (152) determined the conformation of the oligonucleotide 
duplex d(CAB3 PB
C
PAB3 BG)·(CT B6 BG), which contains an extra, unpaired cytosine 
residue.  The conformation was investigated by using NMR methods to 
observe both the aromatic base protons and the base-pairing imino protons.  
The presence of NOE interactions between imino protons on either side of the 
potential intercalation site for the dC residue indicates that this extra base flips 
out into solution.  If the cytosine were stacked into the helix, the distance 
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between base pairs 4 and 5 would be almost 7 Å, and no such NOEs would 
have been observed.  The extrahelical cytosine was shown to cause a decrease 
in the duplex melting temperature of 15 ºC. 
 
The self-complementary duplex d(CCGPC PGAATTCCGG) B2 B has an extra 
cytidine on each strand in its duplex form, and was studied by Kalink et al. 
(109).  NOE and chemical shift parameters establishes that the predominant 
conformation at 273 K has the extra cytidine looped out of the helix.  
Specifically, the H5 and H6 proton chemical shifts correspond closely to the 
high temperature (343 K) unstacked strand values.  The conformational 
equilibrium shifted towards a structure with a stacked in extrahelical cytidine 
on raising the temperature to 313 K prior to helix-coil melting transition, as 
evidenced by the marked upfield shift in H5 and H6 proton resonances. 
 
3.1.8  Thymine Bulges 
Studies on the preferred conformation of extrahelical bases have also been 
carried out on oligomers with unpaired thymidines.  Kalnik et al. (107) used 
two 13-mers with extra dT residues, but otherwise self-complemenatry, to 
observe the effect of flanking bases and temperature on thymidine bulges.  For 
the oligonucleotide d(CCGPTPGAATTCCGG) B2 B, the thymidine methyl protons 
had a chemical shift very close to its strand value at  278 K.  This resonance 
shifted upfield by 0.2 ppm upon raising the temperature to 308 K.  This 
demonstrates that when the extra thymidine is flanked by guanosines, the non-
pairing base is in a conformational equilibrium between looped-out and 
stacked states.  The looped-out state is favoured at lower temperatures, but the 
equilibrium shifts to the stacked form at elevated temperatures.  However, 
when the thymidine is flanked by cytosines, as was the case for the 13-mer 
d(CCGGAATTCPTPCGG) B2 B, it remains looped-out regardless of temperature in 
the duplex state.  This was demonstrated by the observation of a temperature 
independent chemical shift of the methyl protons between 278K and 338K, at 
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which temperature the oligomer has exceeded its TBmB and is essentially in the 
strand state. 
 
3.1.9  Relative Stabilities of Bulged Bases 
Wartell and co-workers (112;257) have studied DNA and RNA fragments 
containing single base bulges with a view to assessing how their thermal 
stability is affected by the nature of an included extrahelical base and the 
identity of its flanking bases.  The stabilities of 48 RNA oligomers with 
bulged bases at one of six positions, and 32 DNA oligomers differing by a 
single unpaired base were determined by temperature gradient gel 
electrophoresis (TGGE), using a temperature gradient of 36-41 ºC.  Once 
loaded, the fragments moved into the gel until they reached a temperature at 
which their first melting domain unwound.  This unwinding drastically 
reduced their mobility, so the further an olionucleotide migrated, the greater 
its stability.  In both DNA and RNA, purine bulges were shown to be 
generally less destabilising than pyrimidine bulges.  Additionally, sequences 
containing at least one neighbouring base identical to itself were more stable 
than those where the extrahelical base is different than its nearest neighbours.  
For B-form DNA in solution, it can be said that extrahelical purines are 
generally stacked into the helix, while extrahelical pyrimidines are in 
equilibrium between stacked and looped-out states. 
 
3.1.10 Complexes with Bulged DNA  
Bulged or looped out nucleotides have been proposed to be intermediates in 
frame-shift mutagenesis, arising from the movement of one strand relative to 
the other in homopolymeric DNA sequences (218).  It is possible that drug 
intercalation would increase the lifetime of the mismatched state, increasing 
the probability of a base addition or deletion.  As a result, drug interactions at 
nucleotide bulges have been intensively studied. 
 
3.  DNA Hairpin Loops and Bulges 68
Nelson and Tinoco (156) demonstrated, by competition dialysis, that ethidium 
bromide has a higher affinity for an oligonucleotide containing an extrahelical 
cytidine at the intercalation site compared to a normal duplex of the same 
sequence.  The drug binds approximately an order of magnitude more tightly 
to a bulged site than to a regular duplex binding site. 
 
Woodson and Crothers (246) examined the binding of the intercalator 9-
aminoacridine (9-AA) (Fig.3.4) to guanosine bulges by studying a series of 
small synthetic oligomers containing bulged bases at fixed and unfixed sites.  
9-AA has been shown to bind to DNA at GpC, and to a lesser extent CpG, 
steps (252). Initially pairs of oligomers with perfect Watson-Crick base 
pairing and with guanosine bulged at fixed sites, such as 
d(GATGGGCAG)·(CTGCCCATC) and its bulge containing sister 
d(GATGGGCAG)·(CTGC PGPCCATC), were studied and characterised.  
Competition dialysis between regular and bulged helices showed that, like 
ethidium, 9-AA has a higher affinity for bulged sequences than for normal 
oligomers of similar sequence and length.  Subsequently, similar 
oligonucleotides differing only by the presence or absence of bulged bases in 
their homopolymeric tracts, like d(GATGGPGPGCAG)·(CTGCCCATC) and 
d(GATGGGCAG)·(CTGCCPC PCATC), were studied by NMR methods.  The 
NOESY spectra of these sequences proved impossible to fully assign, 
presumably due to conformation averaging in these regions.  It has been 
suggested that there is no preferred binding site for the drug in these 
sequences, and that the drug most probably intercalates at a number of 
positions along the GC run.  Again, however, competition dialysis confirms a 
higher affinity for the bulged sequences.  Although the data presented were 
limited, these experiments confirmed that intercalating drugs will specifically 
bind and stabilise bulge-containing helices. 
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Fig.3.4: The DNA intercalating drug, 9-aminoacridine. 
 
 
 
Fig.3.5:  Chemical Structure of 13R-1. 
 
Nakatanai and coworkers (154) designed and synthesized the chiral molecule 
13R-1 (Fig.3.5) as an aglycone model for the pluaramycin antibiotic, 
altromycin B.  This molecule has been shown to specifically alkylate guanine 
opposite a thymidine bulge flanked by cytidines.  The chemical modification 
occurred primarily near the bulge as a result of the much more efficient 
formation of an intercalated complex at the bulged site than at an intrinsic 
binding site for the drug.  The drug specifically alkylates guanine opposite a 
dT bulge, not only because of the increased stability, but because of the 
formation of a uniquely oriented complex. 
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Fig.3.6:  2-acylamino-1,8-naphthyridine bound to guanine. 
 
Other work carried out by the Nakatani group in Kyoto demonstrated that 2-
acylamino-1,8-naphthyridine (Fig.3.6), which possesses H-bonding groups 
fully complementary to guanine, selectively binds to a single G-bulge of 
duplex DNA (155).  Upon additon of equimolar drug, the melting temperature 
of the G-bulged duplex oligonucleotide 
d(GTTGCPGPCTGGA)·d(TCCAGGCAAC) was increased by 5 ºC, but no 
increase in TBmB was observed for similar A- and T-bulge sites or for the fully 
complementary duplex.  DNase I footprinting studies indicated a selective 
binding of the drug to the bulge with an association constant of 3.4x10 P-4 P M P-1 P. 
 
As we have previously discussed, bulged dG and dA bases tend to remain 
intrahelical and cause a kink in the helix, whereas the behaviour of bulged dC 
or dT is more variable; either intrahelical or extrahelical depending on 
flanking bases and temperature.  Caceres-Cortes and Wang (27) have studied 
the 2:1 complexes of nogalamycin (Ng) and the dT bulge containing, self-
complementary heptamers d(CPTPGTACG) B2 B and d(CGTACP
T
PG) B2 B to assess what 
happens to the extrahelical dT upon binding of Ng.  When nogalamycin is 
mixed with the bulged DNA duplex in a 1:1 ratio, the spectrum of each 
complex showed resonances from the free DNA, 1:1 drug:DNA complex, and 
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2:1 complex, indicating that the binding equilibrium was slow on the NMR 
timescale (since resonances from all three species co-exist).  The perfectly 
self-complementary form of these two oligomers, d(CGTACG)B2 B, had 
previously been titrated with Ng and the complex characterized by Robinson 
et. al. (182).   
 
NOESY spectra were collected of all four systems; d(CPTPGTACG) B2 B, 
d(CGTACPTPG) B2 B, Ng-d(CP
T
PGTACG) B2 B and Ng-d(CGTAC P
T
PG) B2 B.  Using a standard 
sequential assignment procedure (182) all resonances, except those of the 
deoxyribose H5' and H5" protons, were assigned.  In each case it was expected 
that the extra dT residue at the CpG intercalation site would loop out into 
solution (Fig.3.8 (b);(d)), forming a complex almost identical to Robinsons.  
However, this was not the case.  In both cases the DNA preferred to maintain 
an uninterrupted backbone at the intercalation site, leading to the formation of 
modified base pairs and causing the terminal bases to overhang (Fig.3.8 
(c);(e)).  In the Ng-d(CPTPGTACG) B2 B complex the 5'-C nucleotide was shown to 
overhang into solution while the drug intercalated at the TpG site formed from 
the T2 and G3 bases.  The aglycone system is stacked with a G-T wobble base 
pair (Fig.3.7).  Intercalation occurred for the Ng-d(CGTACPTPG) B2 B complex at 
the 5' terminal CpG site, and in this case the overhang occurred at the 3' end of 
the heptamer.  In this instance, a pyrimidine-pyrimidine C-T base pair was 
formed.  This is significantly less stable than a normal Watson-Crick base pair, 
or even a wobble base pair.   
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Fig.3.7:  G-T wobble base pair. 
 
Binding of nogalamycin may induce the extrahelical base to form a base pair 
over the aglycon ring, and shift the bulged distortion away from its original 
location.  It is therefore important to consider the possible long-range effect of 
a conformational change propagated away from the original bulged site when 
considering the biological function of intercalating anti-tumour drugs. 
 
Most non-covalent, intercalating drugs interact with DNA by inserting their 
planar chromophores between base steps to form elongated and unwound 
duplex structures without disrupting the flanking base pairs.  Actinomycin D 
(ActD) (Fig.3.9) is one of the older chemotherapeutic drugs, which has been 
used in therapy for many years.  It inhibits DNAprimed RNA polymerase by 
complexing with DNA via deoxyguanosine residues.  The drugs phenoxazone 
ring intercalates at a 5'-GC step and the two cyclic pentapeptide lactones 
anchor the chromophore in the minor groove by lying in both 5'- and 3'-
directions along that groove.  Because of its sequence specificity and potency, 
the ActD-DNA complex has been well characterised (36;38;110). 
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Fig.3.8:  Schematic representations of nogalamycin complexed with the DNA 
oligonucleotides d(CGTACG) (a), d(CTGTACG) (b;c) and d(CGTACTG) (d;e).  
 
Chou and co-workers (38) have reported the structures of ActD binding with 
previously uncharacterised DNA recognition sites 5'-GXC/CYG-5', where X/Y 
is an A-T or C-G base pair, in hairpins closed by a mini ACC-loop (39).  Once 
the sequence d(GTCACCGAC) was mixed with an equivalent of ActD, the 
central T-A pair was disrupted, and the bases looped out either side of the drug 
chromophore.  The flanking G-C pairs were both highly buckled due to the 
extrusion of the unpaired T/A residues.  Furthermore, the looped-out bases 
were shown to be perpendicular to the long axis of the flanking base pairs. 
These residues were not disordered, but rather involved in some tertiary 
interactions.  As well as a strong H-bond detected between the O4' of the extra 
thymidine and the quinoid amino group (Fig.3.9), another H-bond was also 
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formed between the looped-out adenosine amino group and the backbone 
phosphate oxygen on the adjacent guanosine nucleotide. 
 
O
N
O
CH3 CH3
NH2
O O NH
CH
NH
HC
N CH
N
CH2
N
CH
OCH
O
CH3
CH3
O
O
O
O CH3
HN
HC
NH
CH
NCH
N
CH2
N
CH
O CH
O
H3C
H3C
O
O
O
OCH3
L-Pro
Sar
L-MeVal
L-Tyr
D-Val
 
Fig.3.9: Actinomycin D. 
 
The ActD-d(GCCACCGGC) complex structure was shown to be very similar 
to the T/A structure, with the amino group of the looped-out guanosine residue 
forming a hydrogen bond with the adjacent guanosine backbone oxygen, and 
the looped dG forming a perpendicular interaction with the ActD chromophore 
(38).  UV melting studies showed that ActD binding caused a considerable 
stabilisation of 12 ºC for the control DNA hairpin d(GCACCGC), but an even 
greater stabilisation of more than 20 ºC was observed for complexes 
containing 5'-GXC sites. 
 
3.1.11  Biological Responses to DNA Bulges 
The ability of many species to repair mismatches in double-stranded DNA has 
been well documented. The first critical step in this process is the recognition 
of the mismatched DNA. In the major mismatch repair pathway in Escherichia 
coli, this is accomplished by the MutS protein. The MutS protein binds to the 
site of a mismatch in double-stranded DNA and, with the cooperation of the 
MutL and MutH proteins, targets a section of one of the DNA strands at that 
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location for removal. Other proteins complete the repair process: the section of 
DNA that has been targeted is removed and degraded, a patch is synthesized 
using the complementary strand as a template, and the patch is ligated into 
place resulting in a repaired section of double-stranded DNA without 
mismatches.  The comparison between eukaryotes and prokaryotes is 
complicated by the fact that eukaryotes encode multiple MutS homologs.  For 
example, in yeast there are six MutS homologs, MSH 1-6 (24).  In yeast, as in 
humans, MSH2, MSH3, and MSH6 are involved in the repair of mismatches 
in nuclear DNA (221;225). MSH2 is required for all such repair and MSH3 
and MSH6 provide specificity for the type of mismatch: MSH6 for base:base 
mismatches and small loops and MSH3 for large loops. 
(a) (b)
 
Fig.3.10:  The Phe-X-Glu region of E.coli MutS protein bound to a G-T mismatch pair 
(a).  Phe P36P  (green) takes part in a ring stacking interaction, while the amino proton of 
Glu P38P (red) is involved in a H-bond with the O2 of the mispaired thymine base (blue). 
 
Recent crystal structures of the MutS protein from Thermus aquaticus and 
Escherichia coli complexed with bulge containing DNA (126;157) have 
revealed that the GluP38 P residue in a conserved Phe-X-Glu motif participates in 
a H-bond with either an unpaired thymidine or the thymidine of a mismatched 
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G-T base pair (Fig.3.10 (b)), while PheP36 P (E. coli) or PheP39 P (Taq) is involved in 
a stacking interaction.  The role of hydrogen bonding in mismatch recognition 
has been assessed by Schofield et al. (189).  The relative affinities of MutS for 
DNA duplexes containing non-polar shape mimics of adenine and thymine, 4-
methylbenzimidazole (4MB) and difluorotluene (DFT) (Fig.3.11), were 
determined in gel mobility shift assays (190).   
 
When both adenine and thymine bases in an A-T base pair were replaced with 
non-polar mimics, both E. coli and Taq MutS were shown to exhibit a 
preference for duplexes containing 4MB and DFT compared to those 
containing normal A-T base pairs.  Overall, a 2- to 3.5-fold increase in binding 
affinity was observed.  This is consistent with an induced fit mode of 
mismatch binding, in which destabilised duplexes are preferred substrates for 
MutS. 
 
The affinity of E. coli MutS for duplexes with single base bulges was also 
measured.  The single unpaired base was either A or T or, alternatively, 4MB 
or DFT.  A reduced affinity for the DFT substrate compared to dT, consistent 
with the loss of a H-bond between GluP38 P and the unpaired or mispaired 
base/analogue, was recorded.  Only a 2-fold difference in relative affinities 
was observed between adenine and its mimic, indicating that the relative 
contribution of hydrogen bond formation was not as significant for dA as dT.  
Qualitatively similar results were also obtained with Taq MutS. 
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Fig.3.11: Thymine (a) and adenine (c) bases and their mimics, difluorotoluene (b) 
and 4-methylbenzimidazole (d).  
 
These data suggest that two modest opposing forces are at work; one being the 
destabilisation of DNA duplexes by 4MB and DFT, that would favour binding 
by MutS, and opposing this the loss of a H-bond that would destabilise 
mismatch binding. 
 
The Klenow fragment of DNA polymerase I is one of the most structurally 
well defined members of the DNA polymerase family.  Proofreading by the 
Klenow fragment is accomplished in a 3'-5' exonuclease site that is separated 
from the polymerase site by 25-30 Å (66;159).  Lam et al. (125) demonstrated 
that the presence of an extrahelical base near the 3' terminus of the template 
strand can significantly increase the occupancy of the 3'-5' exonuclease site, 
suggesting that a DNA substrate will be transferred from the polymerase site 
to the exonuclease site following a misalignment event.  Time resolved 
fluorescence spectroscopy was used to quantify the partitioning of a series of 
dimethylaminonaphthalene-1-sulfonyl (dansyl) labeled 17*/28-mer primer-
template oligonucleotides between the two sites.  The abundance of each of 
these distinct binding modes of the DNA-protein complex was estimated 
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under solution conditions by analyzing the decay of the dansyl probe (86).  
The inclusion of a bulged base at the first position from the primer terminus 
increased this partitioning, in favour of the exonuclease site, ranging from 3- 
to 7-fold, relative to the perfectly base paired primer, depending on the 
identity of the extrahelical base (dG>dA§dT>dC).  The largest effects were 
observed for an extrahelical base at the third or fourth position from the primer 
terminus, where partitioning increased by 8- to 18-fold. 
 
3.2  Experimental Design 
3.2.1   Project Overview 
Here, we examine by NMR a series of DNA hairpin sequences containing 5'-
TpG (5'-CpA) nogalamycin binding sites incorporating an extra bulged 
thymine in both the Watson and Crick strands (5'-CPTPA and 5'-TPTPG) in non-
terminal sites.  This work follows on from preliminary NMR studies of bulge-
containing DNA hairpin loop sequences by Colgrave (40).  
 
This study endeavours to examine in structural detail how specificity for 
binding to a G-C base pair influences the conformation and dynamics of the 
bases at non-standard interacalation sites.  The extra thymine base can 
potentially be accommodated through a drug-induced frameshift with base 
mis-pairing occuring downstream of the drug-binding site, or through local 
stabilisation of an extrahelical T-bulge preserving the Watson-Crick base 
pairing of the duplex regions.  
 
The major aim of this investigation is to show that a key feature of 
nogalamycin binding, namely specific G-C basepair recognition, can induce a 
number of novel structural features when an extrahelical base is inserted into 
the sequence, and to provide structural insights into the stabilisation of these 
non-standard DNA conformations. 
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3.2.3   Sequence Design 
Previous studies have sought to determine whether an unpaired, extrahelical 
nucleotide in a normal B-form DNA duplex will loop out into solution, or 
stack into the helix, and how this is affected by drug binding.  The question of 
whether or not this may give rise to a frameshift mutation has only been 
briefly, and accidentally, addressed by Caceres-Cortes and Wang (27). 
 
To begin to address this issue, a family of novel DNA hairpins containing a 
GNA loop sequence (Section 3.1.1), which has previously been reported to 
show remarkable thermal stability in short mini-hairpins, was designed.P P 
Although the GAA sequence shows the highest stability, it gives the poorest 
NMR visibility in terms of chemical shift dispersion, due to the fact that it 
comprises three purine bases, the protons of which come into resonance over a 
relatively narrow range.  In this context, the GTA loop sequence is most 
amenable to NMR analysis.  Both of these loop sequences have been 
employed in this study.  These loops were included in these sequences in order 
to regulate the direction of any possible frameshift mutation.  For example, the 
sequence d(CCCCC)·d(GGTGG), which contains a mismatched C-T pair, can 
potentially adopt two conformations in which the dT is looped out, depending 
on the direction, 5'-3' or 3'-5', of the frameshift (Fig.3.12(a);(b)).  However, if 
one end of this duplex is capped with a hairpin loop, giving rise to the 
sequence d(CCCCCGNAGGTGG), only one conformation, corresponding to 
the 3'-5' frameshift, is now possible (Fig.3.12(c)).  Based on the more stable 
GAA mini-hairpin sequence, two hairpins with 5'-TG (5'-CA) drug 
intercalation sites in the complementary double-stranded stem region were 
synthesised.  The binding sites of these sequences, d(GCPTPACGAAGTGC) and 
d(GTGCGAAGCPTPAC), each possessed a bulged-thymine (5'-CPTPA) in the 5'-
CA sequence, in each of the two possible orientations with respect to the loop 
(Fig.3.13(a);(b)). 
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5 3
(a) (b) (c)
 
 
Fig.3.12:  Possible conformations of the bulge-containing sequence 
d(CCCCC)·d(GGTGG), with (c) and without (a;b) d(GNA) mini-hairpin.  Cytosines are 
shown in red, guanines in blue, and thymine in green. 
 
 
(a) (b)
 
 
Fig.3.13: Structure of the oligonucleotide sequences d(GTGCGAAGC PT PAC) (a), and 
d(GC PT PACGAAGTGC) (b), in their proposed folded conformation with frayed ends.  
Cytosines are shown in red, thymines in green, guanines in blue, and adenines in 
yellow. 
 
As we have discussed in Section 2.1.2, nogalamycin is an intercalating 
anthracycline antibiotic that binds with high affinity and sequence specificity 
to double stranded DNA through recognition of a 5'-pyr-pur site (CpG or 
TpG) (64;65).  The bound orientation of the drug is dictated by the 
requirement for a guanine on the 3'-side of the intercalation site (CpG or 
TpG).  While a palindromic 5'-CG site permits binding in either orientation, 
binding to the 5'-TG site results in a unique binding orientation dictated by the 
presence of a guanine base on only one strand (Section 2.1.2).  The sequences 
d(GCPTPACGAAGTGC), d(GTGCGAAGCPTPAC) and d(CCCACGTAGTPTPGG) 
have been designed to ascertain whether TpG sites, which incorporate an extra 
bulged thymine on either face, can still bind nogalamycin and, if so, what 
effect this has on the structure of the surrounding sequence. 
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3.3   Materials & Methods 
3.3.1   Synthesis & Purification 
The oligonucleotides were synthesised and purified as described in Section 
2.3.1, and were shown to be > 95% pure and in the hairpin form by P1 PH NMR 
spectroscopy.  The oligonucleotide sample was quantified 
spectrophotometrically.  The NMR samples were prepared in the single strand 
concentration range of 4.8-7.6mM in 600 µl of mixed solvent, having a final 
salt concentration of 100 mM NaCl and 10 mM NaB2 BHPOB4 B, for WATERGATE 
experiments.  The hairpins were lyophilised and redissolved in DB2 BO solution 
(600 µl) for the observation of non-exchangeable proton resonances. 
 
3.3.2   NMR Analysis 
NMR experiments were performed on either a Bruker DRX500 or Bruker 
Avance600 spectrometer, as described in Section 2.3.3.  WATERGATE 
NOESY spectra at 300 ms, 150 ms, 100 ms and 75 ms mixing times were 
acquired using samples dissolved in 90% HB2 BO and 10% DB2 BO.  All TOCSY 
experiments employed a spin-locking field of 7 kHz.  Two-dimensional data 
were zero-filled to 2048 x 1024 points prior to Fourier transformation, 
optimised with a shifted sine squared function in both dimensions, and treated 
with automatic baseline correction. 
 
3.3.3 Distance Restraints 
Interproton distances for nogalamycin-d(GCPTPACGAAGTGC) were derived 
from integration of NOE cross peak volumes from NOESY experiments (288 
K, DB2 BO) with mixing times of 150 ms, 100 ms, and 75 ms. Distances were 
determined by extrapolation to zero mixing time as described in Section 2.3.4.  
A full description of the criteria for selecting upper and lower error bounds, 
and for comparing geometrical inconsistencies arising from the application of 
distance restraints can be found in Section 4.3.3. 
 
3.  DNA Hairpin Loops and Bulges 82
3.3.4 Starting Structures 
NMR structure determination of DNA molecules has been shown to be more 
difficult than for proteins because the network of NOEs in nucleic acid spectra 
is less dense than in protein spectra (249).  For this reason, structure 
calculations based on Cartesian space molecular dynamics often fail to find 
nucleic acid conformers that satisfy the experimental data (216) unless ad hoc 
assumptions about the 3D structure are made.  In such instances, torsion angle 
dynamics have been shown to be successful in finding structures that satisfy 
the experimental restraints.  The program DYANA (87) (DYnamics Algorithm 
for NMR Applications) for efficient calculation of three-dimensional protein 
and nucleic acid structures from distance constraints and torsion angle 
constraints collected by NMR experiments, performs simulated annealing by 
molecular dynamics in torsion angle space and uses a fast recursive algorithm 
to integrate the equations of motions.  The principal benefit of a torsion angle 
dynamics (TAD) approach is that it works with internal rather than Cartesian 
coordinates:  the covalent structure parameters (bond lengths, bond angles, 
chiralites & planarities) are kept fixed at their optimal values.  The strong 
potentials required in traditional Cartesian MD to retain the covalent structure, 
and the high-frequency motions caused by such potentials are absent in torsion 
angle dynamics.  Thus, torsion angle dynamics can be more efficient than 
molecular dynamics in Cartesian coordinate space because of the reduced 
number of degrees of freedom and the concomitant absence of high-frequency 
bond and angle vibrations, which allows for the use of longer time-steps 
and/or higher temperatures in the structure calculation.  Test calculations (87) 
starting from conformers with random torsion angle values have shown that 
DYANA is capable of efficient calculation of high-quality protein structures 
with up to 400 amino acid residues, and of nucleic acid structures.  
 
The torsion-angle molecular dynamics algorithm starts from an extended-
strand conformation and proceeds in four stages: high-temperature torsion-
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angle dynamics, slow-cooling torsion-angle dynamics, Cartesian molecular 
dynamics, and minimisation. 
 
Candidate structures were generated from NMR-derived distance restraints 
using simulated annealing combined with torsion angle dynamics from 100 
randomly generated structures using DYANA.  The sequence 
d(GCTACGAAGTGC) was created by combining DYANA nucleic acid 
library files, in the appropriate order.  Each file declares atom types, 
connectivities, dihedral angles and standard geometries.  The covalent 
geometry of the nucleotides is based on the AMBER (29) force field. 
 
Calculations with more than one molecule are made possible with DYANA 
through the use of special linker residues.  These "invisible" linkers consist 
exclusively of pseudoatoms that have zero van der Waals interactions and thus 
can penetrate the real molecules without causing any steric repulsion, and so 
allow the program to formally treat a multimolecular system in the same way 
as a single molecule.  Various linkers included in the DYANA library were 
used to attach the oligomer, d(GCTACGAAGTGC), to nogalamycin:  An NL 
(nucleotidegeneric linker) linker was used to link the 3'-dC nucleotide 
residue to a chain of four generic linkers, LL5, each with 5 Å bond lengths and 
90° bond angles.  Finally, a modified LN (generic linkernucleotide) linker 
attached the terminal generic linker to the C10 position of the drug molecule.  
Each of these linker residue types in the standard library provides three 
rotatable bonds.  A total of six linkers were used to separate drug from DNA, 
as a sufficient number of these linker residues must be used between two 
molecules such that no artificial constraint on the relative positioning of the 
two molecules with respect to each other is introduced by the finite length and 
flexibility of the stretch of linker residues. The linkers essentially create a 
flexible "chain" between two molecules.  The drug molecule was modelled as 
a fixed unit with no free torsion angles, the internal co-ordinates of which 
were taken from a previous complex (241). 
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Upper bound distance restraints were derived from NOE data obtained at 75, 
100 and 125 ms mixing time and corrected for spin diffusion by extrapolating 
distances to 0 ms mixing time as before (Section 2.3.4).  For all distances, 
upper error bounds of either 10% or 20 % were applied.  The lower error value 
was applied by default, while the higher value was reserved for those peaks 
that did not appear on all three low mixing time NOESY spectra.  In total 260 
distance restraints were applied, of which 221 were intra-DNA and 39 drug-
DNA restraints.  As the drug was treated as a rigid body, intra-drug distances 
restrains were excluded from the DYANA calculations.  Forty-five torsion 
angle restraints were applied based on observed ȈJ BH1' B values from P1 PH and 
DQF-COSY spectra at 288 K (Fig.3.14).  Although the number of NOEs in the 
loop region is low, chemical shift information (Section 3.4.1) indicates the 
formation of the GAA loop.  Therefore, the loop was further defined by the 
addition of 40 distance restraints derived from previous GNA loop structures 
(98;258).  Additionally, eleven H-bonding restraints were added for those 
residues that could be clearly identified as having imino protons involved in 
slow exchange processes.  The sequence d(GCTACGAAGTGC) and 
associated restraints were allowed to undergo 10000 steps of TAD simulation, 
3000 of which used the elevated temperature function.  The resulting output 
structures were scored based on the target function and the lowest energy 
structures were selected for further simulation.  Two structures were selected 
from a total of 20 on each of two independent dynamics runs, and two 
structures from a reduced annealing time simulation (600 high temperature 
steps, 6000 total steps), giving rise to a total of six structures.  DYANA 
outputs conformations in Cartesian coordinate format, which can subsequently 
be read into AMBER for minimisation and traditional Cartesian rMD 
simulations. 
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Fig.3.14:  Sugar pucker restraints for nogalamycin-d(GC PT PACGAAGTGC) were fixed 
by reference to coupling constants obtained from deconvoluted P1PH NMR spectra 
broadened using a gaussian window function (a), or from crosspeaks on the DQF-
COSY spectrum (b), each at 288 K. 
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Minimisation was followed by ten iterations of molecular dynamic simulation.  
Each of the first nine rounds of MD comprised 10 ps of simulation, split into 
5000 steps of 0.002 ps duration.  During the opening three iterations, the 
restraining field of 100 kcal ÅP-2 P mol was applied only to the DNA and 
counter-ions, while the temperature of the system was increased from 100K to 
300K.  At this temperature, the sodium ions were released from the restraining 
field and another round of simulation was run.  Over the next five iterations 
the restraining field was reduced to 50, 20, 10, 5 and 2 kcal ÅP-2 P mol.  The final 
round of MD was made up of 50000 steps, totalling 100 ps, during which the 
entire system was unrestrained.  Following minimisation, all six structures 
were found to be superimposable with an RMSD of 1.15 (±0.1) Å. 
 
 
Fig.3.15:  3D representations of nogalamycin-d(GC PT PACGAAGTGC) before and after 
TAD simulation with DYANA.  
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3.3.5 Hairpin Structures 
Following minimisation and unrestrained MD simulations, NMR restraints 
were introduced to the equilibrated structure and the system allowed to 
undergo 1 ns of restrained MD to satisfy the NMR restraints and search 
adequate conformational space under the influence of water molecules and 
cations.  A total of 347 NOE-derived distance restraints were applied to 
nogalamcyin-d(GCPTPACGAAGTGC), and the system was subjected to rMD 
for 1 ns with all restraints active.  230 DNA-DNA distance restraints, 68 drug-
drug and 39 drug-DNA restraints were applied together with 13 H-bonding 
restraints corresponding to the four Watson-Crick pairs and single G-A base 
pair.  Pseudrotational phase angles (PRPAs) were fixed for each of the twelve 
DNA bases, based on relative intensities of their (H1'ļH2') and (H1'ļH2") 
NOE crosspeaks at 288 K.  rMD was followed by energy minimisation.  
Snapshots were extracted throughout the rMD run at picosecond intervals.  In 
the final averaged energy minimised structure, only one of the applied distance 
restraints were violated by more than 0.5 Å, while five deviated by more than 
0.3 Å. All of the violated restraints corresponded to weak NOEs between 
nogalamycin and the terminal residues of the DNA stem region.  The mean 
pairwise RMSD, calculated for all heavy atoms, over the final 100 acquired 
snapshots was 0.73 (±0.1) Å.  This figure is reduced to 0.65 (±0.1) Å if only 
DNA atoms are considered, and further to 0.65 (±0.1) Å if the looped-out T3 
residue is excluded from the calculation.  The NMR restraints for 
nogalamycin-d(GCPTPACGAAGTGC) were satisfied well within the 
nanosecond of simulation. 
 
3.4 Results & Discussion 
3.4.1 Overview of NMR Analysis of Hairpin Loops 
The investigations of these unusual loop-containing structures were 
undertaken by first characterising the free oligonucleotides followed by 
examination of the adducts formed upon reaction with nogalamycin.  The 
NMR spectra of d(GCTACGAAGTGC) and d(GTGCGAAGCTAC) were 
assigned based on observations from previous studies (40).  The 
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conformations of uncomplexed d(GCTACGAAGTGC), 
d(GTGCGAAGCTAC) and d(CCCACGTAGTTGG) were investigated in the 
absence of drug using 1D and 2D NMR in H2O and D2O solutions (Section 
2.4.2).  
 
It has been well documented that the H4' proton of the bridging nucleotide in a 
GNA loop undergoes a large upfield shift as a consequence of characteristic 
stacking interactions in the loop region (98).  When a GNA loop is formed, the 
H4', H5' and H5" protons are subject to the ring current of the adenine in the 
sheared G-A base pair  (Fig.3.16) and the H4' resonances are observed to be 
shifted upfield by ~2 ppm relative to the other H4' signals from nucleotides in 
the stem region (98).  The H5' and H5" protons, although still affected by the 
adenine ring current, are not in such close proximity to the electrostatic 
surface of the ring, and are therefore shifted upfield to a lesser extent, typically 
0.5-1.5 ppm. 
 
Fig.3.16:  Stick model of the d(GCGAAGC) hairpin loop, viewed from the major 
groove and illustrating the proximity of the A6H4' (red) to the A5 ring system (green).  
Structure solved by Hirao et al. (98). 
 
Stacking of the loop base occurs largely with the guanine of the G-A base pair.  
This is reflected in very weak sequential NOE connectivities between base 
H6/H8 and deoxyribose H1' and H2'/H2" protons for both 
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d(GCPTPACGAAGTGC) and d(GTGCGAAGCPTPAC) across the ApA steps of 
their GAA loops (41;240).  This stacking interaction is unaffected by the 
nature of the base, as evidenced by a similar weak interaction across the TpA 
step of d(CCCACGTAGTPTPGG) (Fig.3.30) (Section 3.4.4.5). 
 
Further evidence for the formation of a sheared G(anti)-A(anti) conformation 
in these sequences is provided by the fact that the GH1'-GH8 and AH1'-AH8 
crosspeaks are both weak in comparison with the reference NOEs observed 
between the H5 and H6 of cytosine, consistent with anti glycosidic torsion 
angles for the G and A bases at the mismatch site (Section 4.4.1).  
Additionally, the GN1H proton invariably appears as a broad peak at 
approximately 10 ppm, indicative of a non-H-bonded imino proton, such as 
would be involved in a sheared G-A base pair (Fig.3.2). 
 
3.4.2 Drug Titrations 
1D P1 PH NMR titration studies of d(GTGCGAAGCPTPAC), 
d(GCPTPACGAAGTGC) and d(CCCACGTAGTPTPGG) show that nogalamycin 
intercalates with a 1:1 stoichiometry with the free and bound species at 
intermediate drug:DNA ratios in slow exchange on the chemical shift 
timescale.  
 
3.4.3 NMR Analysis of d(GCPTPACGAAGTGC) 
3.4.3.1 Loop Formation 
Fig.3.17(a) illustrates the H4'-H2'/H2" region, expanded from the NOESY 
spectrum (DB2 BO, 288 K, 300 ms) (Fig.3.18) of d(GCP
T
PACGAAGTGC).  The 
NOEs between the H2' & H2", H4' & H2', and H4' & H2" protons of the 
bridging adenine, A7, are indicated.  The loops in this sequence, and in 
d(GTGCGAAGCPTPAC) and d(CCCACGTAGTPTPGG), were determined to be 
formed by the observation of the upfield shifted H4' and H5'/H5" sugar 
resonances and the pattern and intensity of NOEs across the GNA loop.  In the 
NOESY spectrum of bulge sequence d(GCPTPACGAAGTGC) the A7 sugar H4', 
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H5' and H5" protons observed at 2.116, 2.241 and 2.361 ppm respectively. 
These were again >2 ppm upfield of the stem region A4 sugar H4', H5' and 
H5" protons, which came into resonance at 4.414, 4.024 and 4.122 ppm 
correspondingly.  
 
Fig.3.17:  Expanded region of the 500 MHz NOESY spectrum of 
d(GC PT PACGAAGTGC) (288 K, D2O, 300 ms) showing (a) the H4'-H2'/H2" interactions 
of the loop nucleotide, and (b) sequential H1'-H6/H8 connectivity, typical of B-like 
DNA, along the oligonucleotide chain. 
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Additionally, the C5H1'-G6H8 NOE crosspeak in the sequential H1'-H6/H8 
connectivity pathway of d(GCTACGAAGTGC) (Fig.3.17(b)) is relatively 
weak.  Weakness in, or often absence of, this interaction between the stem and 
loop regions has been shown to be another good indicator of loop formation 
(41). 
 
 
 
Fig.3.18:  NOESY spectrum of nogalamycin-d(GCTACGAAGTGC) in D2O solution, 
recorded at 288 K with a mixing time of 300 ms. 
 
3.4.3.2 Imino Protons of Free DNA 
For this sequence, only two imino resonances, at 12.80 and 13.85 ppm, which 
are indicative of stabilised Watson-Crick pairs, can be detected on the 1H 
spectrum. (Fig.3.21(b)) These correspond to the G9 and T10 protons, with the 
latter (T10) showing significant exchange broadening.  This demonstrates that 
while the stem region close to the loop is well formed, the ends of this hairpin, 
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and of d(GTGCGAAGCTAC) (Section 3.4.4.1) and d(CCCACGTAGTTGG) 
(Section 3.4.5.2) are destabilised by the introduction of the extra dT residue 
and, as a result, are poorly structured.  Although, the absence of signals from 
the imino protons for the terminal residues of these hairpins is indicative of 
fraying at the stem ends, the oligonucleotides still appears to be in the B-like 
conformation.  NOEs allowing the sequential H1'-H6/H8, and H2' & H2"-
H6/H8, connectivity pathways to be traced along the DNA strand were 
observed, indicating internucleotide stacking consistent with helical B-form 
DNA.  If the strands were adopting a random conformation, there would be no 
discernable pattern of backbone NOEs to follow, which is not the case 
(Fig.3.17).  Many of the sequential NOEs are, however, quite weak suggesting 
some degree of conformational averaging. 
 
3.4.3.3 Titration 
Fig.3.20 shows the aromatic region of the 1D P1 PH NMR spectra resulting from 
the addition of aliquots of nogalamycin to d(GCPTPACGAAGTGC).  As with 
d(GTGCGAAGCPTPAC), titration studies showed that nogalamycin formed a 
clean 1:1 complex with d(GCPTPACGAAGTGC), with resonances from the free 
DNA replaced by those of a complex containing a single-bound ligand.  In this 
case, the most pronounced changes to chemical shifts upon ligand binding 
occurred at the intercalation site.  In particular, the A4H8 proton was shifted 
downfield by 0.18 ppm to 8.55 ppm (Fig.3.20). 
 
 
Fig.3.19:  Schematic representation of the titration of d(GCPT PACGAAGTGC) with 
nogalamycin. 
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Fig.3.20:  1D 1H NMR spectra of the titration of  d(GCTACGAAGTGC) with 
nogalamycin (D20, 288K), highlighting the aromatic region (7.0-8.5 ppm), at drug:DNA 
ratios of (a) 0:1, (b) 1:6, (c) 1:3, (d) 3:4 and (e) 1:1. The downward facing arrows 
highlight clearly defined signals from the free DNA that decrease upon addition of the 
nogalamycin.  Upward facing arrows indicate new signals that increase owing to 
complex formation. 
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Nogalamycin intercalation with d(GCPTPACGAAGTGC) produces a highly 
stable 1:1 complex.  Six exchangeable resonances can be detected in the 1D 
spectrum of nogalamycin-d(GCPTPACGAAGTGC) peaks in the 12-15 ppm 
range.  Two of these peaks correspond to the H4 and H6 phenolic protons of 
nogalamycin (Fig.3.21(a)) at 11.50 and 12.10 ppm respectively, while the 
remaining signals correspond to the DNA base imino protons.  Four imino 
proton resonances can be identified on the P1 PH spectrum (Fig.3.21(a)), which 
are indicative of the involvement of G1, G9, T10 and G11 in stable Watson-
Crick base pairs.  Although the G1 and T10  (13.30 ppm) protons are 
overlapped on the 1D spectrum, their mutual presence was verified by 
integration of the peaks in the imino region (11.0-14.0 ppm), and their 
identities confirmed by connectivites between imino protons and aromatic 
base protons on the 2D WATERGATE spectrum (288 K, 300 ms) of the 
complex, in the same manner as described for nogalamycin-
d(GTGCGAAGCPTPAC) (Fig.3.28).   
 
3.4.3.4 Imino Protons of Drug-DNA Complex 
The peak observed at 13.30 ppm relating to the T10 imino proton is shifted 
upfield compared with the T10 in the free oligonucleotide (ǻį = 0.65 ppm) 
(Fig.3.21(b)), consistent with a thymine at a 5'-TG intercalation site (41).  The 
G1 imino proton also comes into resonance at | 13.20 ppm.  This peak, 
however, has a much greater linewidth in its complexed form, which can be 
attributed to the overlap of the G1 and T10 imino protons.  The peak at 13.20 
ppm, attributed to the G9 imino proton assigned based on imino-aromatic 
proton connectivities, is also shifted upfield (ǻį = 0.40 ppm).  Using similar 
methodology, the peak observed at 12.71 ppm can be attributed to the G11 
imino proton.  These peaks were further resolved at elevated temperature (318 
K) (data not shown).  Only the terminal guanine base shows any evidence for 
exchange broadening at temperatures above 308K.  The absence of a signal 
relating to the T3NH proton indicates that it is not involved in base-pairing, 
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and not protected from NH/ND exchange.  It can, therefore, be deduced that 
the T3 nucleotide must be extrahelical. 
 
 
 
Fig.3.21:  Imino-proton region of the 500 MHz P1PH NMR spectrum (288 K) of (a) 
nogalamycin- d(GC PT PACGAAGTGC)and (b) d(GC PT PACGAAGTGC). 
 
A detailed analysis of chemical shift perturbations and NOE data is strongly 
indicative of the drug stabilising an extrahelical conformation of T3 in which 
the pyrimidine base is flipped-out of the helical stack into a more solvent-
accessible environment.  This allows complementary pairing downstream of 
the intercalation site.  Chemical shift data show that both the base and sugar 
P
1
PH resonances of T3 are significantly downfield of those of the uncomplexed 
DNA ('G H1' = 0.75 ppm; 'G CHB3 B = 0.48 ppm; 'G+ ppm), which is 
indicative of diminished ring current effects that would only arise from a de-
stacking of the thymine base.  This is confirmed by the pattern and intensity of 
NOEs, which show very weak connectivities between C2H2'/H2" and T3H6, 
and an absence of the sequential NOE between C2H1' and T3H6 (Fig.3.23(b)).  
There are only very weak NOE crosspeaks evident between the protons on T3 
and A4.  These data are consistent with T3 not being accommodated within 
the helical stack but flipped-out into the major groove.  
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3.4.3.5 Drug-DNA Interactions 
The orientation of T3 in the major groove is confirmed by the observation of 
weak NOEs from T3CHB3 B to C2H6 and C2H3', but only very weak NOEs, 
attributable to spin-diffusion, from the extrahelical base protons to C2H1' and 
C2H2'/2" (Fig.3.22). 
 
 
Fig.3.22:  Expanded regions of the P1PH and NOESY spectra (90% H B2BO, 10% D B2BO, 
288K, 300 ms) of nogalamycin-d(GC PT PACGAAGTGC), showing NOE connectivity 
pathways between aromatic and thymine methyl protons. The crosspeak labelled [A] 
corresponds to the T3CH B3B-C2H6 interaction, and defines the orientation of T3 in the 
major groove. 
 
A large number of drug-DNA NOEs that provides details of the drug 
orientation and stabilising interactions in the grooves can be observed on the 
NOESY spectrum of nogalamycin-d(GCPTPACGAAGTGC).  NOEs from Nog-
H11 to T10H1' and G11H1' (Fig.3.23(b)) unambiguously establish 
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intercalation at the 5'-TpG step, with NOEs from Nog-H1" and Nog-5"-CHB3 B to 
T10CHB3 B confirming that the bicycloaminoglucose is located in the major 
groove with the 2"-OH and 4"-OH groups positioned to hydrogen bond with 
the C2-G11 base pair.  These interactions determine the orientation of the 
bound antibiotic.  The bulky hydrophobic nogalose sugar is located in the 
minor groove with numerous NOEs from drug methyl and methoxy groups to 
deoxyribose H1' and H4' of the C2-G11 and G1-C12 base pairs demonstrating 
that a significant hydrophobic surface area is buried in the minor groove. 
 
The H8/H6-H2'/H2" connectivity along the DNA backbone is conserved in the 
NOESY spectrum of nogalamycin-d(GCPTPACGAAGTGC), further indicating 
the location of the intercalation site (Fig.3.23(a)).  The connectivity can be 
followed from G1 to C2 to T3, although the latter C2-T3 step is significantly 
weaker than the G1-C2 step.  There is a break in the pathway between C2 and 
A4, which when combined with the weak C2-T3 interaction, favours a model 
in which the thymine is extrahelical.  Connectivity through A4-G5-A6-A7 can 
also be observed.  A loss of sequential connectivity is noted in the loop region 
between A7 and A8, again indicating that the loop A7 is stacked primarily on 
the G6 ring system.  The connectivity along the 3'-strand can then be traced 
from A8 to G9, G9 to T10, from T10 to Nog-H11 and Nog-H11 to G11, and 
from G11 to C12.  As was the case with nogalamycin-d(GTGCGAAGCPTPAC), 
the connectivity along the DNA backbone can be followed with the drug 
bridging the gap between the bases at the intercalation site, namely T10 and 
G11.  As for nogalamycin-d(GTGCGAAGCPTPAC), the H8/H6-H1' sequential 
connectivity can be followed along the DNA backbone through the 
intercalation site, with the ligand bridging the gap between the T2 and G3 
resonances.  In this case, the C2-T3 NOE is absent, while the T3-A4 
interaction is weak compared with others of the same type.  These data clearly 
establish that the site of nogalamycin intercalation is in the expected TpG step, 
and suggests that the unpaired dT is not stacked into the stem helix.  
Furthermore, interactions between the non-exchangable base protons, T3H6 & 
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T3CHB3 B, and C2 protons in the major groove suggest that the extrahelical base 
is oriented in the major groove and cannot interact freely with the solvent.  
Strong crosspeaks can be detected on the NOESY spectrum (288 K, DB2 BO, 300 
ms) corresponding to interactions between T3-CH3 and C2H6 & C2H3', while 
an albeit weaker interaction is evident between T3H6 and C2H2".  Since it has 
already been unambiguously shown that the unapired thymine is not 
incorporated into the helix, these intractions can only be explained in terms of 
the extrahelical base resides in the major groove, and oriented towards the 5' 
end of the oligomer. 
 
 
 
Fig.3.23:  Expanded regions of the NOESY spectrum of nogalamycin-
d(GCTACGAAGTGC), showing NOE connectivity pathways between (a) H6/H8 & 
H2'/H2" protons, and (b) H6/H8 & H1' protons. 
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3.4.4 NMR Analysis of d(GTGCGAAGCTAC) 
 
 
 
Fig.3.24:  NOESY spectrum of d(GTGCGAAGCTAC) in D2O solution, recorded at 288 
K with a mixing time of 300 ms. 
 
3.4.4.1 Loop Formation 
For the bulge sequence d(GTGCGAAGCTAC), the A6H4', A6H5'/H5" 
protons of the bridgehead adenosine (data not shown) were observed at 2.094 
and 2.299 ppm whilst the A11H4' and A11H5'/H5" protons from the stem 
region were observed at 4.163 and 4.073 ppm respectively.  The difference in 
chemical shift between the stem and loop adenine H4' and H5'/H5" sugar 
protons is >2 ppm in this case, consistent with the observations of Hirao et al. 
(98).  (N.B. The H5' and H5" resonances were overlapped for both A6 & A11; 
the average value of each is reported). 
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3.4.4.2 Imino Protons of Free DNA 
The imino proton region of the spectrum at 278K (Fig.3.25(b)) reveals only 
two resonances for stabilised Watson-Crick pairs in each hairpin structure.  
The G3 and G8 imino resonances, at 13.15 and 13.05 ppm, are evident for 
d(GTGCGAAGCPTPAC), 
 
 
 
Fig.3.25:  Imino-proton region of the 500 MHz P1PH NMR spectrum (278 K) of (a) 
nogalamycin-d(GTGCGAAGC PT PAC) and (b) d(GTGCGAAGC PT PAC). 
 
3.4.4.3 Titration 
In the 1D P1 PH NMR of d(GTGCGAAGCPTPAC), for example, the resonance at 
8.24 ppm, corresponding to the A11H8 of the free oligonucleotide, decreases 
in intensity upon addition of nogalamycin, whilst a resonance appears at 8.43 
ppm, corresponding to the A11H8 of the bound species (Fig.3.26).  The 
downfield shift can be rationalised in terms of nogalamycin intercalating 
between the base pairs.  This is consistent with other studies, in which such a 
shift has been found to be typical of an adenine involved in a 5'-CA 
intercalation site (240;241). 
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Fig.3.26: 1D P1PH NMR spectra of the titration of  d(GTGCGAAGC PT PAC) with 
nogalamycin (D B2B0, 288K), highlighting the imino region (7.0-8.5 ppm), at drug:DNA 
ratios of (a) 0:1, (b) 1:4, (c) 1:2, (d) 3:4 and (e) 1:1. The downward pointing arrows 
highlight clearly defined signals from the free DNA that decrease upon addition of the 
nogalamycin.  Upward pointing arrows indicate new signals that increase owing to 
complex formation. 
3.  DNA Hairpin Loops and Bulges 102
3.4.4.4 Imino Protons for Drug-DNA Complex 
The nogalamycin-d(GTGCGAAGCPTPAC) complex reveals two sharp imino 
proton resonances corresponding to G3 and G8, as evident for uncomplexed 
d(GTGCGAAGCPTPAC), plus two additional weaker resonances of similar 
intensity at 13.01 and 13.08 ppm (Fig.3.25(a)), which simultaneously broaden 
and disappear above 288 K.  Theses signals can be unambiguously assigned 
based on the 2D WATERGATE NOESY spectrum (90 % HB2 BO, 10% DB2 BO, 288 
K, 300 ms):  strong NOEs can be observed between the resonance at 13.01 
ppm and the A11 amino proton at 8.44 ppm, and between the signal at 13.08 
ppm and both G3NHB2 B protons at 6.71 and 7.90 ppm, indicating that these are 
the T2 and T10 protons respectively (Fig.3.28).  The relative broadness of 
these peaks is indicative of some form of conformational averaging.  Imino-
amino NOE crosspeaks can be similarly used to identify the G3NH (13.46 
ppm), which interacts strongly with the G3NHB2 B protons at 6.68 and 7.95 ppm, 
and the G8NH (12.99 ppm), which gives strong crosspeaks to the G8NH B2 B 
protons at 6.30 and 8.06 ppm. 
 
Examination of the imino region of the WG-NOESY spectrum provides an 
insight into the structure of the drug-DNA complex.  NOE crosspeaks are 
observed between the adjacent base pairs in the loop-closing region of the 
complex:  strong interactions are evident between the G8 imino proton of the 
C4-G8 base pair and the G3 imino proton of the adjacent G3-C9 base pair 
(Fig.3.29(a)).  This through-space interaction is typical of stacked C-G base 
pairs on B-form DNA (106). 
 
The broad NOE crosspeak between the G3 and T10 imino protons would 
initially appear to indicate that the T10 base is stacked onto the flanking G3-
C9 base pair.  However, since these bases are separated by more than 4.5 Å, 
which is the maximum interproton distance over which NOEs can normally be 
detected, by the presence of the drug chromophore, it would seem unlikely 
that this NOE would be observed.  This observation can, however, be 
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rationalised in terms of spin-diffusion:  as a consequence of spin diffusion, 
NOE crosspeaks between pairs of protons that are far apart can gain intensity 
from magnetisation that has been transferred via an intervening spin.  In this 
case, the H3 proton of nogalamycin at 7.06 ppm, which gives strong NOEs to 
each of the T2 and T10 iminos (data not shown), is the proton involved in the 
magnetisation transfer.  This is supported by the absence of NOEs between 
G3NH and T10NH at lower mixing times of 125 and 100 ms.  Cross-strand 
interactions between G3 and T10, together with the presence of a strong NOE 
between the T2 and T10 imino protons, rule out the formation of an 
extrahelical T10 bulge.  When combined with the absence of a G1 imino 
resonance, which would indicate the formation of the G1-C12 base pair, this 
forms compelling evidence that both thymines are involved in a T-T wobble 
base pair (Fig.3.29(b)) on the upper face on the nogalamycin chromophore.  
This would induce a 5'-3' frameshift at the 3'-terminal of the hairpin, 
precluding the formation of the terminal G-C base pair and resulting in a 
single 3'-dC overhang (Fig.3.27). 
 
 
Fig.3.27:  Schematic of the proposed conformation of nogalamycin-
d(GTGCGAAGC PT PAC).  Cytosines are shown in red, thymines in green, guanines in 
blue, and adenines in yellow. 
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Fig.3.28:  A section of the NOESY contour plot (90% H B2BO, 10% D B2BO, 288 K, 300 ms) 
of nogalamycin-d(GTGCGAAGC PT PAC), expanded to show the NOEs between the 
exchangeable base protons in the stem region.  NOEs, labelled (A)-(G) are assigned 
as follows: (A) G8NH B2B*-G8NH, (B) G3NH B2B*-G3NH, (C) G3NH B2B*-T2NH, (D) G3NH B2B-
G3NH, (E) G3NH B2B-T2NH (F) G8NH B2B-G8NH, and (G) A11NH B2B-T10NH. 
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Fig.3.29:  (a) 1PH NMR and NOESY spectra of nogalamycin-d(GTGCGAAGC PT PAC) at 
288K (300 ms, 90% H B2BO, 10% D B2BO), expanded to highlight the imino region (12.8-
13.7 ppm).  Note the crosspeaks between T2NH (13.01 ppm) and T10NH (13.08 
ppm) are partially obscured due to their closeness to the diagonal.  (b) Schematic 
representation of spin-diffused NOE interactions between G3 and T10 imino protons. 
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3.4.4.5 Drug-DNA Interactions 
The location and orientation of the bound drug molecule is readily established 
on the basis of drug-DNA NOEs.  The aromatic proton Nog-H11 presents 
clear interactions with T2 and G3, indicating that the drug is intercalating at 
the 5'-TG step.  A large number (34) of drug-DNA contacts were observed in 
the NOESY spectrum (DB2 BO, 288 K, 300ms) of nogalamycin-
d(GTGCGAAGCPTPAC). 
 
 
 
Fig.3.30:  Expanded region of the P1PH and NOESY spectra (D B2BO, 288 K, 300ms) of 
nogalamycin-d(GTGCGAAGC PT PAC), showing NOE connectivity pathways between 
H6/H8 & H1' protons. 
 
The H6/H8-H1' sequential connectivity can be followed along the DNA 
backbone through the intercalation site, with the ligand bridging the gap 
between the T2 and G3 resonances, and on through a break in the pathway at 
the C4-G5 step consistent with loop formation (Fig.3.30).  The T2H1' proton 
interacts with its own H6 proton and also to the H11 proton of nogalamycin. A 
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crosspeak can also be observed corresponding to the NOE between the H11 
proton of nogalamycin and the H1' sugar proton of G3.  The H11 proton also 
gives weaker crosspeaks to the G3H1' and C4H6 resonances.  These data 
clearly define the intercalation site to be the TpG step as was expected. 
 
There were extensive drug-DNA NOEs observed in nogalamycin-
d(GTGCGAAGCPTPAC) between nogalamycin methyl resonances and the T2 
sugar, as would be expected as the thymine was positioned within the 
intercalation site. There were, however, NOEs noted for the nogalose sugar 
protons (H2", H4' and H5') to T10, suggesting that this thymine was not in a 
bulged conformation and had taken the place of the A11 as would occur for a 
frame shift event. 
 
 
 
Fig.3.31: Expanded region of the NOESY spectrum of nogalamycin-
d(GTGCGAAGCTAC), highlighting key drug-DNA interactions at the intercalation site.  
NOEs, labelled (A)-(E), are assigned as follows: (A) Nog-3'-CH3C4H1', (B) T2CH3
NogH1", (C) Nog-3'-CH3NogH1', (D) Nog-5"-CH3NogH1" and (E) Nog-9-CH3
G3H1'. 
 
Among the drug-DNA NOEs at the intercalation site are those between Nog-
H1" and T2CHB3 B (Fig.3.31), Nog-H7 and T2H4', Nog-H11 and all T2 sugar 
protons H1'-H4', and between the nogalamycim methyl ester (H21) and 
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T2H1'/H2'.  There is no evidence of any NOEs between these protons on the 
drug chromophore and the A11 adenosine.  This suggests that the A11 base is 
not adjacent to the drug.  The presence of weak crosspeaks between T10 base 
protons and the drug chromophore further favours a model in which both T2 
and T10 are stacked over the drug. 
 
Numerous NOEs from methyl and methoxy groups on the nogalose sugar 
identify hydrophobic interactions within the minor groove consistent with 
previous studies (194;241;256).P P NOEs from NogH1" and Nog-5"-CHB3 B on the 
bicycloamino glucose sugar to T2CHB3 B confirm its orientation in the major 
groove with the drug hydroxyl groups positioned to interact with the G3-C9 
base pair (data not shown).  
 
The resonances for T10 show evidence for significant exchange broadening.  
However, weak NOEs from Nog-2'-OCH B3 B to T10H2"/H4', together with the 
observation of the two broadened imino proton resonances (Section 3.4.3), 
verify that the drug stacks with a weakly stabilised T2-T10 mismatched pair 
with the 3'- and 5'-termini poorly structured, suggesting considerable 
conformational averaging in which the T2-T10 may be only one possible 
contributor.  Thus, the precise nature of the terminal base pairs remains poorly 
defined in this complex. 
 
3.4.5 NMR Analysis of d(CCCACGTAGTPTPGG) 
The effects of a bulged thymine on the complementary strand were examined 
in the context of the hairpin d(CCCACGTAGTPTPGG), where an additional 
thymine is inserted at the 5'-TG step (5'-TPTPG).  In this case, the marginally less 
stable, but more easily characterised, GTA loop sequence was incorporated.  
In order to facilitate a frameshift, a homopolymeric run of three dC residues 
was included at the 5'-terminal of this oligomer. Two of the three cytosines 
were matched, by normal Watson-Crick base pairing, to guanine bases at the 
3'-terminal end.  The remaining residue, which was included to form part of 
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the symmetry-related CpA step associated with a normal TpG nogalamycin 
binding site, was mispaired with a dT residue.  The most likely conformation 
for this sequence to adopt is shown in Fig.3.32. 
 
 
 
Fig.3.32: Structure of the oligonucleotide sequence d(CCCACGTAGTPT PGG) in its 
proposed folded conformation with frayed ends. Colour scheme as for Fig.3.13. 
 
3.4.5.1 Imino protons of Free DNA 
As stated, only two imino resonances can be detected on the 1H spectra of 
d(GTGCGAAGCTAC) and d(GCPTPACGAAGTGC).  Similarly, the 1D 
spectrum of d(CCCACGTAGTTGG) reveals only two imino resonances;  the 
G9 imino at 13.24 ppm, corresponding to the loop-closing C-G base pair, and 
an exchange-broadened T10 imino at 13.53 ppm from the A-T base-pair. 
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3.4.5.2 Loop Formation 
GNA hairpin loop formations was verified for d(CCCACGTAGTPTPGG) by 
reference to the H4'-H2'/H2" region of the NOESY spectrum (DB2 BO, 298 K, 
300 ms) (Fig.3.33) as described for d(GCPTPACGAAGTGC) (Section 3.4.3.1). 
 
 
Fig.3.33:  Expanded region of the NOESY spectrum of d(CCCACGTAGTPT PGG) 
showing the H4'-H2'/H2" interactions of the loop nucleotide. 
 
3.4.5.3 Titration 
When d(CCCACGTAGTPTPGG) is titrated with nogalamycin, the resonances of 
the free DNA are replaced not by a single set of new resonances, as for 
d(GTGCGAAGCPTPAC) and d(GCPTPACGAAGTGC), but rather by two sets 
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corresponding to two species that are approximately equally populated at 278 
K (data not shown). 
 
3.4.5.4 Drug-DNA interactions 
The hydroxyl region (10.2-11.8 ppm) of the P1 PH spectrum (278 K, 90% HB2 BO, 
10% DB2 BO, 300 ms) shows matched pairs of drug protons (Fig.3.35).  This 
strongly indicates the presence of two, non-equivalent species in equilibrium.  
No assumptions were made about the nature of these two equilibrium states.  
Given the requirement at the binding site for a 5'-TG step, two possible drug-
induced DNA conformations that are consistent with the NMR data can be 
envisaged (Fig.3.34).  The first has the extra dT flipped out of the stack 
resulting in a one-base frameshift, preserving Watson-Crick base pairing down 
stream (C3-G12 and C2-G13), but resulting in a single dC overhang 
(Fig.3.34(a)).  Alternatively, the drug stabilises a mismatch C-T base pair at 
the drug intercalation site with complementary base pairing elsewhere in the 
structure (Fig.3.34(b)). 
 
 
Fig.3.34:  Schematic representations of the two proposed conformations of 
nogalamycin-d(CCCACGTAGTPT PGG), based on the requirement for a 5'-TG 
intercalation step. 
 
As discussed, the P1 PH WATERGATE spectrum of nogalamycin-
d(CCCACGTAGTPTPGG) shows matched pairs of drug protons at 278 K 
(Fig.3.35(b)), indicating the presence of two non-equivalent species in 
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equilibrium.  The sample was heated from 273K to 308K in 5K steps, and a P1 PH 
WATERGATE spectrum collected at each temperature.  Upon heating, these 
exchanging peaks broaden and coalesce until, at 303K, only the loop and 
terminal stem protons, which are relatively unaffected by the exchange 
process, can still be detected and assigned.  To determine the nature of the 
various species present, further studies were carried out at 278K and 303K. 
 
 
 
Fig.3.35:  Imino and hydroxyl regions of 1D P1PH WATERGATE spectra of 
nogalamycin-d(CCCACGTAGTPT PGG) complex at (a) 303K, and (b) 278K, illustrating 
matched pairs of drug protons at the lower temperature. 
 
The imino region (12.0-14.3 ppm) also provides an insight into the nature of 
the exchanging species:  The stacking of an A-T base pair directly on the drug 
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has previously been shown to result in a characteristic upfield shift of the 
thymine N3 proton by § 1 ppm to § 13 ppm (240).  At 278 K, a resolved peak 
at 13.95 ppm in a position characteristic of Watson-Crick A-T base pair 
stacked onto nogalamycin can be seen (Fig.3.35).  Since nogalamycin-
d(CCCACGTAGTPTPGG) has only a single A-T basepair, this resonance can be 
attributed to the C-T mismatched structure (Fig.3.34(b)), in which the A4-T10 
base pair is isolated from the shielding effect of the drug chromophore by the 
mismatch base pair.  At the lower temperature, this proton is in slow exchange 
with another thymine N3 proton, which comes into resonance at 12.87 ppm 
(Fig.3.35(a)), indicating that it is directly adjacent to the intercalated drug.  
This can be attributed to the alternative conformation of the complex, in which 
T11 is flipped out and T10 forms part of the interaclation site. 
 
Despite the fact that a full assignment of d(CCCACGTAGTTGG) could not be 
obtained, a sufficient number of signals were unambiguously resolved to allow 
the orientation of the nogalamycin to be verified by reference to drug-DNA 
NOEs on the NOESY spectrum at 303 K.  Since deoxyribose H1' protons form 
part of the floor of the minor groove in B-form DNA, the presence of 
crosspeaks between these protons on residues C2, C3, G12, & G13, and Nog-
2'-OCHB3 B, Nog-3'-OCH B3 B, Nog-4'-OCH B3 B & Nog-5'-CHB3 B on the nogalose sugar 
(Fig.3.36) verify that the nogalose resides in the minor groove and is oriented 
away from the loop sequence towards the ends on the oligomer.  The absence, 
as well as the presence, of NOESY crosspeaks can also tell us about the 
structure of the complex.  The absence of a second downfield shifted H6 
proton, corresponding to C3 cytosine, provides sufficient evidence that this 
residue remains stacked into the helix, and does not flip out as in previous 
studies (Section 3.1.7).   
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Fig.3.36:  Nogalamycin, highlighted to emphasise Nog-2'-OCH B3B, Nog-3'-OCH B3B, Nog-
4'-OCH B3B & Nog-5'-CH B3B protons on the nogalose sugar. 
 
The presence of two species in equilibrium makes analysis of these data 
extremely difficult.  Even at 278 K, the NOESY spectrum is complex and 
broad, making it impossible to fully assign.  However, sufficient information 
can be gleaned from key regions of the spectrum to deduce the conformations 
of these co-existing species.  Examination of the H6/H8-H1' region of the 
NOESY spectrum collected at 278 K also points to the existence of two 
species in equilibrium (Fig.3.37).  The assignment pathway is common for 
both species for the loop sequence d(ACGTAG), but bifurcates for the  3'-
terminal residues.  The first of these two deviating pathways (red) involves a 
downfield shifted T11 thymine H6 proton indicating a looped-out dT residue, 
and a four-step H6/H8-H1' assignment pathway between T10 and G13; T10-
(Nog-H11)-G12-G13.  The second species (blue) lacks a flipped-out base, and 
with a five-step assignment pathway; T10-T11-(Nog-H11)-G12-G13.  The 
latter data are consistent with the model in which nogalamycin intercalates in 
the T11-G12 pyrimidine-purine step. 
 
The structural differences between a TpG nogalamycin binding site containing 
a mismatched C-T pair and one with a flipped-out thymidine are sufficient to 
significantly change the magnetic environment that the drug experiences.  The 
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structure of nogalamycin in each of these distinct environments, with specific 
reference to the aglycone hydroxyl protons is shown in Fig.3.38.  The Nog-4-
OH and Nog-6-OH protons of nogalamycin, when intercalated into a 
mismatch containing TpG site, are subject to ring currents from the base-pairs 
adjacent to both faces of its aglycone chromophore (Fig.3.38(a;c)).  However, 
the localised unwinding of the DNA helix associated with the presence of a 
looped-out base effectively translates the A-T pair flanking the top face of the 
drug from the centre of the chromophore towards the amino end of the drug 
(Fig.3.38(b;d)), and shifting the ring currents away from the Nog-4-OH, and 
even more so the Nog-6-OH, protons. 
 
 
Fig.3.37:  Expanded region of the 600 MHz NOESY (278 K, 90% HB2BO, 10% D B2BO, 300 
ms) of nogalamycin-d(CCCACGTAGTPT PGG), showing two distinct sequential H1'-
H6/H8 connectivity pathways at the 3'-terminal end. 
 
This observation is consistent with the data from the 1-D spectra of the 
complexes (Fig.3.35).  Since the environmental change is greater for the Nog-
4-OH protons, it is in slow exchange between the two equilibrium states on the 
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NMR timescale.  The Nog-6-OH protons, in contrast, are less affected by the 
movement of the flanking bases relative to the drug, and subsequently are in 
fast exchange, appearing as one broadened peak on the spectrum. 
 
(a) (b)
(d)(c)
 
Fig.3.38:  Structure of the TpG intercalation site of nogalamycin containing a C-T pair 
(a;c), and a looped out dT (b;d) after 100ps of MD simulation.  Drug hyroxyl protons, 
4-OH and 6-OH, are shown in red. 
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Fig.3.39:  Alternate flipped-out orientations of nogalamycin-d(CCCACGTAGTPT PGG). 
 
In these variable-temperature studies, the signal at 13.95 ppm and its partner at 
12.87 ppm (Fig.3.35(a;b)) become exchange broadened above 298K as the 
two conformations begin to rapidly interconvert.  Although the data show 
evidence for T11 in the extrahelical conformation at both temperatures, the 
possibility cannot be excluded that T10 and T11 are also interconverting 
between alternate flipped-out structures; one with an extrahelical T11 bridging 
the T10-G12 intercalation site, and another in which a looped out T10 
precedes a T11-G12 binding site (Fig.3.39(b)).  These structures could not be 
differentiated by the methods employed.  Thus, the data are considerably more 
ambiguous than described for nogalamycin-d(GCPTPACGAAGTGC).  Despite 
extensive efforts to optimise the spectra of nogalamycin-
d(CCCACGTAGTPTPGG), none of the interconverting species could be isolated 
to such a degree that a full assignment could be completed and distance 
restraints could be derived. 
 
3.5 Redesign of C-T Mismatch Sequence 
To test the effect of nogalamycin on a mismatch base pair adjacent to its 
binding site, the C-T mismatch observed in nogalamycin-
d(CCCACGTAGTPTPGG) was incorporated into a new sequence.  This new 
sequence was designed to eliminate the possibility of forming multiple species 
in solution.  Again a GTA mini-hairpin loop was employed to stabilise the 
structure and to eliminate the need to synthesise multiple DNA strands.  One 
C-G Watson-Crick base pair and the hairpin loop flanked the mismatch base 
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pair on one face, while two C-G pairs were incorporated on the other.  These 
base pairs were aligned so as to have alternating purines and pyrimidines and 
so eliminate the risk of the frameshift that occurred in nogalamycin-
d(CCCACGTAGTPTPGG).  In order for nogalmycin to bind, the 5'-TG step must 
be conserved, and so the potential for the helical thymine to flip out as before 
is annulled.  Thus, d(GCCCGTAGTGC) should give rise to only one possible 
complex containing a high affinity nogalamycin 5'-TG binding site (Fig.3.40), 
and this conformation contains the desired C-T base pair. 
 
 
Fig.3.40:  Schematic representation of the proposed conformation of nogalamycin- 
d(GCCCGTAGTGC). 
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3.6  Materials & Methods 
3.6.1  Distance Restraints 
Interproton distances for nogalamycin-d(GCCCGTAGTGC) were derived 
from integration of NOE cross peak volumes from NOESY experiments (288 
K, DB2 BO) with mixing times of 150 ms, 100 ms, and 75 ms as describe in 
Section 3.3.3. 
 
3.6.2  Starting Structure 
The mismatched conformation of nogalamycin-d(GCCCGTAGTGC) was 
generated by simulated annealing with DYANA, using a broadly similar 
procedure to that used for the looped-out structure, nogalamycin-
d(GCPTPACGAAGTGC) (Section 3.3.4).  In this case, 232 distance restraints 
were applied, of which 214 were intra-DNA and 18 drug-DNA restraints.  The 
loop was further defined by the addition of 32 distance restraints as before.  H-
bonding restraints were added for the sheared G-A base pair and for all 
Watson Crick base pairs.  The output structures were scored based on the 
target function and the lowest energy structure was selected for further 
simulation.  Minimisation protocol is as described in Section 3.3.4.   
 
In order to test whether the assumptions that must be made when constructing 
a hairpin loop from Cartesian coordinates are valid in this context, a second 
starting structure was generated by these methods for comparison with the 
DYANA model:  A Cartesian coordinate model for DNA structure 
d(GCCC)·d(GTGC), containing a mismatched C-T pair, was generated using 
NUCGEN (29).  NUCGEN requires specification of two strands, and though it 
only generates reasonable geometries for Watson-Crick base pairs, a single 
mismatch in a run of complementary pairs is generally well tolerated.  The 
Cartesian coordinates were used to generate an output file in PDB format. 
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Fig.3.41: Steps involved in generating a model for the sequence d(GCCCGTAGTGC) 
containing a mismatched C-T base pair and bound to nogalamycin. 
 
A PDB coordinate file of the structure of d(CAATGCAATG) (Fig.3.41(a)), 
determined by Zhu et. al. (258)  was downloaded from the archives of the 
Protein Data Bank.  This structure contained a GCA hairpin loop consisting of 
a single cytidine residue closed by a sheared G-A pair.  The PDB file was 
edited so as to remove the terminal residues, leaving only the GCA turn and 
the flanking T-A pair (Fig.3.41(b)).  The coordinates of this shortened 
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sequence, d(TGCAA), were loaded into MolMol (123), together with those for 
d(GCCC)·d(GTGC) (Fig.3.41(c)). 
 
The deoxyribose heavy atoms, C1'-C5' and O4', of the A-T pair of d(TGCAA), 
and  the 3'-terminal C-G pair of d(GCCC)·d(GTGC) were superimposed using 
MolMol (Fig.3.41(d)).  The RMSD to the mean averaged over both molecules 
for the selected atoms was 1.02 Å.  A PDB file of the new, overlaid structure 
was generated and edited to remove the A-T pair from the former structure.  
The residue numbers of the resulting file were updated, giving rise to the 11-
mer d(GCCCGCAGTGC) (Fig.3.41(e)). 
 
In order to create a GTA turn from the pre-existing GCA hairpin, further 
editing of the PDB was required.  The residue name of the pyrimidine in the 
loop was changed from CYT (cytidine) to THY (thymidine).  The N4 (amino) 
nitrogen was changed to oxygen, and the amino protons deleted.  The proton 
on C5 was substituted with a carbon, which was named C7, consistent with the 
standard numbering system for a thymine base.  The structure of the resulting, 
transitional, base is shown in (Fig.3.42(b)).  The revised PDB file was read 
into the LEaP module of AMBER 6.0, a program used to prepare input for the 
AMBER molecular mechanics programs.  LEaP attempts to match atoms from 
the PDB file by atom on a residue-by-residue basis.  If atoms are missing 
relative to its own library file, as is often the case with hydrogens in structures 
generated by x-ray diffraction methods, LEaP will generate their coordinates 
using the internal coordinates in its library.  Thus, the transitional base is 
recognised as a thymine by LEaP, which then generates the missing atoms.  
Once this was completed a PDB file of the new oligomer, 
d(GCCCGTAGTGC) was generated (Fig.3.41(g)). 
 
As before (Section 2.3.6), the separation between the stacked bases of the TpG 
intercalation site was increased, and nogalamycin manually docked.  The 
orientation of the drug in the binding site was based on NOE data from the 2D 
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NOESY spectrum of nogalamycin- d(GCTACGAAGTGC) (Section 3.4.4), 
and by reference to previously published structures (211;240;241).  The 
nogalose was placed in the minor groove, and the aminoglucose inserted into 
the major groove. 
 
 
 
Fig.3.42: Steps involved in generating a thymine base from cytosine using LEaP. 
 
Sodium counter-ions were again used to negate the negative charge on the 
backbone, and the model was solvated to within a distance of 5 Å using boxes 
of 216 TIP3P HB2 BO molecules.  The entire system was then energy minimised 
(Fig.3.41(h)).  Following minimisation, the structure was compared to the 
DYANA starting structure, and these structures shown to have an RMSD of 
1.21 (±0.1) Å.  In this case, the inherent assumptions associated with creating 
a starting structure by combining and editing existing structures are 
reasonable, and produce starting structures of similar quality to those 
generated by simulated annealing using the torsion angle dynamics protocol of 
DYANA. 
 
3.6.3  Structure Calculations 
The rMD protocol for nogalamycin-d(GCCCGTAGTGC) was identical to that 
used for for nogalamycin-d(GCPTPACGAAGTGC) (Section 3.3.5).  In this case, 
the system was subject to 268 NOE-derived distance restraints, of which 214 
corresponed to DNA-DNA interactions, 36 to drug-drug interactions, and 18 
to drug-DNA interactions.  PRPAs were fixed as before, and 11 additional H-
bonding restraints were applied.  The final averaged energy minimised 
structure, none of the applied distance restraints were violated by more than 
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0.5 Å, and the mean pairwise RMSD, calculated for all heavy atoms, over the 
final 100 acquired snapshots was 0.53 (±0.1) Å.  Again for nogalamycin-
d(GCCCGTAGTGC), the NMR restraints were satisfied well within the 
nanosecond of simulation. 
 
3.7  Results & Discussion 
3.7.1 NMR Spectra 
 
 
 
Fig.3.43:  NOESY spectrum of nogalamycin-d(GCCCGTAGTGC)in 90% H B2BO 
solution, recorded at 288 K with a mixing time of 300 ms. 
 
NMR studies of the free hairpin show that the loop of d(GCCCGTAGTGC) is 
formed along with the flanking C4-G8 basepair.  The T6 sugar protons, H4', 
H5' & H5", are shifted upfield to below 3.5 ppm, indicating that the GTA loop 
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is well formed (Fig.3.45).  Furthermore, examination of the imino proton 
region (12.0-13.5 ppm) of the free oligomer at 288 K (Fig.3.44(b)) reveals that 
the stem region is well formed, even in the absence of drug, as evidenced by 
the presence of relatively sharp peaks corresponding to the G8 & G10, as well 
as the G1 imino protons. 
 
 
 
Fig.3.44:  Imino and hydroxyl regions of the 600 MHz P1PH NMR spectrum of  (a) 
nogalamycin- d(GCCCGTAGTGC) and (b) d(GCCCGTAGTGC) at 288 K, indicating 
that the stem regions are well formed in both cases. 
 
Drug binding to d(GCCCGTAGTGC) produces a clean 1:1 complex with only 
a single species present in solution (Fig.3.46), which proves amenable to a 
detailed NMR analysis.  The T9H6 peak at 7.12 ppm is replaced by a clearly-
resolved signal at 6.82 ppm corresponding to the same proton in the 
nogalamycin-d(GCCCGTAGTGC) complex. 
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Fig.3.45:  Expanded region of the 600 MHz NOESY spectrum of d(GCCCGTAGTGC) 
(288 K, D B2BO) showing interactions between H2'/H2", H3', H4' and H5'/H5" sugar 
protons on the loop (T6) nucleotide. 
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Fig.3.46: 1D P1PH  NMR spectra of the titration of  d(GCCCGTAGTGC) with 
nogalamycin (D B2B0, 298K), highlighting the imino region (7.0-8.5 ppm), at drug:DNA 
ratios of (a) 0:1, (b) 1:4, (c) 1:2, (d) 3:4 and (e) 1:1. The downward facing arrows 
highlight clearly defined signals from the free DNA that decrease upon addition of the 
nogalamycin.  Upward facing arrows indicate new signals that increase owing to 
complex formation. 
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Fig.3.47:  Expanded regions of the 600 MHz NOESY spectrum (288 K, 90% H B2BO, 
10% D B2BO) of nogalamycin-d(GCCCGTAGTGC), showing NOE connectivity pathways 
between H6/H8 and H1' protons, and revealing the location of the intercalation event.  
 
2D NMR (NOESY, TOCSY, DQF-COSY) analysis at 278 K and 288 K 
enabled a complete sequential assignment to be made, and intermolecular 
NOEs and chemical shift changes consistent with the proposed structure of 
nogalamycin-d(GCCCGTAGTGC) to be determined:  the sequential 
connectivities between base H6/H8 and deoxyribose H1' are traced out in 
Fig.3.47, and show that the NOEs are contiguous except where interrupted 
across the 5'-TG step due to structural distortions associated with drug 
intercalation.  Loop formation is again verified by sugar H4', H5' and H5" 
proton shifts (Fig.3.45).  The diagnostic NOEs from Nog-H11 to the 
deoxyribose H1' of T9 and G10 confirm binding at the 5'-TG step.  The 
stacking of the T9 base results in an unusual upfield shift of the T9CHB3 B to 0.64 
ppm, which is clearly indicative of direct stacking with the bound drug 
(Section 3.4.3).  Strong NOEs from the T9CHB3 B to Nog 5"-CHB3 B and Nog- H1" 
confirm this interaction (data not shown).  A detailed analysis of the NOE data 
identifies many of the drug-DNA interactions previously described (Section 
3.4.4).  Although intermolecular NOEs confirm the stacking of the C-T pair 
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with the intercalated drug, the imino proton of T9 is exchange broadened, 
suggesting that the C-T mismatch is not significantly stabilised by strong base 
pair hydrogen bonding. 
 
3.7.2  Molecular Dynamics 
Further simulations without NOE-restraints were used to examine the 
dynamics of the C-T base pair over 1 ns.  Snapshots taken over the final 500 
ps show that the DNA hairpin conformation has many of the structural 
features previously described for nogalamycin-d(CCCACGTAGTPTPGG), with 
well-formed loop- and stem-regions.  However, the C-T mismatch base pair 
has an average N3-N3 hydrogen bond distance, calculated over the entire 
nanosecond of the simulation, which is unusually long (3.4(r0.4) Å).  The C-T 
pair samples two major conformations, both of which have a single H-bond 
that is significantly populated for a portion of the rMD simulation 
(Fig.3.48(a);(b)).  In the first comformer, a single H-bond if formed between 
the cytosine amino proton and the oxygen at position 4 of thymine 
(Fig.3.48(a);(c)).  The average N4-O4 distance in this case was measured at 
2.9(r0.1) Å.  The formation of a this form of the C-T base pair requires a 
significant narrowing of the minor groove to a C1'-C1' distance of less than 8 
Å that, in this case, is partly precluded by helix unwinding and steric 
interactions with the bound drug.  The second of these two conformers 
(Fig.3.48(b);(d)), which becomes more populated as the simulation progresses, 
also has a stabilising H-bond between the cytosine amino proton and the 
oxygen at position 2 of thymine, but does not require any groove narrowing in 
order to form, as evidenced by an average C1'-C1' distance of 8.6(r0.2) Å, 
which is typical of B-DNA.  The H-bond formed is of similar length to that of 
the first conformer, at 3.0(r0.2) Å. 
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Fig.3.48:  C-T mismatch base pair (a);(b), and the two C-T base pair conformations 
sampled by nogalamycin-d(GCCCGTAGTGC) (c);(d) during a 1 ns rMD simulation.  
 
The autocorrelation plot showed that the structure of nogalamycin-
d(GCCCGTAGTGC) had become completely independent of the starting 
structure after approximately 350 ps of the rMD simulation.  Of the 500 
structures sampled from the end of the run, the final 400 were shown to be in 
the second, more open, conformation (Fig.3.48(b)), following a transition from 
the first conformer during the 599Pth P step of the simulation.  Prior to this, step 
the former (a) form of the C-T base pair was exclusively occupied.  Analysis 
of base-pair opening (Fig.3.49) before, and after, the transition shows an 
average difference of 11.2º, reflecting the movement of the bases on the XY 
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plane required to flip between the two conformations.  The N4H···O2 
hydrogen bond occupancy, measured using the CARNAL module of the 
AMBER 6.0 suite, was shown to be 100% for the final 400 ps of rMD.  
Although both forms of the C-T pair possess a single hydrogen bond, the latter 
conformation maximises overlap with the flanking base pair and nogalamycin 
(Fig.3.50).  Thus, stacking interactions, rather than hydrogen bonding, appear 
to be the major stabilising factor for the C-T base pair of nogalamycin-
d(GCCCGTAGTGC). 
 
 
 
Fig.3.49:  Schematic representation of base pair opening (ı). 
 
(a)
(b)
 
Fig.3.50:  Stacking patterns of the C-T mismatch base pair (red) on the flanking C-G 
base pair (blue), with the mismatch in its (a) hydrogen bonded and (b) non-hydrogen 
bonded forms, as determined by 1 ns of unrestrained molecular dynamics simulation. 
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3.8 Conclusions 
For nogalamycin-d(GCCCGTAGTGC), a GNA hairpin loop structure with B-
DNA stem regions, the inherent assumptions associated with creating a 
starting structure by combining & editing existing structures are reasonable, 
and produce a starting structure with remarkably similar topology to that 
generated by simulated annealing using the torsion angle dynamics protocol of 
DYANA (87). 
 
 
Fig.3.51:  Average minimised structure of nogalamycin-d(GCCCGTAGTGC) from the 
last 100 ps of a 1 ns rMD simulation. 
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The terminal residues of nogalamycin-d(GTGCGAAGCPTPAC) are not 
significantly stabilised by the intercalation of nogalamycin.  The groove-lining 
aminoglucose and nogalose sugars of the drug are oriented towards the already 
highly-stabilised GAA loop and, as such, have little effect on the frayed 
terminal region.  The desired 3'-5' frameshift at the 5'-terminal of the hairpin, 
and associated looping-out of the T10 thymine do not occur.  Spectroscopic 
evidence verifies the formation of a T-T wobble base pair adjacent to the 
upper face of the drug chromophore.  The T-T pair is estimated to be 
reasonably stable, as evidenced by sharp T2NH and T10NH peaks on the P1 PH 
WATERGATE spectrum at 288 K.  The lack of any structure at the terminal 
ends of nogalamycin-d(GTGCGAAGCPTPAC) make this complex unsuitable for 
rMD simulation. 
 
Nogalamycin-d(CCCACGTAGTPTPGG) was shown to exchange rapidly 
between at least two conformers at temperatures ranging between 278 K and 
318 K.  The effects of a bulged thymine at the TpG step proved impossible to 
characterise in great structural detail, due mainly to the rapid interconversion 
between two species; one with an extrahelical thymine at the interacalation 
site, and another with a C-T mismatch base pair adjacent to it.  Additionally, 
the presence of two consecutive thymines, allowed for the formation of both 
5'-TPTPG and 5'- PTPTG interacalation sites, which have very similar NMR 
characteristics, and could not be distinguished by the methods employed in 
this study.  Frameshifting of looped-out bases, even when occuring over a 
single base step, as in this case, can significantly complicate the analysis of 
otherwise straightforward DNA structures, and must be carefully considered 
during sequence design, particularly when the structures contain 
homopolymeric runs of bases.  In this case, interconversion between these 
species precluded any further study into extrahelical thymines on the 
complementary (5'-TG) face of the nogalamycin binding site, but did intimate 
the design of a sequence to study a C-T base pair adjacent to the drug.  
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Fig.3.52:  (a) Schematic representation of the average minimised structure of 
nogalamycin-d(GC PT PACGAAGTGC) from the last 100 ps of a 1 ns rMD simulation, 
showing the extrahelical thymine (green) in the major groove.  (b) 25 randomly 
chosen snapshots from the last 250 ps of a 1 ns rMD simulation of nogalamycin-
d(GC PT PACGAAGTGC). 
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In this study, the high-resolution solution structures of drug-stabilised hairpin 
loops have been determined by NMR restrained simulated annealing and 
Cartesian molecular dynamics methods.  The structure of nogalamycin-
d(GCPTPACGAAGTGC) has been shown to incorporate an extrahelical 
thymidine, which resides in the major groove and is oriented towards the 5' 
end of the DNA oligomer (Fig.3.52).  In contrast, nogalamycin-
d(GCCCGTAGTGC) contains a thymine that is forced to form a mis-match 
base pair with cytosine.  rMD of this structure has shown that the C-T pair can 
form an N4H···O2 H-bond, which maximises overlap with ring systems of 
the flanking bases.  Due to the requirement for significant groove narrowing in 
the formation of a pyrimidine-pyrimidine base pair (21) (Fig.3.51), the N4
H···O4 H-bond does not form. 
 
  nogalamycin- nogalamycin- 
 d(GC PT PACGAAGTGC) d(GCCCGTAGTGC) 
DYANA   
 drug-DNA 39 18 
 DNA-DNA 221 214 
 loop 40 32 
 H-bonds 11 20 
 torsion angles 45 N/A 
AMBER   
 drug-DNA 39 18 
 DNA-DNA 230 214 
 drug-drug 68 36 
 H-bonds 22 20 
 PRPA 12 11 
Restraint Violations   
 >0.3Å 5 3 
 >0.5Å 1 0 
RMSD   
 heavy atoms 0.73 (±0.1) Å 0.54 (±0.1) Å 
 
Table 3.1:  Summary of modelling statistics for the final 100 ps of 1 ns rMD 
trajectories of nogalamycin-d(GC PT PACGAAGTGC) and nogalamycin-
d(GCCCGTAGTGC). 
 
4. Structural Studies of an A-Tetrad in Quadruplex 
DNA 
 
4.1  Introduction 
4.1.1  G-tetrads 
The phenomenon of unusual, non-Watson-Crick base pairing in guanine-rich 
oligonucleotides was identified over 40 years ago by Gellert et al. (77).  
Guanine residues were found to self-associate into a quadruplex structure, held 
together by Hoogsteen pairing between the bases (Fig.4.1(a)).  The basic unit 
of the quadruplex was shown to be the G-tetrad, which is formed by a H-
bonded network of square, planar aligned guanines.  Adjacent guanine bases 
are hydrogen-bonded on their Watson-Crick and Hoogsteen edges, with their 
carbonyl groups oriented towards the centre of the quadruplex.  One amino 
proton is involved in a H-bond with the N7 nitrogen of the adjacent base, 
while the other is solvent exposed.  G-tetrad formation requires the presence 
of monovalent cations (244).  The location of the stabilising cations has been 
well defined by a high resolution (0.95Å) crystallographic study of the 
structure of d(TGB4 BT) B4 B(170).  Sodium ions have been shown to reside between 
adjacent tetrad planes and to be involved in octahedral coordination with the 
O6 oxygen atoms of the flanking guanines  (Fig.4.1(b)). 
 
It was not until 1988, when Sen and Gilbert (196) discovered the self-
association of guanine-rich DNA motifs under physiologically feasible ion 
concentrations, that any biological significance for DNA quadruplexes was 
hypothesised.  Guanine-rich motifs can be found within numerous regions of 
chromosomal DNA including immunoglobulin switch regions (20) and 
telomeres (198), and sequences from these regions have been shown to form 
quadruplexes. In this review DNA quadruplexes will be discussed with 
particular attention to their biological significance and methods of study.
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Fig.4.1: (a) G-tetrad structure.  The ring is planar; Hoogsteen bonding is indicated by 
dashed lines.  (b) Coordination of monovalent cations midway between tetrad planes. 
 
4.1.2  Quadruplex Structure 
DNA quadruplexes can assume a wide array of different structures, usually 
dependent on the sequence of the component oligomers.  In many cases, 
however, a change in conditions can cause a nucleotide to switch from one 
quadruplex structure to another (111;213).  Quadruplexes can be composed of 
one, two or four strands containing dGBn Brepeats, in either a parallel or 
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antiparallel orientation.  Quadruplexes containing tetrads of bases other than 
guanine have also been documented (59;73;200).  Most recently, a solution 
structure of d(TGGTGGC)B4 B, demonstrated a stable T-tetrad in the centre of a 
quadruplex (166).  Thymine bases at the 5' terminal of parallel quadruplex 
structures have also been shown to form stable tetraplexes, but not at 
physiological pH (76).  The subject of non-guanine tetrad formation, with 
specific reference to stacking interactions with G-tetrads has been further 
explored in a comparative NMR study of the solution structures of 
d(AGGGT) B4 B and d(TAGGGT) B4 B in the presence of KP
+
P (166).  The thymine 
residues of the latter sequence were shown to sample a huge range of 
conformations leading to poor stacking.  Only the adenine residues were 
shown to exhibit good stacking interactions with the adjacent G-tetrad and 
form stable A-tetrads.  The formation of tetrad alignment by residues other 
than guanine is highly dependent on the overall sequence and their position 
within it.  Where non-guanine or mixed base tetrads have been shown to form, 
they are invariably stabilised by stacking interactions with flanking G-tetrads.  
The features of G-quadruplexes will be further explored in the following 
section, and formation of stable non-guanine tetrads will be discussed 
presently in Section 4.1.7. 
 
4.1.3  Four-stranded Quadruplexes 
G-quadruplexes composed of four individual strands, each containing one dGBn B 
repeat, are among the best understood and well documented quadruplexes; 
complex intramolecular quadruplexes found in biological systems are often 
studied in simplified, intermolecular forms.  In all known cases the four 
strands lie parallel to form a complex of general structure d(GBn B) B4 B, as in the case 
of  the hexanucleotide d(TGB4 BT) B4 B (Fig.4.2) (170).  Several four-stranded, 
parallel quadruplexes have been solved by NMR (88;136;166) or X-ray 
crystallographic methods (170), including short sequences derived from 
telomeric DNA (166).  Structurally, the backbone parameters of parallel four-
stranded DNA quadruplexes are analogous to B-DNA duplexes (128) in that 
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glycosidic torsion angles are all anti and sugar puckers are C2'-endo.  The 
complementary base-pair parameters of buckle, opening, propellor twist, 
shear, stagger and stretch are not amenable to comparison with non-Watson-
Crick DNA structures (160).  However, the base step parameters (rise, roll, 
shift, slide, tilt and twist) of single-stranded quadruplex structures are 
equivalent to those of B-DNA structures. 
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Fig.4.2: Schematic of the X-ray crystal structure of G-tetrads in d(TG B4BT) B4 B(170).   
 
4.1.4  Hairpin Dimeric Quadruplexes 
Each strand in a two-stranded G-quadruplex generally contains two dGBn 
Brepeats connected by a short, usually T-rich, linker sequence to give structures 
of the type d(GBn BTBn BGBn B) B2 B.  The first two-stranded quadruplex to be identified was 
d(GB4 BTB4 BGB4 B) B2 B, a motif corresponding to the repeat array found in Oxytrichia 
telomeres (111).  Kang and coworkers studied this structure extensively by X-
ray crystallography.  The study of this sequence, and the in vitro structures it 
forms, illustrates the profound polymorphism that is characteristic of two-
stranded DNA quadruplexes.  The quadruplex was found to consist of four 
tetrads composed of two lateral bound dimeric hairpin loop structures 
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(Fig.4.3(a)), so that the two TB4 B loops are at opposite ends of the molecule and 
connect strands along the same edge of the complex.  All parallel strands have 
two neighbouring antiparallel strands such that each strands runs in the same 
direction as that diagonally opposite.  Since each base within a tetrad must be 
similarly oriented, the glycosidic conformation also alternates around the ring 
within each tetrad, and along the backbone within each strand.  Any anti 
conformation on a parallel strand must be matched with a syn conformation on 
an antiparallel strand to facilitate tetrad formation.   
 
However, when Smith et al (213) solved the same sequence using NMR the 
following year, a quite different structure was observed.  Their study 
demonstrated that the quadruplex had a TB4 B loop crossing each end of the 
structure diagonally, so that strands on diagonally opposite vertices share the 
same phosphodiester backbone (Fig.4.3(b)).  Each strand has one parallel and 
one antiparallel neighbouring strand, and glycosidic conformation follows the 
pattern syn-syn-anti-anti around each tetrad.  In this case, the conformation 
alternates along the backbone of each strand. 
 
These two studies of d(GB4 BTB4 BGB4 B) B2 Bexemplify the two major topologies of two-
stranded quadruplexes; structures where the loops run along one face of the 
complex are commonly known as chair dimers, and those where loops cross 
over the structure to connect opposite vertices are known as basket dimers.  
The fact that different structures are observed for the complexes also 
demonstrates the differing results that NMR and X-ray crystallography studies 
can produce.  Another point of interest, which we will return to later, is the use 
of different monovalent cations; in the NMR study NaP+P was used as opposed 
to KP+P, which was used to solve the x-ray structure. 
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Fig.4.3: Quadruplex structures formed by [d(G B4BTB4BG B4B)]B2B. (a): crystal structure 
solved by x-ray crystallography (111); (b): solution structure solved by NMR 
(213). 
 
Further polymorphism of two-stranded G-quadruplexes is demonstrated by the 
solution structure of the complex [d(GB3 BTB4 BGB3 B)]B2 B (214) (Fig.4.4(a)).  This 
complex forms three G-quartets and has a diagonal hairpin loop structure and 
strand orientation analogous to that found in the solution form of 
[d(GB4 BTB4 BGB4 B)]B2 B.  The complex also shares the syn-syn-anti-anti pattern of 
glycosidic conformation within quartets.  However, the pattern along the 
backbone of strands is quite different.  One strand has the sequence syn-syn-
anti-(TB4 B)-syn-anti-anti whilst the other runs syn-anti-anti-(TB4 B)-syn-syn-anti.  
Thus, although the sequence within the strand is asymmetric, it gives rise to a 
symmetrical pattern within the folded back structure of the complex.  Despite 
the differences between d(GB3 BTB4 BGB3 B) B2 Band d(GB4 BTB4 BGB4 B) B2 B, the shared diagonal loop 
structure suggests a common folding intermediate in the formation of the two 
quadruplexes (114).   
 
Diagonal-looped quadruplexes are favoured at higher strand concentrations 
when association of the strands occurs first, followed by folding of the loops 
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(Fig.4.4(b)).  Since guanine is the most hydrophobic of the bases, the 
conformation in which the guanine at the 3' end of the GB4 B repeat is stacked 
over the following thymine is favoured.  Due to the requirement for strand 
reversal, some of the bases must rearrange to the syn conformation in order to 
form the quartet, but the quartet formation is accomplished so that there are 
fewer 5'-G(anti)-G(syn)-3' sequential base pairs than either 5'-G(syn)-G(anti)-
3' or 5'-G(syn)-G(syn)-3' base pairs.  It appears difficult for the 5'-G(anti)-
G(syn)-3' stack to achieve stable -  interactions, and hence it is energetically 
less stable (217).  This explains the different pattern of glysosidic 
conformations between [d(GB3 BTB4 BGB3 B)]B2 B and [d(GB4 BTB4 BGB4 B)]B2 B.  The loop structure is 
further stabilised by hydrogen bonding between the third thymine and the first 
thymine in the loop (115). 
 
 
Fig.4.4: (a) Solution structure of [d(GB3BTB4BG B3B]B2B, solved by NMR (214). Blue rectangles 
indicate guanines in the anti conformation; Purple rectangles indicate guanines in the 
syn conformation. Image adapted from (114). (b) Association of two strands followed 
by folding of the two strands about the T B4B segment as exemplified by the diagonal-
looped quadruplex, [d(G B4BTB4BG B4B)]B2B. Image adapted from (114). 
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4.1.5 Single-stranded Quadruplexes 
Single-stranded, intramolecular quadruplexes consist of a folded DNA 
molecule containing four dGBn B repeats. The four repeats are connected by three 
loops, which most commonly form either a chair structure, where all three 
loops are laterally orientated, or a basket structure, in which the second loop 
crosses diagonally from one vertex to the other.  As an example of a chair 
structure let us consider the thrombin binding aptamer d(GB2 BTB2 BGB2 BTGTGB2 BTB2 BGB2 B), 
the solution structure of which was solved by Schultze et al. in 1994 (192).  
The folded structure of thrombin binding aptamer contains two guanine 
quartets, each with a regular syn-anti-syn-anti conformation pattern (Fig.4.5).  
Two TB2 loops at one end of the complex and a TGT loop at the other end link 
the four strands, which alternate between parallel and antiparallel around the 
quartet, consistent with the conformation of the individual tetrads.  As we can 
see, the orientation of loop connectivities in quadruplexes is dependent on the 
sequence and can affect the general folding topology of the structure.  
Intramolecular G-quadruplexes have been extensively studied in recent years.  
As we will discuss presently, they are more likely to form at the G-rich 3' 
overhang of telomeric DNA.  Intermolecular two- and four-stranded structures 
are less biologically relevant, though they are significant in vivo in phenomena 
such as end to end pairing (143;203).  The human telomeric repeat motif 
d(T2AG3)3 forms a single-stranded quadruplex.  It was first studied in solution 
with Na P+P by NMR techniques (234), and found to form a basket structure 
(Fig.4.6(a)).  The quadruplex consists of 3 guanine tetrads joined by three 
TTA loops; two lateral loops at one end of the structure and a diagonal loop at 
the opposite end.  Nucleotides are arranged in a syn-syn-anti-anti 
conformation pattern within the quartets, and conformation alternates within 
G3 repeats, such that each anti base stacks onto a syn base and vice versa.  
Each strand lies adjacent to one parallel and one antiparallel strand. 
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Fig.4.5: Solution structure of d(G2T2G2TGTG2T2G2) solved by NMR (192).  
 
More recent work using x-ray crystallography has identified another structural 
form of the human telomeric repeat.  The crystal structure (162) is completely 
novel, unlike any previously documented quadruplex.  All four repeats are 
parallel, with all glycosidic angles in the anti conformation.  Repeats are 
connected by TTA loops extending out from the sides of the complex to form 
a propeller-like structure (Fig.4.6(b)).  The simpler, more regular nature of the 
structure appears more rational than more complex fold-back structures for the 
rapid folding and unfolding of telomeric DNA in vivo. However, the question 
of the biological relevance of crystalline structures arises again, despite the use 
of physiological KP+P concentrations.  
 
Further illustrating the structural diversity of single-stranded G-quadruplexes 
is the structure formed by the Tetrahymena telomeric sequence d(T2G4)4. The 
quadruplex formed contains three G-quartets; strands are linked by two lateral 
loops: a GTTG loop links the first and second G3 repeat, and at the opposite 
end of the molecule a TTG loop links the second and third repeat. Finally, a 
TT loop traverses one of the grooves within the DNA to connect the third and 
fourth repeat (234). 
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Fig.4.6: Quadruplex structures formed by d[AG3(T2AG3)3]. (a) solution structure 
solved by NMR (234); (b) crystal structure solved by x-ray crystallography (162). 
 
Quadruplexes containing bases other than guanine have also been reported.  
Mixed quartets exist which contain G and at least one other base, such 
as[d(G3CT4G3C)2 , which forms a four-quartet structure where the outer two 
tetrads each contain two cytosine residues (116).  Entire non-guanine quartets 
have also been identified; the S. cerevisae telomere motif d(TG2TG2C)4 
contains a T-tetrad (166); the SV40 repeat sequence d(TG3CG2T)4 contains a 
C-quartet (165); and an A-quartet has been identified in the human telomeric 
sequence [d(AG3T)]4 (73;167). 
 
4.1.6  Roles of Counter Ions 
Negative charge contributed by the phosphate backbone of DNA mean that it 
is stabilised by positively charged ions.  In the case of quadruplex DNA 
counter ions are explicitly required for formation.  The most abundant 
physiological cations are NaP+ Pand KP+P and hence these are most commonly used 
in the study of quadruplexes in vitro.  As discussed, monovalent cations bind 
between stacked G-tetrads with 8-fold coordination to the lone pair of the each 
O6 atom.  The nature of the coordinating ion can affect the stability of certain 
types of quadruplex structure.  Some sequences will adopt different 
conformations dependent on ion type and concentration, which suggests that 
conformational switching in vivo may be brought about by localised changes 
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in intracellular ion concentration.  Some general rules for ion requirements in 
quadruplex formation have been proposed by Patel and coworkers (164) based 
on NMR experiments in the presence of varying KP+ Pand Na P+P concentration.  
They have stated that four-stranded parallel quadruplexes have no specific 
requirement for KP+ Por Na P+P and will form provided that at least one of these 
ions is present at sufficient concentration.  However, electrophoretic and UV 
studies have shown that KP+ Pis generally more stabilising than Na P+ (139).  Due 
to the polymorphic nature of the quadruplex sequence and conformation, there 
are some cases where these rules do not hold, particularly for quadruplexes 
involving adenine or cytosine (117;244).  In four-stranded parallel 
quadruplexes, KP+P has been shown to coordinate between every pair of adjacent 
G-tetrads.  Binding can take place at other sites, such as at the ends of stacks, 
or between G- and non-G-tetrads.  Ion binding at these sites is largely 
dependent on the surrounding sequence (73;139;164;167). 
 
4.1.7  A-tetrads 
As previously stated, there is a limited potential for non-guanine tetrads to 
form in DNA quadruplexes.  These structures are, however, liable to be much 
less stable than G-tetrads, and are more likely to be found flanked on either or 
both sides by their more stable relatives than in guanine-free quadruplex 
sequences.  The alternative tetrad structure with the greatest potential to form 
is the A-tetrad, as these have the greatest potential to form stabilising 
hydrogen bonds in the core of the quadruplex (Fig.4.7).  Unlike their guanine 
containing cousins however, A-tetrads have little potential to bind potassium 
ions in their central channel, as they lack the electron rich O6 atom, or any 
substitute in their purine ring structure. 
 
Octahedrally-coordinated cations between adjacent G-tetrads must first be 
displaced in order for a drug molecule to intercalate.  Since A-tetrads lack the 
requisite electronegative functional groups, intercalated ions may be more 
easily dislplaced, or absent.  As such, A-tetrads are of particular interest in the 
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context of drug stabilisation of quadruplexes.  As will be discussed further in 
Section 4.1.10, cellular DNA must be converted from its paranemic form to 
unstructured single strands in order to be enzymatically activated and so drugs 
that stabilise the paranemic form can inactivate gene.expression 
 
 
 
Fig.4.7:  The two possible forms of A-tetrad alignment; with N6H···N1 (a) and N6
H···N7 (b) hydrogen bonding patterns. 
 
A previous study of drug recognition and stabilisation of the parallel-stranded 
quadruplex d(TTAGGGT)4, determined the solution structure of a 2:1 
complex of an intercalating drug with the oligomer (73).  They observed that 
the drug molecules bound on the ends of the G-quadruplex, at the ApG and 
GpT steps, rationalising that the stabilising effects of (potassium) ions within 
the central channel precluded intercalation at a GpG step because the energetic 
cost of displacing a potassium ion is not sufficiently compensated by stacking 
interactions with the drug. 
 
Patel & co-workers (167) have described NMR structural studies on two 
truncated human telomericP PDNA sequences, d(AG3T)4 and d(TAG3T)4 in 
solutions containing KP+ Pions. The G3 stretches in both the oligonucleotides 
were seenP Pto form parallel-stranded quadruplexes. Their report included the 
formation and characterization of a novel P PKP+P-stabilized d(AG3)4 quadruplex in 
the sequence d(AG3T)4.  This isP
 
Pa parallel-stranded quadruplex in which an A-
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tetrad is formedP Pat the 5' end.  Such a feature was not seen in the d(TAG3T)4 
sequence P Pwhere the AG3 stretch was flanked by T nucleotides at the 5'P
 
Pend.  
They observed that the G3 parts had overall similar characteristicsP
 
Pin both the 
molecules, but in d(AG3T)4, the adenines had synP Pglycosidic conformations 
and the A-tetrad stacked well over the adjacentP PG-tetrad. The data also 
indicated dynamism in the alignmentsP Pof adenine in the A-tetrad over 100 ps 
of rMD simulation.   
 
At the endP Pof the above calculations for d(AG3T)4 quadruplex, the final 
structuresP Pwere seen to be distributed between two distinct patterns ofP PA 
alignment, with hydrogen bonds formed between the N6 amino nitrogen of 
one adenine and either the N1 or N7 nitrogen of an adjacent adenine, 
consistent with Fig.4.7.  A rapid equilibrium between these N61 (Fig.4.7(a)) 
and N67 (Fig.4.7(b)) models has been postulated, as only one resonance was 
observed for each proton.  The exchangeP Prate, thus, must be fast compared to 
the chemical shift differencesP Pbetween the two models, but slower than the 
NOE time scales, and was estimated in the study to be on the nanosecond 
timescale. 
 
Gavathiotis & SearleP P(73) have also resolved a d(AG3T)4-containing 
quadruplex by NMR methods as part a study of the human telomeric repeat.  
In this case, the A-tetrad is flanked on its 5' face by two T-tetrads, which do 
not form any recognisable hydrogen bonding alignment during the 1 ns of 
restrained MD simulation they describe.  The A-tetrads in this model had anti 
glycosidic conformations, and, again, stacked well over the adjacent G-tetrad.  
The NOE assignment, in this case, was consistent with the formation of an 
N61-aligned A-tetrad (Fig.4.7(a)).  However, the RMSD of hydrogen bond 
distances was greater for the A-tetrads than G-tetrads, attributed to the 
proximity of the As to the amorphous 5'-end of the molecule.  
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These previous studies have failed to unambiguously resolve the 
conformation, N61 or N67, preferred by A-tetrads incorporated into DNA 
quadruplexes.  Additionally, little effort has been made to address the exact 
number of potassium ions bound to these adenine-containing structures, 
though in the latter study, KP+P ions bind between G-tetrads consistent with 
existing stochiometric studies (233). 
 
4.1.8  Telomeres 
Telomeres are the specialised nucleoprotein structures found at the end of 
eukaryotic chromosomes, which are essential for chromosome stability.  
Telomeric sequences are characterised by tandem repeats of short, guanine-
rich DNA.  The exact sequence of the repeat is species-dependent.  Examples 
of such repeat sequences are TTGGGG, TTTTGGGG, TTTAGGG, 
TTTTAGGG and TTAGGG, which are found in the telomeric regions of 
Tetrahymena, Oxytrichia, Arabidopsis, Chlamydomona and human DNA, 
respectively (254).  Early genetic studies found that chromosomes with broken 
ends fused to produce unstable structures such as circular chromosomes (19).  
Subsequent molecular biological studies identified another crucial role: the 
prevention of chromosome shortening on the 5' strand with successive rounds 
of semi-conservative replication.  Further research has also identified 
telomeres as involved in transcriptional silencing, recombination events, and 
nuclear organisation of chromosomes (180).  
 
In terms of sequence and structure, telomeres are highly conserved throughout 
even the most distantly related eukaryotes.  Telomeres consist of short, G-rich, 
tandemly repeated motifs, paired with C-rich repeats on the complementary 
strand (Fig.4.8).  A section of G-rich strand overhangs the C-rich strand, 
running 5' to 3' with respect to the chromosome end.  The length of telomeres 
varies widely throughout eukaryotes, from a few tens of base pairs in 
Oxytrichia to 300-450 bp in yeast and between 1.5 and 150 kb in vertebrates 
(180).  Furthermore, the length by which the G-strand overhangs also varies.  
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In ciliated protozoa the G-strand overhangs by 12-16 nucleotides, compared 
with up to 300 nucleotides in yeast (237). 
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Fig.4.8:  Schematic representation of the telomere. 
 
In vertebrates, the majority of telomeric DNA is organised into nucleosome-
like structures analogous to packaging of the majority of chromosomal DNA 
by histones (138;223), but with the significant difference that some histone 
proteins are absent from packaged telomeric DNA.  Rat hepatocyte telomeric 
DNA or chromatin consists of a structure that repeats every 157bp, as opposed 
to 200bp in bulk chromatin.  This is due to the absence of the linker histone 
H1 (138). However, chicken erythrocytes do contain a linker histone; usually 
H5 as this has a higher binding affinity for telomeric DNA than H1 (153).  
Yeast telomere organisation depends primarily on the protein Rap1p, which is 
essential for regulation of telomere length, as well as stimulation and 
repression of transcription (199).  In lower eukaryotes no telomeric DNA 
organisation or packaging appears to be present (138). 
 
4.1.9  Quadruplexes in vivo 
A quadruplex containing a telomeric DNA sequence was first reported in 
1989, when the Tetrahymena telomeric DNA motif d(T2G4)2 was found to 
form a two-stranded fold-back quadruplex (220).  Over the next decade many 
different DNA sequences, from a wide range of eukaryotic organisms, were 
found to form stable quadruplex structures in vitro under physiological ion 
concentrations.  These studies have presented convincing evidence for 
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quadruplex formation in vivo.   Proteins have been identified in lower 
eukaryotes (61;79) and vertebrates (58), which bind to DNA quadruplexes and 
in some cases stimulate quadruplex formation.  Recently, binding of 
quadruplex-specific antibodies to telomeric DNA in Stylonychia lemnae 
macronuclei has been detected using immunofluorescence (187), providing the 
first direct evidence of quadruplex formation in vivo.  
 
So far the most compelling evidence of quadruplex formation in human cells 
is the identification of two different quadruplex structures in the Nuclease 
Hypersensitivity Element III1, which forms part of the promoter of the c-myc 
oncogene (200).  Identification of quadruplexes at human cell telomeres is 
hindered by low concentrations of telomeric DNA.  In contrast, macronuclei 
of ciliates contain gene-sized chromosomes each with telomeric ends, 
providing a high concentration of telomeric DNA relative to total nucleic acid 
concentration, which is well-suited to the study of telomeres (176). 
 
4.1.10  Biological Roles 
With the evidence for in vivo existence of telomeric quadruplexes becoming 
more compelling, their possible function or functions must be addressed.  G-
quadruplex formation may be important in stabilising the 3' overhang of 
telomeres (220) during cell quiescence, with rapid protein-mediated unfolding 
occurring during the replicative stage of the cell cycle.  Immunofluorescence 
studies of Stylonychia lemnae macronuclei support the theory that 
quadruplexes at telomeres are disassembled during replication (187).  It has 
been suggested that quadruplexes are present at telomeres as part of higher 
order structures, in a form that can be assembled and disassembled rapidly 
(162).  
 
In somatic cells, telomeres shorten with each round of semi-conservative 
replication; typically by 100bp per cell cycle.  Below a certain telomere length 
the cell becomes senescent, thus restricting the cell to a finite number of 
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replications (91).  In cancer cells, telomere length is shorter than normal, but is 
maintained by the enzyme telomerase, which is inactive in normal somatic 
cells but activated in 85-90% of all human cancers (120).  Inhibition of 
telomere maintenance in cancer cells leads to telomere shortening, lack of cell 
proliferation and apoptosis (255).  Quadruplex DNA cannot be recognised by 
telomerase; disasembly of the telomere to unwound single-stranded DNA is 
required for telomere extension (253).  Inhibition of telomerase via G-
quadruplex-binding ligands presents an important target for development of 
anti-cancer drugs.  
 
G-quadruplex forming sequences are also found in several transcriptional 
regulatory regions of important oncogenes, including c-MYC, c-MYB, c-FOS 
and c-ABL (205).  Because of the polypurinepolypyrimidine nature of these 
duplex sequences, which contain four or more runs of clusters of three or more 
guanines on the purine-rich strand, they often show a single-stranded character 
and hence are hypersensitive to nucleases.  Expression of the c-MYC oncogene 
is linked to potentiation of cellular proliferation and to inhibition of 
differentiation,P Pleading to its association with a number of human and animal 
malignancies,P Pincluding carcinomas of the breast, colon, and cervix, as wellP Pas 
small-cell lung cancer, osteosarcomas, glioblastomas, and myeloidP Pleukemias 
(60;140;168;215).   
 
The nuclease hypersensitivity element III1 upstream of the P1 promoter of c-
MYC controls 85-90% of the transcriptional activationP Pof this gene 
(175;186;224).  In the c-MYC promoter, the purine- and pyrimidine-rich 
strands bind transcription factors (cellular nucleic-acid-binding protein, 
CNBP, and heterogeneous nuclear ribonucleoprotein, hnRNP) that are 
required for transcriptional activation.  As these elements can also potentially 
form G-quadruplex and i-motif structures (204;206), it is possible that the 
secondary DNA structures inactivate transcription, and their conversion to the 
duplex form is required for transcriptional activation.  Hurley et al. (201) have 
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demonstrated that the proposed chairP PG-quadruplex, and possibly an i-motif 
structure P Pformed in the complementary strand, that can form in the c-MYC 
promoter region need to be converted to unstructuredP Ppurine and pyrimidine 
single-stranded forms before c-MYC can be P Ptranscriptionally activated 
(Fig.4.9).  Stabilised G-quadruplex structures that would prevent this transition 
would therefore inactivate c-MYC expression.  As downregulation of c-MYC 
expression in tumour cells by only 30% leads to a marked reduction in their 
transformation by RAS or RAF (14), the selective stabilisation of G-
quadruplex structures in the promoter regions of c-MYC should lead to 
selective effects on cancer cells.   
 
To date, no structure of the paranemic form of the NHE III1 region of the c-
MYC oncogene has been determined by NMR or X-ray crystallographic 
methods.  Although the proposed structure of the quadruplex is an 
intramolecular complex stabilised by G-tetrads, this is based solely on DMS 
footprinting studies (201).  The proposed structure also contains one 
heterogenous tetrad.  Furthermore, this region of the c-MYC ongogene 
contains several d(GGAGG) repeats along its 27 base-pair length, which, as 
we have discussed in Section 4.1.7, can potentially form A-tetrads stabilised 
by flanking G-tetrads. 
 
A number of molecules have been identified that bind to and stabilise G-
quadruplexes formed from telomeric DNA sequences in vitro 
(62;178;219;238) and in vivo (81).  These are aromatic compounds, which are 
frequently heterocyclic in nature, and carry an overall positive charge.  G-
quadruplex stabilising molecules have been shown to bind DNA through 
intercalation at both ends of, but not within, a stack of tetrads.  We have stated 
that current ligands cannot penetrate a quadruplex and bind between two G-
tetrads is most likely due to their inability to displace counterions normally 
present between the tetrads (Section 4.1.1).  In this context, incorporation of 
non-guanine bases into tetrad structures could greatly expand the biological 
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function and diversity of quadruplex forming structures, particularly from the 
point of view of stabilising and destabilising these structures by 
pharmacological intervention.  The potential of drug molecules to stabilise 
non-guanine tetrads, which would not normally form, warrants a structural 
study into these structures, particularly A-tetrads, which have the greatest 
potential to form stable quadruplexes. 
  
 
 
Fig.4.9:  Model for the activation and repression of gene transcription involving the 
accessory role of NM23-H2 in interconversion of the unstructured purine and 
pyrimidine single-stranded DNA forms to the paranemic secondary DNA structures. 
Interaction of the G-quadruplex structure with the drug molecule TMPyP4 stabilises 
the gene-off form by inhibition of conversion to the single-stranded gene-on forms. 
Reproduced from (201). 
 
4.2  Experimental Design 
We have carried out a careful NMR/MD approach to determine the details of a 
family of quadruplex structures, each containing a d(GGAGG)4 core.   
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Intermolecular G-quadruplexes may have less biological significance than 
intramolecular G-quadruplexes, which can be formed at the 3' overhang of 
telomeric DNA, but are likely to play a role in vivo in phenomena such as 
recombination and end to end pairing.  In addition to the strong interest in the 
structure and stability of G-quadruplexes, there is also the need to explore the 
role of guanine and other neighbouring residues in the G-quadruplex structure 
vis-à-vis stability and how adjacent residues are perceived in molecular 
recognition by proteins and small ligands.   
 
Previous studies of A-tetrads (Section 4.1.7) have been described in terms of 
the human telomeric repeat, d(TTAGGG)n.  The 3' overhang of telomeric 
DNA is believed to form an intramolecular quadruplex in which the adenines 
do not form a tetrad, but rather form part of the connecting loops (162;234).  
However, the c-MYC promoter region contains d(GGAGG) repeats, which 
could potentially assemble to form A-tetrads.  For this reason, it was decided 
to study sequences containing this repeat within the purine-rich sequence.  We 
have, however, endeavoured to keep this study relevant to those that have 
gone before, while attempting to maximise the potential for formation of a 
stable A-tetrad. 
 
The initial sequence d(TAGGAGGT)4 was chosen as it contained two A-
tetrads, one sandwiched between two sets of G-tetrads, and another at the end 
of a run of guanines, analogous to those studied previously.  It was hoped that 
this could provide an insight into how the flanking sequence affected the 
conformation of an A-tetrad.  This structure, however, was a mixture of one 
minor & one major species, and so a second sequence, d(TGGAGGC)4 was 
designed in order to concentrate on the more stable sandwiched A-tetrad.  A 
cytosine residue was incorporated into this second sequence to provide an 
additional reference for assignment purposes, and from which to derive 
distance restraints using the relaxation matrix approach.  Also, to remove the 
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symmetry of the purine-rich sequence, an extra guanine residue was added on 
the 5' side of the A-tetrad, giving rise to the sequence d(TGGGAGGC)4. 
 
4.3 Materials & Methods 
4.3.1  Synthesis & Purification 
The oligonucleotides were synthesised and purified as described in Section 
2.3.1, and were shown to be > 95% pure and in the quadruplex form by P1 PH 
NMR spectroscopy.  The oligonucleotide sample was quantified 
spectrophotometrically.  The NMR samples were prepared in the single strand 
concentration range of 5.0-8.0 mM (1.3-2.0 mM in quadruplex) in 600 µl of 
mixed solvent, having a final salt concentration of 100 mM KCl and 10 mM 
K2HPO4, for WATERGATE experiments.  The quadruplexes were lyophilised 
and redissolved in D2O solution (600 µl) for the observation of non-
exchangeable proton resonances. 
 
4.3.2  NMR Analysis 
NMR experiments were performed on a Bruker Avance600 spectrometer.  
All one-dimensional NMR experiments were recorded over 32768 data points 
in the f2 dimension, with spectral width of 16.022 ppm and a delay time of 2 s.  
Phase-sensitive Double Quantum Filtered COrrelated SpectroscopY (DQF-
COSY) (171;177), TOtal Correlated SpectroscopY (TOCSY) (11), and NOE 
SpectroscopY (NOESY) (12) experiments were performed, collecting either 
1024 or 2048 points in f2, and between 400 and 512 points in f1.  NOESY 
data at mixing times ranging from 75 ms to 300 ms were collected with a 
spectral width of 16.022 ppm in each dimension for D2O experiments, and 
20.028 ppm for H2O experiments, each with a delay time of 2 s.  Quadrature 
detection in f1 was achieved using time-proportional phase incrementation 
(TPPI).  The solvent signal was suppressed by pre-saturation or using the 
WATERGATE pulse sequence (173).  WATERGATE NOESY spectra at 300 
ms, 150 ms, 100 ms and 75 ms mixing times were acquired using samples 
dissolved in 90% H2O and 10% D2O.  All TOCSY experiments employed a 
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spin-locking field of 7 kHz.  Two-dimensional data were zero-filled to 2048 x 
1024 points prior to Fourier transformation, optimised with a shifted sine 
squared function in both dimensions, and treated with automatic baseline 
correction. 
 
4.3.3  Distance Restraints 
Interproton distances were derived from integration of NOE cross peak 
volumes from NOESY WATERGATE experiments with mixing times of 150 
ms, 100 ms, and 75 ms (90% H2O, 10% D2O).  Distances were determined by 
extrapolation to zero mixing time as before (Section 2.3.4).  For 
d(TAGGAGGT)4, the thymine H6-Me fixed distance (3.0 Å) was used a  
reference distance for all NOEs involving base protons, and the sugar H2'-H2" 
fixed distance (1.85 Å) for NOEs involving only sugar protons.  For 
d(TGGAGGC)4 and d(TGGGAGGC)4, the cytosine H5-H6 distance (2.45 Å) 
was applied to all distances involving base protons, except those involving 
methyls, where the H6-Me distance was again employed as a reference.   
 
For well resolved non-exchangeable cross peaks the distances were given 
upper and lower error bounds of 10% of the calculated distance.  Partially 
overlapped non-exchangeable cross peaks distances were given upper and 
lower error bounds of 20%.  Due to the relative broadness of their 
exchangeable crosspeaks, only non-exchangables were used for distance 
restraint derivation for d(TAGGAGGT)4 and d(TGGGAGGC)4.  For 
d(TGGAGGC)4, where exchangeable crosspeaks were considered, the 
resulting distances were given upper and lower error bounds of 25%.  As well 
as their broadness relative to their non-exchangable relatives, the solvent 
system used for WATERGATE experiments means that the maximum 
theoretical intensity of exchangeable crosspeaks is 90% of that observed for 
non-exchangables. H-bond restraints were included for atoms involved in the 
ideal hydrogen-bonding geometry of the G-tetrad.  The heavy atom-heavy 
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atom distance restraints for O6N6 and N7N7 distances were set to 2.85 r 
0.10 Å.   
 
Fig.4.10:  Selected distance restraints (green) and associated violations (red) for one 
strand of the energy minimised structure of d(TGGACCG)4. Displayed using MolMol. 
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Distance restraints were checked for large geometrical inconsistencies by 
comparing visually with the distances of the energy-minimised quadruplex 
structure derived from unrestrained molecular dynamics simulation using 
MolMol (Fig.4.10).  In order to distinguish between interstrand and intrastrand 
distance restraints resulting from the symmetry of the quadruplex structure, 
the energy-minimised structure was examined using MolMol.  Interstrand 
restraints were manually determined by matching significantly violated 
intrastrand distances with their equivalent symmetry translated interstrand 
distances from the initial energy-minimised structure.   
 
4.3.4  Starting Structures 
The initial model for the quadruplex structures d(TGGAGGC)4 was generated 
using the LEaP module of AMBER 6, and representations of 
d(TGGGAGGC)4 and d(TAGGAGGT)4 were constructed by editing the PDB 
file of the parent structure. 
 
G- and A-tetrads were made by aligning four nucleotide bases, each in the anti 
glycosidic conformation, symmetrically in a plane to form the appropriate H-
bonds.  The A-tetrads were aligned in the N61 pattern (167) with the amino 
hydrogens in H-bonding distance range from the N1 receptor nitrogens.  Since 
no stable H-bonding pattern has been documented for either C- or T-tetrads, 
these were constructed by arbitrarily aligning the bases symmetrically in a 
plane, having overlaid the heavy atoms of the sugars on those of a G-tetrad to 
allow easier construction of the quadruplex.  The quadruplex itself was made 
by stacking these constructed tetrads on top of each other in the desired order, 
with a separation of 3.4 Å between consecutive planes and a 36º twist, 
consistent with B-form DNA (52).  Dephosphorylation of the 5' ends of each 
strand and capping of 3' ends were achieved automatically when the 
quadruplex coordinates were read into LEaP. 
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An initial model of d(TGGGAGGC)4 was generated by reading two copies of 
the coordinates of d(TGGAGGC)4 into MOLMOL and overlaying them with a 
one-residue stagger (Fig.4.11).  This was achieved by superimposing the 
deoxyribose heavy atoms, C1'-C5' and O4', of the overlapping nucleotides.  
The RMSD to the mean averaged over both molecules for the selected atoms 
was 1.02 Å.  Residues 1T and 2G were removed from each strand of one 
quadruplex, and residues 4A to 7C removed from each strand of the other. The 
two PDB files were then combined and edited, and the residues renumbered to 
give the required starting structure. 
 
RMSD fitting of individual A- and T-tetrads to d(TGGGAGGC)4 and 
subsequent editing of the PDB file was also used to generate the structure of  
d(TAGGAGGT)4. 
 
Subsequently, each system was treated as follows: potassium ions were 
inserted between the planes of each tetrad (separated by 3.4 Å).  Further 
potassium counter-ions were then used to negate the negative charge on the 
backbone, and the model was solvated to within a distance of 5 Å using boxes 
of 216 TIP3P H2O molecules.  The periodic box of the d(TAGGAGGT)4 
system measured 47x49x56 Å and contained 2537 water molecules.  The 2196 
H2O molecules surrounding d(TGGGAGGC)4 were enclosed in a periodic box 
measuring 50x47x50 Å.  The periodic box of d(TGGAGGC)4 was 
significantly smaller than the others, at 48x44x49 Å, reflecting the shorter 
sequence length, and housed 1961 TIP3P waters.  In each case, the solvated 
systems were energy minimised at constant pressure using the same procedure 
employed for the duplex and hairpin models. 
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Fig.4.11:  Steps involved in the generation of an initial model for d(TGGGAGGC)4.  
Two copies of d(TGGAGGC)4 were overlaid (a); the top two stacks (d(TG)4) were 
selected from one copy (b), and the bottom four stacks (d(GGAGGC)4) selected from 
the other (c). The selected residues were then combined into one structure (e).  
 
4.3.5  Structure Calculations 
Minimisation was followed by ten iterations of molecular dynamic simulation.  
Each of the first nine rounds of MD comprised 10 ps of simulation, split into 
5000 steps of 0.002 ps duration.  During the opening three iterations, the 
restraining field of 100 kcal ÅP-2 P mol was applied only to the DNA and 
4. Structural Studies of an A-Tetrad in Quadruplex DNA 161
counter-ions, while the temperature of the system was increased from 100K to 
300K.  At this temperature, the potassium ions were released from the 
restraining field and another round of simulation was run.  Over the next five 
iterations the restraining field was reduced to 50, 20, 10, 5 and 2 kcal Å-2 mol.  
The final round of MD was made up of 50000 steps, totalling 100 ps, during 
which the entire system was unrestrained.   
 
Following minimisation and unrestrained MD simulations, NMR restraints 
were introduced to the equilibrated structure and the system allowed to 
undergo 2 ns of restrained MD to satisfy the NMR restraints and search 
adequate conformational space under the influence of water molecules and 
cations.  Typically, the NMR restraints are satisfied well within the 2 ns 
simulation with a tendency towards only small violations associated with the 
terminal residues. 
 
4.3.6  Quadruplex Structures 
For d(TAGGAGGT)4, a total set of 332 restraints was used for energy 
minimizations and restrained molecular dynamics simulations.  No overlapped 
peaks, or peaks not occurring at all three mixing times were considered, and 
thus error bounds of 10% were applied to all distances.  Restrained molecular 
dynamics continued for 1 ns with all NOE restraints active.  This was followed 
by energy minimisation. Snapshots from the final 100 ps of rMD were 
extracted every picosecond.  In the final averaged energy minimised structure, 
none of the applied restraints showed restraint violations >0.5 Å.  The mean 
pairwise RMSD calculated over the final 100 snapshots was 0.82 (r0.1) Å 
over all heavy atoms.  d(TGGAGGC)4 underwent 2 ns of molecular dynamics 
simulation, restrained by a set of 656 NOE-derived restraints and 16 H-bond 
restraints.  Of the experimentally-derived restraints, 620 were developed from 
well-resolved non-exchanging crosspeaks, and 36 involving exchangeable 
base protons.  The latter restraints were thus subject to the highest error 
bounds (25%).  In this case, only 6 of the 155 per strand NOEs showed 
4. Structural Studies of an A-Tetrad in Quadruplex DNA 162
restraint violations >0.5 Å but <0.8 Å, all of which corresponded to very weak 
NOEs.  The mean RMSD for the final 100 snapshots of d(TGGAGGC)4 was 
0.58 (r0.1) Å.  d(TGGGAGGC)4 was modelled as above for 2 ns, subject to 
112 high quality (10% error bounds) NOE derived restraints per strand (448 
total for quadruplex) and a total of 20 H-bonding restraints.  Again, the mean 
pairwise RMSD calculated over the final 100 snapshots was low, at 0.55 
(r0.1) Å. 
  d(TAGGAGGT) d(TGGAGGC) d(TAGGAGGC)
NOE-derived restraints     
non-exchangable 332 620 448 
exchangable N/A 36 N/A 
Implied restraints    
H-bonds N/A 16 20 
Restraint Violations    
>0.5Å 0 24 0 
>0.8Å 0 0 0 
RMSD    
heavy atoms 0.82 (±0.1) Å 0.58 (±0.1) Å 0.55 (±0.1) Å 
 
Table 3.1:  Summary of modelling statistics for the final 100 ps of 1 ns rMD 
trajectories of d(TAGGAGGT) and d(TAGGAGGC), and the final 100 ps of a 2 ns 
trajectory for d(TGGAGGC). 
 
4.4  Results & Discussion 
4.4.1  Non-Exchangable Proton Assignments 
Quadruplex DNA structures have been shown to exhibit helical parameters of 
twist and rise close to those of B-DNA duplexes, in both crystalline (170) and 
solution (2) states.  As such, many of the assignment pathways for B-form 
DNA described in Section 2.4.2 are also relevant for tetraplex structures.  
Resonance assignments of exchangeable and non-exchangable protons were 
based on information from NOESY spectra at various mixing times (75-300 
ms) and through-bond scalar coupling interactions observed from TOCSY and 
DQF-COSY spectra.  Full WATERGATE NOESY spectra (tm=300 ms) are 
shown for d(TGGAGGC)4 (Fig.4.12), d(TAGGAGGT)4 (Fig.4.13), and 
d(TGGGAGGC)4 (Fig.4.14).  
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Expanded portions of the NOESY spectrum of d(TGGAGGC)4, recorded at 
278 K with a mixing time of 300 ms, and showing the sequential pathway 
followed for the assignment of the sugar H1' protons and the base H6/H8 
protons of each nucleotide, can be plotted (Fig.4.15(b)).  The sequential 
connectivities of each H6/H8 base proton involving its own and its 5'-flanking 
H1' sugar protons can be traced in the same manner as for B-like duplex DNA 
structures.   Fig.4.15(a) shows NOE connectivities between the base H6/H8 
protons and their own and their 5'-flanking H2' and H2" sugar protons.  These 
pathways have also be traced out on the NOESY contour plots of 
d(TGGAGGC)4 and d(TAGGAGGT)4 (data not shown). 
 
 
 
Fig.4.12:  NOESY spectrum of d(TGGAGGC)4 in H2O solution, recorded at 278 K 
with a mixing time of 300 ms. 
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Fig.4.13:  NOESY spectrum of d(TAGGAGGT)4 in H2O solution, recorded at 273 K 
with a mixing time of 300 ms. 
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Fig.4.14:  NOESY spectrum of d(TGGGAGGC)4 in H2O solution, recorded at 298 K 
with a mixing time of 300 ms. 
 
Assignments of all the deoxyribose spin systems, encompassing H1', H2', H2", 
H3', H4', H5' and H5" protons, were obtained from a combination of NOESY 
and TOCSY spectra.  As was the case for the duplex and hairpin loop 
structures, the H2' & H2" and, where possible, H5' & H5" resonances were 
assigned stereospecifically on the basis of their NOE cross peak intensities in 
the 125 ms NOESY spectra.  According to Shugar & Rhemins rule (179), in 
any sugar conformation the interproton distance between H1'-H2' is always 
shorter than the H1'-H2" distance.  The opposite holds true for H4'- H5'/H5" 
interproton distances.  Thus the resonances of the H2' for all the nucleotides in 
d(TGGAGGC)4 and its sister quadruplexes appear upfield of the resonance of 
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the H2" protons, while H5' protons come into resonance downfield of their 
neighbours.   
 
 
 
Fig.4.15:  Expanded regions of the NOESY spectrum of d(TGGAGGC)4, showing 
NOE connectivity pathways between (a) H6/H8 & H2'/H2" protons, and (b) H6/H8 & 
H1' protons. 
 
In each model system, an unusually downfield shifted non-exchangeable 
resonance at approximately 9.3 ppm can be observed (Fig.4.16).   This gives 
strong NOEs to the imino protons of the guanines flanking the adenine base in 
the conserved central region (G3 & G5 in d(TGGAGGC)4, and G4 & G6 in 
d(TAGGAGGT)4 & d(TGGGAGGC)4).  These observations imply that the 
peak corresponds to the sandwiched adenines H2 proton.  If this is the case, 
the proton would have to be subjected to strong ring current effects, or near to 
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another strongly desheilding environment in order to perturb the proton to its 
observed chemical shift, some 1.1 ppm downfield of that typically seen for 
AH2 protons.  This phenomenon is discussed more fully in the context of A-
tetrad arrangement in Section 4.4.4.   
 
 
 
Fig.4.16:  A section of the NOESY contour plot of d(TGGGAGGC)4, expanded to 
show the NOEs between the H2 proton of the adenine base and the imino protons of 
the flanking guanines, G4 & G6. 
 
The intensities of the NOE crosspeaks between base H6/H8 protons and the 
sugar protons H1', H2' and H2" on their 5'-flanking residues are similar for all 
residues in these models, not just for their highly stabilised d(GGAGG)4 core 
sequences (Fig.4.15).  This suggests that the 5'- and 3'-terminal pyrimidine 
residues are not randomly located or flipped-out of the helix, as suggested by 
some previous studies (162;170), but are involved in stacking with their 
neighbouring nucleotides.  Although stable pyrimidine tetrads have been 
observed previously (166), these have always been flanked on both sides by 
stable G-quartets, and have shown no evidence for H-bond formation.  It is 
therefore unlikely that these terminal residues hydrogen bond with their 
interstrand neighbours, but that stacking interactions are their main stabilising 
force. 
 
The sequential NOE connectivity pathways along the DNA backbone of these 
systems give patterns and intensities of NOEs consistent with their adenine 
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bases stacking within the quadruplex with all purine glycosidic torsion angles 
in the anti range. 
 
Glycosidic anti and syn conformations can be differentiated by distances of 
3.7 Å and 2.5 Å, respectively, between the H6/H8 and H1 protons (131).  
These distances were calculated to be in the range 3.33.8 Å for all bases in 
these three models, using the relaxation matrix approach, as described in 
Section 2.3.4.  This indicates that all residues in d(TGGAGGC)4, and the 
related quadruplex structures, adopt anti glycosidic torsion angle 
conformations.  This agrees with what has been found with all the 
intermolecular G-quadruplex structures, with the exception of d(AGGGT)4 
(232), in which the terminal adenines have been shown to adopt a syn 
conformation.  The data presented here are consistent with all bases adopting 
the anti conformation. 
 
4.4.2  Exchangable Proton Assignments 
1D and 2D NMR spectra of this series of quadruplex structures (pH 7.0, 100 
mM KCl, 10 mM phosphate) show that these structures display four-fold 
symmetry with well-resolved guanine NH resonances consistent with the 
presence of stable G-tetrads.  Both d(TAGGAGGT)4 and d(TGGAGGC)4 
exhibit four exchangeable imino proton resonances, while d(TGGGAGGC)4 
gives rise to five such signals on the 1D P1 PH NMR spectrum.  
 
The presence of these four imino signals, one for each G-tetrad, on the 
NOESY contour plot of d(TGGAGGC)4 (Fig.4.17) suggests a four-fold 
symmetry, where imino-imino contacts within the tetrad are between 
magnetically equivalent protons.  This gives rise to only one signal per tetrad, 
and implies a parallel stranded structure.  The equivalent anti-parallel structure 
would be expected to give rise to two sets of intra-tetrad imino signals (2), one 
for each pair of parallel strands. 
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Fig.4.17:  P1PH NMR and NOESY spectra (600 MHz) of d(TGGAGGC)4 at 279K (90% 
H2O, 10% D2O), expanded to highlight the imino region (10.3-11.8 ppm). Imino 
resonaces are evident for each of the four G-tetrads.  NOE crosspeaks are clearly 
evident between adjacent tetrads G2 (11.6 ppm) & G3 (11.2 ppm), and G4 (10.7 
ppm) & G5 (10.5 ppm).  
 
The equivalent expanded region of the NOESY spectrum of d(TAGGAGGT)4 
(Fig.4.18) clearly shows two conformations, one major and one minor, 
involved in chemical exchange.   The significance of this exchange process 
will be discussed in detail in Section 4.4.3.  For the purpose of our current 
discussion, it is sufficient to note that there are four imino signals evident for 
each conformer, which again implies a parallel, four-stranded structure 
containing four G-tetrads. 
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Fig.4.18:  P1PH NMR and NOESY spectra of d(TAGGAGGT)4 at 279K (90% H2O, 10% 
D2O), expanded to highlight the imino region (10.3-11.8 ppm).  In addition to the 
sequential crosspeaks, as described in Fig.1, exchange crosspeaks between minor 
(11.0-11.3 ppm) and major conformers are evident. 
 
Similarly, the imino region of the NOESY spectrum of d(TGGGAGGC)4 
(Fig.4.19) clearly exhibits five distinct resonances; one for each of the G-
tetrads in the conserved d(GGAGG)4 core, and an additional signal 
corresponding to the stable 5'-flanking G-tetrad.  
 
Additionally, guanine imino protons give NOEs with their own base protons 
and to the base protons of their 5'-flanking neighbours in the conserved 
d(GGAGG)4 portion of each system.  Thus, for the shorter 7-mer sequence, 
d(TGGAGGC)4, the 11.6 ppm imino proton of G2 gives NOEs to the base 
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protons G2H8 and T1H6, the 11.2 ppm imino proton of G3 interacts with base 
protons G3H8 and G2H8, while downstream of the A-tetrad, NOE interactions 
can be seen between the 10.5 ppm G5NH and the base protons G5H8, A4H8 
and A4H2, and between the G6NH at 10.7 ppm and both G6H8 and G5H8 
(Fig.4.20(a)).  Similar interactions can be traced out for the longer 8-mer 
sequences d(TAGGAGGT)4 and d(TGGGAGGC)4.  The latter sequence 
contains an extra step, between the additional G2 imino at 11.5 ppm and the 
G2H8 and T1H6 base protons (Fig.4.20(b)), which is absent in its adenine 
containing sister.  This is, of course, due to the lack of an imino proton on 
adenine bases.  
 
 
 
Fig.4.19:  P1PH NMR and NOESY spectra of d(TGGGAGGC)4 at 298K (90% H2O, 10% 
D2O), expanded to highlight the imino region (10.3-11.8 ppm).  Note the crosspeaks 
between G3NH (11.12 ppm) and G4NH (11.09 ppm) are partially obscured due to 
their closeness to the diagonal. 
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Fig.4.20:  Expanded region of the NOESY spectra of (a) d(TGGAGGC)4, and (b) 
d(TGGGAGGC)4, showing interactions between base protons.  NOEs, labelled (A)-
(T), are assigned as follows: (A,J) G2NH-G2H8, (B,K) G2NH-T1H6, (C,L) G3NH-
G3H8, (D,M) G3NH-G2H8, (E) G5NH-G5H8, (F) G5NH-A4H8, (G) G5NH-A4H2, (H) 
G6NH-G6H8, (I) G6NH-G5H8, (N) G4NH-G4H8, (O) G4NH-G3H8, (P) G6NH-G6H8, 
(Q) G6NH-A5H2, (R) G6NH-A5H8, (S) G7NH-G7H8 and (T) G7NH-G6H8. 
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The expanded region of the NOESY spectrum of d(TGGAGGC)4 in Fig.4.21 
includes distinct NOEs between each guanine imino proton and its own amino 
protons.  Fig.4.21 also demonstrates NOEs between amino protons on the 
same bases, which resonate at two distinct chemical shifts.  The observation of 
two distinct amino protons is consistent with slow rotation of the CN bond at 
low temperature.  One hydrogen of the amino group resonates near 6.00 ppm 
and is exposed to the solvent, while the other hydrogen near 9.00 ppm exhibits 
a NOE with the its own base H8 proton.  Since the amino proton is over 7.3 Å 
from its own H8 proton, the NOE can be attributed to the closeness of this 
amino group to a symmetry related guanine base within the G-tetrad.  The G2 
imino proton gives NOEs with its 5.8 ppm and 9.9 ppm amino protons, the G3 
imino with its 6.1 ppm and 9.4 ppm aminos, and the G5 imino with its 5.6 
ppm and 9.4 ppm aminos.  The G6 amino proton of this sequences, as with the 
G7 amino in its longer cousins, could not be unambiguously assigned, due to 
the high density of crosspeaks in this region of the spectrum.  Characteristic of 
the amino NOEs is broadness implying a degree of exchange with the solvent. 
 
Particularly strong NOEs are also observed between A4H8 and G5NH2, 
suggesting strong stacking interactions across the 5'-AG step (Fig.4.22).  
These interactions are reflected in the relative stabilities of the G-tetrads as 
evident from NHoND exchange experiments (Section 4.4.5), where the 
disappearance of signals in the 1D spectrum after redissolving the lyophilised 
sample in D2O can be observed.  
 
These NOEs provide evidence of the interstrand interactions between the 
guanine residues that are involved in G-tetrad formation, as they cannot be 
accounted for by NOEs within the same strand.  In addition, such NOEs 
impart evidence of good stacking interactions between adjacent G-tetrads.  
More importantly, NOEs between adjacent A- and G-tetrads demonstrate 
favourable interactions between these tetrads in this conserved family of 
quadruplex structures. 
4. Structural Studies of an A-Tetrad in Quadruplex DNA 174
 
Fig.4.21:  Expanded region of the NOESY spectrum of d(TGGAGGC)4 showing NH2-
NH2* interactions, and NH-NH2* interactions.  NOEs, labeled (A)-(G), are assigned 
as follows:  (A) G2NH2-G2NH2*, (B) G2NH2-G3NH2*, (C) G3NH2-G3NH2*, (D) 
G5NH2-G5NH2*, (E) G2NH-G2NH2*, (F) G3NH-G3NH2* and (G) G5NH2-G5NH2*.  
Solvent exposed amino hydrogens are denoted NH2*. 
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Fig.4.22:  Portion of the NOESY spectrum of d(TGGAGGC)4 showing amino-base 
proton interactions in the conserved central portion.  NOEs, labeled (A)-(F), are 
assigned as follows: (A) G5NH2-A4H8, (B) G5NH2-G5H8, (C) C7H6-G6H8, (D) 
C7H5-H6, (E) G5NH2*-A4H8 and (F) G5NH2*-G5H8. 
 
The amino protons of the sandwiched adenine were not observed in the 1D 
NMR spectra of d(TGGAGGC)4, d(TGGGAGGC)4 or d(TAGGAGGT)4.  
Prior NMR studies have rationalised the absence of ANH2 resonances in terms 
of an A-tetrad that is not significantly stabilised by H-bonding (167).  In 
studies where these amino resonances have been observed, they have been 
assigned on the basis of NOE connectivities with 3'-flanking guanine imino 
protons.  In such cases, the A-tetrad was located either on the 5' terminal end 
of the structure (167) or flanked on its 5' face by non-tetrad forming 
pyrimidine bases (73), so that purine-purine stacking interactions across the 
NpA step did not factor, and the formation of stable H-bonds was intrinsic to 
tetrad formation. 
 
4.4.3  Patterns of Potassium Ion Binding 
Previous theoretical studies looking at electrostatic surface potentials (ESP) of 
A-tetrads using density functional theory (DFT) have shown the negatively 
charged binding pocket present in guanine tetrads is lacking, leading to the 
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conclusion that adenine is unlikely to coordinate a monovalant cation (83).  
This is in agreement with the molecular mechanical picture that shows the 
relatively weak electrostatic interactions with the nitrogen lone pair on the 
adenine 6-NH2 group do not appear to compensate for the repulsion between 
potassium ions.  These models show that one potassium cation bound between 
the GpA or ApG site is tolerated but gives no indication as to the relative 
stability of models in which the GpA or ApG sites are devoid of potassium 
ions.  
 
The DFT calculation carried out by Gu and Leszczynski (84) suggests that 
out-of-plane positive electrostatic density on the A-tetrad itself could interact 
with the ESP located around the guanine carbonyls in a stacked GpA, or ApG, 
quadruplex. Contour plots of the electrostatic potentials of planar adenine 
tetrads in both N61 and N67 conformations revealed positive areas in the 
central part approximately 1.5 Å above the tetrad plane.  Since the negative 
ESP appears around the central area 1.6 Å above the guanine tetrad plane 
(129), this positive centre of the adenine tetrads is expected to reinforce the 
stacking between the A-tetrads and the G-tetrad in stacked tetraplexes.  This 
strongly suggests a mechanism that placates guanine-adenine tetrad 
interactions without the need for an intervening cation. 
 
The role of KP+P ion binding in A-tetrad stabilisation is at present unclear and 
was further investigated by molecular dynamics simulations using the 
AMBER 5.0 package employing an explicit solvent model. 
 
NMR structural models of d(TGGAGGC)4 and its related quadruplexes were 
generated on the basis of a large number of NOE-derived distance restraints as 
described in Section 4.3.6.  Initially, KP+P ions were inserted only between G-
tetrads (GxG-A-GxG).  These structures give a stable MD trajectory over 2 ns 
of simulation.  Similar structures were subsequently modeled with KP+P ions 
inserted between each pair of tetrads (GxGxAxGxG).  After careful 
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equilibration of the solvent, the DNA co-ordinates were slowly released 
according to the standard protocol (see Section 4.3.5) to undergo free 
dynamics at 300K.P P Very rapidly (<2 ps) it was observed that one KP+P ion was 
ejected from the structure at either the 5'-AG or 5'-GA step without apparent 
discrimination.  Repeat simulations with the homologous sequence 
d(TGGGAGGC)4 demonstrated this to occur irrespective of the bases flanking 
the conserved d(GGAGG)4 core.  The resulting structures with one vacant site 
(GxG-AxGxG and GxGxA-GxG) are stable for at least 1 ns of unrestrained 
dynamics and are of comparable stability to the initial structure with both 5'-
GA and 5'-AG sites vacant.  
 
The ANAL module of AMBER 5.0, a function of which is energy 
decomposition of different groups of atoms, was used to find the interaction 
energies between different parts of our systems.  Previous studies have shown 
that the negative areas of ESP in the plane of an A-tetrad are limited to the 
space around the N1 and N6 nitrogens, and that the O6 oxygens are the only 
area of significant negative ESP in G-tetrads (83;84).  Electrostatic 
components of interactions between these selected groups and intercalated 
potassium cations, and between the entire tetrad and the ions were found to be 
in good agreement.  Dissection of the electrostatic energy components from 
the molecular mechanics data, as represented in Fig.4.23, shows that 
repulsions between KP+P ions bound between adjacent tetrads is large, with a 
mean value of approximately 30 kJ mol P-1 P averaged over all such interactions in 
both d(TGGAGGC)4 and d(TGGGAGGC)4.  However, when the tetrads 
consist of guanines in the form (GxGxN) or (NxGxG), favourable interactions 
between KP+P ions and the G bases, which exceed 100 kJ mol P-1 P for each tetrad-
ion pair, more than offset the repulsion between charges.  This is not the case 
when KP+P ions are bound on either face of an A-tetrad; (G-AxG) or (GxA-G).  
In such cases, there is a favourable interaction of 30 kJ mol P-1 P between the ion 
and the A-tetrad, which even when added to the complementary relationship 
between that ion and the adjacent G-tetrad (100 kJ molP-1 P), does not offer 
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nearly as much compensation for the repulsive force between ions.  It was not 
possible to analyse the electrostatic energy components for the (GxAxG) 
because, as we have discussed, this system was stable for less than 2 ps of the 
MD trajectory. 
 
 
 
Fig.4.23:  Electrostatic energy components of the conserved d(GGAGG)4 core of 
d(TGGAGGC)4 and d(TGGGAGGC)4, averaged from 1 ns of MD simulation of each 
quadruplex.  Analysis was carried out for models with no ions on either face of the A-
tetrad (a), with a vacant ApG step (b) and with a vacant GpA step (c).  Attractive (-) 
and repulsive (+) interactions are in units of kJ mol P-1P. 
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The data seem to favour versions of both d(TGGAGGC)4, d(TGGGAGGC)4, 
and of the major conformer of d(TAGGAGGT)4, without potassium ions 
intercalated at either GpA or ApG steps.  There are insufficient stabilising 
interactions, as calculated by ab initio DTF calculations, to favour a potassium 
bound site over a vacant one, which is stabilised by complementary 
electrostatic surfaces on the stacked tetrads.  Indeed, the electrostatic energy 
components from the molecular mechanics data show that the constructive 
electrostatic interaction (-23 kJ molP-1 P) between stacked A- and G-tetrads is 
reversed to an adverse interaction of 25 kJ molP-1 P upon the introduction of a KP+P 
ion (Fig.4.23(b);(c)). 
 
Surprisingly, a change in the sequence of the unstructured 3'- and 5'-termini to 
d(TAGGAGGT)4 results in the partial stabilisation of a minor conformer 
(~20%) with guanine imino protons resonating over a much narrower 
chemical shift range (11.0-11.4 ppm) (Fig.4.18).   2D NOESY spectra at 298K 
(pH 7.0, 100 mM KCl) reveal strong chemical exchange cross-peaks between 
the two species, which we estimate to be interconverting on a time scale of a 
few seconds.  The major conformer shows the same pattern of protection 
towards NH/ND exchange seen for d(TGGAGGC)4.  The observed time scale 
of interconversion between conformers demonstrated in Fig.4.18 is fast 
enough to preclude a conformational equilibrium that involves disruption of 
A- or G-tetrads, since strand dissociation and re-annealing has been shown to 
occur over a period of hours at 298K (Section 4.4.5).   
 
The presence of a minor conformer of d(TAGGAGGT)4 can be rationalised in 
terms of a KP+P ion binding at either the 5'-GA or 5'-AG site.  Though either 
model has been shown to possess comparable stability, the G4H8 resonance 
corresponding to the guanine at the 5'-GA step is perturbed more significantly 
than any other base proton in the NOESY spectrum at 279K (Fig.4.24).  
Although the minor conformer is only weakly populated, the G4H8 is clearly 
split into two resolved signals consistent with a KP+P ion binding with low 
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affinity at the 5'-GA step (GxGxA-GxG), rather than at the 5'-AG step where 
the purine-purine stacking interactions appear to be stronger (Section 4.4.4).  
Additionally, the A5H8 resonance is significantly broadened, though two 
signals could not be resolved.  Based on the ratio of major and minor 
conformers observed by NMR, we estimate a binding energy of only ~3 kJ 
mol P-1 P, although the kinetic barrier to exchange is clearly significant since the 
two conformers are in slow exchange. It is uncertain why a terminal 5'-TA 
versus 5'-T should produce such a subtle difference in KP+P binding affinity at 
the 5'-GA step resulting in the observation of two conformers for 
d(TAGGAGGT)4 but only one for d(TGGAGGC)4 and d(TGGGAGGC)4.  It 
has, however, been shown that the presence of extra bases at the ends of 
quadruplexes can have a destabilising effect (89;147;167). 
 
 
Fig.4.24:  Expanded region of the NOESY spectrum of d(TAGGAGGT)4, showing 
NOE connectivity pathways between H6/H8 & H1' protons with a particular emphasis 
on G4H8 signal splitting. 
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4.4.4  A-Tetrad Orientation 
As we have discussed in Section 4.4.1, both d(TGGAGGC)4 and 
d(TGGGAGGC)4, exhibited strong NOEs between the AH2 base protons and 
the imino protons of the flanking guanines, providing evidence for good 
stacking across the GpA and ApG steps. 
 
Observed NOEs can be used to rationalise which A-tetrad orientation is 
preferred by these models:  Distances between base protons across the GpA 
step are broadly similar in both N61 and N67 models.  The distance between 
GH1 and AH2 in an idealised quadruplex is 3.8 Å when the A-tetrad is in the 
N61 orientation and 4.1 Å when the N67 conformer is preferred.  The GNH2-
AH2 distance across the GpA is maintained at approximately 4.0 Å in both 
models.  This is of little use in determining which conformation is adopted, as 
both models are consistent with the NMR data, in which NOESY crosspeaks 
can be observed for these interactions (Fig.4.16). 
 
Across the ApG step, however, there are significant differences in interproton 
distances between the two proposed A-tetrad forms.  The AH2-GH1 
interatomic distance for the N61 model is 4.9 Å, compared with 4.2 Å for the 
N67 conformer.  Similarly, the AH2-GNH2 distance is much larger for the 
N61 model, at 5.6 Å, while this distance is 3.8 Å for an idealised N67 A-tetrad 
sandwich.  In the NOESY spectra of both d(TGGAGGC)4 and 
d(TGGGAGGC)4, relatively intense crosspeaks can be observed between AH2 
and GH1 protons, which are inconsistent with the larger distance measured in 
the N61 model.  The NOE crosspeaks observed for interactions involving 
GNH2 protons were generally broad, and of little use in distinguishing 
between the two models. 
 
To assist further with the task of deciding which conformation is preferred by 
the A-tetrads in our models, the same NOE derived restraints were applied to 
two structural models with different A-tetrad alignments (Fig.4.7), following 
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unrestrained molecular dynamics.  Over the course of the 1 ns rMD 
simulation, both models should ideally converge to a similar alignment, and 
thus give an insight into which of these two is the preferred orientation of an 
A-tetrad. 
 
For these simulations, the potential ion binding sites on each face of the A-
tetrads were vacant, consistent with Section 4.4.3.  In each case, the N67 
model reverted to N61 orientation before the first 100ps of rMD was 
completed, with the resultant structure giving a stable MD trajectory over at 
least 1 ns.  The transition from N67 to N61 occurred over one 2 ps timestep, 
with no intermediate orientation evident on the MD sampling timescale.  Both 
final averaged energy minimised structures of d(TGGAGGC)4 (calculated 
over  the final 100 ps of each simulation) were superimposable and gave a 
pairwise RMSD fit of 0.78 (±0.1) Å, indicating that the final structures had 
converged from very different starting structures. 
 
In order to facilitate a comparison between backbone torsion angles in both 
N61 and N67 versions of d(TGGAGGC)4 over a meaningful timescale, a full 
nanosecond of molecular dynamics simulation was carried out on an enforced 
N67 model.  This system was subject only to ideal H-bonding restraints for 
each G-tetrad (Section 4.1.1), and heavy atom-heavy atom distance of 3.15 
(r0.1) Å for N6-N7 distances in the A-tetrad.  This allowed for the study of a 
N67 oriented A-tetrad over a timescale for which it would not normally be 
stable.  Dials plots of backbone torsion angles were plotted for A-tetrad 
nucleotides in each system for the final 500 ps of their 1 ns rMD simulation 
(Fig.4.25). 
 
The dials plots clearly illustrate the difference in backbone conformation at the 
A-tetrad following conversion from N67 to N61 species.  Although the overall 
conformation is relatively unchanged, certain angles in the N67 species do 
show a much larger range of backbone dynamics than in the N61 type.  The 
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increased amplitude of fluctuations of ȗ, Į, and Ȥ angles reflects the inherent 
instability of the former model.  The unfavourable torsion angle values seem 
to be imposed by the relative inflexibility of the enforced N67 tetrad.  
Backbone torsion angles for all G-tetrads are consistent for both models, as are 
pyrimidine tetrads (data not shown).  Terminal residues display large 
fluctuations in torsion angles, consistent with the large volume of 
conformational space they sample over the duration of the rMD run. 
 
 
 
Fig.4.25:  Dials plots of backbone torsion angles of adenosine nucleotides in (a) N67 
and (b) N61 conformers of d(TGGAGGC)4 representing the final 500 ps of a 1 ns rMD 
simulation. 
 
Although a large number of NMR studies of nucleic acids have been carried 
out over the years, and general chemical shift trends are known (250), attempts 
to understand this behaviour have lagged behind similar work for proteins.  X-
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ray derived structures of proteins are often good models for protein behaviour 
in solution, but this is less true for nucleic acids, since differences between 
water and electrolyte conditions in solid- and solution-states can be associated 
with significant structural changes (61;62;162;234).  The quality of published 
solution structures of nucleic acids has been adversely affected by a general 
lack of long-range constraints that help define global conformations for 
proteins.  In spite of these difficulties, there now exists a large enough body of 
high quality structural information about nucleic acids to allow for the 
empirical examination of chemical shifts (49). 
 
Empirical analysis of shift dispersion involves using an average value of the 
chemical shift for each type of proton from a database of nucleic acids, or a 
random coil value from single stranded DNA.  These shifts are then adjusted 
to allow for environmental factors in the context of the structure of interest 
that give rise to shielding or deshielding at the probe nuclei.  There are many 
potential contributions to chemical shift dispersion in nucleic acids, including 
ring currents, other magnetic anisotropies, electrostatics and solvent effects.  
When considering only sugar H1' and base protons, it has been shown to be 
sufficient to consider only ring current contributions from aromatic bases and 
electrostatic interactions from partial charges in the sugars and bases (239).  A 
substantial part of the observed chemical shift dispersion can be explained by 
ring current theories, with smaller estimated contributions coming from 
electrostatic effects.  As the name suggests, empirical analysis involves simple 
addition of the database values and the calculated proton shift contributions to 
give predicted values of chemical shift amenable to comparison with 
experimental results.  This process can prove very useful when trying to 
determine which of a series of starting structures best matches with 
experimentally derived data. 
 
To compare expected chemical shifts in the two possible A-tetrad 
conformations, SHIFTS 4.1.1 (30), a program to estimate chemical shifts in 
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nucleic acids, was employed.  SHIFTS uses a database of 20 structures, 
including 3 quadruplexes, and 1631 proton shifts.  Only protons bonded to 
carbon are considered, since protons bonded to electronegative atoms are 
subject to H-bonding and solvent effects not measured by the program (207).  
SHIFTS approximates the origin of the ring current as a single point-dipole 
located in the center of each aromatic ring, recognizing a single ring for 
pyrimidines and two distinct rings for each purine base.  The chemical shift 
perturbation is then calculated based on the distance and the angle between the 
proton and the center of the aromatic ring.  Electrostatics contributions are 
calculated by ab initio methods using the Cornell empirical force field (47).  
This is also the force field employed by AMBER to calculate electrostatics. 
 
SHIFTS was used to compute H1', H2 and H8 proton chemical shifts for 
various models containing N61 and N67 oriented A-tetrads, with a view to 
comparing the calculated shifts with those from the NOESY assignments of 
d(TGGAGGC)4, d(TGGGAGGC)4 and d(TAGGAGGT)4, and so ascertaining 
which orientation the A-tetrads prefer in these systems.   
 
Although SHIFTS analysis of both N61 and N67 conformers of 
d(TGGAGGC)4 did not accurately estimate the observed chemical shift of the 
A4H2, analysis of isolated component elements of each did offer an insight 
into the unusually downfield shifted resonance of the H2 proton.  Predicted 
shifts for the A4H2 protons in the N61 and N67 models were 7.75 ppm and 
7.80 ppm respectively.  However, in these models SHIFTS calculated the 
downfield shifting effect of the neighbouring N7 would be cancelled out by 
the shielding effect from the adjacent G-tetrads.  Empirical analysis of an 
isolated A-tetrad, where ring current effects from flanking G-tetrads are no 
longer a consideration, did predict a chemical shift of 9.27 ppm for A4H2 in 
the N61 conformation, which is consistent with the NMR data.  Combined 
with the lack of evidence for stable hydrogen bonding of the adenine NH2 
protons, this suggests that the orientation of A-tetrads is not determined by the 
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formation of stable N1···H···N1 bonds.  Molecular modelling shows that the 
structure does adopt a conformation amenable to the formation of these 
hydrogen bonds, though it may be that some other stabilising force, such as 
electrostatic and stacking interactions, are involved. This strongly suggests 
that transient, unstable H-bonds do play some part in the overall stabilisation 
of these A-tetrads. 
 
Hunter (102) analysed the sequence dependent structure of duplex DNA on 
the basis of base stacking (ʌ-ʌ) interactions.  This study showed that sugar-
phosphate backbones are relatively flexible and, while they constrain the bases 
to a small region of conformational space, they play no role in determining the 
sequence-dependent structure of DNA.  It is the stacking interactions that 
provide the crucial link between sequence, structure and properties.  Stacking 
interactions refer to not only the interactions between ʌ-electrons on 
consecutive bases, but also include Van Der Waal's interactions and other 
electronic terms.  There are four principal components of ʌ-ʌ interactions.  
VdW interactions are the major contributing factors, but electrostatic 
interactions between partial atomic charges, between charge distributions 
associated with ʌ-electron density, and between charge distributions and 
partial atomic charges must also be considered.  The latter term in particular 
plays an important role in determining sequence-dependent effects in DNA.  
Hunter analysed the stacking interactions for the ten possible base-pair steps in 
Watson-Crick DNA. 
 
Although this and other previous studies (103) concentrated solely on duplex 
DNA, they are still largely amenable to the study of quadruplex DNA.  
Though the six co-ordinates that describe the degrees of freedom within a 
single base pair (buckle, propeller-twist, etc.) are relevant only to duplex 
DNA, the co-ordinates which define an individual base step (rise, twist, etc.) 
are also relevant to quadruplex DNA, as each individual strand of the tetraplex 
is B-like.   
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These studies have shown that, in B-form duplex DNA, a 5'-AG base step is 
more stable than a 5'-GA base step, due largely to less repulsive electrostatic 
interactions between ʌ-electron charge distributions and partial atomic charges 
on consecutive bases.  This also holds true to the analogous base steps in 
quadruplex DNA, as demonstrated in Section 4.4.5. 
 
Attractive VdW interactions are maximised when overlap between stacked 
bases is maximised.  In the N61 orientation of the A-tetrad, the six-membered 
ring of the adenine base lies over the five-membered ring of the 5'-flanking 
guanine.  This is a similar stacking arrangement to that found between 
adjacent G-tetrads in parallel quadruplex structures (170), and in poly(dG)-
poly(dA) B-form duplex DNA.  In projection, this orientation of the rings 
resembles a decagon, where the vertices of one five-membered ring lie 
between those of the ring below (Fig.4.26(a)).  As well as demonstrating 5'-
GA ring-stacking interactions similar to duplex DNA, the five-membered ring 
of the adenine eclipses the six-membered ring of its 3'-flanking guanine in an 
identical manner to that observed in its duplex analogue (Fig.4.26(b)).  This 
has been shown to be a favourable interaction, allowing the five-membered 
ring of the adenine base to maximally overlap the six-membered ring of the 3'-
flanking guanine (146).  It is interesting to note that a similar stacking 
interaction has been observed accross 5'-GG steps in quadruplex structures 
(111;234).  In poly(dG) quadruplex structures, this type of stacking geometry 
brings the carbonyl oxygens of the upper and lower tetrads into proximity.  In 
this case, potassium binding adds an additional driving force for the bases to 
adopt this orientation that is absent in adenine-containing steps. 
 
However, these interactions are largely absent in the N67 conformation.  In 
both 5'-GA and 5'-AG steps, there is minimal overlap, and minimal VdW 
contact, between consecutive bases.  On the 5'-GA step, the ring systems of 
the adenine and guanine bases are offset entirely from each other (Fig.4.27(a)), 
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while on the 5'-AG step the six-membered ring of adenine staggers both ring 
systems of guanine so that the ʌ-electron densities are offset from each other 
(Fig.4.27(b)).   
 
 
Fig.4.26:  Stacking patterns of the 5'-GA (a), and 5'-AG (b) steps of the average 
minimised structure of d(TGGAGGC)4 in the N61 conformation.  For clarity, adenines 
are displayed in red and guanines in blue. 
 
 
 
Fig.4.27:  Stacking patterns of the 5'-GA (a), and 5'-AG (b) steps of the average 
minimised structure of d(TGGAGGC)4 in the N67 conformation. 
 
A quantum chemical study of the stability and structures of the two isolated 
forms of the adenine tetrad (84), which made the assumption that the stability 
of tetrads in the isolated form is the main contribution to the formation of  
tetrads in quadruplexes, showed that the H-bonds in the A-tetrad do not 
significantly alter the geometric parameters of the adenines.  This was not 
unexpected because the H-bonding between the H atom of the amino group 
and the N1 or N7 atom was shown not to be very strong.  The hydrogen bonds 
holding the adenines together in N61 were shown to be 1.3 kcal molP-1 P stronger 
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than those in N67, though H-bonding energies were shown to be insignificant 
compared with potential stacking energy between the A-tetrad and a flanking 
G-tetrad (Section 4.4.3).   
 
For these model systems, a downfield ring-current shift for the AH2 resonance 
(Section 4.4.1) appears to be diagnostic of a stabilised A-tetrad with a putative 
6-NH2 to N1 hydrogen bonding geometry.  The absence of clearly resolved 
resonances for the 6-NH2 group, analogous to those of the 2-NH2 group of 
guanine, suggests that base-specific electrostatic interactions from S-stacking 
of A and G bases, rather than hydrogen bonding between adenines, may be 
largely responsible for A-tetrad stabilisation in this context. 
 
4.4.5  Relative Stabilities of G-tetrads 
The relative stabilities of the G-tetrads in d(TGGAGGC)4, d(TAGGAGGT)4 
and d(TGGGAGGC)4 were assessed by NH/ND exchange experiments, where 
the disappearance of signals in the 1D spectrum after redissolving the 
lyophilised sample in D2O were observed.  A prior analogous experiment 
reported the high kinetic stability of G-tetrads in quadruplex structures (73).   
 
Our studies show that exchange is extremely slow at 298 K, at which 
temperature the G5NH proton of d(TGGAGGC)4 was still detectable 50 days 
after the sample was redissolved in D2O.  The exchange process can, however, 
be accelerated at elevated temperatures (308 K).  Even under these conditions 
marked sequence-specific effects can be seen showing that the G5NH (G6NH 
in d(TAGGAGGT)4) resonance persists considerably longer than other 
guanine NH signals.  The reverse experiment, in which the quadruplex is first 
melted at high temperature and reannealed in D2O to trap ND groups, and then 
redissolved in H2O solution, shows that the G6NH signal of d(TAGGAGGT)4 
is very slow to reappear, indicating specific protection and stabilisation against 
ND/NH exchange (Fig.4.28). These observations are again consistent with 
particularly good base stacking interactions at the 5'-AG step, as indicated in 
Section 4.4.4. 
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Fig.4.28:  Stacked plots of 1D WATERGATE spectra of d(TAGGAGGT)4 (308 K) 
collected (a) 15 mins, (b) 1 hour, (c) 6 hours, (d) 18 hours, and (e) 7 days after 
reconstituting the dry sample in H2O, demonstrating protection against ND/NH 
exchange.  
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In d(TGGGAGGC)4, the analogous G6NH also shows enhanced stability 
following resolvation in D2O.  However, the longer run of guanines upstream 
of the A-tetrad significantly alters the relative stabilities of the other tetrads.  
The iminos of the outermost guanines, G2 and G7, still exchange rapidly after 
redissolving in D2O, and have disappeared completely from the 1D 
WATERGATE spectrum after the first sampling interval (15 mins) (Fig.4.29).  
The G3 and G4 imino protons are still detectable after 24 hours at 298K, and 
show no apparent loss of intensity.  A temperature study of d(TGGGAGGC)4 
(Fig.4.30) shows that the iminos of G3, G4 and G6 are all still detectable to 
temperatures in excess of 338 K, though there is a noticeable decrease in the 
intensity of the latter two peaks above 328 K.  G3NH is stable at temperatures 
in excess of 348K, and its resonance shows no intensity drop after 6 hours at 
this temperature. 
 
The increased stability of the G3NH proton in the longer sequence can be 
attributed to the fact that the G3 tetrad is flanked on both faces by stable G-
tetrads, which decrease solvent accessibility to the core of the quadruplex in 
this region.  The exchange data from d(TGGAGGC)4 suggest that the 5'-AG 
step has stronger stacking interactions than the 5'-GA step, and this would not 
be expected to change in d(TGGGAGGC)4, as the core sequence in these 
models is conserved.  The stability of the G4 tetrad is greater in the longer 
sequence due to the presence of a greater number of neighbouring G-tetrads 
adjacent to its 5' face.  Combined with the unusually stable G7 tetrad on the 3' 
side of the quadruplex, these act like clamps, preventing solvent from reaching 
the G4NH protons from the long axis of the structure. 
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Fig.4.29:  Stacked plots of 1D WATERGATE spectra of d(TGGGAGGC)4 (298 K) 
collected (a) before and (b) 15 mins, (c) 6 hours, and (d) 18 hours after reconstituting 
the sample in D2O.  
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Fig.4.30:  Stacked plots of 1D WATERGATE spectra of d(TGGGAGGC)4 collected at 
(a) 298 K, (b) 308 K, (c) 338 K, and (d) 348 K. 
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4.5  Conclusions 
This study has determined the high-resolution structure of the quadruplex 
structures d(TAGGAGGT)4, d(TGGAGGC)4, and d(TGGGAGGC)4 by an 
NMR-restrained molecular dynamics approach that includes explicit treatment 
of solvent and stabilising ions.  These structures are each suitable for 
deposition to the Nucleic Acids Database.  These sequences form similar 
stable structures in the conserved d(GGAGG)4 purine core region, which are 
enhanced by strong stacking interactions.   
 
As well as verifying the presence of stable G-tetrads, the structure 
determination, supported by NMR data, demonstrated that the adenine 
nucleotides on separate strands could also form H-bonded tetrads.  These A-
tetrads have been shown to adopt anti glycosidic torsion angles, and have a 
single preferred conformation with H-bonds between N6 and N1 atoms on 
adjacent tetrads, as demonstrated by chemical shifts analysis and rMD 
simulation.  In this way, these structures differ from the previously reported 
structures of d(AGGGT)4 and d(TAGGGT)4, which were shown to be in 
equilibrium between N61 and N67 A-tetrad orientations.  In the current 
context, the A-tetrad conformation is strongly influenced by favourable base 
stacking geometries.  Terminal pyrimidine residues do not seem to have the 
potential to form stable tetrads, as stabilising purine tetrads do not surround 
them.  Thymine and cytosine nucleotides do not form H-bonds of any kind, 
but do appear to stack with their adjacent nucleotides in a B-like 
conformation.  
 
MD simulations and dissection of electrostatic energy components have 
shown that stabilising potassium ions cannot reside on both faces of an A-
tetrad simultaneously.  Though temperature studies suggest that the 5'-AG step 
has stronger stacking interactions than the 5'-GA step, structures with either 
site occupied have proved to be equally stable.  However, the exclusively 
observed species in d(TGGAGGC)4 and d(TGGGAGGC)4 have both sites 
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vacant, while only in the minor conformer of d(TAGGAGGT)4 is the 5'-GA 
step occupied by a cation. 
 
These high-resolution structures add valuable information to the pre-existing 
family of parallel quadruplex structures studied so far.  
 
 
Fig.4.31:  Schematic representation of the average minimised structure of 
d(TGGAGGC)4 from the last 100 ps of a 2 ns rMD simulation, showing interstitial 
potassium ions.  Guanines are coloured in blue, adenines in yellow, thymines in 
green, and cytosines in red. 
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Fig.4.32:  25 randomly chosen structures from the last 500 ps of a 2ns rMD 
simulation of d(TGGAGGC)4 
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Fig.4.33:  (a) Schematic representation of the average minimised structure of 
d(TAGGAGGT)4 from the last 100 ps of a 1 ns rMD simulation, showing interstitial 
potassium ions.  (b) 25 randomly chosen snapshots from the last 250 ps of a 1 ns 
rMD simulation of d(TAGGAGGT)4. 
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Fig.4.34:  Schematic representation of the average minimised structure of 
d(TGGGAGGC)4 from the last 100 ps of a 1 ns rMD simulation, showing interstitial 
potassium ions.  
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Fig.4.35:  Cross-eye stereo view of 25 randomly chosen structures from the last 250 
ps of a 1 ns of restrained dynamics simulation of d(TGGGAGGC)4. 
5.  Determination of Hydration Patterns by rMD 
Methods 
 
5.1 Introduction: The Role of Solvent in DNA Structure 
Since water-DNA interactions are comparable in strength to the noncovalent 
interactions within the double helix, hydration and helical fine structure are 
inextricably linked.  In fact, water is often regarded in NMR studies as an 
integral part of DNA (104).  Solvation has been shown to play an important 
part in determining the overall conformation of DNA using a variety of 
experimental techniques, including NMR (121;135), X-ray crystallography 
(16;56), and thermodynamics (33).  B-DNA requires the greatest hydration of 
all the DNA conformers, and requires about 30% water, by weight, to 
maintain its native conformation in the crystalline state (144).  Partial 
dehydration converts it to A-DNA by decreasing the free energy required for 
A-DNA deformation and twisting, which is usefully employed by encouraging 
supercoiling but eventually leads to denaturation.  Further dehydration will 
result in the least hydrated Z-DNA, which has a very narrow minor groove.  
Hydration is greater and more strongly held around the phosphate groups that 
run along the inner edges of the major grooves.  The water molecules are not 
permanently situated however, due to the rather diffuse electron distribution of 
the phosphate groups.  Hydration is more ordered and more persistent around 
the bases with their more directional hydrogen-bonding ability and restricted 
space.  Consequently, water molecules are held relatively strongly around the 
bases.  Because of the regular structure of DNA, hydrating water is held in a 
cooperative manner along the double helix in both the major and minor 
grooves.  The cooperative nature of this hydration aids both the annealing and 
unwinding of the double helix. 
 
The so-called spine of hydration in the minor groove of DNA is thought to 
stabilise the structure (22;23), particularly in AT tracts (50;145), and is known 
to favour B-DNA.  Water molecules donate two hydrogen bonds, so bridging 
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between thymine 2-keto(s) and/or adenine ring N3(s) on sequential bases.  
This water is fully hydrogen bonded by accepting two further H-bonds from a 
secondary layer of hydration water, so fixing the primary hydration water 
more firmly in place (50;127).  Optimisation of interactions with water 
molecules has been used to rationalise both the observed transition of B-DNA 
to A-DNA in water/alcohol mixtures (54) and the opposite A- to B-form 
conversion under fully hydrating conditions (35).  In aqueous solution, the 
concentration of water is very high, at approximately 55 M.  Statistically, 
therefore, all exposed sites on the surface of a solute particle can be expected 
to be close to a water molecule at any given time (45;46). 
 
For the purpose of the investigation of hydration by rMD simulation, it is 
useful to think of water of solvation as falling into one of three categories.  
Bulk water is defined as that which is not associated with, nor influenced by, 
the solute.  It is essentially the matrix in which the solute molecules are 
solvated.  Weakly associated water molecules are typically found on the 
surface of the solute, where their accessibility to the bulk solvent gives short 
residence times at the solute-solvent interface.  These weak associations may 
also be evident in wide grooves if no additional stabilising interactions are 
present (242).  Strongly associated solvent molecules are usually isolated from 
the bulk solvent, in locations such as the core of proteins or deep narrow 
surface grooves in macromolecular complexes (78).  In the latter cases, 
exchange of associated solvent with the bulk is restricted. 
 
The term residence time refers to the length of time that a single water 
molecule is associated with a specific site on a macromolecule.  Occupancy is 
a measure of the total time that the site is associated with any water molecule.  
Though site occupancy and residence time are two distinctly different 
concepts, there is some correlation between the two:  if a single water 
molecule has a high residence time at a given site, then the occupancy of that 
site will increase relative to those sites with lower residence times.  However, 
the measure of occupancy makes no distinction between individual water 
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molecules.  Therefore, a promiscuous site, which is occupied sequentially by 
many different water molecules, may have high occupancy, but a low 
residence time for each individual water molecule.  On the surface of the 
molecule, and in wide grooves, accessibility to the bulk solvent leads to 
relatively short residence times.  Waters with restricted access to the bulk 
solvent, such as those in narrow DNA grooves, have elevated residence times, 
due mainly to their inability to exchange with the bulk.  Due to the inability of 
the water molecules to escape from the groove floor, these sites would also be 
expected to have higher occupancy.  Longer residence times are also observed 
for water molecules in the core of proteins, but internalised waters are not 
usually observed in short DNA structures. 
 
NMR can be used to calculate residence times of those water molecules close 
to detectable DNA protons based on the polarity and magnitude of the 
observed NOE and ROE signals.  The measurement of residence times extends 
beyond the remit of this study, and so further discussion will be limited to the 
concept of occupancy. 
 
5.2 Aims & Objectives 
The study of DNA structure by NMR methods can be extended beyond the 
examination of 3-D architecture and molecular dynamics:  the involvement of 
water in DNA structure can also be examined using rMD methods.  In this 
study, the principle objective is to distinguish between water molecules that 
form bulk solvent and those associated with the DNA, and to investigate those 
water molecules that are potentially interacting with DNA.  We aim to achieve 
this by integrating the water population over the duration of molecular 
dynamics simulations to identify water occupancy that is significantly greater 
than in bulk water. 
 
This study attempts to compare the hydration patterns of the NMR-derived 
rMD structures of nogalamycin-d(TGATCA) and d(TG4T)4 with those from 
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previously published x-ray structures (170;212) with a view to assessing if 
those waters that are strongly associated with the macromolecule, and not 
freely exchanging with the bulk solvent or affected by the requirements of 
crystal packing, are similar in both solid- and solution-states.   
 
By way of contrast, it is also of interest to know to what degree those solvent 
molecules that weakly associate with the macromolecular surface differ 
between solid- and solution-states, and to what degree crystal-packing 
influences the distribution of water on the external surface of each of the DNA 
complexes studied. 
 
5.3 Materials & Methods 
5.3.1 rMD study of Complex Hydration 
Molecular dynamics using explicit solvent models is a useful tool for probing 
solvent interactions in macromolecular systems.  Water molecules in the rMD 
simulation are represented using the Jorgensen TIP3P parameterisation (105) 
within AMBER 6.0.  It is a three-particle model that includes the oxygen atom 
and two hydrogen atoms.  There is no internal flexibility, such as stretching 
and bending, allowed for in this model.  Interactions between water molecules 
are described by a Lennard-Jones potential (8) between oxygen atoms and 
electrostatic contributions between all atoms.  TIP3P solvent molecules have 
been shown to accurately reproduce experimentally derived parameters of 
water, including density and co-ordination (137). 
 
5.3.2 Calculation of Water Occupancy 
Calculations of water occupancy were carried out on snapshots taken at 1 ps 
intervals of a 1ns restrained molecular dynamics simulation of the complex of 
d(TGATCA)2 with nogalamycin. Each snapshot was normalised with respect 
to a standardised PDB co-ordinate set of the model system taken from an 
arbitrary point during the molecular dynamics run.  This allowed the DNA 
atoms from each snapshot to be superimposed within the limits of the applied 
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distance restraints. This procedure has been shown to give rise to atom 
misplacements of less than 0.5 ÅP3 P relative to the standard PDB (242). 
 
For each snapshot, the space around the macromolecular complex was 
enclosed in a cubic grid, equal in size to that of the periodic box, and centred 
on the centre of mass of the complex.  The periodicity of the grid was 1 Å in 
each dimension.  The number of water molecules in each 1 ÅP3 P cube was then 
measured, giving a numerical measure of water occupancy around the solute 
(Fig.5.1(b)).  A cumulative total for each cubic angstrom of space around the 
complex could then be calculated by summing the number of water molecules 
in each superimposed cube for each snapshot of the entire rMD simulation 
(Fig.5.1(c)). 
 
 
 
Fig.5.1:  Schematic representation of the method used to determine water occupancy 
from rMD simulation:  The periodic box is divided into 1 ÅP3 Pcubes (a).  The number of 
water molecules in each cube is summed for each snapshot of the simulation (b), and 
the values from each snapshot are subsequently added to give a figure for total water 
occupancy (c).  Using this method, higher occupancy sites can readily be identified. 
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Fig.5.2:  Graph of cumulative cell numbers as a function of occupancy for 
nogalamycin-d(TGATCA), showing the number of cells for each given occupancy 
value.  Significant occupancy, defined by the cut-off value, shown inset. 
 
5.  Determination of Hydration Patterns by rMD Methods 206
In order to discriminate between bulk solvent and associated water molecules, 
it was necessary to define at what level of occupancy an individual cell 
exceeds background levels.  For the periodic box dimension of the 
d(TGATCA)2 complex, for example, which measures 38x40x43 Å, there are 
over 65000 individual cubes.  The box contains approximately 4000 water 
molecules and 1000 snapshots were taken over the duration of the simulation.  
It is, therefore, reasonable to assume that every 1 ÅP3 P cube that is accessible to 
the solvent would contain a water molecule during some part of the dynamics 
run.  To discriminate what constituted background occupancy, the distribution 
of cumulative occupancy values was tabulated and parsed (Fig.5.2), and a cut-
off value was subsequently selected for each model.  All cubes with 
cumulative totals of less than the cut-off were treated as bulk solvent.  The 
cut-off value is specific to the system being studied, and should be chosen to 
give a small enough sample of cells to accurately represent water occupancy 
while minimising the effect of baseline noise.  Although the threshold value is 
arbitrary, a value that selects only 2% of the total number of cells gives 
significant occupancy information while avoiding background untidiness.   
 
5.3.3 Starting Structures for d(TG4T)4 
In order to compare hydration patterns between solid and solution states, a 
starting model of the quadruplex structure of d(TGGGGT)4 was generated 
using the atom coordinates from the crystal structure (PDB ID: 352D).  The 5'- 
and 3'-terminal thymine bases were reoriented to maintain a separation 
between consecutive planes and a helical twist consistent with B-form DNA 
along the entire length of the quadruplex.  Hydrogen atom positions were 
calculated and atoms added using the LEaP module of AMBER 6.0.  All 
sodium ions were removed, and a central core of five potassium ions, 
coincident with the helical axes and equidistant from each tetrad, was added so 
that each of the three core metal ions was bipyrimidally coordinated by eight 
guanine carbonyl atoms.  Potassium counter-ions were added with LEaP to 
negate the negative charge on the backbone, and the model was solvated to 
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within a distance of 5 Å using boxes of 216 TIP3P H2O molecules.  The 
structure was subsequently minimised and allowed to undergo 2 ns of 
unrestrained MD simulation using the protocol described in Section 4.3.5. 
 
5.4 Results & Discussion 
5.4.1 Density Calculations for Nogalamycin-d(TGATCA) 
From the 2 ns trajectory of the d(TGATCA)-nogalamycin complex, a cut-off 
of 78 water molecules per 1 ÅP3 P cube was selected to distinguish between bulk 
solvent molecules and those with significant site occupancy.  Cells with a 
cumulative total less than 78 (>98%) were discarded.  The analysis 
highlighted 40 cells with significant occupancy, which were subsequently 
overlaid on the average DNA structure for analysis using MolMol. 
 
The crystal structure of d(TGATCA)-nogalamycin (PDB ID: 182D) was 
displayed using MolMol.  To facilitate comparison between crystal and 
solution structures, water molecules within 3.8 Å of the VDW surface of the 
complex were selected.  Those waters selected included those in direct contact 
with the structure while largely excluding the outer layer of water molecules, 
which are largely an artefact of crystal packing. 
 
5.4.2 Comaprison of rMD and X-ray Data for Nogalamycin-
d(TGATCA) 
The crystal structure (212) contains two DNA-nogalamycin complexes, one 
spermine molecule, two acetates, one sodium ion, and 97 water molecules in 
the asymmetric unit, although the spermine and acetates do not possess any 
biological relevance to the drug binding.  Although each DNA strand has the 
same sequence, differences in hydration patterns of both complexes exist, due 
to different solvent channels generated in each complex by crystal packing.  
There are also significant differences in sugar-phosphate geometry between 
the two complexes.  This illustrates, albeit in a distinctly non-dynamic manner, 
the inherent flexibility of DNA, which allows conservation of water-mediated 
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contacts in both conformers.  The existence of two conformationally-distinct 
structures, the absence of stabilising ions, and the presence of additional 
molecules, all to facilitate crystal packing, highlights the shortcomings of x-
ray crystallography in the study of large molecules in a biologically-relevant 
environment.  The solvent environment allows greater flexibility in the nature 
of interactions stabilising the complex through direct and solvent-mediated 
effects.  
 
Each of the four nogalamycin molecules makes at least two direct hydrogen 
bonds to the DNA, all of which are conserved in the NMR solution structure.  
One H-bond between the O15 proton of nogalamycin (Fig.5.3) and the N7 
nitrogen of guanine in the major groove (O···N, 2.8 Å) is maintained 
throughout the rMD simulation.  In the minor groove, a second H-bond 
between O7 of nogalamycin and the guanine amino proton (H21) can be 
observed.  The hydroxyl group at position 6 on the drug chromophore has a 
donor-hydrogen that can be accepted by either the O7 of the drug or the O2 of 
cytosine.  The latter interaction can exist only in the absence of the 
intramolecular H-bond.  Should this be the case, the O7 oxygen is also free to 
form a strong H-bond (3.0 Å, ș=12 º) with the N2 of the complementary 
guanine.  It seems reasonable that the formation of two strong intermolecular 
bonds is more favourable than one intramolecular bond, and this is borne out 
by H-bond residency studies carried out over 1ns of rMD, where the 
inetrmolecular O7···HN2 bond is occupied for 63% of the simulation, 
compared with 31% for the equivalent intramolecular bond.  No H-bonding is 
evident for 6% of the duration of the simulation. 
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Fig.5.3:  Direct water contacts and water-mediated interactions in the X-ray crystal 
structure (a) and NMR-derived rMD structure (b) of nogalamycin-d(TGATCA).  Water 
molecules are depicted by the letter W, drug-water interactions by dotted lines, and 
water-DNA interactions by solid arrows.   
 
Potential hydrogen bonding interactions mediated by water molecules were 
determined by a 3.8 Å distance cut-off and a 34° angular cut-off between the 
drug/DNA heavy atom and the centre of mass of the water molecule.   
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In the major groove of the crystal structure complex, there are many solvent-
mediated interactions between nogalamycin and the DNA at the intercalation 
site.  The majority of water-mediated contacts are to the bases of DNA, rather 
than to the sugar-phosphate backbone.  There are no contacts, water-mediated 
or otherwise, between nogalamycin molecules in the crystal structure of 
nogalamycin-d(TGATCA).  However, in the X-ray structure of nogalamycin-
d(TGTACA) (210), a chain of four water molecules in the major groove links 
the amino nitrogen atoms of each drug molecule in the same complex 
(Fig.5.4).  Why altering the order of the nucleotides between the two TpG 
binding should affect these water-mediated drug-drug interactions remains 
unclear (210).  Three water molecules that fulfil the criteria for H-bond 
formation similarly link the amino nitrogens in the NMR-derived structure.  In 
each case these water molecules can potentially form stabilising H-bonds to 
electronegative heavy base atoms on the groove floor (Fig.5.3(b)).  The 
dimethylamino group of the bicyclic sugar is stabilised in the same orientation 
in the solid state by a water-mediated interaction between the N1 atom and the 
N6 of the central adenine.  The nogalamycin model used for the solvent 
structure was initially derived from the x-ray data, and its structure is 
maintained throughout the simulation by a solvent-mediated interaction 
between N1 and the O4 of the central thymine.  Though it is also possible for 
the bridging water to form a H-bond with T4N6, the residency study strongly 
favours O4 as the receptor. 
 
One of the two crystal structure complexes possesses extended minor groove 
solvent networks.  Water-mediated contacts between nogalose and adenine N2 
and O3' atoms stabilise the minor groove side of the complex.  The solution 
structure is stabilised in the minor groove by bridging water molecules 
between the nogalose 3'-meothoxy oxygen and phosphate backbone atoms on 
the central thymine and terminal adenine residues, and by a similar interaction 
between the nogalose 1'-oxygen and the terminal adenine O3' oxygen 
(Fig.5.5).  The water oxygen atom is positioned 3.95 (±0.2) Å from each of the 
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drug and DNA heavy atoms, and makes an angle of 69.0 (±0.5)° between 
them.  Additionally, a water molecule acts as a bridgehead between oxygen 
atoms on opposite sides of the nogalose ring, providing extra stability in this 
region. 
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Fig.5.4:  Direct water contacts and water-mediated interactions in the X-ray crystal 
structure of nogalamycin-d(TGTACA).  Image adapted from (210).  
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Fig.5.5:  An example of a water-mediated drug-DNA interaction: between the 
nogalose 1'-oxygen and the terminal adenine O3' oxygen, across the minor groove.  
Nogalamycin is shown in grey and DNA in black.  Interacting atoms are shown in 
green. 
 
The spines of water molecules lining both major and minor grooves of the 
crystal structure (Fig.5.6(a)) are not evident in the solution structure as 
initially examined.  However, if the cumulative water cut-off value is reduced 
to 68 molecules per 1 ÅP3 P cube, the number of selected cubes increases to 105, 
and these hydration tracts become evident (Fig.5.6(b)).  To eliminate the 
incidence of cubes being highlighted in the bulk solvent, only the 88 waters 
within 5 Å of the VDW surface of the complex were selected at the new, 
lower cut-off.  As expected, those sites with the highest occupancies were 
located in the DNA grooves and around the groove binding sugars of the 
intercalated drugs, as shown using a graduated scale of occupancy in 
Fig.5.6(b).  This can be attributed to the inability of the water molecules in 
these sites to easily exchange with the bulk solvent. 
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Fig.5.6:  Comparison of X-ray determined (a) and rMD calculated (b) hydration 
patterns for the complex of nogalamycin with d(TGATCA)2.  DNA is shown in grey, 
and nogalamycin in black.  Water in shown in blue for the X-ray structure.  A 
graduated scale from orange (lowest occupancy) to yellow (highest occupancy) is 
used to display water on the rMD structure. View is to highlight hydration spine in 
DNA grooves. 
 
5.  Determination of Hydration Patterns by rMD Methods 214
5.4.3 Density Calculations for d(TG4T)4 
Phillips et. al. (170) have reported the crystal structure at 0.95 Å of the 
parallel-stranded quadruplex formed by d(TG4T)4 in the presence of sodium 
ions at 100 K.  The asymmetric unit of the d(TGGGGT)4 is inordinately 
complex (Fig.5.7).  It is comprised of four independent quadruplexes, which 
can be grouped into two pseudo-equivalent sets.  In each set, a pair of 
tetraplexes is coaxially stacked in a 5' to 5' orientation.  This generates a ladder 
of eight guanine tetrads, as the terminal thymines on each pair do not stack 
onto the end of the quadruplexes.  Calcium ions at the interface serve to 
stabilise contacts between adjacent tetrads. 
 
 
 
Fig.5.7:  Contents of the asymmetric unit of d(TGGGGT)4 (PDB ID: 352D). 
 
5.4.2 Comaprison of MD and X-ray Data for d(TG4T)4 
To facilitate comparison with X-ray hydration patterns, the cumulative water 
cut-off value of the MD structure was set to 84 per 1 ÅP3 P cube, which selected 
96 cubes.  To isolate only those cubes that interact directly with the 
quadruplexes only those with a centre of gravity within 4 Å of the DNA 
surface were considered (Fig.5.8(b)).  This highlighted 42 water molecules for 
comparative study.  A 5Å upper distance threshold was also applied to the 
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crystal structure leading to the selection of 68 water molecules within this 
distance of a single quadruplex isolated from the asymmetric unit (Fig.5.8 (a)). 
 
Fig.5.8:  Comparison of X-ray determined (a) and MD calculated (b) hydration 
patterns for d(TG4T)2.  DNA bases are shown in grey, and sugar & backbone atoms 
in black.  Water is shown in blue for the X-ray structure, while a graduated scale from 
orange (lowest occupancy) to yellow (highest occupancy) is used to display water on 
the rMD structure.  Only those water molecules within 5 Å of the groove floor of each 
molecule are highlighted. 
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All four grooves in the crystal structure were found to be almost equivalent 
with respect to hydration patterns (170).  Water molecules were shown to 
cluster around individual phosphate groups, but there was no evidence of 
water bridging adjacent phosphate groups, as occurs in A and Z forms.  The 
average intra-strand separation was shown to be 6.6 Å, similar to that of B-
DNA.  The four grooves are relatively narrow, measuring between 2.3 and 3.3 
Å in width, as measured by cross-strand phophate separations between non-
adjacent tetrads (Fig.5.9).  This is in good agreement with the MD structure, 
where analagous measurements showed the groove width to be in the range 
2.3x3.8 Å.  Hence, they are favourable binding sites for water molecules, 
which in both X-ray and MD structures form hydrogen bonds with the 
exposed guanine N2 amino group, its heterocyclic N3, and with each other to 
create a well-supported network.  The crystal structure was noted to have 
water molecules deep in each groove near each of the O4' oxygens.  These 
molecules accept H-bonds from the N2 atoms of the guanine bases and are 
linked together in a spine by a second layer of water molecules.  The mean 
distance between the guanine N2 and water heavy atoms in this case is 2.95 
(±0.05) Å.  In the solution structure, the analogous distance is 4.5 (±0.1) Å 
(Fig.5.10).  However, the distance between the hetrocyclic N3 atom and the 
water oxygen is only 3.1 (±0.1) Å.  This agrees well with the previous 
observation that N3 is preferred over N2 as a H-bond acceptor in B-like DNA, 
while N2 is preferred over N3 under poorer hydrating conditions (188).  In this 
case (Fig.5.10), the water acts as a bridging molecule between the guanine N3 
and furanose O4' atoms, presumably adding stability to the G-tetrad.  The 
groove-embedded water molecules in both x-ray and NMR structures are 
sheltered from the bulk water by enveloping layers of water molecules.  These 
outer layers are, in the former case, affected by the restrictions of crystal 
packing and, as such, the surface water molecules are not amenable to direct 
comparison with those in the solution structure.  However the patterns of the 
groove lining waters are similar in both cases, forming the same H-bonds, and 
aligning in the same hydration spine in both cases (Fig.5.8). 
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Fig.5.9:  Cross-strand phosphate separations (green) between i and (i+3) tetrads 
were used as a measure of groove widths.  Measurements were made between the 
centres of mass of the phosphate groups, and their VDW radii were subsequently 
subtracted to give a measure of groove width.  Oxygens adjacent to the highlighted 
phosphorus atoms have been removed for clarity. 
 
 
 
Fig.5.10:  Interaction of water molecules in the groove of the solution structure of 
d(TG4T)4 with tetrad-forming guanines.  Nucleotide is shown in black, except N2 
nitrogen (blue) and O4' (red).  
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5.5 Conclusions 
Comparison of the rMD and x-ray structures reveals that both are extensively 
hydrated, with particularly high water occupancy in discreet regions of the 
complexes.  The hydration patterns in the major and minor grooves of both 
crystal and solution structures of the complex of d(TGATCA)2 with 
nogalamycin are broadly similar.  Though there is no water mediated contact 
between drug molecules in the crystal structure of nogalamycin-d(TGATCA), 
in its solution structure and also in the crystal structure of nogalamycin-
d(TGTACA), the dimethylamino groups of the aminoglucose sugars are 
connected by a chain of water molecules in the major groove, while the minor 
groove is stabilised by water interactions, both between the drug and the DNA 
backbone, and between adjacent methoxy groups on the nogalose. 
 
Groove lining spines of hydration are also present in both x-ray crystal 
structure and NMR-derived solution structure of d(TGGGGT)4.  In each case 
these molecules accept H-bonds from the N3 atoms of the guanine bases and 
are linked together in a spine by a second layer of water molecules, which 
serves to isolate them from the bulk solvent.  It was not possible to compare 
hydration patterns at the terminal thymidine residues, as these are displaced by 
stabilising calcium ions at the interface between adjacent molecules in the 
asymmetric unit of the crystal structure, unlike the solution structure, in which 
they form T-tetrads (Section 4.4.1). 
 
Occupancy was observed to be highest in the DNA grooves for NMRderived 
structures of both duplex and quadruplex structures, which is consistent with 
that observed in previous studies of macromolecules in aqueous media.  
Additionally, for both the duplex and the quadruplex studied, hydration 
patterns outside the DNA grooves do not correlate well between x-ray and 
NMR-derived structures.  It is reasonable to assume that these waters are 
ordered to benefit crystal packing in the solid state, and so bear little or 
noresemblance to the solution structure. 
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Appendices 
 
Appendix 1:  P1PH Chemical Shift Data 
Appendix 1.1:  DNA P1 PH chemical shifts of the complex of nogalamycin 
with d(TGATCA)2 at 298 K. 
 
 T1 G2 A3 T4 C5 A6 
H1' 5.930 5.137 6.155 5.976 5.902 6.517 
H2'1 2.636 2.512 2.459 1.897 2.317 2.488 
H2'2 2.872 2.666 2.689 2.352 2.620 2.545 
H3' 4.846 --- 4.956 4.861 4.997 4.736 
H4' 4.208 --- 4.305 4.050 4.238 4.354 
H5'1 3.884 4.136 4.133 --- --- 4.202 
H5'2 3.948 4.234 4.172 --- --- --- 
H5 --- --- --- --- 5.688 --- 
H6 7.504 --- --- 7.077 7.688 --- 
H8 --- 7.948 8.036 --- --- 8.467 
Me 1.485 --- --- 1.073 --- --- 
 
 
Appendix 1.2:  DNA P1 PH chemical shifts of nogalamycin-
d(CTGATCAG)2 at 298 K. 
 
 C1 T2 G3 A4 T5 C6 A7 G8 
H1' 5.755 6.190 5.202 6.117 5.958 5.881 6.323 6.084 
H2'1 2.126 2.662 2.519 2.446 1.897 2.295 2.443 2.319 
H2'2 2.482 2.760 2.594 2.703 2.359 2.605 2.816 2.475 
H3' 4.562 5.086 4.936 4.928 4.862 5.013 5.062 4.665 
H4' 4.016 4.226 4.509 4.279 4.047 4.227 4.526 4.216 
H5'1 3.794 4.149 4.080 4.182 4.185 4.060 4.239 3.962 
H5'2 3.847 --- 4.359 --- 4.301 4.104 4.280 4.142 
H5 5.692 --- --- --- --- 5.686 --- --- 
H6 7.776 7.387 --- --- 7.072 7.690 --- --- 
H8 --- --- 7.881 8.005 --- --- 8.428 7.700 
Me --- 1.436 --- --- 1.094 --- --- --- 
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Appendix 1.3:  DNA P1 PH chemical shifts of nogalamycin-
d(CCTGATCAGG)2 at 298 K. 
 
 C1 C2 T3 G4 A5 T6 
H1' 5.727 5.900 6.122 5.185 6.103 5.939 
H2'1 2.194 2.088 2.603 2.499 2.445 1.882 
H2'2 2.454 2.503 2.751 2.595 2.691 2.343 
H3' 4.615 4.734 5.038 4.936 4.926 4.856 
H4' 4.057 4.136 4.362 4.489 4.252 4.029 
H5'1 3.764 4.087 4.177 4.032 4.168 4.179 
H5'2 3.801 --- 4.235 4.366 --- 4.279 
H5 5.840 5.471 --- --- --- --- 
H6 7.678 7.589 7.268 --- --- 7.060 
H8 --- --- --- 7.872 7.992 --- 
Me --- --- 1.404 --- --- 1.081 
       
 C7 A8 G9 G10   
H1' 5.843 6.268 6.103 5.651   
H2'1 2.262 2.433 2.364 2.357   
H2'2 2.593 2.765 2.480 2.592   
H3' 4.999 5.084 4.652 4.651   
H4' 4.220 4.530 3.948 4.221   
H5'1 4.033 4.189 --- ---   
H5'2 4.181 4.228 --- ---   
H5 5.672 --- --- ---   
H6 7.678 --- --- ---   
H8 --- 8.384 7.678 7.735   
Me --- --- --- ---   
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Due to restrictions imposed by the PDB format, the following naming 
convention is used for nogalamycin throughout the appendices: 
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Appendix 1.4:  Nogalamycin P1 PH chemical shifts of the complex of 
nogalamycin with d(TGATCA)2 at 298 K. 
 
 BIC7 NGL8
H11 5.669 --- 
H12 --- 5.310 
H21 4.215 3.036 
H22 --- 3.669 
H31 --- 1.464 
H32 4.681 3.443 
H41 3.957 3.581 
H42 --- 3.183 
H51 1.631 3.822 
H52 --- 1.411 
HC 6.927 --- 
HJ1 4.718 --- 
HK1 2.914 --- 
HK2 1.917 --- 
HL2 1.459 --- 
HM2 4.495 --- 
HO 6.649 --- 
HS2 3.787 --- 
M31 2.891 --- 
M32 2.973 --- 
 
Appendix 1.5:  Nogalamycin P1 PH chemical shifts of the complex of 
nogalamycin with d(CTGATCAG)2 at 298 K. 
 
 BIC9 NGL10
H11 5.777 --- 
H12 --- 5.144 
H21 --- 3.051 
H22 --- 3.631 
H31 --- 1.398 
H32 --- 3.579 
H41 --- 3.180 
H42 --- 3.417 
H51 1.660 3.819 
H52 --- 1.459 
HC 6.939 --- 
HJ1 4.634 --- 
HK1 2.902 --- 
HK2 1.911 --- 
HL2 1.501 --- 
HM2 4.500 --- 
HO 6.669 --- 
HS2 3.794 --- 
M31 2.928 --- 
M32 2.980 --- 
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Appendix 1.6:  Nogalamycin P1 PH chemical shifts of the complex of 
nogalamycin with d(CCTGATCAGG)2 at 298 K. 
 
 BIC11 NGL12
H11 5.747 --- 
H12 --- 5.099 
H21 4.210 3.027 
H22 --- 3.605 
H31 --- 1.386 
H32 4.653 3.399 
H41 --- 3.161 
H42 --- 3.566 
H51 1.643 3.787 
H52 --- 1.440 
HC 6.920 --- 
HJ1 4.574 --- 
HK1 2.911 --- 
HK2 2.947 --- 
HL2 1.600 --- 
HM2 4.225 --- 
HO 6.630 --- 
HS2 3.948 --- 
M31 2.910 --- 
M32 2.990 --- 
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Appendix 1.7:  DNA P1 PH chemical shifts of the complex of nogalamycin 
with d(GCTACGAAGTGC) at 288 K. 
 
 G1 C2 T3 A4 C5 G6 
H1' 5.970 6.388 6.665 6.347 5.991 --- 
H2'1 2.680 2.352 2.540 2.434 1.704 2.527 
H2'2 2.794 2.449 2.645 2.730 2.264 2.666 
H3' 4.877 5.039 4.987 5.080 4.839 --- 
H4' 4.263 4.284 4.449 4.470 4.305 4.425 
H5'1 3.755 4.216 --- 4.269 4.116 --- 
H5'2 --- --- --- 4.357 --- --- 
H5 --- 5.450 --- --- 4.875 --- 
H6 --- 7.474 7.828 --- 7.032 --- 
H8 7.964 --- --- 8.545 --- 8.079 
Me --- --- 2.022 --- --- --- 
       
 A7 A8 G9 T10 G11 C12 
H1' 5.978 6.274 5.515 6.132 5.577 5.931 
H2'1 3.029 2.874 2.591 2.655 2.564 2.013 
H2'2 3.375 --- --- 2.694 --- 2.180 
H3' 4.572 4.826 4.933 4.980 5.000 4.423 
H4' 2.043 --- 4.392 --- 4.621 4.252 
H5'1 2.268 --- 4.185 4.305 4.342 3.900 
H5'2 --- --- --- 4.349 --- 4.012 
H5 --- --- --- --- --- 5.225 
H6 --- --- --- 7.188 --- 7.432 
H8 8.100 7.992 7.971 --- 7.999 --- 
Me --- --- --- 1.110 --- --- 
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Appendix 1.8:  DNA P1 PH chemical shifts of the complex of nogalamycin 
with d(GCCCGTAGTGC) at 298 K. 
 
 G1 C2 C3 C4 G5 T6 
H1' 5.693 6.067 6.025 5.934 5.737 5.599 
H2'1 2.413 2.039 1.614 1.731 2.393 1.595 
H2'2 2.496 2.394 2.339 2.135 2.558 1.908 
H3' 4.68 4.89 4.638 4.686 4.746 4.264 
H4' 4.049 4.17 4.216 4.147 4.34 --- 
H5'1 3.624 3.957 4.028 3.798 3.936 3.107 
H5'2 --- 4.03 4.108 3.849 4.023 3.242 
H5 --- 5.308 5.684 5.487 --- --- 
H6 --- 7.51 7.726 7.209 --- 6.965 
H8 7.796 --- --- --- 8.038 --- 
Me --- --- --- --- --- 1.225 
       
 A7 G8 T9 G10 C11  
H1' 6.072 5.338 5.694 5.593 5.852  
H2'1 2.57 2.272 2.372 2.371 1.779  
H2'2 2.734 2.411 2.428 2.512 1.993  
H3' 4.651 --- 4.872 4.735 4.221  
H4' 4.174 4.214 4.084 4.503 3.783  
H5'1 3.59 3.97 3.962 3.977 3.633  
H5'2 3.77 4.085 3.981 4.195 ---  
H5 --- --- --- --- 4.969  
H6 --- --- 6.802 --- 7.127  
H8 7.821 7.747 --- 7.404 ---  
Me --- --- 0.643 --- ---  
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Appendix 1.9:  Nogalamycin P1 PH chemical shifts of the complex of 
nogalamycin with d(GCTACGAAGTGC) at 288 K. 
 
 BIC13 NGL14
H11 5.754 --- 
H12 --- 5.117 
H21 4.318 3.161 
H22 --- 3.786 
H31 --- 1.289 
H32 4.742 3.201 
H41 3.988 3.512 
H42 --- 3.518 
H51 1.654 --- 
H52 --- 1.392 
HC 7.024 --- 
HJ1 4.437 --- 
HK1 2.000 --- 
HK2 2.949 --- 
HL2 1.522 --- 
HM2 4.342 --- 
HO 6.881 --- 
HS2 3.876 --- 
M32 3.118 --- 
M31 2.979 --- 
 
Appendix 1.10:  Nogalamycin P1 PH chemical shifts of the complex of 
nogalamycin with d(GCCCGTAGTGC) at 298 K. 
 
 BIC12 NGL13
H11 5.580 --- 
H12 --- --- 
H21 4.141 2.641 
H22 --- 3.745 
H31 --- 1.258 
H32 4.451 3.393 
H41 3.832 3.640 
H42 --- 3.779 
H51 1.427 1.824 
H52 --- --- 
HC 6.750 --- 
HD 11.639 --- 
HH 11.457 --- 
HJ1 4.821 --- 
HK1 1.990 --- 
HK2 3.079 --- 
HL2 1.505 --- 
HM2 4.503 --- 
HO 6.797 --- 
M31 2.845 --- 
M32 2.894 --- 
Appendices 245
Appendix 1.11:  DNA P1 PH chemical shifts of d(TAGGAGGT)4 at 298 K. 
 
 T1 A2 G3 G4 A5 G6 G7 T8 
H1' 5.846 6.155 5.969 6.014 6.048 6.056 6.160 5.999 
H2'1 1.676 2.825 2.520 2.246 2.672 2.665 2.476 2.122 
H2'2 2.198 --- 2.928 2.958 2.835 2.753 2.622 --- 
H3' 4.544 4.998 4.968 5.021 5.163 5.096 4.938 --- 
H4' 3.487 --- 4.499 4.413 4.443 4.585 4.478 --- 
H5'1 3.940 --- 4.169 4.185 4.291 4.244 4.199 --- 
H5'2 4.050 --- 4.237 4.299 4.412 4.309 4.244 --- 
H1 --- --- 11.537 --- --- --- 10.729 --- 
H2 --- --- --- 11.300 --- --- --- --- 
H6 7.122 --- --- --- --- --- --- 7.283 
H8 --- 8.225 7.912 7.146 8.257 8.054 7.648 --- 
Me 1.528 --- --- --- --- --- --- 1.598 
 
Appendix 1.12:  DNA P1 PH chemical shifts of d(TGGAGGC)4 at 298 K. 
 
 T1 G2 G3 A4 G5 G6 C7 
H1' 5.918 6.063 6.034 6.082 6.119 6.167 5.969 
H2'1 2.220 2.612 2.365 2.657 2.528 2.529 2.081 
H2'2 2.540 3.024 2.956 2.780 2.802 2.686 2.137 
H3' 4.720 5.031 5.047 5.163 5.124 4.946 4.969 
H4' 4.104 4.453 4.468 4.371 4.651 4.523 4.465 
H5'1 3.796 4.123 4.221 4.298 4.243 4.062 4.018 
H5'2 --- --- 4.328 --- 4.293 4.234 4.227 
H1 --- 11.568 11.238 --- 10.496 10.777 --- 
H2 --- --- --- 9.362 --- --- --- 
H21 --- 5.803 6.067 --- 5.589 --- --- 
H22 --- 9.925 9.358 --- 9.363 --- --- 
H5 --- --- --- --- --- --- 5.561 
H6 7.522 --- --- --- --- --- 7.452 
H8 --- 8.104 7.315 8.252 8.076 7.670 --- 
Me 1.369 --- --- --- --- --- --- 
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Appendix 1.13:  DNA P1 PH chemical shifts of d(TGGGAGGC)4 at 298 K. 
 
 T1 G2 G3 G4 A5 G6 G7 C8 
H1' 5.925 6.078 6.056 5.988 6.020 6.074 6.141 6.024 
H2'1 2.148 2.713 2.414 2.294 2.637 2.712 2.491 2.082 
H2'2 2.427 3.007 2.886 2.964 2.790 2.786 2.626 2.164 
H3' 4.702 5.000 4.993 5.053 5.156 5.090 4.934 4.449 
H4' 4.067 4.401 4.543 4.496 4.495 4.612 4.489 4.177 
H5'1 3.695 4.060 4.205 4.286 4.282 4.228 4.180 4.031 
H5'2 3.717 4.120 4.307 4.369 4.372 4.292 4.257 4.056 
H5 --- --- --- --- --- --- --- 5.552 
H6 7.420 --- --- --- --- --- --- 7.465 
H8 --- 8.004 7.626 7.246 8.238 8.028 7.649 --- 
Me 1.407 --- --- --- --- --- --- --- 
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Appendix 2:  Distance Restraints 
Appendix 2.1:  Nogalamycin2-d(TGATCA)2 
 
Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
1 DT H1' 13 BIC HO 3.37 
1 DT H1' 1 DT H6 3.67 
1 DT H2'1 1 DT H1' 2.75 
1 DT H2'2 13 BIC HO 2.73 
1 DT H2'2 1 DT H1' 2.85 
1 DT H2'2 1 DT H3' 3.02 
1 DT H2'2 1 DT H5'1 3.42 
1 DT H3' 1 DT H6 2.63 
1 DT H6 13 BIC HO 3.80 
1 DT H6 1 DT H2'1 3.20 
1 DT H6 1 DT H2'2 2.46 
1 DT H7 13 BIC H11 2.46 
1 DT H7 1 DT H6 3.10 
1 DT H7 2 DG H4' 2.47 
2 DG H1' 13 BIC HO 3.81 
2 DG H1' 2 DG H2'2 3.53 
2 DG H1' 2 DG H4' 3.93 
2 DG H1' 2 DG H5'1 2.22 
2 DG H1' 2 DG H8 3.83 
2 DG H1' 3 DA H8 2.54 
2 DG H2'1 2 DG H8 2.49 
2 DG H2'2 2 DG H8 2.65 
2 DG H3' 2 DG H1' 3.41 
2 DG H3' 2 DG H8 3.54 
2 DG H4' 13 BIC HO 4.18 
2 DG H4' 2 DG H1' 4.25 
2 DG H4' 2 DG H3' 3.10 
2 DG H4' 2 DG H8 3.73 
2 DG H5'1 2 DG H1' 3.36 
2 DG H5'2 2 DG H3' 2.78 
2 DG H8 1 DT H5'2 0.66 
2 DG H8 3 DA H8 2.14 
3 DA H1' 14 NGL H52 2.48 
3 DA H1' 3 DA H4' 3.86 
3 DA H1' 3 DA H5'1 3.90 
3 DA H1' 4 DT H6 3.05 
3 DA H2'1 3 DA H2'2 1.69 
3 DA H2'1 3 DA H8 2.02 
3 DA H2'2 3 DA H8 2.91 
3 DA H2'2 4 DT H6 3.25 
3 DA H3' 3 DA H2'1 2.90 
3 DA H3' 3 DA H2'2 3.54 
3 DA H3' 3 DA H4' 2.70 
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Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
3 DA H3' 3 DA H5'1 2.41 
3 DA H3' 3 DA H8 3.06 
4 DT H1' 4 DT H3' 3.57 
4 DT H1' 4 DT H4' 3.90 
4 DT H1' 4 DT H6 3.85 
4 DT H1' 5 DC H6 3.26 
4 DT H2'1 14 NGL H51 3.10 
4 DT H2'1 4 DT H1' 3.56 
4 DT H2'1 4 DT H2'2 2.78 
4 DT H2'1 4 DT H6 2.54 
4 DT H2'1 5 DC H6 2.77 
4 DT H2'2 4 DT H1' 2.59 
4 DT H3' 4 DT H2'1 3.94 
4 DT H3' 4 DT H4' 3.71 
4 DT H3' 4 DT H6 4.00 
4 DT H4' 4 DT H3' 3.19 
4 DT H5'1 4 DT H3' 1.38 
4 DT H5'2 4 DT H3' 1.54 
4 DT H6 3 DA H2'1 3.57 
4 DT H6 3 DA H2'2 2.77 
4 DT H6 4 DT H2'2 3.69 
4 DT H6 4 DT H3' 3.56 
4 DT H7 3 DA H2'1 3.88 
4 DT H7 3 DA H2'2 3.93 
4 DT H7 3 DA H8 3.42 
4 DT H7 4 DT H6 3.12 
5 DC H2'1 5 DC H1' 2.61 
5 DC H2'1 5 DC H2'2 1.31 
5 DC H2'1 5 DC H6 2.25 
5 DC H2'1 6 DA H8 3.32 
5 DC H2'2 5 DC H1' 3.21 
5 DC H2'2 5 DC H2'1 2.56 
5 DC H2'2 5 DC H3' 2.29 
5 DC H2'2 6 DA H8 3.74 
5 DC H3' 5 DC H2'1 4.08 
5 DC H3' 5 DC H5'1 3.33 
5 DC H5 4 DT H6 3.37 
5 DC H6 5 DC H2'2 2.14 
6 DA H1' 6 DA H3' 4.08 
6 DA H2'1 6 DA H1' 4.21 
6 DA H2'1 6 DA H2'2 1.67 
6 DA H2'1 6 DA H8 2.64 
6 DA H2'2 6 DA H1' 3.10 
6 DA H2'2 6 DA H8 4.03 
6 DA H3' 6 DA H4' 1.69 
6 DA H4' 6 DA H8 2.10 
13 BIC H51 13 BIC HC 1.90 
Appendices 249
Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
13 BIC HK2 13 BIC HJ1 2.14 
13 BIC HK2 14 NGL H51 2.58 
13 BIC HK2 1 DT H7 4.29 
14 NGL H21 14 NGL H12 2.94 
14 NGL H21 14 NGL H22 1.71 
14 NGL H21 14 NGL H31 3.12 
14 NGL H21 14 NGL H32 1.04 
14 NGL H22 13 BIC HM2 2.97 
14 NGL H22 14 NGL H12 2.85 
14 NGL H22 5 DC H1' 2.83 
14 NGL H22 6 DA H8 3.61 
14 NGL H31 13 BIC HJ1 1.97 
14 NGL H31 14 NGL H12 2.50 
14 NGL H31 14 NGL H41 1.49 
14 NGL H31 14 NGL H51 2.11 
14 NGL H31 4 DT H2'1 1.49 
14 NGL H32 14 NGL H21 2.41 
14 NGL H32 14 NGL H22 1.83 
14 NGL H32 14 NGL H42 1.61 
14 NGL H32 14 NGL H51 4.41 
14 NGL H32 4 DT H1' 2.71 
14 NGL H41 14 NGL H32 1.37 
14 NGL H41 14 NGL H51 4.26 
14 NGL H42 14 NGL H12 2.75 
14 NGL H51 14 NGL H42 2.39 
14 NGL H52 13 BIC HJ1 3.43 
14 NGL H52 14 NGL H21 2.92 
14 NGL H52 14 NGL H41 4.11 
14 NGL H52 14 NGL H51 2.05 
14 NGL H52 2 DG H1' 2.48 
14 NGL H52 2 DG H4' 2.65 
14 NGL H52 3 DA H2'1 2.06 
14 NGL H52 4 DT H2'1 1.78 
14 NGL H52 4 DT H5'1 2.81 
7 DT H1' 15 BIC HO 3.37 
7 DT H1' 7 DT H6 3.67 
7 DT H2'1 7 DT H1' 2.75 
7 DT H2'2 15 BIC HO 2.73 
7 DT H2'2 7 DT H1' 2.85 
7 DT H2'2 7 DT H3' 3.02 
7 DT H2'2 7 DT H5'1 3.42 
7 DT H3' 7 DT H6 2.63 
7 DT H6 15 BIC HO 3.80 
7 DT H6 7 DT H2'1 3.20 
7 DT H6 7 DT H2'2 2.46 
7 DT H7 15 BIC H11 2.46 
7 DT H7 7 DT H6 3.10 
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Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
7 DT H7 8 DG H4' 2.47 
8 DG H1' 15 BIC HO 3.81 
8 DG H1' 8 DG H2'2 3.53 
8 DG H1' 8 DG H4' 3.93 
8 DG H1' 8 DG H5'1 2.22 
8 DG H1' 8 DG H8 3.83 
8 DG H1' 9 DA H8 2.54 
8 DG H2'1 8 DG H8 2.49 
8 DG H2'2 8 DG H8 2.65 
8 DG H3' 8 DG H1' 3.41 
8 DG H3' 8 DG H8 3.54 
8 DG H4' 15 BIC HO 4.18 
8 DG H4' 8 DG H1' 4.25 
8 DG H4' 8 DG H3' 3.10 
8 DG H4' 8 DG H8 3.73 
8 DG H5'1 8 DG H1' 3.36 
8 DG H5'2 8 DG H3' 2.78 
8 DG H8 7 DT H5'2 0.66 
8 DG H8 9 DA H8 2.14 
9 DA H1' 16 NGL H52 2.48 
9 DA H1' 9 DA H4' 3.86 
9 DA H1' 9 DA H5'1 3.90 
9 DA H1' 10 DT H6 3.05 
9 DA H2'1 9 DA H2'2 1.69 
9 DA H2'1 9 DA H8 2.02 
9 DA H2'2 9 DA H8 2.91 
9 DA H2'2 10 DT H6 3.25 
9 DA H3' 9 DA H2'1 2.90 
9 DA H3' 9 DA H2'2 3.54 
9 DA H3' 9 DA H4' 2.70 
9 DA H3' 9 DA H5'1 2.41 
9 DA H3' 9 DA H8 3.06 
10 DT H1' 10 DT H3' 3.57 
10 DT H1' 10 DT H4' 3.90 
10 DT H1' 10 DT H6 3.85 
10 DT H1' 11 DC H6 3.26 
10 DT H2'1 16 NGL H51 3.10 
10 DT H2'1 10 DT H1' 3.56 
10 DT H2'1 10 DT H2'2 2.78 
10 DT H2'1 10 DT H6 2.54 
10 DT H2'1 11 DC H6 2.77 
10 DT H2'2 10 DT H1' 2.59 
10 DT H3' 10 DT H2'1 3.94 
10 DT H3' 10 DT H4' 3.71 
10 DT H3' 10 DT H6 4.00 
10 DT H4' 10 DT H3' 3.19 
10 DT H5'1 10 DT H3' 1.38 
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Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
10 DT H5'2 10 DT H3' 1.54 
10 DT H6 9 DA H2'1 3.57 
10 DT H6 9 DA H2'2 2.77 
10 DT H6 10 DT H2'2 3.69 
10 DT H6 10 DT H3' 3.56 
10 DT H7 9 DA H2'1 3.88 
10 DT H7 9 DA H2'2 3.93 
10 DT H7 9 DA H8 3.42 
10 DT H7 10 DT H6 3.12 
11 DC H2'1 11 DC H1' 2.61 
11 DC H2'1 11 DC H2'2 1.31 
11 DC H2'1 11 DC H6 2.25 
11 DC H2'1 12 DA H8 3.32 
11 DC H2'2 11 DC H1' 3.21 
11 DC H2'2 11 DC H2'1 2.56 
11 DC H2'2 11 DC H3' 2.29 
11 DC H2'2 12 DA H8 3.74 
11 DC H3' 11 DC H2'1 4.08 
11 DC H3' 11 DC H5'1 3.33 
11 DC H5 10 DT H6 3.37 
11 DC H6 11 DC H2'2 2.14 
12 DA H1' 12 DA H3' 4.08 
12 DA H2'1 12 DA H1' 4.21 
12 DA H2'1 12 DA H2'2 1.67 
12 DA H2'1 12 DA H8 2.64 
12 DA H2'2 12 DA H1' 3.10 
12 DA H2'2 12 DA H8 4.03 
12 DA H3' 12 DA H4' 1.69 
12 DA H4' 12 DA H8 2.10 
15 BIC H51 15 BIC HC 1.90 
15 BIC HK2 15 BIC HJ1 2.14 
15 BIC HK2 16 NGL H51 2.58 
15 BIC HK2 7 DT H7 4.29 
16 NGL H21 16 NGL H12 2.94 
16 NGL H21 16 NGL H22 1.71 
16 NGL H21 16 NGL H31 3.12 
16 NGL H21 16 NGL H32 1.04 
16 NGL H22 15 BIC HM2 2.97 
16 NGL H22 16 NGL H12 2.85 
16 NGL H22 11 DC H1' 2.83 
16 NGL H22 12 DA H8 3.61 
16 NGL H31 15 BIC HJ1 1.97 
16 NGL H31 16 NGL H12 2.50 
16 NGL H31 16 NGL H41 1.49 
16 NGL H31 16 NGL H51 2.11 
16 NGL H31 10 DT H2'1 1.49 
16 NGL H32 16 NGL H21 2.41 
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Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
16 NGL H32 16 NGL H22 1.83 
16 NGL H32 16 NGL H42 1.61 
16 NGL H32 16 NGL H51 4.41 
16 NGL H32 10 DT H1' 2.71 
16 NGL H41 16 NGL H32 1.37 
16 NGL H41 16 NGL H51 4.26 
16 NGL H42 16 NGL H12 2.75 
16 NGL H51 16 NGL H42 2.39 
16 NGL H52 15 BIC HJ1 3.43 
16 NGL H52 16 NGL H21 2.92 
16 NGL H52 16 NGL H41 4.11 
16 NGL H52 16 NGL H51 2.05 
16 NGL H52 8 DG H1' 2.48 
16 NGL H52 8 DG H4' 2.65 
16 NGL H52 9 DA H2'1 2.06 
16 NGL H52 10 DT H2'1 1.78 
16 NGL H52 10 DT H5'1 2.81 
 
Appendices 253
Appendix 2.2:  Nogalamycin2-d(CCTGATCAGG)2 
 
Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
1 DC H1' 1 DC H6 2.86 
1 DC H1' 2 DC H6 3.01 
1 DC H2'1 1 DC H2'2 2.32 
1 DC H2'1 1 DC H3' 2.96 
1 DC H2'1 1 DC H5 3.05 
1 DC H2'1 1 DC H6 2.54 
1 DC H2'1 2 DC H6 2.22 
1 DC H2'2 1 DC H2'1 2.41 
1 DC H2'2 1 DC H5 2.99 
1 DC H3' 1 DC H2'1 6.71 
1 DC H3' 1 DC H6 3.52 
1 DC H3' 2 DC H6 3.47 
1 DC H5 1 DC H6 3.62 
1 DC H5'1 1 DC H3' 4.89 
1 DC H5'1 1 DC H6 4.62 
1 DC H5'2 1 DC H3' 4.41 
1 DC H5'2 1 DC H6 4.74 
2 DC H1' 2 DC H2'2 3.09 
2 DC H1' 2 DC H4' 4.21 
2 DC H1' 2 DC H6 3.83 
2 DC H1' 3 DT H6 4.65 
2 DC H2'1 2 DC H1' 4.05 
2 DC H2'1 2 DC H2'2 2.33 
2 DC H2'1 2 DC H6 2.72 
2 DC H2'1 3 DT H6 2.46 
2 DC H2'2 2 DC H1' 2.85 
2 DC H2'2 2 DC H2'1 2.19 
2 DC H2'2 2 DC H4' 3.42 
2 DC H3' 2 DC H2'1 4.96 
2 DC H3' 2 DC H6 3.75 
2 DC H5 21 BIC H11 3.03 
2 DC H6 1 DC H2'2 2.45 
2 DC H6 2 DC H5 2.69 
3 DT H1' 21 BIC HO 3.37 
3 DT H1' 3 DT H3' 5.22 
3 DT H1' 3 DT H6 3.67 
3 DT H1' 4 DG H5'1 7.18 
3 DT H2'1 3 DT H1' 2.75 
3 DT H2'1 4 DG H4' 7.33 
3 DT H2'2 21 BIC HO 2.73 
3 DT H2'2 3 DT H1' 2.85 
3 DT H2'2 3 DT H3' 3.02 
3 DT H2'2 3 DT H5'1 3.42 
3 DT H3' 21 BIC HO 9.29 
3 DT H3' 3 DT H6 2.63 
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Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
3 DT H4' 21 BIC HO 5.23 
3 DT H5'2 3 DT H2'2 4.95 
3 DT H6 21 BIC HO 3.80 
3 DT H6 2 DC H2'2 2.99 
3 DT H6 3 DT H2'1 3.20 
3 DT H6 3 DT H2'2 2.46 
3 DT H7 21 BIC H11 2.46 
3 DT H7 2 DC H2'1 2.47 
3 DT H7 2 DC H2'2 4.22 
3 DT H7 2 DC H3' 4.67 
3 DT H7 2 DC H5 6.88 
3 DT H7 3 DT H6 3.10 
3 DT H7 4 DG H4' 2.47 
4 DG H1' 21 BIC HO 3.81 
4 DG H1' 4 DG H2'1 4.60 
4 DG H1' 4 DG H2'2 3.53 
4 DG H1' 4 DG H4' 3.93 
4 DG H1' 4 DG H5'1 2.22 
4 DG H1' 4 DG H8 3.83 
4 DG H1' 5 DA H8 2.54 
4 DG H2'1 4 DG H8 2.49 
4 DG H2'2 4 DG H5'2 5.45 
4 DG H2'2 4 DG H8 2.65 
4 DG H3' 4 DG H1' 3.41 
4 DG H3' 4 DG H8 3.54 
4 DG H4' 21 BIC HO 4.18 
4 DG H4' 4 DG H1' 4.25 
4 DG H4' 4 DG H3' 3.10 
4 DG H4' 4 DG H8 3.73 
4 DG H4' 5 DA H8 6.46 
4 DG H5'1 3 DT H1' 6.21 
4 DG H5'1 4 DG H1' 3.36 
4 DG H5'1 5 DA H8 6.56 
4 DG H5'2 4 DG H3' 2.78 
4 DG H8 3 DT H5'2 0.66 
4 DG H8 5 DA H8 2.14 
5 DA H1' 22 NGL H52 2.48 
5 DA H1' 5 DA H3' 4.92 
5 DA H1' 5 DA H4' 3.86 
5 DA H1' 5 DA H5'1 3.90 
5 DA H1' 5 DA H8 4.62 
5 DA H1' 6 DT H6 3.05 
5 DA H2'1 22 NGL H52 5.60 
5 DA H2'1 5 DA H2'2 1.69 
5 DA H2'1 5 DA H8 2.02 
5 DA H2'2 5 DA H8 2.91 
5 DA H2'2 6 DT H6 3.25 
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Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
5 DA H3' 5 DA H2'1 2.90 
5 DA H3' 5 DA H2'2 3.54 
5 DA H3' 5 DA H4' 2.70 
5 DA H3' 5 DA H5'1 2.41 
5 DA H3' 5 DA H8 3.06 
5 DA H3' 6 DT H6 5.05 
5 DA H8 5 DA H4' 6.16 
5 DA H8 5 DA H5'1 8.97 
6 DT H1' 6 DT H3' 3.57 
6 DT H1' 6 DT H4' 3.90 
6 DT H1' 6 DT H6 3.85 
6 DT H1' 7 DC H6 3.26 
6 DT H2'1 22 NGL H51 3.10 
6 DT H2'1 6 DT H1' 3.56 
6 DT H2'1 6 DT H2'2 2.78 
6 DT H2'1 6 DT H4' 7.62 
6 DT H2'1 6 DT H6 2.54 
6 DT H2'1 7 DC H5 4.93 
6 DT H2'1 7 DC H6 2.77 
6 DT H2'2 6 DT H1' 2.59 
6 DT H3' 6 DT H2'1 3.94 
6 DT H3' 6 DT H4' 3.71 
6 DT H3' 6 DT H6 4.00 
6 DT H4' 21 BIC HO 2.30 
6 DT H4' 6 DT H2'2 8.24 
6 DT H4' 6 DT H3' 3.19 
6 DT H5'1 6 DT H3' 1.38 
6 DT H5'2 6 DT H3' 1.54 
6 DT H6 5 DA H2'1 3.57 
6 DT H6 5 DA H2'2 2.77 
6 DT H6 5 DA H3' 5.25 
6 DT H6 5 DA H8 6.26 
6 DT H6 6 DT H2'2 3.69 
6 DT H6 6 DT H3' 3.56 
6 DT H6 7 DC H6 5.60 
6 DT H7 5 DA H1' 6.68 
6 DT H7 5 DA H2'1 3.88 
6 DT H7 5 DA H2'2 3.93 
6 DT H7 5 DA H3' 5.69 
6 DT H7 5 DA H8 3.42 
6 DT H7 6 DT H6 3.12 
6 DT H7 7 DC H5 8.63 
7 DC H1' 8 DA H8 4.98 
7 DC H2'1 7 DC H1' 2.61 
7 DC H2'1 7 DC H2'2 1.31 
7 DC H2'1 7 DC H5 6.02 
7 DC H2'1 7 DC H6 2.25 
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7 DC H2'1 8 DA H8 3.32 
7 DC H2'2 7 DC H1' 3.21 
7 DC H2'2 7 DC H2'1 2.56 
7 DC H2'2 7 DC H3' 2.29 
7 DC H2'2 8 DA H8 3.74 
7 DC H3' 7 DC H2'1 4.08 
7 DC H3' 7 DC H5'1 3.33 
7 DC H4' 7 DC H1' 6.39 
7 DC H5 6 DT H1' 7.65 
7 DC H5 6 DT H6 3.37 
7 DC H6 7 DC H2'2 2.14 
8 DA H1' 8 DA H3' 4.08 
8 DA H2'1 8 DA H1' 4.21 
8 DA H2'1 8 DA H2'2 1.67 
8 DA H2'1 8 DA H8 2.64 
8 DA H2'2 8 DA H1' 3.10 
8 DA H2'2 8 DA H8 4.03 
8 DA H2'2 9 DG H8 2.17 
8 DA H3' 8 DA H4' 1.69 
8 DA H4' 8 DA H1' 4.97 
8 DA H4' 8 DA H8 2.10 
8 DA H8 7 DC H3' 6.41 
8 DA H8 8 DA H1' 4.63 
8 DA H8 8 DA H3' 5.97 
9 DG H1' 9 DG H2'1 3.13 
9 DG H2'1 10 DG H8 2.00 
9 DG H2'1 9 DG H3' 3.48 
9 DG H3' 9 DG H2'2 3.89 
9 DG H4' 9 DG H3' 5.19 
9 DG H4' 9 DG H3' 8.48 
9 DG H8 9 DG H2'1 2.39 
10 DG H2'1 10 DG H1' 4.73 
10 DG H2'2 10 DG H1' 3.49 
10 DG H3' 10 DG H4' 2.50 
10 DG H3' 10 DG H8 2.88 
10 DG H3' 21 BIC HC 8.47 
10 DG H8 9 DG H2'2 2.03 
11 DC H1' 11 DC H6 2.86 
11 DC H1' 12 DC H6 3.01 
11 DC H2'1 11 DC H2'2 2.32 
11 DC H2'1 11 DC H3' 2.96 
11 DC H2'1 11 DC H5 3.05 
11 DC H2'1 11 DC H6 2.54 
11 DC H2'1 12 DC H6 2.22 
11 DC H2'2 11 DC H2'1 2.41 
11 DC H2'2 11 DC H5 2.99 
11 DC H3' 11 DC H2'1 6.71 
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11 DC H3' 11 DC H6 3.52 
11 DC H3' 12 DC H6 3.47 
11 DC H5 11 DC H6 3.62 
11 DC H5'1 11 DC H3' 4.89 
11 DC H5'1 11 DC H6 4.62 
11 DC H5'2 11 DC H3' 4.41 
11 DC H5'2 11 DC H6 4.74 
12 DC H1' 12 DC H2'2 3.09 
12 DC H1' 12 DC H4' 4.21 
12 DC H1' 12 DC H6 3.83 
12 DC H1' 13 DT H6 4.65 
12 DC H2'1 12 DC H1' 4.05 
12 DC H2'1 12 DC H2'2 2.33 
12 DC H2'1 12 DC H6 2.72 
12 DC H2'1 13 DT H6 2.46 
12 DC H2'2 12 DC H1' 2.85 
12 DC H2'2 12 DC H2'1 2.19 
12 DC H2'2 12 DC H4' 3.42 
12 DC H3' 12 DC H2'1 4.96 
12 DC H3' 12 DC H6 3.75 
12 DC H5 21 BIC H11 3.03 
12 DC H6 11 DC H2'2 2.45 
12 DC H6 12 DC H5 2.69 
13 DT H1' 21 BIC HO 3.37 
13 DT H1' 13 DT H3' 5.22 
13 DT H1' 13 DT H6 3.67 
13 DT H1' 14 DG H5'1 7.18 
13 DT H2'1 13 DT H1' 2.75 
13 DT H2'1 14 DG H4' 7.33 
13 DT H2'2 21 BIC HO 2.73 
13 DT H2'2 13 DT H1' 2.85 
13 DT H2'2 13 DT H3' 3.02 
13 DT H2'2 13 DT H5'1 3.42 
13 DT H3' 21 BIC HO 9.29 
13 DT H3' 13 DT H6 2.63 
13 DT H4' 21 BIC HO 5.23 
13 DT H5'2 13 DT H2'2 4.95 
13 DT H6 21 BIC HO 3.80 
13 DT H6 12 DC H2'2 2.99 
13 DT H6 13 DT H2'1 3.20 
13 DT H6 13 DT H2'2 2.46 
13 DT H7 21 BIC H11 2.46 
13 DT H7 12 DC H2'1 2.47 
13 DT H7 12 DC H2'2 4.22 
13 DT H7 12 DC H3' 4.67 
13 DT H7 12 DC H5 6.88 
13 DT H7 13 DT H6 3.10 
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13 DT H7 14 DG H4' 2.47 
14 DG H1' 21 BIC HO 3.81 
14 DG H1' 14 DG H2'1 4.60 
14 DG H1' 14 DG H2'2 3.53 
14 DG H1' 14 DG H4' 3.93 
14 DG H1' 14 DG H5'1 2.22 
14 DG H1' 14 DG H8 3.83 
14 DG H1' 15 DA H8 2.54 
14 DG H2'1 14 DG H8 2.49 
14 DG H2'2 14 DG H5'2 5.45 
14 DG H2'2 14 DG H8 2.65 
14 DG H3' 14 DG H1' 3.41 
14 DG H3' 14 DG H8 3.54 
14 DG H4' 21 BIC HO 4.18 
14 DG H4' 14 DG H1' 4.25 
14 DG H4' 14 DG H3' 3.10 
14 DG H4' 14 DG H8 3.73 
14 DG H4' 15 DA H8 6.46 
14 DG H5'1 13 DT H1' 6.21 
14 DG H5'1 14 DG H1' 3.36 
14 DG H5'1 15 DA H8 6.56 
14 DG H5'2 14 DG H3' 2.78 
14 DG H8 13 DT H5'2 0.66 
14 DG H8 15 DA H8 2.14 
15 DA H1' 24 NGL H12 2.48 
15 DA H1' 15 DA H3' 4.92 
15 DA H1' 15 DA H4' 3.86 
15 DA H1' 15 DA H5'1 3.90 
15 DA H1' 15 DA H8 4.62 
15 DA H1' 16 DT H6 3.05 
15 DA H2'1 24 NGL H12 5.60 
15 DA H2'1 15 DA H2'2 1.69 
15 DA H2'1 15 DA H8 2.02 
15 DA H2'2 15 DA H8 2.91 
15 DA H2'2 16 DT H6 3.25 
15 DA H3' 15 DA H2'1 2.90 
15 DA H3' 15 DA H2'2 3.54 
15 DA H3' 15 DA H4' 2.70 
15 DA H3' 15 DA H5'1 2.41 
15 DA H3' 15 DA H8 3.06 
15 DA H3' 16 DT H6 5.05 
15 DA H8 15 DA H4' 6.16 
15 DA H8 15 DA H5'1 8.97 
16 DT H1' 16 DT H3' 3.57 
16 DT H1' 16 DT H4' 3.90 
16 DT H1' 16 DT H6 3.85 
16 DT H1' 17 DC H6 3.26 
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16 DT H2'1 24 NGL H12 3.10 
16 DT H2'1 16 DT H1' 3.56 
16 DT H2'1 16 DT H2'2 2.78 
16 DT H2'1 16 DT H4' 7.62 
16 DT H2'1 16 DT H6 2.54 
16 DT H2'1 17 DC H5 4.93 
16 DT H2'1 17 DC H6 2.77 
16 DT H2'2 16 DT H1' 2.59 
16 DT H3' 16 DT H2'1 3.94 
16 DT H3' 16 DT H4' 3.71 
16 DT H3' 16 DT H6 4.00 
16 DT H4' 21 BIC HO 2.30 
16 DT H4' 16 DT H2'2 8.24 
16 DT H4' 16 DT H3' 3.19 
16 DT H5'1 16 DT H3' 1.38 
16 DT H5'2 16 DT H3' 1.54 
16 DT H6 15 DA H2'1 3.57 
16 DT H6 15 DA H2'2 2.77 
16 DT H6 15 DA H3' 5.25 
16 DT H6 15 DA H8 6.26 
16 DT H6 16 DT H2'2 3.69 
16 DT H6 16 DT H3' 3.56 
16 DT H6 17 DC H6 5.60 
16 DT H7 15 DA H1' 6.68 
16 DT H7 15 DA H2'1 3.88 
16 DT H7 15 DA H2'2 3.93 
16 DT H7 15 DA H3' 5.69 
16 DT H7 15 DA H8 3.42 
16 DT H7 16 DT H6 3.12 
16 DT H7 17 DC H5 8.63 
17 DC H1' 18 DA H8 4.98 
17 DC H2'1 17 DC H1' 2.61 
17 DC H2'1 17 DC H2'2 1.31 
17 DC H2'1 17 DC H5 6.02 
17 DC H2'1 17 DC H6 2.25 
17 DC H2'1 18 DA H8 3.32 
17 DC H2'2 17 DC H1' 3.21 
17 DC H2'2 17 DC H2'1 2.56 
17 DC H2'2 17 DC H3' 2.29 
17 DC H2'2 18 DA H8 3.74 
17 DC H3' 17 DC H2'1 4.08 
17 DC H3' 17 DC H5'1 3.33 
17 DC H4' 17 DC H1' 6.39 
17 DC H5 16 DT H1' 7.65 
17 DC H5 16 DT H6 3.37 
17 DC H6 17 DC H2'2 2.14 
18 DA H1' 18 DA H3' 4.08 
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18 DA H2'1 18 DA H1' 4.21 
18 DA H2'1 18 DA H2'2 1.67 
18 DA H2'1 18 DA H8 2.64 
18 DA H2'2 18 DA H1' 3.10 
18 DA H2'2 18 DA H8 4.03 
18 DA H2'2 19 DG H8 2.17 
18 DA H3' 18 DA H4' 1.69 
18 DA H4' 18 DA H1' 4.97 
18 DA H4' 18 DA H8 2.10 
18 DA H8 17 DC H3' 6.41 
18 DA H8 18 DA H1' 4.63 
18 DA H8 18 DA H3' 5.97 
19 DG H1' 19 DG H2'1 3.13 
19 DG H2'1 20 DG H8 2.00 
19 DG H2'1 19 DG H3' 3.48 
19 DG H3' 19 DG H2'2 3.89 
19 DG H4' 19 DG H3' 5.19 
19 DG H4' 19 DG H3' 8.48 
19 DG H8 19 DG H2'1 2.39 
20 DG H2'1 20 DG H1' 4.73 
20 DG H2'2 20 DG H1' 3.49 
20 DG H3' 20 DG H4' 2.50 
20 DG H3' 20 DG H8 2.88 
20 DG H3' 23 BIC HC 8.47 
20 DG H8 19 DG H2'2 2.03 
21 BIC H11 21 BIC H51 8.03 
21 BIC H11 21 BIC HS2 5.72 
21 BIC H11 3 DT H6 7.58 
21 BIC H51 21 BIC H11 4.77 
21 BIC H51 21 BIC HC 1.90 
21 BIC H51 9 DG H3' 1.24 
21 BIC HK2 21 BIC HJ1 2.14 
21 BIC HK2 22 NGL H51 2.58 
21 BIC HK2 3 DT H7 4.29 
21 BIC HO 22 NGL H51 8.61 
21 BIC HO 3 DT H4' 8.12 
21 BIC HO 4 DG H8 6.39 
21 BIC HS2 21 BIC H11 7.10 
21 BIC HS2 21 BIC HC 4.73 
22 NGL H21 22 NGL H22 2.94 
22 NGL H21 22 NGL H22 1.71 
22 NGL H21 22 NGL H31 3.12 
22 NGL H21 22 NGL H32 1.04 
22 NGL H22 21 BIC HM2 2.97 
22 NGL H22 22 NGL H22 2.85 
22 NGL H22 7 DC H1' 2.83 
22 NGL H22 8 DA H4' 5.08 
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22 NGL H22 8 DA H8 3.61 
22 NGL H31 21 BIC HJ1 1.97 
22 NGL H31 22 NGL H22 2.50 
22 NGL H31 22 NGL H41 1.49 
22 NGL H31 22 NGL H51 2.11 
22 NGL H31 5 DA H3' 5.65 
22 NGL H31 6 DT H2'1 1.49 
22 NGL H32 22 NGL H22 6.39 
22 NGL H32 22 NGL H21 2.41 
22 NGL H32 22 NGL H22 1.83 
22 NGL H32 22 NGL H42 1.61 
22 NGL H32 22 NGL H51 4.41 
22 NGL H32 5 DA H1' 8.81 
22 NGL H32 6 DT H1' 2.71 
22 NGL H32 6 DT H1' 4.73 
22 NGL H41 22 NGL H32 1.37 
22 NGL H41 22 NGL H51 4.26 
22 NGL H42 21 BIC HM2 2.18 
22 NGL H42 22 NGL H22 2.75 
22 NGL H42 7 DC H1' 3.34 
22 NGL H42 8 DA H4' 6.11 
22 NGL H51 22 NGL H42 2.39 
22 NGL H51 3 DT H1' 3.74 
22 NGL H52 21 BIC HJ1 3.43 
22 NGL H52 22 NGL H22 4.64 
22 NGL H52 22 NGL H21 2.92 
22 NGL H52 22 NGL H41 4.11 
22 NGL H52 22 NGL H51 2.05 
22 NGL H52 4 DG H1' 2.48 
22 NGL H52 4 DG H4' 2.65 
22 NGL H52 5 DA H2'1 2.06 
22 NGL H52 5 DA H2'2 5.74 
22 NGL H52 5 DA H3' 5.51 
22 NGL H52 6 DT H2'1 1.78 
22 NGL H52 6 DT H5'1 2.81 
22 NGL H52 6 DT H7 4.67 
23 BIC H21 23 BIC H51 8.03 
23 BIC H21 23 BIC HS2 5.72 
23 BIC H21 13 DT H6 7.58 
23 BIC H51 23 BIC H21 4.77 
23 BIC H51 23 BIC HC 1.90 
23 BIC H51 19 DG H3' 1.24 
23 BIC HK2 23 BIC HJ1 2.14 
23 BIC HK2 24 NGL H51 2.58 
23 BIC HK2 13 DT H7 4.29 
23 BIC HO 24 NGL H51 8.61 
23 BIC HO 13 DT H4' 8.12 
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23 BIC HO 14 DG H8 6.39 
23 BIC HS2 23 BIC H21 7.10 
23 BIC HS2 23 BIC HC 4.73 
24 NGL H21 24 NGL H22 2.94 
24 NGL H21 24 NGL H22 1.71 
24 NGL H21 24 NGL H31 3.12 
24 NGL H21 24 NGL H32 1.04 
24 NGL H22 23 BIC HM2 2.97 
24 NGL H22 24 NGL H22 2.85 
24 NGL H22 17 DC H1' 2.83 
24 NGL H22 18 DA H4' 5.08 
24 NGL H22 18 DA H8 3.61 
24 NGL H31 23 BIC HJ1 1.97 
24 NGL H31 24 NGL H22 2.50 
24 NGL H31 24 NGL H41 1.49 
24 NGL H31 24 NGL H51 2.11 
24 NGL H31 15 DA H3' 5.65 
24 NGL H31 16 DT H2'1 1.49 
24 NGL H32 24 NGL H22 6.39 
24 NGL H32 24 NGL H21 2.41 
24 NGL H32 24 NGL H22 1.83 
24 NGL H32 24 NGL H42 1.61 
24 NGL H32 24 NGL H51 4.41 
24 NGL H32 15 DA H1' 8.81 
24 NGL H32 16 DT H1' 2.71 
24 NGL H32 16 DT H1' 4.73 
24 NGL H41 24 NGL H32 1.37 
24 NGL H41 24 NGL H51 4.26 
24 NGL H42 23 BIC HM2 2.18 
24 NGL H42 24 NGL H22 2.75 
24 NGL H42 17 DC H1' 3.34 
24 NGL H42 18 DA H4' 6.11 
24 NGL H51 24 NGL H42 2.39 
24 NGL H51 13 DT H1' 3.74 
24 NGL H52 23 BIC HJ1 3.43 
24 NGL H52 24 NGL H22 4.64 
24 NGL H52 24 NGL H21 2.92 
24 NGL H52 24 NGL H41 4.11 
24 NGL H52 24 NGL H51 2.05 
24 NGL H52 14 DG H1' 2.48 
24 NGL H52 14 DG H4' 2.65 
24 NGL H52 15 DA H2'1 2.06 
24 NGL H52 15 DA H2'2 5.74 
24 NGL H52 15 DA H3' 5.51 
24 NGL H52 16 DT H2'1 1.78 
24 NGL H52 16 DT H5'1 2.81 
24 NGL H52 16 DT H7 4.67 
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Appendix 2.3:  Nogalamycin-d(GCTACGAAGTGC) 
 
Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
1 DG H1' 2 DC H2'1 2.60 
2 DC H2'1 2 DC H2'2 1.85 
2 DC H3' 2 DC H2'2 1.87 
2 DC H42 2 DC H41 1.74 
2 DC H5 2 DC H41 2.83 
2 DC H5 2 DC H42 2.57 
3 DC H2'1 3 DC H1' 3.06 
3 DC H2'1 3 DC H2'2 1.92 
3 DC H2'1 3 DC H6 3.07 
3 DC H2'2 3 DC H1' 2.27 
3 DC H3' 3 DC H2'1 2.41 
3 DC H3' 3 DC H2'2 3.70 
3 DC H4' 2 DC H5'2 2.81 
3 DC H5'2 3 DC H1' 2.95 
4 DC H1' 5 DG H5'2 2.78 
4 DC H2'1 4 DC H2'2 1.78 
4 DC H2'1 5 DG H8 3.68 
4 DC H2'2 4 DC H1' 2.38 
4 DC H2'2 4 DC H6 3.08 
4 DC H2'2 5 DG H8 2.98 
4 DC H3' 4 DC H2'2 3.18 
4 DC H4' 4 DC H5'2 1.07 
4 DC H42 4 DC H41 1.73 
4 DC H5 4 DC H41 3.58 
4 DC H5 4 DC H42 2.44 
4 DC H5 4 DC H6 2.60 
5 DG H1' 5 DG H8 4.41 
5 DG H2'1 5 DG H1' 2.94 
5 DG H2'1 5 DG H2'2 2.18 
5 DG H2'1 5 DG H8 3.41 
5 DG H2'1 6 DT H6 2.84 
5 DG H2'2 5 DG H1' 3.50 
5 DG H2'2 5 DG H8 2.36 
5 DG H3' 5 DG H2'1 2.53 
5 DG H3' 5 DG H2'2 2.49 
6 DT H1' 6 DT H2'2 2.11 
6 DT H2'1 6 DT H2'2 1.70 
6 DT H2'1 6 DT H3' 3.03 
6 DT H2'1 6 DT H6 2.31 
6 DT H2'2 6 DT H3' 3.51 
6 DT H2'2 6 DT H5'1 2.97 
6 DT H2'2 6 DT H5'2 2.75 
6 DT H2'2 6 DT H6 3.48 
6 DT H3' 6 DT H5'2 2.68 
6 DT H7 5 DG H2'1 3.74 
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7 DA H1' 7 DA H8 3.22 
7 DA H2'1 7 DA H1' 2.81 
7 DA H2'1 7 DA H2'2 2.09 
7 DA H2'1 7 DA H8 2.36 
7 DA H2'2 7 DA H1' 2.40 
7 DA H3' 7 DA H2'1 2.83 
7 DA H3' 7 DA H2'2 2.92 
7 DA H5'1 7 DA H8 3.25 
8 DG H1' 8 DG H2'1 2.70 
8 DG H1' 8 DG H8 4.90 
8 DG H1' 9 DT H6 3.74 
8 DG H2'1 8 DG H2'2 3.90 
8 DG H2'1 8 DG H8 2.41 
8 DG H2'2 8 DG H1' 4.26 
9 DT H3' 9 DT H6 3.43 
9 DT H5'2 9 DT H6 4.65 
9 DT H7 8 DG H2'1 4.33 
9 DT H7 8 DG H2'2 3.65 
10 DG H1' 10 DG H2'2 2.34 
10 DG H1' 10 DG H8 3.46 
10 DG H2'1 10 DG H2'2 2.60 
10 DG H2'2 10 DG H8 2.69 
11 DC H1' 11 DC H2'1 3.13 
11 DC H2'1 11 DC H2'2 2.12 
11 DC H2'2 11 DC H1' 2.55 
11 DC H2'2 11 DC H6 4.26 
11 DC H3' 11 DC H2'1 2.44 
11 DC H3' 11 DC H2'2 2.78 
11 DC H3' 11 DC H6 3.62 
11 DC H4' 11 DC H6 3.60 
11 DC H42 11 DC H41 1.71 
11 DC H5 11 DC H42 2.51 
11 DC H5 11 DC H6 2.97 
12 BIC H21 12 BIC H11 3.49 
12 BIC H51 12 BIC H41 0.63 
12 BIC HJ1 13 NGL H21 2.53 
12 BIC HK2 13 NGL H41 3.86 
12 BIC HL2 11 DC H4' 2.88 
12 BIC HL2 13 NGL H22 3.80 
13 NGL H21 13 NGL H22 5.15 
13 NGL H22 13 NGL H51 2.26 
13 NGL H31 12 BIC HK2 2.70 
13 NGL H31 13 NGL H32 3.31 
13 NGL H31 13 NGL H51 4.58 
13 NGL H42 2 DC H5'2 2.75 
13 NGL H51 13 NGL H21 2.32 
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Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
1 DG H1' 1 DG H8 4.46 
1 DG H1' 2 DC H6 3.82 
1 DG H2'1 1 DG H1' 3.73 
1 DG H2'1 1 DG H5'1 3.51 
1 DG H2'1 2 DC H5 4.38 
2 DC H6 1 DG H2'1 4.90 
1 DG H2'2 1 DG H1' 2.87 
1 DG H3' 1 DG H2'2 3.45 
1 DG H8 1 DG H2'2 3.93 
1 DG H2'2 2 DC H5 3.59 
2 DC H6 1 DG H2'2 3.14 
1 DG H3' 1 DG H8 6.15 
1 DG H1' 1 DG H4' 3.42 
1 DG H5'1 1 DG H3' 3.14 
1 DG H5'1 1 DG H4' 2.86 
1 DG H5'1 1 DG H8 3.68 
10 DT H1' 10 DT H6 5.03 
10 DT H1' 13 BIC HO 4.51 
10 DT H3' 10 DT H6 4.23 
10 DT H7 10 DT H6 3.25 
10 DT H7 13 BIC H11 3.28 
13 BIC H51 10 DT H7 3.35 
10 DT H7 9 DG H1' 6.24 
10 DT H7 9 DG H2'1 3.52 
10 DT H7 9 DG H8 3.89 
11 DG H1' 11 DG H8 5.11 
11 DG H1' 12 DC H6 3.27 
11 DG H1' 13 BIC HO 4.04 
11 DG H2'1 11 DG H1' 2.85 
11 DG H2'1 12 DC H5 3.11 
12 DC H6 11 DG H2'1 2.87 
11 DG H3' 11 DG H8 4.33 
11 DG H4' 11 DG H1' 3.69 
11 DG H3' 11 DG H4' 2.99 
11 DG H4' 13 BIC HO 4.80 
11 DG H5'1 11 DG H1' 3.28 
11 DG H5'1 11 DG H8 4.37 
12 DC H1' 12 DC H6 4.08 
3 DT H7 1 DG H1' 4.02 
12 DC H2'1 12 DC H1' 3.41 
12 DC H2'1 12 DC H2'2 2.23 
12 DC H2'1 12 DC H5'1 3.88 
12 DC H2'1 12 DC H6 2.96 
12 DC H2'2 12 DC H3' 3.69 
12 DC H2'2 12 DC H5'1 3.74 
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12 DC H6 12 DC H2'2 4.58 
12 DC H3' 12 DC H6 3.29 
12 DC H4' 12 DC H6 4.63 
12 DC H5'1 12 DC H1' 3.65 
12 DC H5'1 12 DC H3' 3.25 
12 DC H5'1 12 DC H4' 2.59 
12 DC H5'2 12 DC H6 3.89 
12 DC H5 12 DC H6 2.73 
13 BIC H11 10 DT H6 4.30 
13 BIC H11 13 BIC H21 2.60 
13 BIC H32 13 BIC H21 4.03 
13 BIC H32 13 BIC H11 4.40 
13 BIC H41 13 BIC H11 4.30 
13 BIC H41 13 BIC H32 2.19 
13 BIC H41 13 BIC HC 4.59 
13 BIC H51 13 BIC H11 4.32 
13 BIC H51 13 BIC H41 2.57 
13 BIC HK1 13 BIC HJ1 2.52 
13 BIC HK1 14 NGL H12 4.45 
13 BIC HK1 14 NGL H22 2.60 
13 BIC HJ1 13 BIC HK2 2.54 
14 NGL H12 13 BIC HK2 4.42 
13 BIC HK2 14 NGL H22 3.51 
13 BIC HL2 11 DG H1' 3.00 
13 BIC HL2 11 DG H4' 3.28 
13 BIC HL2 12 DC H1' 3.65 
13 BIC HL2 12 DC H5'1 3.10 
13 BIC HK1 13 BIC HL2 3.02 
13 BIC HL2 13 BIC HK2 3.66 
13 BIC HL2 13 BIC HM2 2.48 
13 BIC HL2 13 BIC HO 4.49 
13 BIC HL2 14 NGL H21 5.47 
13 BIC HL2 14 NGL H22 2.97 
13 BIC HM2 13 BIC HO 2.61 
13 BIC HS2 10 DT H1' 3.94 
4 DA H1' 14 NGL H12 3.51 
13 BIC HJ1 14 NGL H21 4.12 
14 NGL H12 14 NGL H21 2.80 
14 NGL H22 14 NGL H21 3.20 
14 NGL H41 14 NGL H21 2.33 
2 DC H1' 14 NGL H21 4.79 
14 NGL H22 14 NGL H12 4.08 
14 NGL H31 12 DC H1' 2.70 
14 NGL H31 12 DC H2'2 3.93 
14 NGL H31 12 DC H5'1 3.23 
14 NGL H31 13 BIC HK1 4.55 
14 NGL H31 14 NGL H12 4.39 
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14 NGL H31 14 NGL H22 2.44 
14 NGL H31 14 NGL H41 3.62 
14 NGL H41 14 NGL H12 2.55 
14 NGL H41 2 DC H4' 4.45 
14 NGL H41 4 DA H8 3.54 
14 NGL H52 13 BIC HK1 4.32 
13 BIC HK2 14 NGL H52 4.40 
14 NGL H52 14 NGL H12 5.00 
14 NGL H52 14 NGL H41 2.81 
14 NGL H52 14 NGL H42 2.44 
14 NGL H52 14 NGL H42 2.59 
14 NGL H52 14 NGL H42 2.59 
14 NGL H52 14 NGL H42 2.75 
14 NGL H52 4 DA H4' 3.72 
2 DC H1' 2 DC H6 4.46 
2 DC H2'1 2 DC H1' 3.47 
2 DC H3' 2 DC H2'1 2.78 
2 DC H2'1 2 DC H5'1 3.94 
2 DC H6 2 DC H2'1 2.52 
2 DC H2'2 14 NGL H41 3.63 
2 DC H2'2 2 DC H4' 4.26 
2 DC H2'2 2 DC H5'1 4.23 
2 DC H6 2 DC H2'2 3.43 
2 DC H1' 2 DC H3' 4.54 
2 DC H3' 2 DC H6 3.50 
2 DC H4' 2 DC H1' 3.59 
2 DC H5'1 2 DC H6 4.59 
2 DC H5'1 3 DT H6 4.00 
2 DC H5 1 DG H8 4.10 
2 DC H5 2 DC H6 2.69 
3 DT H1' 3 DT H6 3.66 
4 DA H8 3 DT H1' 5.10 
3 DT H6 3 DT H2'1 2.75 
3 DT H2'2 3 DT H6 3.80 
3 DT H4' 3 DT H1' 4.07 
3 DT H3' 3 DT H4' 3.26 
3 DT H7 2 DC H3' 5.52 
3 DT H7 2 DC H6 4.29 
3 DT H7 3 DT H6 3.30 
4 DA H1' 4 DA H8 4.80 
4 DA H2'1 4 DA H2'2 2.27 
4 DA H2'1 4 DA H8 2.85 
5 DC H6 4 DA H2'1 4.73 
4 DA H2'2 4 DA H1' 2.79 
4 DA H3' 4 DA H2'2 3.42 
4 DA H2'2 4 DA H8 4.33 
5 DC H5'1 4 DA H2'2 3.83 
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5 DC H6 4 DA H2'2 3.45 
4 DA H3' 4 DA H8 4.15 
5 DC H2'1 5 DC H2'2 2.17 
5 DC H2'2 5 DC H3' 3.54 
5 DC H6 5 DC H2'2 4.56 
5 DC H1' 5 DC H4' 3.64 
5 DC H5'1 5 DC H3' 3.25 
6 DG H4' 7 DA H2'1 3.58 
7 DA H2'1 7 DA H2'2 2.07 
7 DA H3' 7 DA H2'1 4.11 
7 DA H2'2 7 DA H3' 3.33 
7 DA H4' 7 DA H2'2 3.31 
7 DA H4' 7 DA H3' 3.33 
7 DA H5'1 7 DA H3' 2.68 
7 DA H8 7 DA H5'1 2.66 
8 DA H1' 9 DG H8 4.92 
8 DA H2'1 8 DA H1' 3.11 
8 DA H3' 8 DA H2'1 3.20 
9 DG H1' 10 DT H6 4.09 
9 DG H2'1 9 DG H1' 2.92 
9 DG H2'1 9 DG H4' 3.96 
9 DG H4' 9 DG H1' 3.60 
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Appendix 2.5:  d(TAGGAGGT)4 
 
Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
1 DT H2'1 1 DT H2'2 2.03 
1 DT H3' 1 DT H2'1 2.77 
1 DT H2'2 1 DT H3' 2.72 
1 DT H5'1 1 DT H2'2 5.03 
1 DT H4' 1 DT H3' 2.57 
1 DT H5'1 1 DT H4' 2.83 
1 DT H5'1 1 DT H3' 2.80 
2 DA H2'1 2 DA H1' 2.58 
2 DA H2'1 2 DA H3' 2.25 
3 DG H2'1 3 DG H1' 3.21 
3 DG H2'1 3 DG H2'2 1.82 
3 DG H4' 3 DG H2'1 6.08 
3 DG H5'1 3 DG H2'1 5.35 
3 DG H5'2 3 DG H2'1 5.94 
3 DG H2'2 3 DG H1' 2.47 
3 DG H2'2 3 DG H3' 2.60 
3 DG H3' 3 DG H5'2 2.70 
4 DG H2'1 4 DG H1' 3.03 
4 DG H2'1 4 DG H2'2 1.84 
4 DG H2'1 4 DG H3' 2.13 
4 DG H4' 4 DG H2'1 5.61 
4 DG H2'2 4 DG H1' 2.24 
4 DG H2'2 4 DG H3' 2.55 
4 DG H4' 4 DG H2'2 5.01 
4 DG H1' 4 DG H3' 4.30 
4 DG H5'1 4 DG H3' 3.64 
4 DG H4' 4 DG H5'1 2.68 
4 DG H5'2 4 DG H3' 2.62 
5 DA H2'1 5 DA H1' 2.26 
5 DA H2'1 5 DA H2'2 1.85 
5 DA H2'1 5 DA H3' 2.63 
5 DA H2'2 5 DA H1' 2.99 
5 DA H2'2 5 DA H3' 2.40 
5 DA H5'2 5 DA H2'2 5.67 
5 DA H1' 5 DA H3' 4.38 
5 DA H3' 5 DA H4' 4.77 
5 DA H1' 5 DA H5'1 3.72 
5 DA H5'1 5 DA H3' 2.63 
6 DG H2'2 6 DG H1' 2.31 
6 DG H2'2 6 DG H3' 2.57 
6 DG H4' 6 DG H2'2 6.50 
6 DG H5'1 6 DG H2'2 5.33 
6 DG H3' 6 DG H1' 4.75 
6 DG H4' 6 DG H1' 3.58 
6 DG H4' 6 DG H3' 2.70 
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6 DG H5'1 6 DG H1' 3.84 
6 DG H5'1 6 DG H3' 3.36 
6 DG H5'2 6 DG H3' 2.69 
6 DG H4' 6 DG H5'2 2.51 
7 DG H2'1 7 DG H1' 2.74 
7 DG H2'1 7 DG H2'2 1.88 
7 DG H2'2 7 DG H1' 2.33 
7 DG H2'2 7 DG H3' 2.66 
7 DG H4' 7 DG H2'2 5.71 
7 DG H4' 7 DG H1' 3.04 
8 DT H2'1 8 DT H1' 2.09 
2 DA H8 2 DA H1' 8.02 
3 DG H8 2 DA H1' 9.38 
3 DG H8 3 DG H1' 5.77 
3 DG H1' 4 DG H8 4.46 
3 DG H8 3 DG H2'1 3.01 
3 DG H2'1 4 DG H8 4.26 
3 DG H8 3 DG H2'2 4.27 
4 DG H8 4 DG H1' 5.96 
4 DG H2'1 5 DA H8 3.51 
4 DG H2'2 5 DA H8 3.01 
5 DA H2'1 5 DA H8 3.91 
5 DA H2'2 5 DA H8 2.68 
5 DA H3' 5 DA H8 4.25 
6 DG H8 6 DG H1' 3.93 
7 DG H8 6 DG H1' 4.82 
6 DG H8 6 DG H2'1 2.94 
6 DG H8 6 DG H2'2 3.75 
7 DG H8 7 DG H1' 5.47 
7 DG H2'1 7 DG H8 2.75 
8 DT H6 7 DG H2'1 7.20 
7 DG H8 7 DG H2'2 3.55 
8 DT H6 8 DT H1' 4.34 
8 DT H6 8 DT H2'1 3.29 
9 DT H2'1 9 DT H2'2 2.03 
9 DT H3' 9 DT H2'1 2.77 
9 DT H2'2 9 DT H3' 2.72 
9 DT H5'1 9 DT H2'2 5.03 
9 DT H4' 9 DT H3' 2.57 
9 DT H5'1 9 DT H4' 2.83 
9 DT H5'1 9 DT H3' 2.80 
10 DA H2'1 10 DA H1' 2.58 
10 DA H2'1 10 DA H3' 2.25 
11 DG H2'1 11 DG H1' 3.21 
11 DG H2'1 11 DG H2'2 1.82 
11 DG H4' 11 DG H2'1 6.08 
11 DG H5'1 11 DG H2'1 5.35 
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11 DG H5'2 11 DG H2'1 5.94 
11 DG H2'2 11 DG H1' 2.47 
11 DG H2'2 11 DG H3' 2.60 
11 DG H3' 11 DG H5'2 2.70 
12 DG H2'1 12 DG H1' 3.03 
12 DG H2'1 12 DG H2'2 1.84 
12 DG H2'1 12 DG H3' 2.13 
12 DG H4' 12 DG H2'1 5.61 
12 DG H2'2 12 DG H1' 2.24 
12 DG H2'2 12 DG H3' 2.55 
12 DG H4' 12 DG H2'2 5.01 
12 DG H1' 12 DG H3' 4.30 
12 DG H5'1 12 DG H3' 3.64 
12 DG H4' 12 DG H5'1 2.68 
12 DG H5'2 12 DG H3' 2.62 
13 DA H2'1 13 DA H1' 2.26 
13 DA H2'1 13 DA H2'2 1.85 
13 DA H2'1 13 DA H3' 2.63 
13 DA H2'2 13 DA H1' 2.99 
13 DA H2'2 13 DA H3' 2.40 
13 DA H5'2 13 DA H2'2 5.67 
13 DA H1' 13 DA H3' 4.38 
13 DA H3' 13 DA H4' 4.77 
13 DA H1' 13 DA H5'1 3.72 
13 DA H5'1 13 DA H3' 2.63 
14 DG H2'2 14 DG H1' 2.31 
14 DG H2'2 14 DG H3' 2.57 
14 DG H4' 14 DG H2'2 6.50 
14 DG H5'1 14 DG H2'2 5.33 
14 DG H3' 14 DG H1' 4.75 
14 DG H4' 14 DG H1' 3.58 
14 DG H4' 14 DG H3' 2.70 
14 DG H5'1 14 DG H1' 3.84 
14 DG H5'1 14 DG H3' 3.36 
14 DG H5'2 14 DG H3' 2.69 
14 DG H4' 14 DG H5'2 2.51 
15 DG H2'1 15 DG H1' 2.74 
15 DG H2'1 15 DG H2'2 1.88 
15 DG H2'2 15 DG H1' 2.33 
15 DG H2'2 15 DG H3' 2.66 
15 DG H4' 15 DG H2'2 5.71 
15 DG H4' 15 DG H1' 3.04 
16 DT H2'1 16 DT H1' 2.09 
10 DA H8 10 DA H1' 8.02 
11 DG H8 10 DA H1' 9.38 
11 DG H8 11 DG H1' 5.77 
11 DG H1' 12 DG H8 4.46 
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11 DG H8 11 DG H2'1 3.01 
11 DG H2'1 12 DG H8 4.26 
11 DG H8 11 DG H2'2 4.27 
12 DG H8 12 DG H1' 5.96 
12 DG H2'1 13 DA H8 3.51 
12 DG H2'2 13 DA H8 3.01 
13 DA H2'1 13 DA H8 3.91 
13 DA H2'2 13 DA H8 2.68 
13 DA H3' 13 DA H8 4.25 
14 DG H8 14 DG H1' 3.93 
15 DG H8 14 DG H1' 4.82 
14 DG H8 14 DG H2'1 2.94 
14 DG H8 14 DG H2'2 3.75 
15 DG H8 15 DG H1' 5.47 
15 DG H2'1 15 DG H8 2.75 
16 DT H6 15 DG H2'1 7.20 
15 DG H8 15 DG H2'2 3.55 
16 DT H6 16 DT H1' 4.34 
16 DT H6 16 DT H2'1 3.29 
17 DT H2'1 17 DT H2'2 2.03 
17 DT H3' 17 DT H2'1 2.77 
17 DT H2'2 17 DT H3' 2.72 
17 DT H5'1 17 DT H2'2 5.03 
17 DT H4' 17 DT H3' 2.57 
17 DT H5'1 17 DT H4' 2.83 
17 DT H5'1 17 DT H3' 2.80 
18 DA H2'1 18 DA H1' 2.58 
18 DA H2'1 18 DA H3' 2.25 
19 DG H2'1 19 DG H1' 3.21 
19 DG H2'1 19 DG H2'2 1.82 
19 DG H4' 19 DG H2'1 6.08 
19 DG H5'1 19 DG H2'1 5.35 
19 DG H5'2 19 DG H2'1 5.94 
19 DG H2'2 19 DG H1' 2.47 
19 DG H2'2 19 DG H3' 2.60 
19 DG H3' 19 DG H5'2 2.70 
20 DG H2'1 20 DG H1' 3.03 
20 DG H2'1 20 DG H2'2 1.84 
20 DG H2'1 20 DG H3' 2.13 
20 DG H4' 20 DG H2'1 5.61 
20 DG H2'2 20 DG H1' 2.24 
20 DG H2'2 20 DG H3' 2.55 
20 DG H4' 20 DG H2'2 5.01 
20 DG H1' 20 DG H3' 4.30 
20 DG H5'1 20 DG H3' 3.64 
20 DG H4' 20 DG H5'1 2.68 
20 DG H5'2 20 DG H3' 2.62 
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21 DA H2'1 21 DA H1' 2.26 
21 DA H2'1 21 DA H2'2 1.85 
21 DA H2'1 21 DA H3' 2.63 
21 DA H2'2 21 DA H1' 2.99 
21 DA H2'2 21 DA H3' 2.40 
21 DA H5'2 21 DA H2'2 5.67 
21 DA H1' 21 DA H3' 4.38 
21 DA H3' 21 DA H4' 4.77 
21 DA H1' 21 DA H5'1 3.72 
21 DA H5'1 21 DA H3' 2.63 
22 DG H2'2 22 DG H1' 2.31 
22 DG H2'2 22 DG H3' 2.57 
22 DG H4' 22 DG H2'2 6.50 
22 DG H5'1 22 DG H2'2 5.33 
22 DG H3' 22 DG H1' 4.75 
22 DG H4' 22 DG H1' 3.58 
22 DG H4' 22 DG H3' 2.70 
22 DG H5'1 22 DG H1' 3.84 
22 DG H5'1 22 DG H3' 3.36 
22 DG H5'2 22 DG H3' 2.69 
22 DG H4' 22 DG H5'2 2.51 
23 DG H2'1 23 DG H1' 2.74 
23 DG H2'1 23 DG H2'2 1.88 
23 DG H2'2 23 DG H1' 2.33 
23 DG H2'2 23 DG H3' 2.66 
23 DG H4' 23 DG H2'2 5.71 
23 DG H4' 23 DG H1' 3.04 
24 DT H2'1 24 DT H1' 2.09 
18 DA H8 18 DA H1' 8.02 
19 DG H8 18 DA H1' 9.38 
19 DG H8 19 DG H1' 5.77 
19 DG H1' 20 DG H8 4.46 
19 DG H8 19 DG H2'1 3.01 
19 DG H2'1 20 DG H8 4.26 
19 DG H8 19 DG H2'2 4.27 
20 DG H8 20 DG H1' 5.96 
20 DG H2'1 21 DA H8 3.51 
20 DG H2'2 21 DA H8 3.01 
21 DA H2'1 21 DA H8 3.91 
21 DA H2'2 21 DA H8 2.68 
21 DA H3' 21 DA H8 4.25 
22 DG H8 22 DG H1' 3.93 
23 DG H8 22 DG H1' 4.82 
22 DG H8 22 DG H2'1 2.94 
22 DG H8 22 DG H2'2 3.75 
23 DG H8 23 DG H1' 5.47 
23 DG H2'1 23 DG H8 2.75 
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24 DT H6 23 DG H2'1 7.20 
23 DG H8 23 DG H2'2 3.55 
24 DT H6 24 DT H1' 4.34 
24 DT H6 24 DT H2'1 3.29 
25 DT H2'1 25 DT H2'2 2.03 
25 DT H3' 25 DT H2'1 2.77 
25 DT H2'2 25 DT H3' 2.72 
25 DT H5'1 25 DT H2'2 5.03 
25 DT H4' 25 DT H3' 2.57 
25 DT H5'1 25 DT H4' 2.83 
25 DT H5'1 25 DT H3' 2.80 
26 DA H2'1 26 DA H1' 2.58 
26 DA H2'1 26 DA H3' 2.25 
27 DG H2'1 27 DG H1' 3.21 
27 DG H2'1 27 DG H2'2 1.82 
27 DG H4' 27 DG H2'1 6.08 
27 DG H5'1 27 DG H2'1 5.35 
27 DG H5'2 27 DG H2'1 5.94 
27 DG H2'2 27 DG H1' 2.47 
27 DG H2'2 27 DG H3' 2.60 
27 DG H3' 27 DG H5'2 2.70 
28 DG H2'1 28 DG H1' 3.03 
28 DG H2'1 28 DG H2'2 1.84 
28 DG H2'1 28 DG H3' 2.13 
28 DG H4' 28 DG H2'1 5.61 
28 DG H2'2 28 DG H1' 2.24 
28 DG H2'2 28 DG H3' 2.55 
28 DG H4' 28 DG H2'2 5.01 
28 DG H1' 28 DG H3' 4.30 
28 DG H5'1 28 DG H3' 3.64 
28 DG H4' 28 DG H5'1 2.68 
28 DG H5'2 28 DG H3' 2.62 
29 DA H2'1 29 DA H1' 2.26 
29 DA H2'1 29 DA H2'2 1.85 
29 DA H2'1 29 DA H3' 2.63 
29 DA H2'2 29 DA H1' 2.99 
29 DA H2'2 29 DA H3' 2.40 
29 DA H5'2 29 DA H2'2 5.67 
29 DA H1' 29 DA H3' 4.38 
29 DA H3' 29 DA H4' 4.77 
29 DA H1' 29 DA H5'1 3.72 
29 DA H5'1 29 DA H3' 2.63 
30 DG H2'2 30 DG H1' 2.31 
30 DG H2'2 30 DG H3' 2.57 
30 DG H4' 30 DG H2'2 6.50 
30 DG H5'1 30 DG H2'2 5.33 
30 DG H3' 30 DG H1' 4.75 
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30 DG H4' 30 DG H1' 3.58 
30 DG H4' 30 DG H3' 2.70 
30 DG H5'1 30 DG H1' 3.84 
30 DG H5'1 30 DG H3' 3.36 
30 DG H5'2 30 DG H3' 2.69 
30 DG H4' 30 DG H5'2 2.51 
31 DG H2'1 31 DG H1' 2.74 
31 DG H2'1 31 DG H2'2 1.88 
31 DG H2'2 31 DG H1' 2.33 
31 DG H2'2 31 DG H3' 2.66 
31 DG H4' 31 DG H2'2 5.71 
31 DG H4' 31 DG H1' 3.04 
32 DT H2'1 32 DT H1' 2.09 
26 DA H8 26 DA H1' 8.02 
27 DG H8 26 DA H1' 9.38 
27 DG H8 27 DG H1' 5.77 
27 DG H1' 28 DG H8 4.46 
27 DG H8 27 DG H2'1 3.01 
27 DG H2'1 28 DG H8 4.26 
27 DG H8 27 DG H2'2 4.27 
28 DG H8 28 DG H1' 5.96 
28 DG H2'1 29 DA H8 3.51 
28 DG H2'2 29 DA H8 3.01 
29 DA H2'1 29 DA H8 3.91 
29 DA H2'2 29 DA H8 2.68 
29 DA H3' 29 DA H8 4.25 
30 DG H8 30 DG H1' 3.93 
31 DG H8 30 DG H1' 4.82 
30 DG H8 30 DG H2'1 2.94 
30 DG H8 30 DG H2'2 3.75 
31 DG H8 31 DG H1' 5.47 
31 DG H2'1 31 DG H8 2.75 
32 DT H6 31 DG H2'1 7.20 
31 DG H8 31 DG H2'2 3.55 
32 DT H6 32 DT H1' 4.34 
32 DT H6 32 DT H2'1 3.29 
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Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
2 DG H8 1 DT H1' 3.95 
1 DT H2'1 1 DT H1' 3.35 
1 DT H2'1 1 DT H2'2 2.13 
1 DT H2'1 1 DT H3' 3.50 
1 DT H4' 1 DT H2'1 3.68 
1 DT H2'1 1 DT H5'1 4.07 
1 DT H2'1 1 DT H6 2.78 
1 DT H2'1 2 DG H8 3.22 
1 DT H2'2 1 DT H1' 2.57 
1 DT H2'2 1 DT H3' 3.50 
1 DT H2'2 1 DT H4' 2.89 
1 DT H2'2 1 DT H5'1 4.60 
1 DT H2'2 1 DT H6 3.65 
2 DG H8 1 DT H2'2 2.60 
1 DT H3' 1 DT H1' 4.22 
1 DT H3' 1 DT H6 4.17 
1 DT H3' 2 DG H8 4.71 
1 DT H1' 1 DT H4' 2.92 
1 DT H4' 1 DT H3' 2.92 
1 DT H4' 1 DT H6 4.34 
1 DT H5'1 1 DT H1' 4.33 
1 DT H5'1 1 DT H3' 3.56 
1 DT H5'1 1 DT H4' 2.50 
1 DT H5'1 1 DT H6 3.56 
1 DT H5'1 2 DG H8 4.65 
1 DT H6 2 DG H8 8.13 
2 DG H2'1 2 DG H2'2 2.00 
2 DG H3' 2 DG H2'1 2.44 
2 DG H2'1 2 DG H4' 4.28 
2 DG H2'1 2 DG H5'1 4.07 
2 DG H8 2 DG H2'1 2.51 
2 DG H2'1 3 DG H8 3.25 
2 DG H2'2 2 DG H1' 2.50 
2 DG H3' 2 DG H2'2 2.81 
2 DG H2'2 2 DG H4' 4.25 
2 DG H2'2 2 DG H5'1 4.10 
2 DG H2'2 2 DG H8 3.21 
3 DG H8 2 DG H2'2 2.44 
2 DG H3' 3 DG H8 2.83 
2 DG H3' 2 DG H4' 2.63 
2 DG H4' 2 DG H8 4.60 
2 DG H4' 3 DG H8 4.37 
2 DG H5'1 2 DG H4' 2.58 
2 DG H8 2 DG H5'1 3.32 
2 DG H5'1 3 DG H8 6.20 
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4 DA H8 3 DG H1' 3.37 
3 DG H1' 3 DG H2'1 2.71 
3 DG H2'1 3 DG H2'2 1.97 
3 DG H3' 3 DG H2'1 2.39 
3 DG H2'1 3 DG H4' 4.00 
3 DG H2'1 3 DG H5'1 4.64 
3 DG H2'1 3 DG H5'2 4.44 
3 DG H2'1 3 DG H8 2.40 
3 DG H2'1 4 DA H8 2.94 
3 DG H2'2 3 DG H1' 2.38 
3 DG H3' 3 DG H2'2 2.43 
3 DG H2'2 3 DG H4' 3.44 
3 DG H2'2 3 DG H5'1 4.15 
3 DG H2'2 3 DG H5'2 3.94 
3 DG H8 3 DG H2'2 2.68 
3 DG H2'2 4 DA H8 2.54 
3 DG H3' 4 DA H8 4.20 
3 DG H4' 3 DG H1' 2.60 
3 DG H4' 4 DA H8 4.68 
3 DG H5'1 3 DG H8 4.34 
3 DG H1' 3 DG H5'2 3.06 
3 DG H5'2 3 DG H8 4.41 
3 DG H8 2 DG H8 6.05 
3 DG H8 4 DA H8 3.82 
4 DA H8 4 DA H1' 3.44 
4 DA H2'1 4 DA H2'2 1.99 
4 DA H2'1 4 DA H3' 4.05 
4 DA H2'1 4 DA H4' 3.63 
4 DA H5'1 4 DA H2'1 3.00 
4 DA H2'1 4 DA H8 3.24 
5 DG H8 4 DA H2'1 2.45 
4 DA H2'2 4 DA H1' 2.76 
4 DA H2'2 4 DA H3' 3.09 
4 DA H2'2 4 DA H4' 4.14 
4 DA H2'2 4 DA H8 2.57 
4 DA H3' 4 DA H1' 3.97 
4 DA H3' 4 DA H8 3.02 
4 DA H4' 4 DA H1' 2.85 
4 DA H3' 4 DA H4' 2.79 
4 DA H4' 4 DA H8 4.49 
5 DG H8 4 DA H4' 5.05 
4 DA H5'1 4 DA H8 4.61 
5 DG H8 5 DG H1' 3.52 
6 DG H8 5 DG H1' 2.70 
5 DG H2'1 5 DG H1' 3.87 
5 DG H2'1 5 DG H2'2 3.00 
5 DG H2'1 6 DG H8 2.38 
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5 DG H2'2 5 DG H1' 2.36 
5 DG H2'2 5 DG H3' 3.28 
5 DG H2'2 5 DG H4' 4.00 
5 DG H2'2 5 DG H5'1 3.76 
5 DG H2'2 6 DG H8 2.61 
5 DG H3' 5 DG H1' 3.94 
5 DG H3' 5 DG H8 3.38 
5 DG H3' 6 DG H8 4.14 
5 DG H4' 5 DG H1' 3.31 
5 DG H4' 5 DG H8 4.25 
5 DG H4' 6 DG H8 8.07 
5 DG H8 5 DG H5'1 4.11 
5 DG H8 5 DG H5'2 4.05 
5 DG H1' 5 DG H5'2 4.21 
5 DG H5'2 5 DG H4' 3.93 
6 DG H8 6 DG H5'2 3.64 
6 DG H8 6 DG H1' 3.39 
6 DG H1' 7 DC H6 3.74 
5 DG H2'1 5 DG H5'2 3.78 
6 DG H2'1 6 DG H1' 2.86 
6 DG H2'1 6 DG H2'2 2.10 
6 DG H3' 6 DG H2'1 2.44 
6 DG H2'1 6 DG H4' 3.64 
6 DG H2'1 6 DG H5'1 4.20 
6 DG H2'1 6 DG H5'2 4.01 
6 DG H2'1 7 DC H5 4.26 
6 DG H2'1 7 DC H6 3.26 
6 DG H2'2 6 DG H1' 2.66 
6 DG H3' 6 DG H2'2 2.82 
6 DG H2'2 6 DG H4' 3.41 
6 DG H2'2 6 DG H5'1 4.00 
6 DG H2'2 6 DG H5'2 3.30 
6 DG H2'2 7 DC H5 4.04 
6 DG H2'2 7 DC H6 2.93 
6 DG H3' 6 DG H1' 2.84 
6 DG H3' 6 DG H8 3.33 
6 DG H4' 6 DG H1' 3.34 
6 DG H4' 6 DG H8 4.75 
6 DG H5'1 6 DG H1' 3.81 
6 DG H5'2 6 DG H5'1 1.97 
5 DG H8 6 DG H8 3.95 
7 DC H1' 7 DC H6 3.58 
7 DC H1' 7 DC H2'1 2.54 
7 DC H4' 7 DC H2'1 2.64 
7 DC H5 7 DC H2'1 5.27 
7 DC H5'2 7 DC H2'1 5.73 
7 DC H6 7 DC H2'1 2.47 
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7 DC H1' 7 DC H2'2 2.51 
7 DC H4' 7 DC H2'2 2.88 
7 DC H6 7 DC H2'2 3.08 
7 DC H4' 7 DC H1' 4.11 
7 DC H4' 7 DC H6 3.26 
7 DC H5'1 7 DC H1' 3.14 
7 DC H4' 7 DC H5'1 3.09 
7 DC H5'2 7 DC H5'1 2.33 
7 DC H6 7 DC H5'1 4.38 
7 DC H5'2 7 DC H1' 5.20 
7 DC H4' 7 DC H5'2 2.42 
7 DC H6 7 DC H5'2 4.42 
7 DC H5 6 DG H1' 4.73 
7 DC H5 6 DG H8 4.71 
7 DC H5 7 DC H6 2.69 
6 DG H8 7 DC H6 6.33 
9 DG H8 8 DT H1' 3.95 
8 DT H2'1 8 DT H1' 3.35 
8 DT H2'1 8 DT H2'2 2.13 
8 DT H2'1 8 DT H3' 3.50 
8 DT H4' 8 DT H2'1 3.68 
8 DT H2'1 8 DT H5'1 4.07 
8 DT H2'1 8 DT H6 2.78 
8 DT H2'1 9 DG H8 3.22 
8 DT H2'2 8 DT H1' 2.57 
8 DT H2'2 8 DT H3' 3.50 
8 DT H2'2 8 DT H4' 2.89 
8 DT H2'2 8 DT H5'1 4.60 
8 DT H2'2 8 DT H6 3.65 
9 DG H8 8 DT H2'2 2.60 
8 DT H3' 8 DT H1' 4.22 
8 DT H3' 8 DT H6 4.17 
8 DT H3' 9 DG H8 4.71 
8 DT H1' 8 DT H4' 2.92 
8 DT H4' 8 DT H3' 2.92 
8 DT H4' 8 DT H6 4.34 
8 DT H5'1 8 DT H1' 4.33 
8 DT H5'1 8 DT H3' 3.56 
8 DT H5'1 8 DT H4' 2.50 
8 DT H5'1 8 DT H6 3.56 
8 DT H5'1 9 DG H8 4.65 
8 DT H6 9 DG H8 8.13 
9 DG H2'1 9 DG H2'2 2.00 
9 DG H3' 9 DG H2'1 2.44 
9 DG H2'1 9 DG H4' 4.28 
9 DG H2'1 9 DG H5'1 4.07 
9 DG H8 9 DG H2'1 2.51 
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9 DG H2'1 10 DG H8 3.25 
9 DG H2'2 9 DG H1' 2.50 
9 DG H3' 9 DG H2'2 2.81 
9 DG H2'2 9 DG H4' 4.25 
9 DG H2'2 9 DG H5'1 4.10 
9 DG H2'2 9 DG H8 3.21 
10 DG H8 9 DG H2'2 2.44 
9 DG H3' 10 DG H8 2.83 
9 DG H3' 9 DG H4' 2.63 
9 DG H4' 9 DG H8 4.60 
9 DG H4' 10 DG H8 4.37 
9 DG H5'1 9 DG H4' 2.58 
9 DG H8 9 DG H5'1 3.32 
9 DG H5'1 10 DG H8 6.20 
11 DA H8 10 DG H1' 3.37 
10 DG H1' 10 DG H2'1 2.71 
10 DG H2'1 10 DG H2'2 1.97 
10 DG H3' 10 DG H2'1 2.39 
10 DG H2'1 10 DG H4' 4.00 
10 DG H2'1 10 DG H5'1 4.64 
10 DG H2'1 10 DG H5'2 4.44 
10 DG H2'1 10 DG H8 2.40 
10 DG H2'1 11 DA H8 2.94 
10 DG H2'2 10 DG H1' 2.38 
10 DG H3' 10 DG H2'2 2.43 
10 DG H2'2 10 DG H4' 3.44 
10 DG H2'2 10 DG H5'1 4.15 
10 DG H2'2 10 DG H5'2 3.94 
10 DG H8 10 DG H2'2 2.68 
10 DG H2'2 11 DA H8 2.54 
10 DG H3' 11 DA H8 4.20 
10 DG H4' 10 DG H1' 2.60 
10 DG H4' 11 DA H8 4.68 
10 DG H5'1 10 DG H8 4.34 
10 DG H1' 10 DG H5'2 3.06 
10 DG H5'2 10 DG H8 4.41 
10 DG H8 9 DG H8 6.05 
10 DG H8 11 DA H8 3.82 
11 DA H8 11 DA H1' 3.44 
11 DA H2'1 11 DA H2'2 1.99 
11 DA H2'1 11 DA H3' 4.05 
11 DA H2'1 11 DA H4' 3.63 
11 DA H5'1 11 DA H2'1 3.00 
11 DA H2'1 11 DA H8 3.24 
12 DG H8 11 DA H2'1 2.45 
11 DA H2'2 11 DA H1' 2.76 
11 DA H2'2 11 DA H3' 3.09 
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11 DA H2'2 11 DA H4' 4.14 
11 DA H2'2 11 DA H8 2.57 
11 DA H3' 11 DA H1' 3.97 
11 DA H3' 11 DA H8 3.02 
11 DA H4' 11 DA H1' 2.85 
11 DA H3' 11 DA H4' 2.79 
11 DA H4' 11 DA H8 4.49 
12 DG H8 11 DA H4' 5.05 
11 DA H5'1 11 DA H8 4.61 
12 DG H8 12 DG H1' 3.52 
13 DG H8 12 DG H1' 2.70 
12 DG H2'1 12 DG H1' 3.87 
12 DG H2'1 12 DG H2'2 3.00 
12 DG H2'1 13 DG H8 2.38 
12 DG H2'2 12 DG H1' 2.36 
12 DG H2'2 12 DG H3' 3.28 
12 DG H2'2 12 DG H4' 4.00 
12 DG H2'2 12 DG H5'1 3.76 
12 DG H2'2 13 DG H8 2.61 
12 DG H3' 12 DG H1' 3.94 
12 DG H3' 12 DG H8 3.38 
12 DG H3' 13 DG H8 4.14 
12 DG H4' 12 DG H1' 3.31 
12 DG H4' 12 DG H8 4.25 
12 DG H4' 13 DG H8 8.07 
12 DG H8 12 DG H5'1 4.11 
12 DG H8 12 DG H5'2 4.05 
12 DG H1' 12 DG H5'2 4.21 
12 DG H5'2 12 DG H4' 3.93 
13 DG H8 13 DG H5'2 3.64 
13 DG H8 13 DG H1' 3.39 
13 DG H1' 14 DC H6 3.74 
12 DG H2'1 12 DG H5'2 3.78 
13 DG H2'1 13 DG H1' 2.86 
13 DG H2'1 13 DG H2'2 2.10 
13 DG H3' 13 DG H2'1 2.44 
13 DG H2'1 13 DG H4' 3.64 
13 DG H2'1 13 DG H5'1 4.20 
13 DG H2'1 13 DG H5'2 4.01 
13 DG H2'1 14 DC H5 4.26 
13 DG H2'1 14 DC H6 3.26 
13 DG H2'2 13 DG H1' 2.66 
13 DG H3' 13 DG H2'2 2.82 
13 DG H2'2 13 DG H4' 3.41 
13 DG H2'2 13 DG H5'1 4.00 
13 DG H2'2 13 DG H5'2 3.30 
13 DG H2'2 14 DC H5 4.04 
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13 DG H2'2 14 DC H6 2.93 
13 DG H3' 13 DG H1' 2.84 
13 DG H3' 13 DG H8 3.33 
13 DG H4' 13 DG H1' 3.34 
13 DG H4' 13 DG H8 4.75 
13 DG H5'1 13 DG H1' 3.81 
13 DG H5'2 13 DG H5'1 1.97 
12 DG H8 13 DG H8 3.95 
14 DC H1' 14 DC H6 3.58 
14 DC H1' 14 DC H2'1 2.54 
14 DC H4' 14 DC H2'1 2.64 
14 DC H5 14 DC H2'1 5.27 
14 DC H5'2 14 DC H2'1 5.73 
14 DC H6 14 DC H2'1 2.47 
14 DC H1' 14 DC H2'2 2.51 
14 DC H4' 14 DC H2'2 2.88 
14 DC H6 14 DC H2'2 3.08 
14 DC H4' 14 DC H1' 4.11 
14 DC H4' 14 DC H6 3.26 
14 DC H5'1 14 DC H1' 3.14 
14 DC H4' 14 DC H5'1 3.09 
14 DC H5'2 14 DC H5'1 2.33 
14 DC H6 14 DC H5'1 4.38 
14 DC H5'2 14 DC H1' 5.20 
14 DC H4' 14 DC H5'2 2.42 
14 DC H6 14 DC H5'2 4.42 
14 DC H5 13 DG H1' 4.73 
14 DC H5 13 DG H8 4.71 
14 DC H5 14 DC H6 2.69 
13 DG H8 14 DC H6 6.33 
16 DG H8 15 DT H1' 3.95 
15 DT H2'1 15 DT H1' 3.35 
15 DT H2'1 15 DT H2'2 2.13 
15 DT H2'1 15 DT H3' 3.50 
15 DT H4' 15 DT H2'1 3.68 
15 DT H2'1 15 DT H5'1 4.07 
15 DT H2'1 15 DT H6 2.78 
15 DT H2'1 16 DG H8 3.22 
15 DT H2'2 15 DT H1' 2.57 
15 DT H2'2 15 DT H3' 3.50 
15 DT H2'2 15 DT H4' 2.89 
15 DT H2'2 15 DT H5'1 4.60 
15 DT H2'2 15 DT H6 3.65 
16 DG H8 15 DT H2'2 2.60 
15 DT H3' 15 DT H1' 4.22 
15 DT H3' 15 DT H6 4.17 
15 DT H3' 16 DG H8 4.71 
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15 DT H1' 15 DT H4' 2.92 
15 DT H4' 15 DT H3' 2.92 
15 DT H4' 15 DT H6 4.34 
15 DT H5'1 15 DT H1' 4.33 
15 DT H5'1 15 DT H3' 3.56 
15 DT H5'1 15 DT H4' 2.50 
15 DT H5'1 15 DT H6 3.56 
15 DT H5'1 16 DG H8 4.65 
15 DT H6 16 DG H8 8.13 
16 DG H2'1 16 DG H2'2 2.00 
16 DG H3' 16 DG H2'1 2.44 
16 DG H2'1 16 DG H4' 4.28 
16 DG H2'1 16 DG H5'1 4.07 
16 DG H8 16 DG H2'1 2.51 
16 DG H2'1 17 DG H8 3.25 
16 DG H2'2 16 DG H1' 2.50 
16 DG H3' 16 DG H2'2 2.81 
16 DG H2'2 16 DG H4' 4.25 
16 DG H2'2 16 DG H5'1 4.10 
16 DG H2'2 16 DG H8 3.21 
17 DG H8 16 DG H2'2 2.44 
16 DG H3' 17 DG H8 2.83 
16 DG H3' 16 DG H4' 2.63 
16 DG H4' 16 DG H8 4.60 
16 DG H4' 17 DG H8 4.37 
16 DG H5'1 16 DG H4' 2.58 
16 DG H8 16 DG H5'1 3.32 
16 DG H5'1 17 DG H8 6.20 
18 DA H8 17 DG H1' 3.37 
17 DG H1' 17 DG H2'1 2.71 
17 DG H2'1 17 DG H2'2 1.97 
17 DG H3' 17 DG H2'1 2.39 
17 DG H2'1 17 DG H4' 4.00 
17 DG H2'1 17 DG H5'1 4.64 
17 DG H2'1 17 DG H5'2 4.44 
17 DG H2'1 17 DG H8 2.40 
17 DG H2'1 18 DA H8 2.94 
17 DG H2'2 17 DG H1' 2.38 
17 DG H3' 17 DG H2'2 2.43 
17 DG H2'2 17 DG H4' 3.44 
17 DG H2'2 17 DG H5'1 4.15 
17 DG H2'2 17 DG H5'2 3.94 
17 DG H8 17 DG H2'2 2.68 
17 DG H2'2 18 DA H8 2.54 
17 DG H3' 18 DA H8 4.20 
17 DG H4' 17 DG H1' 2.60 
17 DG H4' 18 DA H8 4.68 
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17 DG H5'1 17 DG H8 4.34 
17 DG H1' 17 DG H5'2 3.06 
17 DG H5'2 17 DG H8 4.41 
17 DG H8 16 DG H8 6.05 
17 DG H8 18 DA H8 3.82 
18 DA H8 18 DA H1' 3.44 
18 DA H2'1 18 DA H2'2 1.99 
18 DA H2'1 18 DA H3' 4.05 
18 DA H2'1 18 DA H4' 3.63 
18 DA H5'1 18 DA H2'1 3.00 
18 DA H2'1 18 DA H8 3.24 
19 DG H8 18 DA H2'1 2.45 
18 DA H2'2 18 DA H1' 2.76 
18 DA H2'2 18 DA H3' 3.09 
18 DA H2'2 18 DA H4' 4.14 
18 DA H2'2 18 DA H8 2.57 
18 DA H3' 18 DA H1' 3.97 
18 DA H3' 18 DA H8 3.02 
18 DA H4' 18 DA H1' 2.85 
18 DA H3' 18 DA H4' 2.79 
18 DA H4' 18 DA H8 4.49 
19 DG H8 18 DA H4' 5.05 
18 DA H5'1 18 DA H8 4.61 
19 DG H8 19 DG H1' 3.52 
20 DG H8 19 DG H1' 2.70 
19 DG H2'1 19 DG H1' 3.87 
19 DG H2'1 19 DG H2'2 3.00 
19 DG H2'1 20 DG H8 2.38 
19 DG H2'2 19 DG H1' 2.36 
19 DG H2'2 19 DG H3' 3.28 
19 DG H2'2 19 DG H4' 4.00 
19 DG H2'2 19 DG H5'1 3.76 
19 DG H2'2 20 DG H8 2.61 
19 DG H3' 19 DG H1' 3.94 
19 DG H3' 19 DG H8 3.38 
19 DG H3' 20 DG H8 4.14 
19 DG H4' 19 DG H1' 3.31 
19 DG H4' 19 DG H8 4.25 
19 DG H4' 20 DG H8 8.07 
19 DG H8 19 DG H5'1 4.11 
19 DG H8 19 DG H5'2 4.05 
19 DG H1' 19 DG H5'2 4.21 
19 DG H5'2 19 DG H4' 3.93 
20 DG H8 20 DG H5'2 3.64 
20 DG H8 20 DG H1' 3.39 
20 DG H1' 21 DC H6 3.74 
19 DG H2'1 19 DG H5'2 3.78 
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20 DG H2'1 20 DG H1' 2.86 
20 DG H2'1 20 DG H2'2 2.10 
20 DG H3' 20 DG H2'1 2.44 
20 DG H2'1 20 DG H4' 3.64 
20 DG H2'1 20 DG H5'1 4.20 
20 DG H2'1 20 DG H5'2 4.01 
20 DG H2'1 21 DC H5 4.26 
20 DG H2'1 21 DC H6 3.26 
20 DG H2'2 20 DG H1' 2.66 
20 DG H3' 20 DG H2'2 2.82 
20 DG H2'2 20 DG H4' 3.41 
20 DG H2'2 20 DG H5'1 4.00 
20 DG H2'2 20 DG H5'2 3.30 
20 DG H2'2 21 DC H5 4.04 
20 DG H2'2 21 DC H6 2.93 
20 DG H3' 20 DG H1' 2.84 
20 DG H3' 20 DG H8 3.33 
20 DG H4' 20 DG H1' 3.34 
20 DG H4' 20 DG H8 4.75 
20 DG H5'1 20 DG H1' 3.81 
20 DG H5'2 20 DG H5'1 1.97 
19 DG H8 20 DG H8 3.95 
21 DC H1' 21 DC H6 3.58 
21 DC H1' 21 DC H2'1 2.54 
21 DC H4' 21 DC H2'1 2.64 
21 DC H5 21 DC H2'1 5.27 
21 DC H5'2 21 DC H2'1 5.73 
21 DC H6 21 DC H2'1 2.47 
21 DC H1' 21 DC H2'2 2.51 
21 DC H4' 21 DC H2'2 2.88 
21 DC H6 21 DC H2'2 3.08 
21 DC H4' 21 DC H1' 4.11 
21 DC H4' 21 DC H6 3.26 
21 DC H5'1 21 DC H1' 3.14 
21 DC H4' 21 DC H5'1 3.09 
21 DC H5'2 21 DC H5'1 2.33 
21 DC H6 21 DC H5'1 4.38 
21 DC H5'2 21 DC H1' 5.20 
21 DC H4' 21 DC H5'2 2.42 
21 DC H6 21 DC H5'2 4.42 
21 DC H5 20 DG H1' 4.73 
21 DC H5 20 DG H8 4.71 
21 DC H5 21 DC H6 2.69 
20 DG H8 21 DC H6 6.33 
23 DG H8 22 DT H1' 3.95 
22 DT H2'1 22 DT H1' 3.35 
22 DT H2'1 22 DT H2'2 2.13 
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22 DT H2'1 22 DT H3' 3.50 
22 DT H4' 22 DT H2'1 3.68 
22 DT H2'1 22 DT H5'1 4.07 
22 DT H2'1 22 DT H6 2.78 
22 DT H2'1 23 DG H8 3.22 
22 DT H2'2 22 DT H1' 2.57 
22 DT H2'2 22 DT H3' 3.50 
22 DT H2'2 22 DT H4' 2.89 
22 DT H2'2 22 DT H5'1 4.60 
22 DT H2'2 22 DT H6 3.65 
23 DG H8 22 DT H2'2 2.60 
22 DT H3' 22 DT H1' 4.22 
22 DT H3' 22 DT H6 4.17 
22 DT H3' 23 DG H8 4.71 
22 DT H1' 22 DT H4' 2.92 
22 DT H4' 22 DT H3' 2.92 
22 DT H4' 22 DT H6 4.34 
22 DT H5'1 22 DT H1' 4.33 
22 DT H5'1 22 DT H3' 3.56 
22 DT H5'1 22 DT H4' 2.50 
22 DT H5'1 22 DT H6 3.56 
22 DT H5'1 23 DG H8 4.65 
22 DT H6 23 DG H8 8.13 
23 DG H2'1 23 DG H2'2 2.00 
23 DG H3' 23 DG H2'1 2.44 
23 DG H2'1 23 DG H4' 4.28 
23 DG H2'1 23 DG H5'1 4.07 
23 DG H8 23 DG H2'1 2.51 
23 DG H2'1 24 DG H8 3.25 
23 DG H2'2 23 DG H1' 2.50 
23 DG H3' 23 DG H2'2 2.81 
23 DG H2'2 23 DG H4' 4.25 
23 DG H2'2 23 DG H5'1 4.10 
23 DG H2'2 23 DG H8 3.21 
24 DG H8 23 DG H2'2 2.44 
23 DG H3' 24 DG H8 2.83 
23 DG H3' 23 DG H4' 2.63 
23 DG H4' 23 DG H8 4.60 
23 DG H4' 24 DG H8 4.37 
23 DG H5'1 23 DG H4' 2.58 
23 DG H8 23 DG H5'1 3.32 
23 DG H5'1 24 DG H8 6.20 
25 DA H8 24 DG H1' 3.37 
24 DG H1' 24 DG H2'1 2.71 
24 DG H2'1 24 DG H2'2 1.97 
24 DG H3' 24 DG H2'1 2.39 
24 DG H2'1 24 DG H4' 4.00 
Appendices 287
Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
24 DG H2'1 24 DG H5'1 4.64 
24 DG H2'1 24 DG H5'2 4.44 
24 DG H2'1 24 DG H8 2.40 
24 DG H2'1 25 DA H8 2.94 
24 DG H2'2 24 DG H1' 2.38 
24 DG H3' 24 DG H2'2 2.43 
24 DG H2'2 24 DG H4' 3.44 
24 DG H2'2 24 DG H5'1 4.15 
24 DG H2'2 24 DG H5'2 3.94 
24 DG H8 24 DG H2'2 2.68 
24 DG H2'2 25 DA H8 2.54 
24 DG H3' 25 DA H8 4.20 
24 DG H4' 24 DG H1' 2.60 
24 DG H4' 25 DA H8 4.68 
24 DG H5'1 24 DG H8 4.34 
24 DG H1' 24 DG H5'2 3.06 
24 DG H5'2 24 DG H8 4.41 
24 DG H8 23 DG H8 6.05 
24 DG H8 25 DA H8 3.82 
25 DA H8 25 DA H1' 3.44 
25 DA H2'1 25 DA H2'2 1.99 
25 DA H2'1 25 DA H3' 4.05 
25 DA H2'1 25 DA H4' 3.63 
25 DA H5'1 25 DA H2'1 3.00 
25 DA H2'1 25 DA H8 3.24 
26 DG H8 25 DA H2'1 2.45 
25 DA H2'2 25 DA H1' 2.76 
25 DA H2'2 25 DA H3' 3.09 
25 DA H2'2 25 DA H4' 4.14 
25 DA H2'2 25 DA H8 2.57 
25 DA H3' 25 DA H1' 3.97 
25 DA H3' 25 DA H8 3.02 
25 DA H4' 25 DA H1' 2.85 
25 DA H3' 25 DA H4' 2.79 
25 DA H4' 25 DA H8 4.49 
26 DG H8 25 DA H4' 5.05 
25 DA H5'1 25 DA H8 4.61 
26 DG H8 26 DG H1' 3.52 
27 DG H8 26 DG H1' 2.70 
26 DG H2'1 26 DG H1' 3.87 
26 DG H2'1 26 DG H2'2 3.00 
26 DG H2'1 27 DG H8 2.38 
26 DG H2'2 26 DG H1' 2.36 
26 DG H2'2 26 DG H3' 3.28 
26 DG H2'2 26 DG H4' 4.00 
26 DG H2'2 26 DG H5'1 3.76 
26 DG H2'2 27 DG H8 2.61 
Appendices 288
Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
26 DG H3' 26 DG H1' 3.94 
26 DG H3' 26 DG H8 3.38 
26 DG H3' 27 DG H8 4.14 
26 DG H4' 26 DG H1' 3.31 
26 DG H4' 26 DG H8 4.25 
26 DG H4' 27 DG H8 8.07 
26 DG H8 26 DG H5'1 4.11 
26 DG H8 26 DG H5'2 4.05 
26 DG H1' 26 DG H5'2 4.21 
26 DG H5'2 26 DG H4' 3.93 
27 DG H8 27 DG H5'2 3.64 
27 DG H8 27 DG H1' 3.39 
27 DG H1' 28 DC H6 3.74 
26 DG H2'1 26 DG H5'2 3.78 
27 DG H2'1 27 DG H1' 2.86 
27 DG H2'1 27 DG H2'2 2.10 
27 DG H3' 27 DG H2'1 2.44 
27 DG H2'1 27 DG H4' 3.64 
27 DG H2'1 27 DG H5'1 4.20 
27 DG H2'1 27 DG H5'2 4.01 
27 DG H2'1 28 DC H5 4.26 
27 DG H2'1 28 DC H6 3.26 
27 DG H2'2 27 DG H1' 2.66 
27 DG H3' 27 DG H2'2 2.82 
27 DG H2'2 27 DG H4' 3.41 
27 DG H2'2 27 DG H5'1 4.00 
27 DG H2'2 27 DG H5'2 3.30 
27 DG H2'2 28 DC H5 4.04 
27 DG H2'2 28 DC H6 2.93 
27 DG H3' 27 DG H1' 2.84 
27 DG H3' 27 DG H8 3.33 
27 DG H4' 27 DG H1' 3.34 
27 DG H4' 27 DG H8 4.75 
27 DG H5'1 27 DG H1' 3.81 
27 DG H5'2 27 DG H5'1 1.97 
26 DG H8 27 DG H8 3.95 
28 DC H1' 28 DC H6 3.58 
28 DC H1' 28 DC H2'1 2.54 
28 DC H4' 28 DC H2'1 2.64 
28 DC H5 28 DC H2'1 5.27 
28 DC H5'2 28 DC H2'1 5.73 
28 DC H6 28 DC H2'1 2.47 
28 DC H1' 28 DC H2'2 2.51 
28 DC H4' 28 DC H2'2 2.88 
28 DC H6 28 DC H2'2 3.08 
28 DC H4' 28 DC H1' 4.11 
28 DC H4' 28 DC H6 3.26 
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28 DC H5'1 28 DC H1' 3.14 
28 DC H4' 28 DC H5'1 3.09 
28 DC H5'2 28 DC H5'1 2.33 
28 DC H6 28 DC H5'1 4.38 
28 DC H5'2 28 DC H1' 5.20 
28 DC H4' 28 DC H5'2 2.42 
28 DC H6 28 DC H5'2 4.42 
28 DC H5 27 DG H1' 4.73 
28 DC H5 27 DG H8 4.71 
28 DC H5 28 DC H6 2.69 
27 DG H8 28 DC H6 6.33 
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Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
1 DT H1' 1 DT H2'2 2.62 
1 DT H1' 1 DT H4' 3.18 
1 DT H2'1 1 DT H2'2 2.01 
1 DT H2'2 1 DT H3' 2.60 
1 DT H2'2 2 DG H8 1.87 
1 DT H4' 1 DT H3' 2.78 
2 DG H2'1 2 DG H2'2 1.80 
2 DG H2'1 2 DG H3' 2.38 
2 DG H2'1 2 DG H8 1.84 
2 DG H2'2 2 DG H1' 2.38 
2 DG H2'2 2 DG H3' 2.58 
2 DG H2'2 2 DG H8 2.10 
2 DG H2'2 3 DG H8 1.88 
2 DG H3' 2 DG H4' 2.81 
2 DG H4' 2 DG H1' 3.63 
2 DG H4' 2 DG H5'1 2.85 
2 DG H4' 2 DG H5'2 2.33 
2 DG H5'1 2 DG H3' 2.86 
2 DG H5'2 2 DG H3' 3.02 
3 DG H2'1 3 DG H1' 3.25 
3 DG H2'1 3 DG H2'2 1.85 
3 DG H2'1 3 DG H3' 2.36 
3 DG H2'1 3 DG H8 1.84 
3 DG H2'1 4 DG H8 2.32 
3 DG H2'2 3 DG H1' 2.35 
3 DG H2'2 3 DG H3' 2.57 
3 DG H2'2 3 DG H8 2.10 
3 DG H2'2 4 DG H8 1.80 
3 DG H3' 3 DG H5'2 3.24 
3 DG H4' 3 DG H1' 3.36 
3 DG H4' 3 DG H3' 2.93 
3 DG H5'1 3 DG H1' 2.69 
3 DG H5'1 3 DG H3' 2.67 
3 DG H5'1 3 DG H4' 2.26 
3 DG H5'2 3 DG H4' 2.54 
3 DG H8 3 DG H3' 3.40 
4 DG H2'1 4 DG H1' 2.84 
4 DG H2'1 4 DG H2'2 1.87 
4 DG H2'1 4 DG H3' 2.23 
4 DG H2'1 4 DG H8 1.90 
4 DG H2'1 5 DA H8 1.83 
4 DG H2'2 4 DG H1' 2.26 
4 DG H2'2 4 DG H3' 2.41 
4 DG H2'2 4 DG H3' 2.51 
4 DG H2'2 4 DG H8 1.95 
Appendices 291
Identifier A Residue A Atom A Identifier B Residue B Atom B Distance 
4 DG H2'2 5 DA H8 1.89 
4 DG H4' 4 DG H1' 3.39 
4 DG H4' 4 DG H3' 2.63 
4 DG H5'1 4 DG H1' 4.40 
4 DG H5'1 4 DG H4' 1.89 
4 DG H5'2 4 DG H1' 2.42 
4 DG H5'2 4 DG H3' 2.64 
4 DG H8 3 DG H1' 3.00 
4 DG H8 4 DG H3' 2.93 
5 DA H1' 5 DA H3' 4.13 
5 DA H2'1 5 DA H1' 2.31 
5 DA H2'1 5 DA H2'2 1.89 
5 DA H2'1 5 DA H3' 2.80 
5 DA H2'1 5 DA H8 2.28 
5 DA H2'1 6 DG H8 1.81 
5 DA H2'2 5 DA H1' 2.82 
5 DA H2'2 5 DA H3' 2.25 
5 DA H2'2 5 DA H8 1.82 
5 DA H3' 5 DA H8 2.01 
5 DA H5'1 5 DA H3' 2.80 
5 DA H5'2 5 DA H1' 3.02 
5 DA H5'2 5 DA H3' 2.63 
6 DG H1' 6 DG H3' 3.77 
6 DG H1' 7 DG H8 2.00 
6 DG H2'1 6 DG H3' 2.15 
6 DG H2'1 6 DG H8 1.89 
6 DG H2'1 7 DG H8 1.88 
6 DG H2'2 6 DG H1' 2.21 
6 DG H2'2 6 DG H3' 2.50 
6 DG H2'2 7 DG H8 1.85 
6 DG H3' 7 DG H8 2.88 
6 DG H4' 6 DG H1' 3.35 
6 DG H4' 6 DG H3' 2.61 
6 DG H5'1 6 DG H1' 3.39 
6 DG H5'1 6 DG H3' 2.94 
6 DG H5'1 6 DG H4' 2.22 
6 DG H5'2 6 DG H1' 3.07 
6 DG H5'2 6 DG H3' 2.40 
6 DG H5'2 6 DG H4' 2.20 
6 DG H8 5 DA H1' 2.88 
6 DG H8 6 DG H1' 3.18 
6 DG H8 6 DG H2'2 1.88 
6 DG H8 6 DG H3' 2.58 
7 DG H2'1 7 DG H1' 2.71 
7 DG H2'1 7 DG H2'2 1.73 
7 DG H2'1 7 DG H3' 2.21 
7 DG H2'1 7 DG H8 1.88 
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7 DG H2'1 8 DC H6 2.00 
7 DG H2'2 7 DG H1' 2.15 
7 DG H2'2 7 DG H3' 2.36 
7 DG H2'2 7 DG H8 1.90 
7 DG H2'2 8 DC H6 1.82 
7 DG H3' 7 DG H1' 4.32 
7 DG H3' 7 DG H4' 2.82 
7 DG H3' 7 DG H8 2.69 
7 DG H4' 7 DG H1' 3.03 
7 DG H5'1 7 DG H1' 3.31 
7 DG H5'2 7 DG H3' 2.50 
7 DG H8 7 DG H1' 2.83 
8 DC H1' 8 DC H6 2.83 
8 DC H2'1 8 DC H1' 3.22 
8 DC H2'1 8 DC H6 1.80 
8 DC H2'2 8 DC H1' 2.66 
8 DC H2'2 8 DC H6 1.85 
8 DC H3' 8 DC H2'1 2.74 
8 DC H3' 8 DC H2'2 3.12 
8 DC H6 8 DC H3' 2.39 
9 DT H1' 9 DT H2'2 2.62 
9 DT H1' 9 DT H4' 3.18 
9 DT H2'1 9 DT H2'2 2.01 
9 DT H2'2 9 DT H3' 2.60 
9 DT H2'2 10 DG H8 1.87 
9 DT H4' 9 DT H3' 2.78 
10 DG H2'1 10 DG H2'2 1.80 
10 DG H2'1 10 DG H3' 2.38 
10 DG H2'1 10 DG H8 1.84 
10 DG H2'2 10 DG H1' 2.38 
10 DG H2'2 10 DG H3' 2.58 
10 DG H2'2 10 DG H8 2.10 
10 DG H2'2 11 DG H8 1.88 
10 DG H3' 10 DG H4' 2.81 
10 DG H4' 10 DG H1' 3.63 
10 DG H4' 10 DG H5'1 2.85 
10 DG H4' 10 DG H5'2 2.33 
10 DG H5'1 10 DG H3' 2.86 
10 DG H5'2 10 DG H3' 3.02 
11 DG H2'1 11 DG H1' 3.25 
11 DG H2'1 11 DG H2'2 1.85 
11 DG H2'1 11 DG H3' 2.36 
11 DG H2'1 11 DG H8 1.84 
11 DG H2'1 12 DG H8 2.32 
11 DG H2'2 11 DG H1' 2.35 
11 DG H2'2 11 DG H3' 2.57 
11 DG H2'2 11 DG H8 2.10 
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11 DG H2'2 12 DG H8 1.80 
11 DG H3' 11 DG H5'2 3.24 
11 DG H4' 11 DG H1' 3.36 
11 DG H4' 11 DG H3' 2.93 
11 DG H5'1 11 DG H1' 2.69 
11 DG H5'1 11 DG H3' 2.67 
11 DG H5'1 11 DG H4' 2.26 
11 DG H5'2 11 DG H4' 2.54 
11 DG H8 11 DG H3' 3.40 
12 DG H2'1 12 DG H1' 2.84 
12 DG H2'1 12 DG H2'2 1.87 
12 DG H2'1 12 DG H3' 2.23 
12 DG H2'1 12 DG H8 1.90 
12 DG H2'1 13 DA H8 1.83 
12 DG H2'2 12 DG H1' 2.26 
12 DG H2'2 12 DG H3' 2.41 
12 DG H2'2 12 DG H3' 2.51 
12 DG H2'2 12 DG H8 1.95 
12 DG H2'2 13 DA H8 1.89 
12 DG H4' 12 DG H1' 3.39 
12 DG H4' 12 DG H3' 2.63 
12 DG H5'1 12 DG H1' 4.40 
12 DG H5'1 12 DG H4' 1.89 
12 DG H5'2 12 DG H1' 2.42 
12 DG H5'2 12 DG H3' 2.64 
12 DG H8 11 DG H1' 3.00 
12 DG H8 12 DG H3' 2.93 
13 DA H1' 13 DA H3' 4.13 
13 DA H2'1 13 DA H1' 2.31 
13 DA H2'1 13 DA H2'2 1.89 
13 DA H2'1 13 DA H3' 2.80 
13 DA H2'1 13 DA H8 2.28 
13 DA H2'1 14 DG H8 1.81 
13 DA H2'2 13 DA H1' 2.82 
13 DA H2'2 13 DA H3' 2.25 
13 DA H2'2 13 DA H8 1.82 
13 DA H3' 13 DA H8 2.01 
13 DA H5'1 13 DA H3' 2.80 
13 DA H5'2 13 DA H1' 3.02 
13 DA H5'2 13 DA H3' 2.63 
14 DG H1' 14 DG H3' 3.77 
14 DG H1' 15 DG H8 2.00 
14 DG H2'1 14 DG H3' 2.15 
14 DG H2'1 14 DG H8 1.89 
14 DG H2'1 15 DG H8 1.88 
14 DG H2'2 14 DG H1' 2.21 
14 DG H2'2 14 DG H3' 2.50 
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14 DG H2'2 15 DG H8 1.85 
14 DG H3' 15 DG H8 2.88 
14 DG H4' 14 DG H1' 3.35 
14 DG H4' 14 DG H3' 2.61 
14 DG H5'1 14 DG H1' 3.39 
14 DG H5'1 14 DG H3' 2.94 
14 DG H5'1 14 DG H4' 2.22 
14 DG H5'2 14 DG H1' 3.07 
14 DG H5'2 14 DG H3' 2.40 
14 DG H5'2 14 DG H4' 2.20 
14 DG H8 13 DA H1' 2.88 
14 DG H8 14 DG H1' 3.18 
14 DG H8 14 DG H2'2 1.88 
14 DG H8 14 DG H3' 2.58 
15 DG H2'1 15 DG H1' 2.71 
15 DG H2'1 15 DG H2'2 1.73 
15 DG H2'1 15 DG H3' 2.21 
15 DG H2'1 15 DG H8 1.88 
15 DG H2'1 16 DC H6 2.00 
15 DG H2'2 15 DG H1' 2.15 
15 DG H2'2 15 DG H3' 2.36 
15 DG H2'2 15 DG H8 1.90 
15 DG H2'2 16 DC H6 1.82 
15 DG H3' 15 DG H1' 4.32 
15 DG H3' 15 DG H4' 2.82 
15 DG H3' 15 DG H8 2.69 
15 DG H4' 15 DG H1' 3.03 
15 DG H5'1 15 DG H1' 3.31 
15 DG H5'2 15 DG H3' 2.50 
15 DG H8 15 DG H1' 2.83 
16 DC H1' 16 DC H6 2.83 
16 DC H2'1 16 DC H1' 3.22 
16 DC H2'1 16 DC H6 1.80 
16 DC H2'2 16 DC H1' 2.66 
16 DC H2'2 16 DC H6 1.85 
16 DC H3' 16 DC H2'1 2.74 
16 DC H3' 16 DC H2'2 3.12 
16 DC H6 16 DC H3' 2.39 
17 DT H1' 17 DT H2'2 2.62 
17 DT H1' 17 DT H4' 3.18 
17 DT H2'1 17 DT H2'2 2.01 
17 DT H2'2 17 DT H3' 2.60 
17 DT H2'2 18 DG H8 1.87 
17 DT H4' 17 DT H3' 2.78 
18 DG H2'1 18 DG H2'2 1.80 
18 DG H2'1 18 DG H3' 2.38 
18 DG H2'1 18 DG H8 1.84 
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18 DG H2'2 18 DG H1' 2.38 
18 DG H2'2 18 DG H3' 2.58 
18 DG H2'2 18 DG H8 2.10 
18 DG H2'2 19 DG H8 1.88 
18 DG H3' 18 DG H4' 2.81 
18 DG H4' 18 DG H1' 3.63 
18 DG H4' 18 DG H5'1 2.85 
18 DG H4' 18 DG H5'2 2.33 
18 DG H5'1 18 DG H3' 2.86 
18 DG H5'2 18 DG H3' 3.02 
19 DG H2'1 19 DG H1' 3.25 
19 DG H2'1 19 DG H2'2 1.85 
19 DG H2'1 19 DG H3' 2.36 
19 DG H2'1 19 DG H8 1.84 
19 DG H2'1 20 DG H8 2.32 
19 DG H2'2 19 DG H1' 2.35 
19 DG H2'2 19 DG H3' 2.57 
19 DG H2'2 19 DG H8 2.10 
19 DG H2'2 20 DG H8 1.80 
19 DG H3' 19 DG H5'2 3.24 
19 DG H4' 19 DG H1' 3.36 
19 DG H4' 19 DG H3' 2.93 
19 DG H5'1 19 DG H1' 2.69 
19 DG H5'1 19 DG H3' 2.67 
19 DG H5'1 19 DG H4' 2.26 
19 DG H5'2 19 DG H4' 2.54 
19 DG H8 19 DG H3' 3.40 
20 DG H2'1 20 DG H1' 2.84 
20 DG H2'1 20 DG H2'2 1.87 
20 DG H2'1 20 DG H3' 2.23 
20 DG H2'1 20 DG H8 1.90 
20 DG H2'1 21 DA H8 1.83 
20 DG H2'2 20 DG H1' 2.26 
20 DG H2'2 20 DG H3' 2.41 
20 DG H2'2 20 DG H3' 2.51 
20 DG H2'2 20 DG H8 1.95 
20 DG H2'2 21 DA H8 1.89 
20 DG H4' 20 DG H1' 3.39 
20 DG H4' 20 DG H3' 2.63 
20 DG H5'1 20 DG H1' 4.40 
20 DG H5'1 20 DG H4' 1.89 
20 DG H5'2 20 DG H1' 2.42 
20 DG H5'2 20 DG H3' 2.64 
20 DG H8 19 DG H1' 3.00 
20 DG H8 20 DG H3' 2.93 
21 DA H1' 21 DA H3' 4.13 
21 DA H2'1 21 DA H1' 2.31 
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21 DA H2'1 21 DA H2'2 1.89 
21 DA H2'1 21 DA H3' 2.80 
21 DA H2'1 21 DA H8 2.28 
21 DA H2'1 22 DG H8 1.81 
21 DA H2'2 21 DA H1' 2.82 
21 DA H2'2 21 DA H3' 2.25 
21 DA H2'2 21 DA H8 1.82 
21 DA H3' 21 DA H8 2.01 
21 DA H5'1 21 DA H3' 2.80 
21 DA H5'2 21 DA H1' 3.02 
21 DA H5'2 21 DA H3' 2.63 
22 DG H1' 22 DG H3' 3.77 
22 DG H1' 23 DG H8 2.00 
22 DG H2'1 22 DG H3' 2.15 
22 DG H2'1 22 DG H8 1.89 
22 DG H2'1 23 DG H8 1.88 
22 DG H2'2 22 DG H1' 2.21 
22 DG H2'2 22 DG H3' 2.50 
22 DG H2'2 23 DG H8 1.85 
22 DG H3' 23 DG H8 2.88 
22 DG H4' 22 DG H1' 3.35 
22 DG H4' 22 DG H3' 2.61 
22 DG H5'1 22 DG H1' 3.39 
22 DG H5'1 22 DG H3' 2.94 
22 DG H5'1 22 DG H4' 2.22 
22 DG H5'2 22 DG H1' 3.07 
22 DG H5'2 22 DG H3' 2.40 
22 DG H5'2 22 DG H4' 2.20 
22 DG H8 21 DA H1' 2.88 
22 DG H8 22 DG H1' 3.18 
22 DG H8 22 DG H2'2 1.88 
22 DG H8 22 DG H3' 2.58 
23 DG H2'1 23 DG H1' 2.71 
23 DG H2'1 23 DG H2'2 1.73 
23 DG H2'1 23 DG H3' 2.21 
23 DG H2'1 23 DG H8 1.88 
23 DG H2'1 24 DC H6 2.00 
23 DG H2'2 23 DG H1' 2.15 
23 DG H2'2 23 DG H3' 2.36 
23 DG H2'2 23 DG H8 1.90 
23 DG H2'2 24 DC H6 1.82 
23 DG H3' 23 DG H1' 4.32 
23 DG H3' 23 DG H4' 2.82 
23 DG H3' 23 DG H8 2.69 
23 DG H4' 23 DG H1' 3.03 
23 DG H5'1 23 DG H1' 3.31 
23 DG H5'2 23 DG H3' 2.50 
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23 DG H8 23 DG H1' 2.83 
24 DC H1' 24 DC H6 2.83 
24 DC H2'1 24 DC H1' 3.22 
24 DC H2'1 24 DC H6 1.80 
24 DC H2'2 24 DC H1' 2.66 
24 DC H2'2 24 DC H6 1.85 
24 DC H3' 24 DC H2'1 2.74 
24 DC H3' 24 DC H2'2 3.12 
24 DC H6 24 DC H3' 2.39 
25 DT H1' 25 DT H2'2 2.62 
25 DT H1' 25 DT H4' 3.18 
25 DT H2'1 25 DT H2'2 2.01 
25 DT H2'2 25 DT H3' 2.60 
25 DT H2'2 26 DG H8 1.87 
25 DT H4' 25 DT H3' 2.78 
26 DG H2'1 26 DG H2'2 1.80 
26 DG H2'1 26 DG H3' 2.38 
26 DG H2'1 26 DG H8 1.84 
26 DG H2'2 26 DG H1' 2.38 
26 DG H2'2 26 DG H3' 2.58 
26 DG H2'2 26 DG H8 2.10 
26 DG H2'2 27 DG H8 1.88 
26 DG H3' 26 DG H4' 2.81 
26 DG H4' 26 DG H1' 3.63 
26 DG H4' 26 DG H5'1 2.85 
26 DG H4' 26 DG H5'2 2.33 
26 DG H5'1 26 DG H3' 2.86 
26 DG H5'2 26 DG H3' 3.02 
27 DG H2'1 27 DG H1' 3.25 
27 DG H2'1 27 DG H2'2 1.85 
27 DG H2'1 27 DG H3' 2.36 
27 DG H2'1 27 DG H8 1.84 
27 DG H2'1 28 DG H8 2.32 
27 DG H2'2 27 DG H1' 2.35 
27 DG H2'2 27 DG H3' 2.57 
27 DG H2'2 27 DG H8 2.10 
27 DG H2'2 28 DG H8 1.80 
27 DG H3' 27 DG H5'2 3.24 
27 DG H4' 27 DG H1' 3.36 
27 DG H4' 27 DG H3' 2.93 
27 DG H5'1 27 DG H1' 2.69 
27 DG H5'1 27 DG H3' 2.67 
27 DG H5'1 27 DG H4' 2.26 
27 DG H5'2 27 DG H4' 2.54 
27 DG H8 27 DG H3' 3.40 
28 DG H2'1 28 DG H1' 2.84 
28 DG H2'1 28 DG H2'2 1.87 
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28 DG H2'1 28 DG H3' 2.23 
28 DG H2'1 28 DG H8 1.90 
28 DG H2'1 29 DA H8 1.83 
28 DG H2'2 28 DG H1' 2.26 
28 DG H2'2 28 DG H3' 2.41 
28 DG H2'2 28 DG H3' 2.51 
28 DG H2'2 28 DG H8 1.95 
28 DG H2'2 29 DA H8 1.89 
28 DG H4' 28 DG H1' 3.39 
28 DG H4' 28 DG H3' 2.63 
28 DG H5'1 28 DG H1' 4.40 
28 DG H5'1 28 DG H4' 1.89 
28 DG H5'2 28 DG H1' 2.42 
28 DG H5'2 28 DG H3' 2.64 
28 DG H8 27 DG H1' 3.00 
28 DG H8 28 DG H3' 2.93 
29 DA H1' 29 DA H3' 4.13 
29 DA H2'1 29 DA H1' 2.31 
29 DA H2'1 29 DA H2'2 1.89 
29 DA H2'1 29 DA H3' 2.80 
29 DA H2'1 29 DA H8 2.28 
29 DA H2'1 30 DG H8 1.81 
29 DA H2'2 29 DA H1' 2.82 
29 DA H2'2 29 DA H3' 2.25 
29 DA H2'2 29 DA H8 1.82 
29 DA H3' 29 DA H8 2.01 
29 DA H5'1 29 DA H3' 2.80 
29 DA H5'2 29 DA H1' 3.02 
29 DA H5'2 29 DA H3' 2.63 
30 DG H1' 30 DG H3' 3.77 
30 DG H1' 31 DG H8 2.00 
30 DG H2'1 30 DG H3' 2.15 
30 DG H2'1 30 DG H8 1.89 
30 DG H2'1 31 DG H8 1.88 
30 DG H2'2 30 DG H1' 2.21 
30 DG H2'2 30 DG H3' 2.50 
30 DG H2'2 31 DG H8 1.85 
30 DG H3' 31 DG H8 2.88 
30 DG H4' 30 DG H1' 3.35 
30 DG H4' 30 DG H3' 2.61 
30 DG H5'1 30 DG H1' 3.39 
30 DG H5'1 30 DG H3' 2.94 
30 DG H5'1 30 DG H4' 2.22 
30 DG H5'2 30 DG H1' 3.07 
30 DG H5'2 30 DG H3' 2.40 
30 DG H5'2 30 DG H4' 2.20 
30 DG H8 29 DA H1' 2.88 
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30 DG H8 30 DG H1' 3.18 
30 DG H8 30 DG H2'2 1.88 
30 DG H8 30 DG H3' 2.58 
31 DG H2'1 31 DG H1' 2.71 
31 DG H2'1 31 DG H2'2 1.73 
31 DG H2'1 31 DG H3' 2.21 
31 DG H2'1 31 DG H8 1.88 
31 DG H2'1 32 DC H6 2.00 
31 DG H2'2 31 DG H1' 2.15 
31 DG H2'2 31 DG H3' 2.36 
31 DG H2'2 31 DG H8 1.90 
31 DG H2'2 32 DC H6 1.82 
31 DG H3' 31 DG H1' 4.32 
31 DG H3' 31 DG H4' 2.82 
31 DG H3' 31 DG H8 2.69 
31 DG H4' 31 DG H1' 3.03 
31 DG H5'1 31 DG H1' 3.31 
31 DG H5'2 31 DG H3' 2.50 
31 DG H8 31 DG H1' 2.83 
32 DC H1' 32 DC H6 2.83 
32 DC H2'1 32 DC H1' 3.22 
32 DC H2'1 32 DC H6 1.80 
32 DC H2'2 32 DC H1' 2.66 
32 DC H2'2 32 DC H6 1.85 
32 DC H3' 32 DC H2'1 2.74 
32 DC H3' 32 DC H2'2 3.12 
32 DC H6 32 DC H3' 2.39 
 
 
